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ABSTRACT 
 
Natural products have been the source of numerous leads for several drugs. As these 
natural products are often isolated in small quantities, it is necessary to produce them 
synthetically to allow testing for biological activity. Furthermore, synthesis allows the 
preparation  of  unnatural  analogues  for  SAR  studies.  Cyclic  peptides  represent  an 
important family of biologically active natural products.  
The hepta- and octacyclopeptides sanguinamide A and sanguinamide B were recently 
isolated  in  submicromolar  amounts  by  the  Molinski  group.
  The  lack  of  material 
prevented biological evaluation of the natural products. For this reason and to confirm 
the  structural  elucidation  we  have  targeted  the  total  synthesis  of  sanguinamides.  In 
addition  to  two  proline  residues,  sanguinamides  A  and  B  include  heterocycles  and 
natural L-amino acid residues. We have completed the total syntheses of sanguinamides 
A  and  B;  however  the  synthetic  rotamers  differed  in  both  cases  from  the  natural 
rotamers.  We  have  investigated  the  influence  of  macrocyclisation  on  cis/trans 
conformational preference of the proline residues for the synthesis of sanguinamide A. 
We attempted several isomerisations and calculated the relative energies of the different 
sanguinamide  conformers.  [D-Ile]-Sanguinamide  A,  Cys(tBu)  analogue  of 
sanguinamide A and the synthetic sanguinamide B displayed antibacterial activity while 
the  synthetic  trans,  trans-sanguinamide  A  displayed  mild  tyrosine  kinase  inhibitory 
activity.  While  extracted  stylissamide  A  showed  inhibition  of  translation  during  the 
elongation  step,  even  though  being  structurally  identical  to  the  natural  product,  the 
synthetic compound prepared by macrocyclisation from a linear precursor was found to 
be totally inactive. 
 
Histones undergo different types of covalent modifications on the N-terminal tails such 
as  acetylation,  phosphorylation  and  methylation.  Histone  modification  is  a  major 
mechanism of regulation in  gene expression, replication and repair. Deregulation of 
histone modifications leads to cancer progression and therefore, inhibitors of enzymes 
which are able to catalyse the addition and removal of these epigenetic marks have 
therapeutic potential for treating cancer. An enzyme of particular interest is the family 
of  zinc-dependent  histone  deacetylases  (HDACs)  that  remove  acetyl  groups  from 
acetylated lysine residues. Depsipeptides were prepared as HDAC inhibitors. We will    
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present our total synthesis of largazole along with a range of analogues and discuss the 
SAR  obtained  from  HDAC  and  cell  proliferation  assays.  We  elucidated  the 
stereochemistry  of  burkholdac  B  by  total  synthesis  of  three  diastereomers.  The 
diastereomers made along with the natural product were tested as HDAC inhibitors.  
We  are  interested  in  inhibitors  of  lysine-specific  demethylase  1  (LSD1)  which  is  a 
different kind of epigenetic enzyme involved in demethylation of histone proteins in 
chromatin. Tranylcypromine is known to be an LSD1 inhibitor. Analogues of PCPA 
have been  synthesised in  order to  explore the  structure-activity relationships  of this 
inhibitor. Analogues were also prepared and tested as LSD1 inhibitors. 
    
iii 
 
CONTENTS 
 
ABSTRACT ................................................................................................................................................................... i 
LIST OF SCHEMES ................................................................................................................................................... vii 
LIST OF FIGURES .......................................................................................................................................................xi 
LIST OF TABLES........................................................................................................................................................  xv 
DECLARATION OF AUTHORSHIP  ....................................................................................................................... xvii 
ACKNOWLEDGEMENTS .........................................................................................................................................xix 
ABBREVIATIONS .....................................................................................................................................................xxi 
1. PROLINE-CONTAINING CYCLIC PEPTIDE NATURAL PRODUCTS ............................1 
1.1. INTRODUCTION .......................................................................................................................... 1 
1.1.1. Natural products .........................................................................................................................................  1 
1.1.2. Proline-containing cyclic peptides .............................................................................................................  3 
1.1.2.1. Yunnanins ..........................................................................................................................................  4 
1.1.2.2. Phakellistatins ....................................................................................................................................  5 
1.1.2.3. Hymenamide C ..................................................................................................................................  9 
1.1.2.4. Stylopeptides, axinellins A and axinastatins ....................................................................................  10 
1.1.2.5. Stylissamides and stylisins ...............................................................................................................  11 
1.1.2.6. Ceratospongamide  ............................................................................................................................  12 
1.1.2.7. Mollamide ........................................................................................................................................  13 
1.1.2.8. Sanguinamides A and B ...................................................................................................................  14 
1.2. AIMS ............................................................................................................................................. 16 
1.3. TOWARDS THE SYNTHESIS OF THE HEPTAPEPTIDE SANGUINAMIDE A .............. 17 
1.3.1. Strategy 1 : macrolactamisation between thiazole and alanine residue ....................................................  17 
1.3.2. Strategy 2: macrolactamisation between Pro
1 and Ile
2 .............................................................................  28 
1.3.3. Strategy 3: macrolactamisation between Phe and Pro
2 .............................................................................  31 
1.3.4. Modification of the stereochemistry of the isoleucine residue next to the thiazole ..................................  33 
1.3.5. Following the biomimetic pathway ..........................................................................................................  35 
1.4. TOWARDS THE SYNTHESIS OF THE OCTAPEPTIDE SANGUINAMIDE B  ................. 43 
1.5. CIS-TRANS ISOMERISATION AND ATTEMPTED REISOLATION ................................. 49 
1.6. BIOLOGICAL ACTIVITY OF SANGUINAMIDES ............................................................... 51 
1.6.1. Antibacterial activity ................................................................................................................................  51 
1.6.2. Tyrosine kinase inhibitory activity ...........................................................................................................  52 
1.7. SYNTHESIS OF STYLISSAMIDE A ........................................................................................ 54 
1.8. BIOLOGICAL ACTIVITY OF STYLISSAMIDE A  ................................................................ 57 
1.9. CONCLUSION ............................................................................................................................. 63 
2. HISTONE DEACETYLASE INHIBITORS ..........................................................................65    
iv 
 
2.1. INTRODUCTION  .........................................................................................................................  65 
2.1.1. Post translational modifications ............................................................................................................... 65 
2.1.2. Histone deacetylases ................................................................................................................................ 66 
2.1.3. Histone deacetylase inhibitors  .................................................................................................................. 68 
2.1.3.1. Acyclic inhibitors  ............................................................................................................................. 68 
A) Hydroxamates .................................................................................................................................... 68 
B) Aliphatics ........................................................................................................................................... 71 
C) Benzamides ........................................................................................................................................ 71 
2.1.3.2. Cyclic peptides  ................................................................................................................................. 71 
A) Cyclic peptides containing an epoxyketone........................................................................................ 72 
B) Azumamides ....................................................................................................................................... 72 
C) Cyclic depsipetides ............................................................................................................................. 73 
a) FK228, FR901375, spiruchostatins and largazole .......................................................................... 73 
b) Thailandepsins ............................................................................................................................... 77 
c) Burkholdacs ................................................................................................................................... 78 
d) New thailandepsins structures ........................................................................................................ 80 
2.1.4. The syntheses of depsipeptides ................................................................................................................ 80 
2.1.4.1. Preparation of the β-hydroxy acid moiety ........................................................................................ 80 
2.1.4.2. Macrolactonisation in the cyclic depsipeptides ................................................................................ 86 
2.1.4.3. Statine unit of spiruchostatins .......................................................................................................... 92 
2.1.4.4. Metathesis in largazole synthesis ..................................................................................................... 94 
2.1.4.5. Thiazoline formation in largazole synthesis  ..................................................................................... 95 
2.1.5. Analogues of the cyclic depsipetides ....................................................................................................... 96 
2.1.5.1. FK228 analogues ............................................................................................................................. 96 
2.1.5.2. Spiruchostatin analogues ................................................................................................................. 98 
2.1.5.3. Largazole analogues prepared by other groups ................................................................................ 98 
2.2. AIMS ............................................................................................................................................  103 
2.3. SYNTHESIS AND BIOLOGICAL ACTIVITY OF LARGAZOLE AND ANALOGUES ..  104 
2.3.1. Total synthesis of largazole .................................................................................................................... 104 
2.3.1.1. Retrosynthesis of largazole ............................................................................................................ 104 
2.3.1.2. Synthesis of the -hydroxy acid derivative .................................................................................... 105 
2.3.1.3. Synthesis of the thiazole-thiazoline fragment ................................................................................ 106 
2.3.1.4. Coupling of the fragments.............................................................................................................. 112 
2.3.2. Synthesis of largazole analogues  ............................................................................................................ 116 
2.3.2.1. Synthesis of glycine and the β-alanine analogues .......................................................................... 117 
2.3.2.2. Synthesis of the Aib analogue  ........................................................................................................ 118 
2.3.2.3. Attempt to synthesise the valine thioester analogue  ....................................................................... 119 
2.3.3. Biological results and metabolic studies of largazole and its analogues ................................................ 120 
2.4. SYNTHESIS AND BIOLOGICAL ACTIVITY OF THAILANDEPSINS AND 
BURKHOLDACS ..............................................................................................................................  124 
2.4.1. Synthesis of thailandepsins .................................................................................................................... 124 
2.4.1.1. First structures of thailandepsins  .................................................................................................... 124 
2.4.1.2. Revised structures of thailandepsins .............................................................................................. 130    
v 
 
2.4.2. Elucidation of the stereochemistry of burkholdacs.................................................................................  134 
2.4.2.1. Synthesis of Brady’s proposed diastereomer (L-Ile, D-Cys and L-Met) ........................................  134 
2.4.2.2. Synthesis of the diastereomer 2.237 (D-Ile, D-Cys and D-Met) ....................................................  138 
2.4.2.3. Synthesis of burkholdac B (D-allo-Ile, D-Cys and D-Met) ............................................................  139 
2.4.3. Biological results for thailandepsin A, burkholdac B and other diastereomers ......................................  143 
2.5. CONCLUSION ........................................................................................................................... 145 
3. HISTONE DEMETHYLASE INHIBITORS  .......................................................................147 
3.1. INTRODUCTION ...................................................................................................................... 147 
3.1.1. Lysine-specific demethylase 1 (LSD1) ..................................................................................................  147 
3.1.1.1. Transcription ..................................................................................................................................  149 
3.1.1.2. LSD2 ..............................................................................................................................................  149 
3.1.1.3. Cancer ............................................................................................................................................  150 
3.1.2. Inhibitors of LSD1 .................................................................................................................................  151 
3.1.2.1. Pargyline and propargyl derivatives ...............................................................................................  151 
3.1.2.2. Tranylcypromine ............................................................................................................................  152 
3.1.2.3. Peptide derivatives and phenelzine ................................................................................................  158 
3.1.2.4. Polyamines .....................................................................................................................................  160 
3.1.3. Jumonji-containing histone demethylases ..............................................................................................  160 
3.2. AIMS ........................................................................................................................................... 162 
3.3. SYNTHESIS OF TRANYLCYPROMINE ANALOGUES .................................................... 163 
3.3.1. First strategy in racemic series ...............................................................................................................  163 
3.3.2. Second strategy using an asymmetric cyclopropanation ........................................................................  165 
3.4. BIOLOGY TESTING OF TRANYLCYPROMINE ANALOGUES ..................................... 169 
3.4.1. Expression and purification of full length human LSD1 ........................................................................  169 
3.4.1.1. Cloning of LSD1 in pET15b and protein expression principles  .....................................................  169 
3.4.1.2. Protein expression ..........................................................................................................................  169 
3.4.1.3. Protein extraction ...........................................................................................................................  169 
3.4.1.4. Protein purification ........................................................................................................................  170 
3.4.2. Mass spectrometric analysis ...................................................................................................................  170 
3.4.3. Fluorescence based LSD1 enzyme assay ...............................................................................................  171 
3.4.4. LNCaP cell growth inhibition assay .......................................................................................................  175 
3.4.5. PSA expression ......................................................................................................................................  178 
3.4.6. Screening of compounds ........................................................................................................................  179 
3.4.6.1. Screening of Taiwanese compounds ..............................................................................................  179 
3.4.6.2. Screening of German compounds ..................................................................................................  181 
A) LSD1 enzyme assay .........................................................................................................................  181 
B) LNCaP cell growth inhibition assay .................................................................................................  183 
C) PSA expression  .................................................................................................................................  183 
3.5. SYNTHESIS OF PHENELZINE ANALOGUES .................................................................... 185 
3.5.1. Route 1 ...................................................................................................................................................  185 
3.5.2. Route 2 ...................................................................................................................................................  186    
vi 
 
3.6. PRELIMINARY STUDIES ON THE BIOLOGY ACTIVITY OF THE PHENELZINE 
ANALOGUES ....................................................................................................................................  189 
3.7. CONCLUSION ...........................................................................................................................  190 
4. CONCLUSIONS AND FUTURE WORK  ............................................................................ 191 
5. EXPERIMENTAL PROCEDURES .................................................................................... 193 
5.1. GENERAL PROCEDURES ......................................................................................................  193 
5.2. EXPERIMENTAL PROCEDURES FOR CHAPTER 1: PROLINE-CONTAINING 
CYCLIC PEPTIDE NATURAL PRODUCTS ................................................................................  195 
5.2.1. Sanguinamide A ..................................................................................................................................... 195 
5.2.2. Sanguinamide B ..................................................................................................................................... 223 
5.2.3. Stylissamide A ....................................................................................................................................... 235 
5.3. EXPERIMENTAL DATA FOR CHAPTER 2 : HISTONE DEACETYLASE 
INHIBITORS ....................................................................................................................................  237 
5.3.1. Experimental procedures for largazole and analogues ........................................................................... 237 
5.3.2. Experimental procedures for thailandepsins and burkholdacs  ................................................................ 275 
5.3.2.1. Towards the synthesis of first structures of thailandepsins ............................................................ 275 
5.3.2.2. Total synthesis of Cheng’s revised thailandepsin A  ....................................................................... 278 
5.3.2.3. Total synthesis of the Brady’s proposed diastereomer ................................................................... 285 
5.3.2.4. Total synthesis of epi-burkholdac B............................................................................................... 292 
5.3.2.5. Total synthesis of burkholdac B  ..................................................................................................... 299 
5.4. EXPERIMENTAL DATA FOR CHAPTER 3: HISTONE DEMETHYLASE INHIBITORS
 .............................................................................................................................................................  306 
5.4.1. Tranylcypromine analogues ................................................................................................................... 306 
5.4.1.1. Synthesis of tranylcypromine analogues ........................................................................................ 306 
5.4.1.2. Biological testing of tranylcypromine analogues ........................................................................... 320 
5.4.2. Phenelzine analogues ............................................................................................................................. 327 
5.4.2.1. Synthesis of phenelzine analogues ................................................................................................. 327 
5.4.2.2. Biological testing of phenelzine ..................................................................................................... 331 
6. APPENDIX ........................................................................................................................... 333 
6.1. X-RAY CRYSTAL STRUCTURE DATA FOR 1.48  ...............................................................  333 
6.2. X-RAY CRYSTAL STRUCTURE DATA FOR 1.59  ...............................................................  335 
6.3. NMR SPECTRA .........................................................................................................................  337 
REFERENCES ........................................................................................................................................................... 437 
 
 
 
    
vii 
 
LIST OF SCHEMES 
 
Scheme 1.1 : Previous retrosynthetic analysis of sanguinamide A ............................................................ 17 
Scheme 1.2 : Retrosynthetic analysis of sanguinamide A .......................................................................... 18 
Scheme 1.3 : Synthesis of the thiazole-containing fragment 1.33  .............................................................. 19 
Scheme 1.4 : Epimerisation at the ʱ-chiral centre of the thiazole ring ....................................................... 19 
Scheme 1.5 : Synthesis of the para-nitro compound 1.48  .......................................................................... 20 
Scheme 1.6 : Thiazole formation using epimerization-free conditions ...................................................... 21 
Scheme 1.7 : Synthesis of the tetrapeptide 1.34 ......................................................................................... 22 
Scheme 1.8 : Synthesis of trans, trans-sanguinamide A ............................................................................ 23 
Scheme 1.9 : New retrosynthesis of sanguinamide A ................................................................................ 28 
Scheme 1.10 : Synthesis of trans, cis-sanguinamide A (1.63) by macrolactamisation between Pro
1 and Ile
.................................................................................................................................................................... 29 
Scheme 1.11 : Alternative retrosynthesis of sanguinamide A .................................................................... 31 
Scheme 1.12 : Synthesis of the dipeptides 1.70 and 1.66  ........................................................................... 32 
Scheme 1.13 : Synthesis of a mixture of conformers of sanguinamide A by macrolactamisation between 
Phe and Pro
2 ............................................................................................................................................... 32 
Scheme 1.14 : Synthesis of [D-Ile]-sanguinamide A ................................................................................. 34 
Scheme 1.15 : Synthesis of [D-allo-Ile]-sanguinamide A  .......................................................................... 35 
Scheme 1.16 : Retrosynthesis of compound 1.81  ....................................................................................... 36 
Scheme 1.17 : Attempt to prepare 1.89 in solution phase .......................................................................... 37 
Scheme 1.18 : Solid phase synthesis of the Cys(tBu) compound 1.101  ..................................................... 39 
Scheme 1.19 : Attempts to prepare sanguinamide A by late thiazole formation from Cys(tBu) compound 
1.101  ........................................................................................................................................................... 40 
Scheme 1.20 : Solid phase synthesis of the Cys(Tr) compound 1.107  ....................................................... 41 
Scheme 1.21 : Attempts to prepare sanguinamide A by late thiazole formation from Cys(Tr) compound 
1.107  ........................................................................................................................................................... 42 
Scheme 1.22 : Retrosynthetic analysis of sanguinamide B ........................................................................ 43 
Scheme 1.23 : Synthesis of dipeptide 1.113  ............................................................................................... 43 
Scheme 1.24 : Synthesis of thiazole-containing fragment 1.119  ................................................................ 44 
Scheme 1.25 : Synthesis of thiazole-oxazole fragment 1.127 .................................................................... 45 
Scheme 1.26 : Synthesis of sanguinamide B .............................................................................................. 46 
Scheme 1.27 : Synthesis of stylissamide A (1.20) ..................................................................................... 54 
Scheme 2.1 : Proposed catalytic mechanism of lysine deacetylation
69 ...................................................... 70 
Scheme 2.2 : Cellular metabolism and mechanisms of HDAC inhibition of FK228 (2.15) and largazole 
(2.18) .......................................................................................................................................................... 77 
Scheme 2.3 : Simon’s synthesis of the β-hydroxy acid 2.36 with the (R) stereochemistry via Carreira 
catalytic asymmetric aldol reaction ............................................................................................................ 81 
Scheme 2.4 : Wentworth and Janda’s synthesis of α,β-unsaturated aldehyde 2.38  .................................... 82    
viii 
 
Scheme 2.5 : Attempt of aldol reaction using oxazolidinethione auxiliary ................................................  82 
Scheme 2.6 : Wentworth and Janda’s synthesis of the β-hydroxy acid 2.36 with the (R) stereochemistry 83 
Scheme 2.7 : Stereoselectivity of different enolates with 2.38 ...................................................................  83 
Scheme 2.8 : Ganesan’s synthesis of the β-hydroxy acid derivative 2.47 ..................................................  84 
Scheme 2.9 : Williams’ synthesis of the β-hydroxy acid 2.36 with the (R) stereochemistry via Noyori 
asymmetric hydrogen transfer reaction  .......................................................................................................  84 
Scheme 2.10 : Katoh’s synthesis of the β-hydroxy acid 2.61 via Julia-Kocienski olefination ...................  85 
Scheme 2.11 : Synthesis of the β-hydroxy ester 2.66 via enzymatic resolution .........................................  86 
Scheme 2.12 : First synthesis of FK228 (2.15) ...........................................................................................  87 
Scheme 2.13 : Wentworth and Janda’s synthesis of FR901375 (2.14) .......................................................  88 
Scheme 2.14 : First synthesis of spiruchostatin A (2.16)  ............................................................................  89 
Scheme 2.15 : Synthesis of fragment 2.86  ..................................................................................................  90 
Scheme 2.16 : Macrolactamisation strategy for FK228 preparation  ...........................................................  91 
Scheme 2.17 : Formation of the statine unit 2.80 .......................................................................................  94 
Scheme 2.18 : Incorporation of the side chain on largazole .......................................................................  94 
Scheme 2.19 : Thiazoline formation via basic condensation ......................................................................  95 
Scheme 2.20 : Thiazoline formation using Charette conditions .................................................................  95 
Scheme 2.21 : Thiazoline formation using Staudinger reduction ...............................................................  95 
Scheme 2.22 : Thiazoline formation by Kelly’s method ............................................................................  96 
Scheme 2.23 : Simultaneous formation of the thiazole and thiazoline rings ..............................................  96 
Scheme 2.24 : Synthesis of the amide isostere of FK228 .........................................................................  102 
Scheme 2.25 : Retrosynthetic analysis of largazole (2.18) .......................................................................  104 
Scheme 2.26 : Synthesis of acetylated Fujita-Nagao auxiliary 2.46 .........................................................  105 
Scheme 2.27 : Synthesis of -hydroxy acid derivative 2.86 .....................................................................  105 
Scheme 2.28 : Retrosynthetic analysis of fragment 2.104 ........................................................................  106 
Scheme 2.29 : Synthesis of fragment 2.147  ..............................................................................................  106 
Scheme 2.30 : Attempt to synthesise fragment 2.104 ...............................................................................  107 
Scheme 2.31 : Synthesis of fragment 2.156  ..............................................................................................  107 
Scheme 2.32 : Protection of (R)-2-methylcysteine ...................................................................................  108 
Scheme 2.33 : Attempt to synthesise fragment 2.162 ...............................................................................  108 
Scheme 2.34 : Synthesis of thiazole-thiazoline fragment 2.165 ...............................................................  109 
Scheme 2.35 : Attempts to synthesise largazole .......................................................................................  110 
Scheme 2.36 : Removal of Alloc protecting group  ...................................................................................  110 
Scheme 2.37 : Synthesis of thiazole fragment 2.147 ................................................................................  111 
Scheme 2.38 : Preparation of (R)-2-methylcysteine hydrochloride (2.157) .............................................  112 
Scheme 2.39 : Synthesis of thiazole-thiazoline fragment 2.109 ...............................................................  112 
Scheme 2.40 : Synthesis of largazole (2.18) .............................................................................................  113 
Scheme 2.41 : Synthesis of largazole analogues 2.179 and 2.180 ............................................................  118 
Scheme 2.42 : Synthesis of largazole analogue 2.181 ..............................................................................  119 
Scheme 2.43 : Attempt to synthesise the valine thioester analogue  ..........................................................  119    
ix 
 
Scheme 2.44 : Simplified reaction scheme of the Fluor de Lys® fluorometric assay  .............................. 121 
Scheme 2.45 : Retrosynthetic analysis of thailandepsins A (2.195) and B (2.196)  .................................. 125 
Scheme 2.46 : Retrosynthetic analysis of thailandepsins A (2.195) and B (2.196)  .................................. 125 
Scheme 2.47 : Synthesis of fragment 2.198 ............................................................................................. 126 
Scheme 2.48 : Synthesis of the carboxylic acid 2.200 ............................................................................. 126 
Scheme 2.49 : Attempts to obtain compound 2.206 from model amide 2.201 ........................................ 127 
Scheme 2.50 : Attempts to synthesise thailandepsin B ............................................................................ 128 
Scheme 2.51 : Attempts to synthesise thailandepsin via aldehyde protection  .......................................... 129 
Scheme 2.52 : Retrosynthesis of thailandepsin A (2.217) with our suggested stereochemistry  ............... 131 
Scheme 2.53 : Retrosynthesis of thailandepsin A (2.217) with our suggested stereochemistry  ............... 132 
Scheme 2.54 : Synthesis of the tetrapeptide fragment 2.224  .................................................................... 132 
Scheme 2.55 : Synthesis of 2.219 by hydrolysis of 2.47 .......................................................................... 133 
Scheme 2.56 : Synthesis of thailandepsin A (2.217) ................................................................................ 133 
Scheme 2.57 : Retrosynthesis of burkholdac B (2.29) with Brady’s predicted stereochemistry .............. 135 
Scheme 2.58 : Synthesis of Brady’s predicted diastereomer 2.29 (L-Ile, D-Cys and L-Met) .................. 136 
Scheme 2.59 : Synthesis of the diastereomer 2.237 (D-Ile, D-Cys and D-Met)....................................... 138 
Scheme 2.60 : Synthesis of the burkholdac B (D-allo-Ile, D-Cys and D-Met) ........................................ 140 
Scheme 3.1 : Mechanism of demethylation by LSD1 on H3K4 .............................................................. 148 
Scheme 3.2 : Mechanism of inactivation of LSD1 by 3.12  ...................................................................... 152 
Scheme 3.3 : Mechanism of inactivation of LSD1 by tranylcypromine .................................................. 153 
Scheme 3.4 : Mechanism of inactivation of MAOB by tranylcypromine ................................................ 154 
Scheme 3.5 : Proposed mechanism of LSD1 inactivation by phenelzine ................................................ 159 
Scheme 3.6 : Demethylation of trimethyl-lysine by the Jumonji proteins ............................................... 161 
Scheme 3.7 : Retrosynthetic analysis of tranylcypromine derivatives ..................................................... 163 
Scheme 3.8 : Attempts to prepare tranylcypromine analogues via rhodium catalysed cyclopropanation 164 
Scheme 3.9 : Asymmetric synthesis of tranylcypromine analogues with (1S, 2R) stereochemistry ........ 165 
Scheme 3.10 : Resolution of (±) racemic tranylcypromine ...................................................................... 166 
Scheme 3.11 : Asymmetric synthesis of tranylcypromine analogues with (1R, 2S) stereochemistry ...... 167 
Scheme 3.12 : Synthesis of the biphenyl tranylcypromine analogues via Suzuki coupling ..................... 167 
Scheme 3.13 : Oxidation of Amplex® Red (3.75) to resorufin (3.76) by hydrogen peroxide and HRP .. 172 
Scheme 3.14 : Retrosynthetic analysis of para- bromo- and phenyl- phenelzine derivatives .................. 185 
Scheme 3.15 : Attempts to synthesise phenelzine analogues ................................................................... 186 
Scheme 3.16 : New retrosynthesis of para- bromo- and phenyl- phenelzine derivatives ........................ 186 
Scheme 3.17 : Synthesis of the bromo- phenelzine derivative ................................................................. 187 
Scheme 3.18: Synthesis of the phenyl- phenelzine derivative ................................................................. 187    
x 
    
xi 
 
LIST OF FIGURES 
 
Figure 1.1: Representation of the chemical space occupied by combinatorial compounds (a), natural 
product database (b) and drugs database (c)
2 “Reprinted from Current Opinion in Chemical Biology, 8, 
Ortholand J.-Y.; Ganesan A., Natural products and combinatorial chemistry: back to the future, 271-280, 
Copyright (2004), with permission from Elsevier.” ..................................................................................... 1 
Figure 1.2 : Structures of taxol (1.1), trabectedin (1.2) and cyclosporin A (1.3) ......................................... 2 
Figure 1.3 : The two possible conformations for the amide peptide bond ................................................... 3 
Figure 1.4: The two possible conformations for the proline peptide bond ................................................... 4 
Figure 1.5 : Structures of yunnanins A (1.4) and C (1.5) ............................................................................. 5 
Figure 1.6 : Structures of phakellistatins 1 (1.6) and 10 (1.7) ...................................................................... 6 
Figure 1.7 : Structure of phakellistatin 2 (1.8) ............................................................................................. 6 
Figure 1.8 : Structure of phakellistatin 5 (1.9) ............................................................................................. 7 
Figure 1.9 : Structures of natural product phakellistatins 7 (1.10), 8 (1.11) and 9 (1.12) ............................ 8 
Figure 1.10 : Structure of phakellistatin 11 (1.13) ....................................................................................... 9 
Figure 1.11 : Structure of the major isomer hymenamide C (1.14)  .............................................................. 9 
Figure 1.12 : Structures of stylopeptide 2 (1.15), axinellins A (1.16) and B (1.17) and axinastatins 2 (1.18) 
and 3 (1.19) ................................................................................................................................................ 10 
Figure 1.13 : Structures of stylissamides A - D.......................................................................................... 11 
Figure 1.14 : Structures of stylisins 1 (1.24) and 2 (1.25) .......................................................................... 12 
Figure 1.15 : Structures of cis, cis-ceratospongamide (1.26) and trans, trans-ceratospongamide (1.27) .. 12 
Figure 1.16 : Structure of mollamide (1.28) ............................................................................................... 13 
Figure 1.17 : Structures of sanguinamides A and B ................................................................................... 14 
Figure 1.18 : Structures of EDCI.HCl (1.35) and PyBOP (1.36) ............................................................... 18 
Figure 1.19 : X-Ray structure of the para-nitro compound 1.48................................................................ 21 
Figure 1.20 : Equilibrium between the two forms of the TFAA.pyridine complex ................................... 22 
Figure 1.21 : Structure of HATU (1.57)  ..................................................................................................... 23 
Figure 1.22 : Atom numbering used for sanguinamide A .......................................................................... 24 
Figure 1.23 : 
1H NMR of trans, trans-sanguinamide A (1.59) in CDCl3 run at 25 ºC ............................... 25 
Figure 1.24 : 
1H NMR of trans, trans-sanguinamide A (1.59) in CDCl3 run at –10 ºC ............................. 25 
Figure 1.25 : X-Ray structure of trans, trans-sanguinamide A (1.59) ....................................................... 27 
Figure 1.26 : Structures of the synthetic material 1.59 and the natural product cis, cis-sanguinamide A 
(1.29) .......................................................................................................................................................... 27 
Figure 1.27 : Structure of the peptide 1.90 ................................................................................................. 37 
Figure 1.28 : Structure of the Wang resin .................................................................................................. 37 
Figure 1.29 : Structure of DIC (1.92) ......................................................................................................... 38 
Figure 1.30 : Structures of the synthetic material 1.130 with the atom numbering used and the natural 
product sanguinamide B (1.30) .................................................................................................................. 47 
Figure 1.31 : Structures of the different compounds tested  ........................................................................ 51    
xii 
 
Figure 1.32 : Comparison of the 
1H NMR of natural (blue) and synthetic (red) stylissamide A in DMSO-
d6
55 .............................................................................................................................................................  56 
Figure 1.33 : Co-injection on LC/MS of natural and synthetic stylissamide A in equal concentration 
ratio
55 ..........................................................................................................................................................  56 
Figure 1.34 : Effect of stylissamide A on cap-dependent and HCV IRES-dependent translation in Krebs-2 
cell extracts
55 ..............................................................................................................................................  58 
Figure 1.35 : Effect of stylissamide A on cap-dependent and HCV IRES-dependent translation in rabbit 
reticulocytes lysate
55 ...................................................................................................................................  58 
Figure 1.36 : Effect of stylissamide A on cap-dependent translation in wheat germ extract
55 ...................  59 
Figure 1.37 : Effect of stylissamide A on translation in yeast extract
55 ......................................................  59 
Figure 1.38 : Effect of stylissamide A on the assembly of initiation complex
55 .........................................  60 
Figure 1.39 : Effect of stylissamide A on actively translating ribosomes
55 ................................................  61 
Figure 1.40 : Effect of stylissamide A on the translation after injection into oocytes
55  ..............................  61 
Figure 2.1 : Simplified representation of the nucleosome “Reprinted with permission from Access 
excellence the national health museum.” ....................................................................................................  65 
Figure 2.2 : Regulation of the transcription by acetylation/deacetylation ..................................................  66 
Figure 2.3 : Structures of SAHA (2.1) and TSA (2.2) ................................................................................  68 
Figure 2.4 : X-ray structure of TSA in the active site of HDLP
69 “Reprinted by permission from 
Macmillan Publishers Ltd: [Nature] (Finnin, M. S. et al., 401, 1999, 188-193), copyright (1999).” .........  69 
Figure 2.5 : Structures of valproic acid (2.3) and sodium phenylbutyrate (2.4) .........................................  71 
Figure 2.6 : Structure of Entinostat (2.5) ....................................................................................................  71 
Figure 2.7: Structures of HC-toxin (2.6), trapoxin B (2.7) and chlamydocin (2.8) ....................................  72 
Figure 2.8 : Structures of azumamides A-E ................................................................................................  73 
Figure 2.9 : Structures of FR901375 (2.14), FK228 (2.15), spiruchostatins (2.16-2.17) and largazole 
(2.18) ..........................................................................................................................................................  75 
Figure 2.10 : Proposed biosynthesis of FK228
81 “Reprinted from Applied and Environmental 
Microbiology, 73, Cheng, Y.-Q.; Matter A. M., Characterization of a Gene Cluster Responsible for the 
Biosynthesis of Anticancer Agent FK228 in Chromobacterium violaceum No. 968, 3460-3469, Copyright 
(2007), with permission from American Society for Microbiology.”  .........................................................  76 
Figure 2.11 : Structures of thailandepsins A (2.21), B (2.22) and C (2.23) ................................................  78 
Figure 2.12 : Structures of thailandepsins A (2.24) and B (2.25) ...............................................................  78 
Figure 2.13 : Structures of Burkholdacs .....................................................................................................  79 
Figure 2.14 : Gene cluster and proposed biosynthesis of burkholdacs
84 “Reprinted with permission from 
Biggins, J. B.; Gleber, C. D.; Brady, S. F. Org. Lett. 2011, 13, 1536-1539, copyright (2011) American 
Chemical Society.” .....................................................................................................................................  79 
Figure 2.15 : Predicted stereochemistry of burkholdacs A (2.28) and B (2.29) .........................................  80 
Figure 2.16 : Final structures of thailandepsins A (2.30) and B (2.31)  .......................................................  80 
Figure 2.17 : Structure of the β-hydroxy acid 2.32 .....................................................................................  81 
Figure 2.18 : Structure of MNBA (2.84) ....................................................................................................  89 
Figure 2.19 : Different strategies employed for the preparation of largazole .............................................  92    
xiii 
 
Figure 2.20 : Macrolactamisation failed because of the presence of –OTBS group .................................. 92 
Figure 2.21 : Structure of the statine subunit ............................................................................................. 93 
Figure 2.22 : Structures of tamandarins A and B, melleumin A and miraziridine A ................................. 93 
Figure 2.23 : Reported analogues of FK228 .............................................................................................. 97 
Figure 2.24 : Spiruchostatins and epimers ................................................................................................. 98 
Figure 2.25 : Variation of largazole side chain .......................................................................................... 98 
Figure 2.26 : Reported analogues of largazole with variation in the side chain ......................................... 99 
Figure 2.27 : Reported analogues of largazole with variation in the macrocycle..................................... 100 
Figure 2.28 : Structure of linear compound 2.134  .................................................................................... 101 
Figure 2.29 : Amide isosteres of FK228 and largazole ............................................................................ 101 
Figure 2.30 : Atom numbering used for largazole ................................................................................... 114 
Figure 2.31 : Structures of FR901375, FK228, spiruchostatins and largazole ......................................... 116 
Figure 2.32 : Structures of largazole thiol and the proposed analogues ................................................... 117 
Figure 2.33 : Western blotting of acH4K8 in MCF7, MDA-MB-231 and SKBr3 cell lines with DMSO 
control, largazole and largazole thiol ....................................................................................................... 120 
Figure 2.34 : HDAC inhibition and growth inhibition of largazole thiol (2.178) and largazole (2.18).... 121 
Figure 2.35 : Structures of thailandepsins A (2.21), B (2.22) and C (2.23) ............................................. 124 
Figure 2.36 : Suggested stereochemistry of thailandepsins A (2.195), B (2.196) and C (2.197) ............. 124 
Figure 2.37 : Revised structures of thailandepsins A (2.24) and B (2.25)  ................................................ 130 
Figure 2.38 : Structures of burkholdacs ................................................................................................... 134 
Figure 2.39 : 
1H NMR spectra of burkholdac B published by Brady
84 in CD2Cl2 (600 MHz) “Reprinted 
with permission from Biggins, J. B.; Gleber, C. D.; Brady, S. F. Org. Lett. 2011, 13, 1536-1539, 
copyright (2011) American Chemical Society.” ...................................................................................... 137 
Figure 2.40 : 
1H NMR spectra of Brady’s proposed diastereomer 2.29 in CD2Cl2 (400 MHz) ............... 137 
Figure 2.41 : 
1H NMR spectra of diastereomer 2.237 (D-Ile, D-Cys and D-Met) in CD2Cl2 (400 MHz) 139 
Figure 2.42 : 
1H NMR spectra of diastereomer (D-allo-Ile, D-Cys and D-Met) in CD2Cl2 (400 MHz) .. 141 
Figure 2.43 : Atom numbering used for burkholdac B............................................................................. 141 
Figure 2.44 : Structures of the different synthesised compounds  ............................................................. 143 
Figure 3.1 : X-Ray structure of the complex LSD1 (in blue) and CoREST (red)
147 “Reprinted from Trends 
in Biochemical Sciences, 33, Forneris, F.; Binda, C.; Battaglioli E.; Mattevi A., LSD1: oxidative 
chemistry for multifaceted functions in chromatin regulation, 181-189 Copyright (2008), with permission 
from Elsevier.” ......................................................................................................................................... 149 
Figure 3.2 : Structures of tranylcypromine (3.6), nialamide (3.7), phenelzine (3.8), deprenyl (3.9), 
chlorgyline (3.10) and pargyline (3.11)  .................................................................................................... 151 
Figure 3.3 : Structure of the N
5 adduct (3.20) .......................................................................................... 153 
Figure 3.4 : FAD-PCPA adduct in LSD1
162 “Reprinted with permission from Yang, M. et al.. 
Biochemistry 2007, 46, 8058-8065, copyright (2007) American Chemical Society.” ............................. 154 
Figure 3.5 : Tranylcypromine analogues prepared by McCafferty .......................................................... 155 
Figure 3.6 : Tranylcypromine analogues prepared by Miyata  .................................................................. 156 
Figure 3.7 : Selection of tranylcypromine analogues prepared by Mai .................................................... 157    
xiv 
 
Figure 3.8 : Selection of tranylcypromine analogues prepared by Yokoyama .........................................  158 
Figure 3.9 : Structures of peptide derivatives ...........................................................................................  159 
Figure 3.10 : Structures of biguanide 3.45 and bisguanidine 3.46 inhibitors of LSD1 .............................  160 
Figure 3.11 : Bicyclic compound carbamates ...........................................................................................  168 
Figure 3.12 : Structures of the prepared tranylcypromine analogues (3.70a-h) ........................................  168 
Figure 3.13 : Mass spectrometric analysis of LSD1 activity with the substrate H3K4me2: top graph MS of 
peptide alone, middle graph: peptide with LSD1 and bottom graph: peptide with LSD1 and 
tranylcypromine ........................................................................................................................................  171 
Figure 3.14 : Effect of substrate concentration on the rate of an enzyme catalysed reaction for three 
different concentrations of the enzyme .....................................................................................................  173 
Figure 3.15 : Lineweaver-Burk plot: effect of substrate concentration on the initial rate of an enzyme-
catalysed reaction......................................................................................................................................  173 
Figure 3.16 : Dose response experiments for racemic tranylcypromine, (+)-tranylcypromine and    (–)-
tranylcypromine ........................................................................................................................................  174 
Figure 3.17 : Predicted lipophilicity of the different analogues 3.77, 3.78, 3.79 and 3.80 using ChemDraw
 ..................................................................................................................................................................  176 
Figure 3.18 : PSA expression following treatment with the different analogues  ......................................  178 
Figure 3.19 : PSA expression following treatment with different analogues ...........................................  179 
Figure 3.20 : Analogues less active than tranylcypromine in LSD1 enzyme assay ..................................  180 
Figure 3.21 : Fluorinated phenylcyclopropylamine analogues less active than tranylcypromine in LSD1 
enzyme assay ............................................................................................................................................  182 
Figure 3.22 : PSA expression following treatment with the fluorinated phenylcyclopropylamines .........  184 
Figure 3.23 : Tranylcypromine derivatives to prepare in the future .........................................................  184 
Figure 3.24 : Synthetic phenelzine and commercially available hydrazine derivatives tested .................  189 
    
xv 
 
LIST OF TABLES 
 
Table 1.1 : 
1H and 
13C NMR data in ppm for synthetic trans, trans-sanguinamide A and natural
32 cis, cis-
sanguinamide A in CDCl3 (see figure 1.22 for numbering) ....................................................................... 26 
Table 1.2 : 
1H and 
13C NMR data in ppm for synthetic trans, cis-sanguinamide A and natural
32 cis, cis-
sanguinamide A in CDCl3 (see figure 1.22 for numbering) ....................................................................... 30 
Table 1.3 : 
1H and 
13C NMR data in ppm for synthetic cis, cis-sanguinamide B and natural
32 trans, trans-
sanguinamide B in CDCl3 .......................................................................................................................... 48 
Table 1.4 : Single point energies of sanguinamide A calculated at BLYP-D/SV(P) geometries with 
solvation in chloroform .............................................................................................................................. 49 
Table 1.5 : Single point energies of sanguinamide A calculated at BLYP-D/SV(P) geometries with 
solvation in chloroform .............................................................................................................................. 50 
Table 1.6 : Minimum inhibitory concentrations in µM for different rotamers and derivatives of 
sanguinamides A and B  .............................................................................................................................. 52 
Table 1.7 : Inhibition in percentage of tyrosine kinase by the different rotamers and derivatives of 
sanguinamides A and B at a concentration of 100 µM .............................................................................. 53 
Table 2.1 : Collected and reported
80 
1H and 
13C NMR data in ppm for largazole in CDCl3 .................... 115 
Table 2.2 : HDAC inhibition and growth inhibition of largazole and related analogues ......................... 122 
Table 2.3 : Half-life of largazole and related analogues  ........................................................................... 123 
Table 2.4 : Comparative table of reported
83 and corrected formula and molecular weight (Mw) for the 
different thailandepsins ............................................................................................................................ 130 
Table 2.5 : Difference between collected 
1H and 
13C NMR data for the three diastereomers 2.29, 2.237 
and 2.243 with that
84 of reported in the literature (values in ppm are written in red if 
1H Δδ > 0.1 ppm and 
if 
13C Δδ > 1 ppm) .................................................................................................................................... 142 
Table 2.6 : HDAC inhibition and cell growth inhibition for the different isomers prepared ................... 144 
Table 3.1 :Activity of the tranylcypromine derivatives in LSD1 enzyme assay and LNCaP growth 
inhibition .................................................................................................................................................. 177 
Table 3.2 : Ki(inact) table of potent Taiwanese compounds ........................................................................ 180 
Table 3.3 : Ki(inact) values of the potent fluorinated phenylcyclopropylamine analogues ......................... 181 
Table 3.4 : Activity of the fluorinated phenylcyclopropylamines in LNCaP growth inhibition .............. 183 
Table 3.5 : Optimisation of the Suzuki coupling reaction ........................................................................ 188 
Table 5.1 : Activity of the tranylcypromine derivatives in LSD1 enzyme assay ..................................... 323 
Table 5.2 : Activity of the tranylcypromine derivatives in LNCaP growth inhibition ............................. 324 
Table 5.3 : Activity of the German compounds in LNCaP growth inhibition  .......................................... 326 
Table 5.4 : Activity of phenelzine in LNCaP growth inhibition .............................................................. 331 
    
xvi 
    
xvii 
 
DECLARATION OF AUTHORSHIP 
 
I, Hanae Benelkebir declare that the thesis entitled “Synthesis of cyclic peptide natural 
products and inhibitors of histone modifying enzymes” and the work presented in the 
thesis are both my own, and have been generated by me as the result of my own original 
research. I confirm that: 
 
  this work was done wholly or mainly while in candidature for a research degree at 
this University; 
  where any part of this thesis has previously been submitted for a degree or any other 
qualification at this University or any other institution, this has been clearly stated; 
  where  I  have  consulted  the  published  work  of  others,  this  is  always  clearly 
attributed; 
  where I have quoted from the work of others, the source is always given. With the 
exception of such quotations, this thesis is entirely my own work; 
  I have acknowledged all main sources of help; 
  where the thesis is based on work done by myself jointly with others, I have made 
clear exactly what was done by others and what I have contributed myself; 
  parts of this work have been published as:  
 
Total synthesis and stereochemical assignment of burkholdac B, a depsipeptide HDAC inhibitor 
Benelkebir, H.; Donlevy, A. M.; Packham, G.; Ganesan, A. Org. Lett. 2011, 13, 6334-6337. 
 
Total  synthesis  of  largazole  and  analogues:  HDAC  inhibition,  antiproliferative  activity  and 
metabolic stability Benelkebir H.; Marie S.; Hayden A.; Lyle J.; Loadman P.; Packham G.; Ganesan A. 
Bioorg. Med. Chem. 2011, 19, 3650-3658. 
 
Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors 
Benelkebir H.; Hodgkinson C.; Duriez P. J.; Hayden A.; Bullied R.; Crabb S. J.; Packham G.; Ganesan A. 
Bioorg. Med. Chem. 2011, 19, 3709-3716. 
 
 
Signed:.………………………………...... 
Date:………………………………….......   
xviii 
    
xix 
 
ACKNOWLEDGEMENTS 
 
I am extremely grateful to my supervisors Prof Ganesan and Prof Packham. I would like 
to thank Prof Ganesan for all his help, advice, support and guidance that he brought me 
all along my PhD. It was a real pleasure working under his supervision for four years. I 
also thank Prof Packham for his help in the biology part of my work. I would also like 
to thank my advisor Dr Bruno Linclau for his continuous encouraging feedbacks about 
my work.  
I am really thankful to Dr Patrick Duriez who explained me the biology notions required 
to perform the LSD1 assay.  
I would like to thank also present and past members of the Ganesan group. I especially 
like to thank Lauren Sudlow who has been of a great help and friend to me. I would like 
to thank Anna Dysko, Angus Dell, Niall Dickinson, Agnes Basseur, Maria Tardugno, 
Ed Neal, Ke Liu, Amelie Marotte, Wendy Goh, Irene Ortin, Miriam Serrano, Lauren, 
Sabrina  Marie  and  the  members  of  Karus  for  providing  an  excellent  working 
atmosphere during my PhD. Many thanks go to Dr Franck Silva, Dr Alex Cecil, Dr 
Cyrille Tomassi and Dr Thomas Hill for their scientific assistance especially in peptide 
chemistry that they brought me all along my PhD. I also acknowledge all the students 
who worked on my projects not only for their work but also their enthusiasts such as 
Charlotte  Poillion,  Sebastian  Schwenk,  Christopher  Hodgkinson,  Emma  Packard, 
Danielle Coomber, Wan-Jun Cheng, Chris Asquith and Jessica Dellar. I would also like 
to thank Sabrina for preparing one of the largazole analogues. I thank Desire, Simone, 
Claudia, Marco, Francesca and the others persons from UEA who made my time in 
UEA very enjoyable. I also want to thank Dr Guillaume Boucher, Gunnar Mallon and 
Scott Twiddy for their support.  
Thanks for all the biological testing done by Dr Simon Crabb, Dr Annette Hayden, 
Rosemary  Bulleid,  Alison  Donlevy,  Dr  Bashar  Zeidan,  Prof  Paul  Townsend  at  the 
General hospital in Southampton and Prof Paul Loadman, Jason Lyle in the University 
of Bradford. I would also like to thank Prof Marcel Jaspars, Mostafa Rateb, Dr Wael 
Houssen  and  Dr  Bruce  Milne  for  their  precious  contribution  in  the  sanguinamides 
project. I thank Prof Mark Hamann, Amanda Waters and Anna J. Kochanowska for 
their  work  in  the  stylissamide  project  and  Prof  Mark  Hamann  for  allowing  me  to 
participate to this project. I would like to thank Neil Wells for his assistance in NMR,    
xx 
 
Julie  Herniman  for  her  help  in  mass  spectrometry  and  Mark  Light  for  the  crystal 
structures. I also thank Professor Günter Haufe and Weir-Torn Jiaang, Yu-Sheng Chao 
and Ting-Yueh Tsai for their tranylcypromine analogues. 
I am very grateful to my family for their encouragement and precious support during 
these years.  
I am once more very grateful and thankful to Prof Ganesan and Dr Lauren Sudlow who 
both proof-read my thesis and corrected the numerous English grammar and misspelling 
mistakes. A big thank you also goes to Angus Dell, Dr Patrick Duriez, Niall Dickinson 
and Amelie Marotte for proof-reading parts of my thesis.  
I would like to thank Cancer Research UK for the funding as this research would not 
have been possible without their financial support.  
    
xxi 
 
ABBREVIATIONS 
 
[]      specific rotation 
Ac      acetyl 
Aib      aminoisobutyric acid 
All      allyl 
Alloc     allyloxycarbonyl 
Aoe      (S)-2-amino-9,10-epoxy-8-oxodecanoic acid  
aq      aqueous 
AR      androgen receptor 
Boc      tert-butoxycarbonyl 
BOP    benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate 
bp      boiling point 
br      broad  
calcd     calculated 
COSMO    conductor-like screening model 
COSY    correlation spectroscopy 
δ      chemical shift in parts per million 
d      day(s), doublet (NMR) 
DABCO    1,4-diazabicyclo[2.2.2]octane 
DAST    diethylaminosulfur trifluoride 
DBU     1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC     N,N’-dicyclohexylcarbodiimide 
DCE     1,2-dichloroethane 
DDQ     2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD    diethylazocarboxylate 
DEPT    distortionless enhancement through polarization transfer 
DFT      density functional theory 
Dhb      dehydrobutyrine 
DIBAL    diisobutylaluminium hydride 
DIC      N,N'-diisopropylcarbodiimide 
DIAD    diisopropylazodicarboxylate 
DIPA      diisopropylamine 
DIPEA    N,N'-diisopropylethylamine 
DMAP    4-(N,N-dimethylamino)pyridine 
DME     1,2-dimethoxyethane 
DMF     dimethylformamide 
DMP     Dess-Martin periodinane 
DMPU    1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMSO    dimethyl sulfoxide 
DNA     deoxyribonucleic acid    
xxii 
 
DPPA    diphenylphosphoryl azide 
dr      diastereomeric ratio 
DTT     dithiothreitol 
EAM     energy absorbing molecule 
EDCI      1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
EDT     ethane dithiol 
ee      enantiomeric exces 
EI      electron impact 
equiv     equivalent 
ER      estrogen receptor 
ES
–      negative electrospray 
ES
+      positive electrospray 
ESI      electrospray ionisation 
Et      ethyl 
FAD     flavin adenine dinucleotide 
Fmoc     9-fluorenylmethoxycarbonyl 
h      hour 
HAT     histone acetyltransferases 
H3K4    lysine residue 4 of histone protein 3 
HATU    2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate 
HBTU    2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate 
HCV     hepatitis C virus 
HDAC    histone deacetylase inhibitor 
HIV      Human immunodeficiency virus 
HMT     histone methyltransferase 
HKMT    histone lysine methyltransferase 
HRMT    histone arginine methyltransferase 
HOBt    hydroxybenzotriazole 
HPLC    high-performance liquid chromatography 
HRMS    high-resolution mass spectrometry 
HRP     horseradish peroxidase 
Hz      hertz 
IC50      half maximal inhibitory concentration 
IPTG     isopropyl-β-D-thiogalactopyranoside 
IR      infrared 
IRES     internal ribosomal entry sites 
J      coupling constant 
Ki      inhibition constant 
LDA     lithium diisopropylamide 
LSD1    lysine-specific demethylase 1 
m      multiplet    
xxiii 
 
MAO     monoamine oxidase 
MCF7    Michigan Cancer Foundation 7 
Me      methyl 
MIC      minimum inhibitory concentration 
min      minute 
MNBA    2-methyl-6-nitrobenzoic anhydride 
mp      melting point 
mRNA    messenger ribonucleic acid 
MS      mass spectrometry 
MSNT    1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole 
Mult     multiplicity 
MW      Molecular weight or microwave 
NAD
+    nicotinamide adenine dinucleotide 
NMP     N-methylpyrrolidone 
NMR     nuclear magnetic resonance 
NOE     nuclear Overhauser effect 
NOESY    nuclear Overhauser effect spectroscopy 
OPA     o-phthalaldehyde 
Oxz      oxazole 
PAL  5-[4-(9-fluorenylmethyloxycarbonyl)aminomethyl-3,5-dimethoxy-
phenoxy] valeric acid 
PCPA    trans-2-phenylcyclopropylamine = tranylcypromine 
PFP      pentafluorophenol 
PG      protecting group 
Ph      phenyl 
Pi      isoelectric point 
PMB     p-methoxybenzyl 
PMP     p-methoxyphenyl 
ppm      parts per millions 
PPTS     pyridinium para-toluenesulfonate 
PSA      prostate-specific antigen 
PyBOP    benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
q      quartet 
quin      quintet 
Red-Al    sodium bis(2-methoxyethoxy)aluminumhydride 
Rf      retention factor 
RFU     relative fluorescence unit 
RNA     ribonucleic acid 
rt      room temperature 
s      singlet 
SAHA    suberoylanilide hydroxamic acid 
SAM     S-adenosylmethionine 
SAR     structure-activity relationships 
SCX     strong cation-exchanger    
xxiv 
 
SELDI    surface-enhanced laser desorption/ionization 
SEM     standard error of the mean 
siRNA     small interfering ribonucleic acid 
SPPS     solid phase peptide synthesis 
spt      septet 
STDEV    standard deviation 
sxt      sextet 
t      triplet 
TBAF    tetra-n-butylammonium fluoride 
TBDA    tert-butyldiazoacetate 
TBDPS    tert-butyldiphenylsilyl 
TBS      tert-butyldimethylsilyl 
Tce      trichloroethyl 
TES      triethylsilyl 
Tf      trifluoromethanesulfonyl 
TFA      trifluoroacetic acid 
TFAA    trifluoroacetic acid anhydride 
THF      tetrahydrofuran 
Thz      thiazole 
TIS or TIPS  triisopropylsilane 
TLC      thin layer chromatography 
TMS     trimethylsilyl 
TMSE    trimethylsilyl ethyl 
TOF      time-of-flight 
Tr      triphenylmethyl (trityl) 
Ts      para-toluenesulfonyl (tosyl) 
TSA      trichostatin A 
                   Proline-Containing Cyclic Peptide Natural Products 
1 
 
1. PROLINE-CONTAINING  CYCLIC  PEPTIDE 
NATURAL PRODUCTS 
 
1.1. INTRODUCTION 
 
1.1.1. Natural products 
 
Natural products are produced by living organisms and come from various origins such 
as plants, animals or microorganisms.
1 They have been the source of numerous leads for 
medicinally important drugs for many years.
2  
For a time, combinatorial chemistry became the method of choice for drug discovery in 
pharmaceutical companies. Some companies stopped developing their natural product 
database  and  concentrated  their  efforts  on  synthetic  compounds.  With  time,  they 
realised that natural products are very important in drug discovery. In fact, statistics 
show  that  the  numbers  of  drugs  discovered  decreased  and  that  natural  products 
remained the major source of new drugs. A total of 24 natural products isolated between 
1970 and 2006 led to an approved drug.
3 A study was carried out in order to compare 
the chemical space occupied by combinatorial compounds to natural product and drug 
databases  (Figure  1.1).
2  It  showed  that  natural  products  present  a  greater  chemical 
diversity  and  cover  a  larger  chemical  space  than  synthetic  compounds  which  only 
occupies a limited chemical space. The pattern of the chemical space of natural product 
database and drug database displays more similarities. 
 
 
Figure 1.1: Representation of the chemical space occupied by combinatorial compounds (a), natural 
product database (b) and drugs database (c)
2 
“Reprinted from Current Opinion in Chemical Biology, 8, Ortholand J.-Y.; 
Ganesan A., Natural products and combinatorial chemistry: back to the future, 271-280, Copyright (2004), with permission from Elsevier.”
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Natural  products  contain  more  oxygen  atoms  but  fewer  halogen  or  sulfur  atoms 
compared  to  synthetic  compounds.  They  also  display  more  complex  features  with 
numerous rings and chiral centres. For example, the well-known taxol (1.1), isolated 
from the bark of the Pacific yew tree, Taxus brevifolia, has a highly complex structure 
with  eleven  stereocentres  and  seven  rings.
4  It  is  a  mitotic  inhibitor  involving  the 
stabilization of microtubules and clinically used for treating several types of cancer 
including lung, breast and ovarian cancer.
4 Trabectedin (1.2) was isolated from a marine 
source: the sea squirt Ecteinascidia turbinata.
5 It is an anti-tumour agent used for the 
treatment of advanced soft tissue sarcoma. Its complex structure contains nine rings and 
seven  chiral  centres.  Cyclosporin  A  (1.3),  isolated  from  the  fungus  Tolypocladium 
inflatum, is a cyclopeptide containing eleven amino acids.
6 It is an immunosuppressant 
drug used during organ transplants to reduce the risk of organ rejection. Cyclosporin A 
is a drug even though its characteristics do not follow the Lipinski’s rule of five.
7 These 
three  natural  products  became  drugs  without  modification  and  illustrate  the  diverse 
structures of natural products along with their various origins and biological activities. 
 
 
Figure 1.2 : Structures of taxol (1.1), trabectedin (1.2) and cyclosporin A (1.3) 
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As  these  natural  products  are  often  isolated  in  small  quantities,  it  is  necessary  to 
synthesise them to allow them to be tested for their biological activity. Furthermore, 
synthesis allows the preparation of unnatural analogues for SAR studies.  
 
1.1.2. Proline-containing cyclic peptides 
 
The amide group, abundant in all living organisms, is a very important group as it is the 
link between the amino acids in peptides and proteins. Several coupling reactions are 
available to synthetically prepare amides.
8 Delocalization of the lone pair electrons from 
nitrogen to the carbonyl group is responsible for the stability of the proteins.
9 This gives 
the C-N bond some double-bond character due to conjugation and thus, no rotation is 
possible around this bond.
9 Due to this restricted rotation, two isomers are possible: the 
cis and trans isomer (Figure 1.3). The latter is more common in nature as the hydrogen 
of the amide has less interaction with the substituent of the carbonyl group.  
 
 
Figure 1.3 : The two possible conformations for the amide peptide bond 
 
Cyclic peptides represent an important family of biologically active natural products. 
They have a wide range of pharmaceutical properties such as cytotoxicity, anticancer, 
antiviral, antifungal and anti-inflammatory activity.
10 The fact that cyclopeptides do not 
possess the ionised C- and N-termini present in linear peptides makes them more cell 
permeable.
10  They  display  a  greater  bioavailability  and  resistance  to  enzymatic 
degradation than their non cyclic analogues and possess a more rigid structure.
10 
 
Many  biologically  important  cyclic  peptide  sequences  and  natural  products  contain 
multiple proline residues. Proline is the only amino acid with a secondary amino group 
based on a pyrrolidine. As seen previously for peptide bonds, the proline amide bond 
can also exist in trans or cis conformations (Figure 1.4). Although the trans amide bond 
is  more  common,  the  occurrence  of  cis  geometry  is  more  frequent  for  the  proline 
peptide bond than for other amino acids.
11 The frequency of cis proline peptide bond is 
higher in cyclic peptides than in linear peptides.
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Cambridge Structural Database showed that 57.4% of proline residues present in cyclic 
peptides were in the cis conformation compared to only 5.6% in acyclic peptides.
12 The 
reason  for  this  high  proportion  of  cis  proline  in  cyclopeptides  is  due  to  the 
conformational restrictions during the cyclisation step.
12 
 
 
Figure 1.4: The two possible conformations for the proline peptide bond 
 
The geometry of the proline amide can be determined on the basis of the difference in 
13C chemical shifts between Cβ and C signals (∆δβ = δβ – δ).
13 A small 
13C chemical 
shift  difference  indicates  that  the  proline  peptide  bond  is  trans  while  a  large 
13C 
chemical shift difference indicates a cis proline residue.  
 
Marine sponges are the main source of proline-rich cyclopeptides. Several examples of 
isolation,  synthesis  and  structural  aspects  of  proline-containing  cyclic  peptides  are 
described in the next section. 
 
1.1.2.1. Yunnanins 
Yunnanins  A  and  C  are  cyclic  heptapeptides  isolated  from  the  roots  of  the  plant 
Stellaria yunnanensis containing two and one proline residues respectively (Figure 1.5). 
Paloma  et  al.  prepared  these  cyclic  peptides  by  solid  phase  synthesis.
14  Synthetic 
yunnanin A displayed the identical proline peptide bond conformation when compared 
to the natural product (both trans). Synthesis of yunnanin C gave a complex mixture of 
a  major  isomer  (trans-Pro)  identical  to  the  natural  yunnanin  C  and  two  different 
rotamers  with  both  cis  conformation  for  the  unique  proline  residue.  The  synthetic 
products displayed weaker biological activity against cancer cell lines even though they 
are identical to natural products. The two conformers of yunnanin C presented a similar 
biological result. Paloma and co-workers gave two different hypotheses to explain this 
surprising result. The first is that traces of a cytotoxic compound responsible for the 
biological activity are retained by the natural cyclopeptides. The second explanation is                   Proline-Containing Cyclic Peptide Natural Products 
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that subtle conformational changes of the prolyl residues are responsible for the activity 
of the natural product. 
 
 
Figure 1.5 : Structures of yunnanins A (1.4) and C (1.5) 
 
1.1.2.2. Phakellistatins 
Phakellistatins were isolated from a marine sponge Phakellia.
15,16 
 
Paloma and co-workers also prepared phakellistatins 1 and 10, a hepta- and octapeptide 
both containing three proline residues (Figure  1.6).
14 They used solid phase peptide 
synthesis with 2-chlorotrityl chloride resin and Fmoc/tBu strategy. Proline structural 
conformation in the synthetic phakellistatin 1 is identical to the natural product (all cis-
Pro). The synthetic octacyclopeptide phakellistatin 10 also possesses identical proline 
geometries as the natural product (all trans-Pro). Even though the synthetic compounds 
have identical connectivity and rotamers to the natural product, the synthetic and natural 
products did not exhibit the same biological activities against cancer cell lines. The 
conclusion they gave is identical to that of yunnanins. 
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Figure 1.6 : Structures of phakellistatins 1 (1.6) and 10 (1.7) 
 
Phakellistatin 2 (1.8) was  isolated by Pettit (Figure  1.7).
17  The natural product  was 
found  to  possess  all  cis  proline  geometry  for  the  peptide  bonds.
18  Kessler  prepared 
phakellistatin 2 by solid phase synthesis with the macrolactamisation between the two 
isoleucine residues (Ile
3-Ile
4).
19 The NMR they obtained did not match the NMR of the 
natural  product.  They  concluded  that  a  mistake  in  the  structure  assignment  was 
previously made. They actually made a different conformer (trans-Pro
2, trans-Pro
5, cis-
Pro
7).
18 Later on, Pettit prepared phakellistatin 2 in solution phase with cyclisation at 
Pro
2-Ile
3 peptide linkage.
20 They believed that the cyclisation at the proline linkage is 
turn inducing. The NMR they obtained matched the NMR of the natural compound 
exactly however the biological activities of the synthetic and natural product differed. 
They believed that the cyclic peptide is able to complex a potent antineoplastic agent 
which is not detectable by spectroscopic analysis and is responsible for the biological 
potency of the natural product. 
 
 
Figure 1.7 : Structure of phakellistatin 2 (1.8) 
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Phakellistatin  2  was  isolated  as  two  separable  conformers.
18  They  studied  their 
conformations and realised that one conformation had all cis proline like the natural 
product  while  the  other  had  trans-Pro
2,  cis-Pro
5,  cis-Pro
7.  The  conformation  was 
changing depending on the polarity of the solvent used: in polar solvent, (methanol) the 
first  form  was  obtained  and  in  less  polar  solvent  (chloroform)  the  second  form  is 
detected. They tested the compounds in solvents of different polarity to find which gave 
the best biological result; this was obtained in the polar solvent methanol.  
 
Pettit and co-workers prepared phakellistatin 5 (1.9) which structure is a perfect match 
with the natural product. They obtained the same conformer in two different ways, by 
solution phase (macrolactamisation between proline and phenylalanine residues) and by 
solid  phase  synthesis  with  PAL  resin  (macrolactamisation  between  asparagine  and 
alanine residues). Nonetheless, the synthetic compound is not biologically identical to 
the natural product in cancer cell growth inhibition.
21 They gave the same hypothesis as 
for  phakellistatin  2  that  the  cyclopeptide  is  capturing  an  active  and  undetectable 
antineoplastic agent.  
 
 
Figure 1.8 : Structure of phakellistatin 5 (1.9) 
 
Paloma  et  al.  also  prepared  the  decapeptides  phakellistatins  7-9  by  Fmoc/tBu  solid 
phase method with 2-chlorotrityl chloride resin.
22 All three compounds contain four 
proline residues present as two prolylproline fragments. The synthesis of phakellistatin 
7 gave a unique conformer identical to the natural product (trans-Pro
1, cis-Pro
2, trans-
Pro
7, cis-Pro
8), whereas the proline geometry in the synthetic phakellistatins 8 and 9 
differed from  the  natural  product.  Both  syntheses  of phakellistatins  8 and 9 gave  a 
mixture of a major isomer (all trans-Pro) and a rotamer with trans-Pro
1, cis-Pro
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Pro
7, trans-Pro
8 bonds. The natural product phakellistatins 8 and 9 displayed trans-Pro
1, 
cis-Pro
2,  trans-Pro
7,  cis-Pro
8  peptide  bonds.  They  also  remarked  that  the  biological 
activity of the natural and synthetic compounds differed, the synthetic phakellistatins 
being  less  potent  in  cancer  cell  line  growth  inhibition.  This  was  expected  for 
phakellistatins 8 and 9 as their conformations differed from that of the natural products 
but  it  is  more  difficult  to  understand  for  phakellistatin  7.  They  believe  that  the 
conformational  changes  occurring  in  the  natural  product  are  responsible  for  the 
biological activity.  
 
 
Figure 1.9 : Structures of natural product phakellistatins 7 (1.10), 8 (1.11) and 9 (1.12) 
 
Synthesis of phakellistatin 11 (1.13) was first attempted by solution phase but issues 
with  the  protecting  groups  led  them  to  use  solid  phase  synthesis  which  gave  the 
cyclopeptide. Both synthetic and natural phakellistatin 11 displayed identical chemical 
characteristics.
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cancer cell lines: the natural product being more active. Pettit et al. once more gave the 
same hypothesis of a potent but undetectable antineoplastic agent being present. 
 
 
Figure 1.10 : Structure of phakellistatin 11 (1.13) 
 
1.1.2.3. Hymenamide C 
Hymenamides  were  isolated  from  a  marine  sponge  Hymeniacidon.  Synthetic 
hymenamide C (1.14) was obtained as a mixture of a major product (cis-Pro
3, trans-
Pro
6) identical to natural product and a minor isomer with cis-Pro
3, cis-Pro
6.
24 Because 
of the presence of glutamine and tryptophan, they used a three-dimensional orthogonal 
solid  phase  method  (Fmoc/tBu/Allyl)  with  PAL  as  resin.  Hymenamide  C  is  a 
micromolar  inhibitor  of  the  elastase  degranulation  release  which  is  important  in 
immunomodulation.  It  could  be  used  to  complement  the  immunosuppressant  drug 
cyclosporine which has a weaker effect on elastase degranulation release. 
 
 
Figure 1.11 : Structure of the major isomer hymenamide C (1.14) 
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1.1.2.4. Stylopeptides, axinellins A and axinastatins  
Several  other  cyclopeptides  have  been  discovered  over  recent  years  such  as 
stylopeptides,  axinellins  and  axinastatins,  a  selection  of  these  is  shown  in  figure 
1.12.
25,26  Stylopeptides  were  isolated  from  the  marine  sponge  Stylotella  sp.
27  For 
example,  stylopeptide  1  (1.15),  a  decapeptide  with  four  proline  residues,  displayed 
micromolar  growth  inhibition  activity  towards  breast  cancer  cell  lines.
27  The 
heptapeptides axinellin A (1.16) and the octapeptide axinellin B (1.17), possessing two 
and three proline residues respectively, were isolated from the marine sponge Axinella 
carteri. Both compounds showed moderate antitumor activity against a lung cancer cell 
line.
26 Axinastatins contain two proline residues and were able to inhibit six different 
cancer cell lines. The synthetic compounds were found to have a significantly lower 
cancer cell growth inhibition activity than the natural products.  
 
 
Figure 1.12 : Structures of stylopeptide 2 (1.15), axinellins A (1.16) and B (1.17) and axinastatins 2 
(1.18) and 3 (1.19) 
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1.1.2.5. Stylissamides and stylisins 
The cyclic heptapeptides stylissamides A-D were isolated from the Caribbean sponge 
Stylissa  caribica  (Figure  1.13).
28  Stylissamides  A,  C  and  D  contain  three  proline 
residues including one  prolylproline segment.  Stylissamide  B possesses  four proline 
residues with three of them linked together (Pro-Pro-Pro linkage). Their structures were 
elucidated by spectroscopic analysis (NMR and mass spectrometry). Marfey’s method 
and the o-phthalaldehyde  method (OPA method) after hydrolysis were  employed to 
assign  the  L-configuration  of  all  the  amino  acid  residues.  The  conformation  of  the 
proline in  the prolylproline segment is  trans, cis as  often observed in  other natural 
products such as phakellistatins 7-9. Stylissamide A was evaluated for antimicrobial or 
cytotoxic activity but it was found to be inactive.  
 
 
Figure 1.13 : Structures of stylissamides A - D 
 
It was unexpected to see that stylisins 1 (1.24) and 2 (1.25), which were isolated from 
the  same  sponge  Stylissa  caribica  as  stylissamides,  were  found  to  be  inactive  even 
though they are very similar to phakellistatin 2.
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anti-malarial, anti-cancer, anti-HIV-1, anti-Mycobacterium tuberculosis (anti Mtb) and 
anti-inflammatory activity yet showed no activity. 
 
 
Figure 1.14 : Structures of stylisins 1 (1.24) and 2 (1.25) 
 
Several cyclic peptides isolated from marine organisms contain in addition to natural or 
unnatural amino acids, five-membered heterocycles such as oxazole, oxazoline, thiazole 
and  thiazoline.  These  five-membered  rings  are  obtained  from  the  biosynthetic 
cyclisation of amino acids such as serine, threonine and cysteine.  
 
1.1.2.6. Ceratospongamide 
Ceratospongamide was  isolated as  two different  isomers:  the major  cis, cis  rotamer 
1.26,  and  the  minor  trans,  trans  rotamer  1.27,  from  the  Indonesian  red  alga 
Ceratodictyon and its symbiotic sponge Sigmadocia symbiotica, by Gerwick et al.
29 
They managed to interconvert the cis, cis isomer to the trans, trans isomer by heating at 
175 ºC in DMSO for 30 min. Trans, trans-Ceratospongamide has anti-inflammatory 
activity whereas cis, cis-ceratospongamide is inactive. The trans, trans-isomer inhibits 
secreted phospholipase A2 (sPLA2) expression in cell-assay which is known to promote 
inflammation (ED50 32 nM). 
29 
 
 
Figure 1.15 : Structures of cis, cis-ceratospongamide (1.26) and trans, trans-ceratospongamide 
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Ceratospongamide was then prepared in solution phase synthesis by Yokokawa and co-
workers.
30  They  obtained  the  cis,  cis  isomer  with  two  different  macrolactamisation 
strategies:  cyclisation  between  thiazole  and  phenylalanine  residue  and  between 
isoleucine and proline peptide linkage. They attempted the thermal interconversion of 
cis, cis to the trans, trans isomer using the conditions described by Gerwick (175 ºC in 
DMSO  for  30  min)  but  only  obtained  a  low  yield  of  10-30%.
30  They  obtained  an 
excellent yield (100%) with heating in DMSO at 100 ºC for a longer time (8 days). 
PPTS as additive reduced the time required for the interconversion to 40 min with a 
75% yield. They have demonstrated that the natural product and the thermodynamic 
compound is not the trans, trans isomer as postulated by Gerwick et al. but the trans, 
trans-[D-allo-Ile]  isomer.
30  An  epimerization  occurred  at  the  ʱ-stereocentre  of  the 
isoleucine residue next to the oxazoline.  
 
1.1.2.7. Mollamide 
Mollamide (1.28) was isolated from the sea squirts Didemnum molle.
31 It contains a 
thiazoline  ring,  several  natural  amino  acids  and  a  modified  serine  residue  with  an 
unusual reverse prenyl unit. This compound is a micromolar inhibitor of several cancer 
cell lines (i.e. murine leukaemia, human lung carcinoma).
31 They obtained the same 
conformer as the natural product using solution phase synthesis.
31 
 
 
Figure 1.16 : Structure of mollamide (1.28) 
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1.1.2.8. Sanguinamides A and B 
Sanguinamides  A  and  B  have  been  isolated  in  microgram  quantities  from  a  single 
specimen of Hexabranchus sanguineus, a nudibranch collected from the Indo-Pacific in 
1987 (Figure 1.17).
32 
 
 
Figure 1.17 : Structures of sanguinamides A and B 
 
The structure elucidation of the cyclic peptides was only reported recently by Molinski 
et al in 2009.
32 The quantities isolated for sanguinamides A (390 µg) and B (190 µg) 
were  insufficient  for  biological  testing.  The  structures  were  elucidated  using 
spectrometric analysis such as NMR and mass spectrometry. They used a 600 MHz 
NMR spectrometer with high-temperature superconducting (HTS) NMR cryoprobe. The 
L-configuration was determined by Marfey’s method. Sanguinamide A is a thiazole-
containing  cyclic  peptide  with  seven  amino  acids  of  the  L-series  comprising  of 
phenylalanine,  proline,  isoleucine  and  alanine.  This  octapeptide  contains  three  five-
membered ring heterocycles (two thiazole rings and one oxazole ring) and five amino 
acid residues comprising of valine, proline, leucine and alanine. Both sanguinamides 
contain two proline residues.  
 
 
The cyclopeptides presented above possess several similarities pointed out by Paloma.
26 
They all come from marine sources and mostly all come from the south Pacific. These 
proline-rich cyclopeptides in general contain seven to eight amino acids even though 
some are larger with ten amino acid residues. They usually include two to four proline 
residues. Most of the amino acids have an L-configuration. Several apolar amino acids                   Proline-Containing Cyclic Peptide Natural Products 
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are  present  in  each  of  these  cyclic  peptides  such  as  alanine,  valine,  leucine  and 
isoleucine.  Most  of  these  cyclopeptides  also  contain  aromatic  residues  such  as 
phenylalanine  or  tyrosine  which  are  next  to  a  proline  residue  in  most  cases.  They 
sometimes also  contain  aspartate or  asparagine  and  glutamate or  glutamine. A high 
frequency of five-membered heterocyclic rings is observed within these cyclopeptides. 
The biological activity of these cyclic peptide natural products is in general interesting 
even though some were reported to be inactive or less active. It is surprising to see that 
in many cases the biological activity is not identical for the natural product and the 
synthetic  product. 
14,21-23  Numerous  groups  mentioned  that  cyclic  peptide  natural 
products may contain a chemically undetectable amount of a strongly active cytotoxic 
agent.
14,21,23 It has also  been hypothesised that  proline interconversion occurs in the 
natural products to give the bioactive molecule with a specific conformation for the 
proline residues.
14,22 Synthetic methods may not form the potential active conformer and 
therefore the synthetic compound shows no activity. 
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1.2. AIMS  
 
We were planning to synthesise sanguinamides A and B in order to carry out biological 
testing as none has ever been reported on these two compounds. We also wanted to 
check the accuracy of the characterisation of the sanguinamide structures by Molinski et 
al. as they used very little material to do so. We planned to study the conformations 
adopted by the proline in the synthesised product and to compare it to that reported for 
the natural products in the literature. 
 
We were also planning to prepare synthetically stylissamide A in order to study the 
cis/trans  geometry  of  the  proline  in  the  synthetic  product.  We  were  working  in 
collaboration  with  a  group  who  was  planning  to  further  investigate  the  biological 
activity of this compound even though preliminary studies on this compound were not 
promising.  
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1.3. TOWARDS  THE  SYNTHESIS  OF  THE  HEPTAPEPTIDE 
SANGUINAMIDE A 
 
Initial work was performed by an undergraduate in the group, Wan-Jun Chung. The 
strategy  she  used  was  to  prepare  the  thiazole-containing  fragment  1.31  and  the 
pentapeptide 1.32 (Scheme 1.1). She successfully prepared the pentapeptide 1.32 but 
encountered  several  difficulties  in  the  synthesis  of  the  Fmoc  protected  thiazole-
containing fragment 1.31.  
 
 
Scheme 1.1 : Previous retrosynthetic analysis of sanguinamide A 
 
1.3.1. Strategy 1 : macrolactamisation between thiazole and alanine residue 
 
Several  disconnections  are  possible  at  the  six  different  amide  bonds.  The  natural 
product will be assembled from the two following fragments: the thiazole-containing 
fragment 1.33 and the tetrapeptide 1.34 prepared from L-phenylalanine, L-isoleucine, L-
proline  and  L-alanine  (Scheme  1.2).  In  order  to  increase  efficiency  and  yield,  a 
convergent synthesis is proposed from two fragments 1.33 and 1.34 of approximately 
equal  size.  The  macrolactamisation  would  be  performed  between  the  thiazole  and 
alanine which we considered to be the least hindered position.                   Proline-Containing Cyclic Peptide Natural Products 
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Scheme 1.2 : Retrosynthetic analysis of sanguinamide A 
 
The coupling reagents we decided to use were a substoichiometric amount of HOBt 
with the carbodiimide EDCI (1.35) because of its water-soluble by-product urea which 
can be easily removed by aqueous washes.
8 For couplings that we considered more 
difficult, we decided to use PyBOP (1.36) a more efficient coupling reagent.
8 
 
 
Figure 1.18 : Structures of EDCI.HCl (1.35) and PyBOP (1.36) 
 
We  planned  to  synthesise  the  thiazole  containing  fragment  1.33  starting  from  L-
isoleucinamide 1.37, the first step being the protection of the amine with a Boc group 
followed by the conversion of the amide to thioamide 1.39 using Lawesson’s reagent 
(Scheme  1.3).  A  Hantzsch  thiazole  synthesis  is  then  performed  with  methyl 
bromopyruvate to form the thiazole 1.40. The Boc is then removed and the resulting 
amine is coupled to Boc-L-Pro-OH using PyBOP to give 1.42. Finally, the Boc group is 
removed from the proline to afford the thiazole-containing fragment 1.33. We chose the 
Boc group because of its compatibility with the subsequent reaction conditions and also 
because of its easy incorporation and removal.  
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Scheme 1.3 : Synthesis of the thiazole-containing fragment 1.33 
 
We encountered some difficulties in the formation of the thiazole ring as epimerization 
occurred at the ʱ-centre of the thiazole ring. Epimerisation was shown to take place due 
to acid catalysed imine-enamine tautomerisation of thiazoline 1.43 by treatment of the 
N-protected thioamide with methyl bromopyruvate in the presence of 0.5 equivalent of 
calcium  carbonate  (Scheme  1.4).
33,34  Racemisation  depends  on  the  rate  of  the 
dehydration step leading to the aromatised compound, and this depends on the stability 
of the carbocation intermediate 1.46.
34 
 
 
Scheme 1.4 : Epimerisation at the ʱ-chiral centre of the thiazole ring                   Proline-Containing Cyclic Peptide Natural Products 
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A mixture of the two diastereomers, 1.40 and 1.47, was obtained and they were not 
separable by flash chromatography as both diastereomers have the same retention factor 
(Rf) on TLC. 
1H NMR showed the presence of diastereomers as some of the peaks are 
doubled. We nevertheless managed to separate the two different diastereomers after 
coupling  with  proline  and  continued  the  synthesis  on  the  major  diastereomer  1.42 
(Scheme 1.5).  
 
 
Scheme 1.5 : Synthesis of the para-nitro compound 1.48 
 
The  major  diastereomer  was  presumed  to  possess  the  correct  stereochemistry.  We 
nevertheless  decided  to  check  the  stereochemistry  of  1.42  by  coupling  it  to  para-
nitrobenzoic acid after Boc removal in order to obtain the X-ray crystal structure of the 
compound.  Lath-shaped  crystals  of  the  para-nitrobenzoic  acid  derivative  1.48  were 
grown  from  a  mixture  of  acetonitrile  and  water.  The  X-ray  structure  of  the  para-
nitrobenzamide derivative of the amine was obtained and confirmed the stereochemistry 
of  the  major  diastereomer  with  the  desired  stereochemistry  (Figure  1.19).  The 
stereochemistry  of  the  isoleucine  residue  was  indeed  shown  to  be  the  (S,  S) 
corresponding to the natural L-isoleucine. 
 
                   Proline-Containing Cyclic Peptide Natural Products 
21 
 
 
Figure 1.19 : X-Ray structure of the para-nitro compound 1.48 
 
A modified Hantzsch reaction described in the literature for epimerisation-free thiazole 
formation  was  then  attempted.
34,35  The  reaction  of  the  thioamide  with  methyl 
bromopyruvate in dimethoxyethane in the presence of finely powdered KHCO3 leads to 
the formation of hydroxythiazoline derivative 1.43. The HBr formed is neutralised by 
the excess KHCO3. Without isolation of this product, the hydroxyl group is activated 
with trifluoroacetic acid anhydride (TFAA) in pyridine followed by formation of the 
thiazole by immediate aromatisation with complete retention of configuration.  
 
 
Scheme 1.6 : Thiazole formation using epimerization-free conditions 
 
TFAA  reacts  with  pyridine  to  form  trifluoroacetylpyridinium  trifluoroacetate  1.49 
which is in equilibrium with tetrahedral intermediate 1.50 (Figure 1.20).
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group of the intermediate thiazoline compound  1.43 is  trifluoroacetylated to  form  a 
good leaving group. 
 
 
Figure 1.20 : Equilibrium between the two forms of the TFAA.pyridine complex 
 
The tetrapeptide Ile-Pro-Phe-Ala 1.34 was prepared using a sequence of coupling and 
deprotection steps (Scheme 1.7). The coupling reagent used is EDCI with a catalytic 
amount  of  HOBt  and  the  Boc  deprotection  is  performed  by  treatment  with  HCl  in 
dioxane. We believed that 1.54, 1.55, 1.56  and 1.34 were obtained as  a mixture of 
conformers due to the presence of the proline residue. 
 
 
Scheme 1.7 : Synthesis of the tetrapeptide 1.34 
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HATU  (1.57),  which  can  exist  as  uronium  (O-form)  salt,  is  generally  the  coupling 
reagent  of  choice  for  macrolactamisation  and  will  be  employed  for  all  our 
macrolactamisations.
8 
 
 
Figure 1.21 : Structure of HATU (1.57) 
 
Coupling  of  the  thiazole  containing  fragment  1.33  with  the  tetrapeptide  1.34  using 
PyBOP  gave  compound  1.58  in  which  the  acid  and  amine  were  successively 
deprotected (Scheme 1.8). Difficulties to obtain a good NMR for this compound were 
encountered. The PyBOP by-product was difficult to remove, so we decided to carry on 
and to purify the final product. The macrolactamisation was performed using HATU as 
coupling  reagent  and  HATU  by-product  was  difficult  to  remove  by  flash 
chromatography. Several attempts to purify the compound led to a low yield for the 
macrolactamisation.  HPLC  was  required  and  was  run  by  our  collaborators  Marcel 
Jaspars and Mostafa Rateb at the University of Aberdeen. 
 
 
Scheme 1.8 : Synthesis of trans, trans-sanguinamide A 
 
The  NMR  of  synthetic  sanguinamide  A  reported  in  table  1.1  shows  significant 
differences with that reported for the natural product.
32 
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Figure 1.22 : Atom numbering used for sanguinamide A 
 
The two proline residues have trans geometry in the synthetic compound 1.59. The 
conformation  was  assigned  by  NOESY  experiments  performed  with  the  help  of 
Professor Marcel Jaspars.  
Broad signals for the 
1H and 
13C NMR spectra were obtained at rt in CDCl3. Marcel 
Jaspars attempted to run the NMR at higher temperature but the signals were still broad. 
Heating usually averages out the rotamers. However in our case, the average signals 
were  broad  and  represented  a  number  of  conformers.  Running  the  NMR  at  lower 
temperature (–10 ºC) gave sharper signals in the 
1H NMR; the low temperature enabled 
to freeze out a conformer. We were able to see one conformer using low temperature 
NMR rather than the average. The NMR spectra at 25 ºC and –10 ºC are considerably 
different (Figures 1.23 and 1.24).  
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Figure 1.23 : 
1H NMR of trans, trans-sanguinamide A (1.59) in CDCl3 run at 25 ºC 
 
 
Figure 1.24 : 
1H NMR of trans, trans-sanguinamide A (1.59) in CDCl3 run at –10 ºC                   Proline-Containing Cyclic Peptide Natural Products 
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Residue  #  ʴ
13C 
13C 
mult. 
Reported
32 
ʴ
13C 
ʴ
1H and mult. 
Reported
32 
ʴ
1H and mult. 
Pro 
 
 
 
 
1  171.4  C  170.6 
   
2  61.4  CH  60.8  4.44 (d)  4.67 (d) 
3  30.6  CH2  30.5  2.19, 2.05 (m, m)  1.81, 2.68 (m, dd) 
4  24.1  CH2  25.0  2.01, 1.89 (m, m)  1.90, 2.02 (m, m) 
5  46.4  CH2  48.1  3.59, 3.48 (t, m)  3.67, 4.00 (m, m) 
Ile 
 
 
 
 
 
 
6  170.63  C  174.5 
   
7  53.0  CH  56.3  4.72 (d)  4.26 (dd) 
8  37.7  CH  35.5  1.56 (m)  2.30 (m) 
9  27.5  CH2  25.3  1.29, 1.08 (m, m)  1.24, 1.70 (m, m) 
10  12.2  CH3  10.3  0.95 (t)  0.91 (t) 
11  13.8  CH3  15.1  0.67 (d)  1.02 (d) 
Pro 
 
 
 
 
12  171.3  C  171.5 
   
13  62.2  CH  60.9  3.85 (t)  3.38 (d) 
14  29.8  CH2  30.4  2.17, 1.93 (m, m)  0.93, 2.10 (m, dd) 
15  25.9  CH2  22.0  2.08, 1.81 (m, m)  1.70, 1.50 (m, m) 
16  47.6  CH2  46.3  3.64, 3.44 (t, m)  3.50, 3.53 (m, m) 
Phe 
 
 
 
 
 
 
 
17  168.9  C  169.2 
   
18  51.3  CH  54.5  4.67 (m)  4.22 (ddd) 
19  35.8  CH2  37.9  3.17, 2.93 (dd, dd)  2.98, 3.08 (dd, dd) 
20  135.3  C  134.3 
   
21/25  131.1  2CH  129.3  7.15 (d)  7.16 (d) 
22/24  128.0  2CH  127.8  7.27 (m)  7.24 (m) 
23  126.7  CH  129.1  7.21 (m)  7.28 (m) 
Ala 
 
 
 
26  170.9  C  171.0 
   
27  48.9  CH  49.1  4.68 (m)  4.69 (qd) 
28  18.3  CH3  17.9  1.53 (d)  1.48 (d) 
Thz 
 
 
 
29  160.8  C  160.3 
   
30  146.6  C  148.5 
   
31  125.6  CH  123.1  7.94 (s)  8.01 (s) 
32  170.58  C  168.1 
   
Ile 
 
 
 
 
 
33  53.1  CH  56.3  5.06 (t)  5.09 (dd) 
34  34.1  CH  40.9  2.27 (br m)  1.80 (m) 
35  25.3  CH2  25.9  1.46, 1.14 (m, m)  1.17, 1.50 (m, m) 
36  10.0  CH3  10.3  0.86 (t)  0.91 (t) 
37  17.0  CH3  15.0  0.92 (d)  0.77 (d) 
Table 1.1 : 
1H and 
13C NMR data in ppm for synthetic trans, trans-sanguinamide A and natural
32 
cis, cis-sanguinamide A in CDCl3 (see figure 1.22 for numbering) 
 
We  obtained  an  X-ray  crystal  structure  to  confirm  our  structure  (Figure  1.25). 
Crystalline rods of sanguinamide A were grown from a mixture of methanol/water. The 
X-ray  structure  confirmed  the  structure  of  the  synthetic  sanguinamide  A,  the 
stereochemistry of its stereogenic centers along with the trans proline peptide bonds.                    Proline-Containing Cyclic Peptide Natural Products 
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Figure 1.25 : X-Ray structure of trans, trans-sanguinamide A (1.59) 
 
In  the 
13C  NMR,  the  synthetic  compound  with  both  prolines  in  the  trans  rotamer, 
determined by NOESY experiment, has Pro
1 (∆δβ = δβ – δ = 6.5 ppm) and Pro
2 (∆δβ 
= 3.9 ppm). The reported values for the natural product with both prolines in the cis 
rotamer are Pro
1 (∆δβ = 5.5 ppm) and Pro
2 (∆δβ = 8.4 ppm).
32 Although the ∆δβ is 
widely  used  to  assign  proline  rotamers  in  the  literature,  this  example  shows  the 
limitations of the calculation method (Figure 1.26). Cis proline residues should have a 
larger 
13C  chemical  shifts  difference  than  trans  proline  residues.  According  to  the 
NOESY experiment, the Pro
1 is in trans conformation but the value obtained by the 
calculation method is larger than the literature value for the cis rotamer. 
 
 
Figure 1.26 : Structures of the synthetic material 1.59 and the natural product cis, cis-
sanguinamide A (1.29)                   Proline-Containing Cyclic Peptide Natural Products 
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DFT  calculations  performed  by  our  collaborator  Bruce  Milne  at  the  University  of 
Coimbra suggest the cis, cis rotamer is higher in energy than trans, trans rotamer. We 
decided to attempt a different synthetic approach in order to obtain the identical rotamer 
to the natural product. 
 
1.3.2. Strategy 2: macrolactamisation between Pro
1 and Ile
2 
 
We decided to try to perform the macrolactamisation at a different position  as it is 
known that coupling next to a proline is a turn inducer allowing cis bond formation.
37,38 
We decided to try to perform the macrolactamisation next to the proline residues and 
began with the disconnection between proline and isoleucine residues. As fragments 
1.61 and 1.62 would easily be prepared from available fragments 1.42 and 1.56, the 
macrolactamisation  between  Pro
1  and  Ile
2  residues  would  easily  be  performed  after 
amide bond formation between our thiazole and alanine (Scheme 1.9).  
 
 
Scheme 1.9 : New retrosynthesis of sanguinamide A 
 
Saponification  of  fragment  1.42  was  performed  by  treatment  with  LiOH  and  Boc 
removal on 1.56 was carried out. Fragments 1.61 and 1.62 were coupled to give the 
compound 1.60 which was only characterised by mass spectrometric analysis as  we 
were not able to remove the PyBOP by-product (Scheme 1.10). Sequential deprotection 
of C- and N- termini and macrolactamisation with HATU afforded 1.63 in low yield.  
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Scheme 1.10 : Synthesis of trans, cis-sanguinamide A (1.63) by macrolactamisation between Pro
1 
and Ile 
 
In our second synthesis, the 
1H and 
13C NMR data that we obtained once again gave 
significant  variations  to  that  reported  by  Molinski  for  the  natural  product  cis,  cis-
sanguinamide A (Figure 1.22 and table 1.2).
32 This time, we had synthesised the trans 
conformation  for  Pro
1  (∆δβ  =  0.8  ppm)  and  cis  for  Pro
2  (∆δβ  =  8.5  ppm).  The 
determination of the proline residue conformations was done using NOESY experiment.                   Proline-Containing Cyclic Peptide Natural Products 
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Residue  #  ʴ
13C 
13C mult. 
Reported
32 
ʴ
13C 
ʴ
1H and mult. 
Reported
32 
ʴ
1H and mult. 
Pro 
 
 
 
 
1  170.7  C  170.6 
 
 
2  60.9  CH  60.8  4.69 (d)  4.67 (d) 
3  25.8  CH2  30.5  2.69, 1.91 (dd, m)  1.81, 2.68 (m, dd) 
4  25.0  CH2  25.0  2.04, 1.91 (m, m)  1.90, 2.02 (m, m) 
5  48.3  CH2  48.1  4.00, 3.63 (td, t)  3.67, 4.00 (m, m) 
Ile 
 
 
 
 
 
 
6  174.4  C  174.5 
 
 
7  56.4  CH  56.3  4.28 (dd)  4.26 (dd) 
8  35.5  CH  35.5  2.29 (m)  2.30 (m) 
9  25.5  CH2  25.3  1.82, 1.28 (m, m)  1.24, 1.70 (m, m) 
10  10.4  CH3  10.3  0.92 (t)  0.91 (t) 
11  15.2  CH3  15.1  1.03 (d)  1.02 (d) 
Pro 
 
 
 
 
12  171.4  C  171.5 
 
 
13  61.1  CH  60.9  3.41 (d)  3.38 (d) 
14  30.4  CH2  30.4  2.11, 0.96 (dd, m)  0.93, 2.10 (m, dd) 
15  21.9  CH2  22.0  1.82, 1.71 (m, m)  1.70, 1.50 (m, m) 
16  46.4  CH2  46.3  3.54, 3.47 (td, m)  3.50, 3.53 (m, m) 
Phe 
 
 
 
 
 
 
 
17  169.9  C  169.2 
 
 
18  54.6  CH  54.5  4.25 (ddd)  4.22 (ddd) 
19  37.8  CH2  37.9  3.11, 3.02 (t, dd)  2.98, 3.08 (dd, dd) 
20  134.7  C  134.3 
 
 
21/25  129.4  2CH  129.3  7.17 (d)  7.16 (d) 
22/24  129.1  2CH  129.1  7.29 (d)  7.28 (m) 
23  127.7  CH  127.8  7.26 (m)  7.24 (m) 
Ala 
 
 
 
26  171.3  C  171.0 
 
 
27  49.2  CH  49.1  4.77 (ddd)  4.69 (qd) 
28  18.0  CH3  17.9  1.48 (d)  1.48 (d) 
Thz 
 
 
 
29  160.5  C  160.3 
 
 
30  148.5  C  148.5 
 
 
31  123.1  CH  123.1  8.01 (s)  8.01 (s) 
32  168.2  C  168.1 
 
 
Ile 
 
 
 
 
 
33  56.3  CH  56.3  5.10 (dd)  5.09 (dd) 
34  41.0  CH  40.9  1.71 (m)  1.80 (m) 
35  25.8  CH2  25.9  1.53, 1.18 (m, m)  1.17, 1.50 (m, m) 
36  11.5  CH3  10.3  0.93 (t)  0.91 (t) 
37  15.1  CH3  15.0  0.78 (d)  0.77 (d) 
Table 1.2 : 
1H and 
13C NMR data in ppm for synthetic trans, cis-sanguinamide A and natural
32 cis, 
cis-sanguinamide A in CDCl3 (see figure 1.22 for numbering) 
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Choosing a different macrolactamisation position, the conformation obtained for the 
proline peptide bonds differed.  
Cis  amide  bonds  in  proteins  are  apparently  more  frequent  in  aromatic  amino  acid-
proline residue pairs because of an interaction occurring between the aromatic ring and 
the proline.
39 In accordance with this observation, we obtained the cis peptide linkage 
for the proline-phenylalanine bond. 
 
1.3.3. Strategy 3: macrolactamisation between Phe and Pro
2 
 
We thought of performing the macrolactamisation next to the other proline (Pro
2-Phe) to 
check the geometry of the proline residues in the final cyclic compound. We decided to 
prepare intermediate 1.65 that we could obtain from the coupling of thiazole-containing 
fragment 1.61 and the dipeptide 1.67 (Scheme 1.11). We had already prepared 1.61 and 
just had to prepare dipeptide 1.67 in order to prepare 1.65. The already made dipeptide 
1.52 will be saponified to give 1.66 and will be used for synthesis of fragment 1.64.  
 
 
Scheme 1.11 : Alternative retrosynthesis of sanguinamide A 
 
Dipeptide 1.69 was prepared in excellent yield by coupling of Boc-Ala-OH to H-Phe-
OMe using PyBOP (Scheme 1.12). The dipeptides 1.70 and 1.66 were prepared by 
respective deprotection of 1.69 and 1.52. 
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Scheme 1.12 : Synthesis of the dipeptides 1.70 and 1.66 
 
We  coupled  the  thiazole-containing  fragment  1.61  with  the  dipeptide  alanine-
phenylalanine 1.70 (Scheme 1.13). After Boc removal, fragment 1.65 is then coupled to 
the  dipeptide  proline-isoleucine  1.66.  Deprotections  followed  by  macrolactamisation 
furnished a mixture of conformers: trans, trans- and trans, cis-sanguinamide A. 
 
 
Scheme 1.13 : Synthesis of a mixture of conformers of sanguinamide A by macrolactamisation 
between Phe and Pro
2                   Proline-Containing Cyclic Peptide Natural Products 
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Thus,  our  three  syntheses  gave  different  conformers  depending  on  the 
macrolactamisation position. However, the cis, cis conformer reported for the natural 
product was not observed. 
 
1.3.4. Modification  of  the  stereochemistry  of  the  isoleucine  residue  next  to  the 
thiazole  
 
A chiral ʱ-stereocentre next to thiazole tends to epimerise. Epimerisation might have 
occurred  during  Molinski’s  stereochemical  assignment  of  the  natural  product  by 
degradation  and  derivatisation  by  Marfey’s  method.  There  are  precedents  for  such 
wrong  assignments  as  in  the  case  of  ceratospongamide.  The  stereochemistry  of  the 
isoleucine residue was assigned as D-isoleucine and was instead D-allo-isoleucine.
30 
We started with the D-isoleucine to see if there would be a difference in the proline 
conformations.  The  synthesis  is  identical  to  the  prior  synthesis  of  trans,  trans-
sanguinamide A. The first step however differs as the starting material is Boc-D-Ile-OH 
instead of the isoleucinamide. The first step is an amidation performed using ammonia 
in dioxane, EDCI, HOBt and Hünig’s base (Scheme 1.14). We also in that case used the 
epimerisation-free  thiazole  formation  method  and  obtained  1.73  as  a  unique 
diastereomer. For the preparation of the amide 1.74, PyBOP was replaced by EDCI in 
order to obtain a cleaner intermediate. The NMR is cleaner but the peaks are very broad 
due to a mixture of rotamers.  
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Scheme 1.14 : Synthesis of [D-Ile]-sanguinamide A 
 
Pro
1 has a trans conformation (∆δβ = 4.2 ppm) and Pro
2 has a cis geometry (∆δβ = 3.6 
ppm). The geometries of the proline residues were attributed by NOESY experiment 
and the values (∆δβ) obtained by calculation showed once again the limitation of the 
method based on the difference in 
13C chemical shifts between Cβ and C signals. The 
cis proline peptide bond is supposed to give large 
13C chemical shifts difference but in 
this case, it is lower than that obtained for the trans. We obtained the trans, cis-[D-Ile]-
sanguinamide A using the same macrolactamisation that previously gave us the trans, 
trans-sanguinamide A.  
 
We decided to make sanguinamide A with D-allo-isoleucine as we obtained different 
rotamers when using either D-Ile and L-Ile but the same macrolactamisation position. 
Synthesis  was  carried  out  as  described  previously  from  D-allo-isoleucine.  Boc 
protection with NaOH as a base in dioxane gave excellent yield (100%) compared to the 
conditions with Et3N in dichloromethane that gave moderate yields (Scheme 1.15).
40 
This  difference  might  be  explained  by  the  higher  solubility  of  D-allo-isoleucine  in 
dioxane or by the strength of the base (NaOH vs. Et3N). We used ethyl bromopyruvate 
in this case instead of methyl bromopyruvate only for availability reasons.  
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Scheme 1.15 : Synthesis of [D-allo-Ile]-sanguinamide A  
 
The compound 1.80 was sent to Marcel Jaspars for HPLC purification but not enough 
material was recovered to elucidate the proline conformations.  
 
1.3.5. Following the biomimetic pathway 
 
We thought of following the likely biosynthesis of sanguinamide A. It is very likely that 
the  last  step  of  the  biomimetic  pathway  is  the  thiazole  formation.  To  do  so,  we 
envisaged a new strategy, in which the thiazole ring formation will be performed after 
the  macrolactamisation.  We  cannot  use  a  Boc  group  in  this  case  as  it  will  not  be 
compatible with the trityl group. We planned to prepare the linear heptapeptide 1.82 
obtained by coupling the tetrapeptide 1.62 to the tripeptide 1.83 (Scheme 1.16). We also 
decided to perform the macrolactamisation between Pro
1 and Ile which has given the 
closest  conformation  to  the  natural  product  so  far,  as  only  the  trans,  cis  isomer  is 
obtained.  
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Scheme 1.16 : Retrosynthesis of compound 1.81 
 
Tetrapeptide 1.62 had been previously made and some was still available. The dipeptide 
Fmoc-Pro-Ile-OMe 1.85 was prepared. Ester hydrolysis with LiOH in THF/water also 
deprotected the Fmoc group. The hydrolysis of the ester, following a milder method 
using Me3SnOH, was attempted but the Fmoc group was also removed.
41 As we got H-
Pro-Ile-OH, the amine was reprotected with Fmoc chloride to give 1.86.
42 The acid is 
then coupled to H-Cys(Tr)-OMe which had been obtained after trityl protection of H-
Cys-OMe. The same problem was encountered during the deprotection of the ester 1.87 
as Fmoc group was also removed however the same procedure as earlier was employed 
to reprotect the amine in order to obtain 1.88. The coupling of 1.88 with 1.62 was tried 
but this coupling failed because of solubility issues. 
                   Proline-Containing Cyclic Peptide Natural Products 
37 
 
 
Scheme 1.17 : Attempt to prepare 1.89 in solution phase 
 
We decide to change the strategy and to prepare the linear peptide 1.90 using solid 
phase peptide synthesis (SPPS). 
 
 
Figure 1.27 : Structure of the peptide 1.90 
 
We employed Fmoc/tBu SPPS method to prepare peptide 1.90 with the Wang resin 
(Figure 1.28). We used the procedure described by White and Wang.
43 
 
 
Figure 1.28 : Structure of the Wang resin                   Proline-Containing Cyclic Peptide Natural Products 
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The first step consists of swelling the resin. We loaded the resin with isoleucine using 
diisopropylcarbodiimide (DIC,  figure  1.29) to  prepare the  symmetrical  anhydride of 
Fmoc-Ile-OH.  
 
 
Figure 1.29 : Structure of DIC (1.92) 
 
Deprotection of the Fmoc group was then performed using a mixture of piperidine in 
DMF (20%) followed by coupling of Fmoc-Pro-OH to the isoleucine using PyBOP. 
This  is  followed  by  deprotection  and  successive  couplings  with  the  corresponding 
amino  acids  (Fmoc-Phe-OH,  Fmoc-Ala-OH,  Fmoc-Cys(tBu)-OH,  Fmoc-Ile-OH  and 
Fmoc-Pro-OH) and deprotection steps (Scheme 1.18). The deprotection and coupling 
steps  were  monitored  using  a  qualitative  ninhydrin  assay  (Kaiser  test)  which  is  a 
colorimetric  test  based  on  the  reaction  of  ninhydrin  with  amino  groups.  We  also 
monitored the reactions by ESI-MS if necessary. In the case of incomplete couplings, 
the coupling step was repeated or if necessary, the peptide was capped by N-acetylation. 
The cleavage of the resin was done using a mixture of TFA, EDT (ethane dithiol), 
anisole, TIPS and water in CH2Cl2 and allowed us to obtain the heptapeptide 1.100. We 
used Fmoc-Cys(tBu)-OH because of its availability in the laboratory and its stability 
during the TFA cleavage of the resin. Solid phase synthesis on Wang resin allowed us to 
obtain the linear peptide 1.100. The carboxylic acid 1.100 was treated with piperidine in 
DMF  to  form  the  unprotected  linear  peptide.  HATU-mediated  macrolactamisation 
afforded Cys(tBu) analogue 1.101.                   Proline-Containing Cyclic Peptide Natural Products 
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Scheme 1.18 : Solid phase synthesis of the Cys(tBu) compound 1.101                   Proline-Containing Cyclic Peptide Natural Products 
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We checked the conformation of the proline residues of the Cys(tBu) compound 1.101 
by 
13C NMR and NOESY experiment. The proline peptide bonds have trans and cis 
conformations (Pro
1: ∆δβ = 4.6 ppm; Pro
2: ∆δβ = 8.8 ppm). We attempted to convert 
1.101  to  the  thiazoline  using  Kelly’s  method  (OPPh3/Tf2O).
44,45  In  the  synthesis  of 
telomestatin, Takahashi  performed the cyclodehydration of a Cys(tBu) moiety using 
Kelly’s method with anisole.
45 In our case the reaction was unsuccessful and no product 
was formed. We decided to try another well-known method using TiCl4 which required 
the free thiol as starting material.
46 To do so, we have to deprotect the tBu thioether. 
Deprotection of the tBu protected thiol is not possible using TFA. Harsher conditions 
are required, such as Hg(OAc)2/TFA then H2S or HF/anisole or BBr3 with AcCl or Br2, 
AcCl and AcOH.
47 We attempted the deprotection with catalytic bromine (Br2, AcCl 
and AcOH) but it gave a messy reaction mixture and no thiol 1.104 was isolated after 
hydrolysis of the thioacetate 1.103.
48 The thioether deprotection was problematic. 
 
 
Scheme 1.19 : Attempts to prepare sanguinamide A by late thiazole formation from Cys(tBu) 
compound 1.101 
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Fmoc-Cys(tBu)-OH was only used for availability reasons. Several thiazoline syntheses 
from Cys(Tr) are described in the literature. We planned to make the cyclic peptide with 
Cys(Tr) and then try to form the thiazoline using first the Kelly method and if necessary 
other methods.  
 
We decided to move on to another protecting group on the cysteine residue: the trityl 
group instead of the  tBu.  I have  repeated the  SPPS using Fmoc-Cys(Tr) instead of 
Fmoc-Cys(tBu). Cleavage of the resin with TFA/TIPS/water also deprotected the trityl 
group  which  had  to  be  reprotected  by  treatment  with  TFA  and  TrOH.
49  Fmoc 
deprotection followed by macrolactamisation affords the compound  1.107 but a low 
yield is obtained (Scheme 1.20).  
 
 
Scheme 1.20 : Solid phase synthesis of the Cys(Tr) compound 1.107 
 
The  Kelly  method  (OPPh3/Tf2O)  failed  on  compound  1.107  (Scheme  1.21).  We 
deprotected the thiol by TFA treatment and use of triisopropylsilane as a scavenger. 
Compound 1.104 was treated with TiCl4 but no product was formed. We tried another 
reaction  condition  found  in  the  literature  using  (NH4)MoO24.H2O  which  gave  the                   Proline-Containing Cyclic Peptide Natural Products 
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thiazoline  1.102.
50  Activated  manganese  dioxide  failed  to  oxidize  the  thiazoline  to 
thiazole ring. Oxidation with bromotrichloromethane and DBU furnished the thiazoline 
but the reaction did not go to completion. Separation of the product from the starting 
material was not possible. We decided to abandon this route as we were not encouraged 
by the conformation of the intermediate 1.101. 
 
 
Scheme 1.21 : Attempts to prepare sanguinamide A by late thiazole formation from Cys(Tr) 
compound 1.107 
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1.4. TOWARDS  THE  SYNTHESIS  OF  THE  OCTAPEPTIDE 
SANGUINAMIDE B 
 
In addition to five amino acids in the L series, sanguinamide B contains one oxazole and 
two  thiazole  rings.  Five  disconnections  at  the  amide  linkage  are  conceivable.  We 
decided to prepare a fragment with the thiazole moiety and another with the thiazole-
oxazole unit. The bond-disconnection strategy provided three key synthetic precursors: 
the dipeptide 1.108, the thiazole-containing fragment 1.109 and the thiazole-oxazole 
moiety  1.110  (Scheme  1.22).  We  decide  to  couple  the  thiazole-containing  fragment 
1.109  to  the  thiazole-oxazole  moiety  1.110  and  then  to  dipeptide  1.108.  The 
macrolactamisation would be performed between alanine and valine as this is a less 
hindered position compared to the alternative. 
 
 
Scheme 1.22 : Retrosynthetic analysis of sanguinamide B 
 
Synthesis of the proline-valine dipeptide 1.112 was performed by coupling Boc-Pro-OH 
and H-Val-OMe using EDCI as coupling reagent in excellent yield (Scheme 1.23). Boc 
deprotection afforded the hydrochloride salt of the desired fragment 1.113. 
 
 
Scheme 1.23 : Synthesis of dipeptide 1.113                   Proline-Containing Cyclic Peptide Natural Products 
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We  synthesised  the  thiazole-containing  fragment  1.119  starting  from  L-alaninamide 
(1.114) in which the amine is first protected with a Boc group and the amide converted 
to the thioamide 1.116 (Scheme 1.24). A Hantzsch thiazole synthesis is then performed 
with methyl bromopyruvate to form the desired product 1.117. We used the modified 
version in order to avoid the epimerization (TFAA/pyridine). The ester is deprotected 
and the resulting acid 1.118 is coupled to H-L-Leu-OMe using PyBOP to afford the 
thiazole-containing fragment 1.119. 
 
 
Scheme 1.24 : Synthesis of thiazole-containing fragment 1.119 
 
We started the synthesis of 1.127 from Boc-Pro-OH (1.51) which was converted to 
thioamide 1.121 in two steps (Scheme 1.25). Synthesis of the thiazole ring was carried 
out as described previously to form compound 1.122; this was saponified to give the 
carboxylic acid 1.123 which was then coupled with H-L-Ser-OMe without needing to 
protect  the  hydroxyl  group  of  serine.  Activation  of  the  hydroxyl  group  using 
diethyl(amino)sulfur trifluoride (DAST) at –78 ºC followed by cyclisation under basic 
conditions with K2CO3 furnished the oxazoline 1.125.
51 This compound was converted 
to the desired oxazole 1.126 by oxidation in the presence of bromotrichloromethane and 
1,8-diazabicyclo[5.4.0]undec-7-ene  (DBU).  The  expected  thiazole-oxazole  fragment                   Proline-Containing Cyclic Peptide Natural Products 
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1.126 was obtained in 64% after cyclisation-oxidation. Boc deprotection affords the 
thiazole-oxazole fragment 1.127. 
 
 
Scheme 1.25 : Synthesis of thiazole-oxazole fragment 1.127 
 
After ester hydrolysis, the thiazole-containing fragment 1.119 is coupled to the thiazole-
oxazole fragment 1.127 (Scheme 1.26). The ester of the compound 1.128 is saponified 
and  coupled  to  the  dipeptide  1.113.  Compounds  1.128  and  1.129  gave  mixture  of 
conformers. After deprotections, the macrolactamisation with HATU is performed to 
form the desired octapeptide 1.130. After several attempts to purify the mixture of two 
compounds by flash chromatography, we decided to send it to our collaborators for 
HPLC purification.                   Proline-Containing Cyclic Peptide Natural Products 
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Scheme 1.26 : Synthesis of sanguinamide B 
 
Comparison of the 
1H and 
13C NMR data of the synthetic compound with that reported 
in the literature for the natural product showed significant differences and suggest that 
the geometry of the proline residues in the natural and synthetic compounds is different 
(Figure  1.30,  table  1.3).  NMR  analysis  and  NOESY  experiment  showed  that  the 
compound is cis, cis-sanguinamide B (Pro
1: ∆δβ = 4.2 ppm; Pro
2: ∆δβ = 3.6 ppm). 
The natural product has the opposite proline conformations as Pro
1 is trans (∆δβ = 4.2 
ppm) and Pro
2 is trans (∆δβ = 2.4 ppm). The limitation of the method of 
13C NMR 
chemical shifts differences is once again observed as even though some of the proline 
residues are cis and some are trans, all the values obtained by this calculation method 
are small. Synthesis of sanguinamide B also gave a different conformer than the natural 
product as was the case for the synthesis of sanguinamide A.  
                   Proline-Containing Cyclic Peptide Natural Products 
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Figure 1.30 : Structures of the synthetic material 1.130 with the atom numbering used and the 
natural product sanguinamide B (1.30)                  Proline-Containing Cyclic Peptide Natural Products 
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Residue  #  ʴ
13C 
13C mult.  Reported
32 
ʴ
13C 
ʴ
1H 
and mult. 
Reported
32 
ʴ
1H and mult. 
Val 
 
1  170.96  C  159.1     
2  56.9  CH  58.7  4.78 (dd)  4.61 (d) 
3  28.4  CH  30.6  2.88 (dq)  2.93 (m) 
4  16.5  CH3  20.4  0.86 (d)  0.87 (d) 
5  19.9  CH3  20.2  0.98 (m)  1.15 (d) 
NH        6.27(d)  9.26 (d) 
Pro 
 
6  173.6  C  170.4     
7  64.3  CH  60.9  4.72 (dd)  4.39 (d) 
8  32.0  CH2  29.4  2.29 (m)  1.74, 2.80 (m, m) 
9  22.7  CH2  25.2  2.13, 2.00 (m, m)  2.22, 1.94 (m, m) 
10  48.1  CH2  45.4  3.88, 3.83 (m, m)  3.75, 3.34 (m, m) 
Oxz 
 
11  162.1  C  169.2     
12  136.7  C  136.7     
13  143.7  CH  141.5  8.37 (s)  8.27 (s) 
14  157.7  C  157.7     
Thz 
 
15  140.7  C  142.3     
16  122.6  CH  121.8  7.43 (s)  7.95 (s) 
17  172.8  C  172.9     
Pro 
 
18  59.0  CH  58.7  5.43 (d)  4.57 (d) 
19  35.8  CH2  31.1  2.32, 1.91 (m, m)  2.94, 2.07 (m, m) 
20  20.3  CH2  28.7  1.95, 1.77 (m, m)  2.10, 1.81 (m, m) 
21  46.7  CH2  48.0  3.87, 3.80 (m, m)  3.81, 3.97 (m, m) 
Leu 
 
22  168.9  C  170.8     
23  49.1  CH  48.4  5.08 (m)  5.29 (dd) 
24  41.6  CH2  41.4  1.95, 1.57 (m, m)  2.02 (m) 
25  24.4  CH  25.6  1.57 (m)  1.63 (m) 
26  22.3  CH3  23.2  0.98 (m)  0.99 (d) 
27  23.5  CH3  22.0  0.92 (d)  1.03 (d) 
NH        7.02 (d)  9.60 (d) 
Thz 
 
28  160.0  C  160.1     
29  146.7  C  149.2     
30  125.7  CH  124.1  7.92 (s)  8.12 (s) 
31  171.02  C  170.6     
32  45.9  CH  47.8  5.10 (m)  5.56 (qd) 
33  16.3  CH3  24.8  1.00 (m)  1.68 (d) 
NH        7.24 (d)  8.42 (d) 
Table 1.3 : 
1H and 
13C NMR data in ppm for synthetic cis, cis-sanguinamide B and natural
32 trans, 
trans-sanguinamide B in CDCl3                   Proline-Containing Cyclic Peptide Natural Products 
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1.5. CIS-TRANS  ISOMERISATION  AND  ATTEMPTED 
REISOLATION 
 
Sanguinamide A  
The energies calculated by Dr Bruce Milne at the University of Coimbra and shown in 
table 1.4 suggest that cis, trans is the only significantly populated conformer at room 
temperature  in  chloroform  solution.  Three  different  levels  of  theory,  hybrid  DFT 
(B3LYP), double-hybrid DFT (B2PLYP) and second order perturbation theory (MP2), 
were  used  and  support  this  fact.  The  COSMO  solvent  model  used  during  the  DFT 
geometry  optimisations  is  chloroform.  The  trans,  cis  rotamer,  that  we  obtained 
synthetically, is also lower in energy followed by the trans, trans rotamer followed by 
the natural product (cis, cis) with the highest energy. 
 
Conformer 
sanguinamide A 
Relative energy (kJ/mol) 
B3LYP-D  B2PLYP-D  MP2 
Cis, trans  0.00  0.00  0.00 
Trans, cis (Synthetic)  7.80  13.30  18.21 
Trans, trans (Synthetic)  19.72  21.49  27.04 
Cis, cis (Natural product)  22.09  24.67  22.73 
Table 1.4 : Single point energies of sanguinamide A calculated at BLYP-D/SV(P) geometries with 
solvation in chloroform 
 
We  tried  to  interconvert  trans,  cis-sanguinamide  A  to  cis,  cis-sanguinamide  A  by 
heating the cyclic peptide in the microwave. Trans, cis-Sanguinamide A was dissolved 
in isopropanol, a polar solvent, and heated at 80 ºC under microwave radiation for 4 h 
but no interconversion occurred. 
1H and 
13C NMR data were identical to the starting 
material trans, cis-sanguinamide A. We are trying to interconvert the thermodynamic 
product to the kinetic isomer and this may explain the lack of success. We are using the 
intermediate  compound  trans,  cis-sanguinamide  A  and  by  heating  it  up  we  might 
interconvert  it  to  trans,  trans-sanguinamide  A  or  cis,  trans-sanguinamide  A. 
Alternatively, it is possible that interconversion occurs during cooling since Molinski’s 
sample was kept in the freezer for 20 years. We decided to take trans, cis-sanguinamide                   Proline-Containing Cyclic Peptide Natural Products 
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A and leave it in the freezer in isopropanol for two weeks in order to check if one 
rotamer would froze out. NMR showed that no isomerisation occurred. 
 
Sanguinamide B 
Calculations by Dr Bruce Milne for the sanguinamide B rotamers showed that the cis, 
cis conformer that we obtained synthetically has the lowest energy by all three methods 
(Table 1.5). Variations are obtained depending on the calculation method for the trans, 
trans-natural product however, the relative energies are higher than that of the cis, cis-
rotamer.  
 
Conformer 
sanguinamide B 
Relative energy (kJ/mol) 
B3LYP-D  B2PLYP-D  MP2 
Cis, cis (Synthetic)  0.00  0.00  0.00 
Trans, trans (Natural product)  9.95  17.50  27.42 
Trans, cis  16.04  12.81  7.27 
Cis, trans   22.21  23.24  24.93 
Table 1.5 : Single point energies of sanguinamide A calculated at BLYP-D/SV(P) geometries with 
solvation in chloroform 
 
Variable-temperature NMR was carried out on sanguinamide B to see if there was any 
interconversion between rotamers. The NMR was run from –10 °C to 55 °C in CDCl3 
but did not show any significant variation in the conformation. Cis-trans Isomerisation 
by adding small amounts of water was attempted since this has been reported to have an 
effect in rotamer population with a synthetic peptide.
52 However the NMR run in CDCl3 
with water did not show any variation in the proline conformations. 
The  various  isomerisation  attempts  were  unsuccessful.  Synthesis  is  leading  to  the 
formation of different rotamers than that of the natural products.  
Sanguinamides were not detected by our collaborators: Marianna Carbone and Ernesto
 
Mollo in attempted reisolation from a different sample of the same nudibranch isolated. 
This  is  raising  a  new  hypothesis  that  the  natural  products  might  be  produced  by  a 
symbiotic component which was in the sample of the sponge Hexabranchus sanguineus 
at the time used in Molinski’s isolation.                   Proline-Containing Cyclic Peptide Natural Products 
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1.6. BIOLOGICAL ACTIVITY OF SANGUINAMIDES  
 
Biological  assays  of  the  synthetic  rotamers  of  sanguinamide  A,  the  [D-Ile]-
sanguinamide A, the Cys(tBu) analogue of sanguinamide A and the synthetic rotamer of 
sanguinamide B were performed by our collaborator Dr Wael Houssen and Prof Jaspars 
from the University of Aberdeen (Figure 1.31). They evaluated the antibacterial activity 
against  several  bacterial  strains  and  the  tyrosine  kinase  inhibitory  activity  of  the 
different compounds. 
 
 
Figure 1.31 : Structures of the different compounds tested 
 
1.6.1. Antibacterial activity 
 
Antibacterial  testing  was  evaluated  against  bacterial  strains:  the  Gram  positive 
Staphylococcus  aureus  ATCC  25923,  Listeria  monocytogenes  NCIMB  13726  and 
Bacillus subtilis NCIMB 9118 and the Gram negative Escherichia coli ATCC 25922 
and Vibrio parahaemolyticus NCTC 10441. Minimum inhibitory concentrations (MIC, 
µM) are reported in table 1.6. The Cys(tBu) analogue, synthetic sanguinamide B and the                   Proline-Containing Cyclic Peptide Natural Products 
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D-isoleucine  modified  sanguinamide  A  were  only  found  to  display  a  micromolar 
antibacterial activity against one bacterial strain: Escherichia coli ATCC 25922. The 
synthetic  rotamers  of  sanguinamide  A  were  inactive  against  all  the  tested  bacterial 
strains. 
 
  MIC (M) 
Compound 
S. aureus 
ATCC 
25923 
L. 
monocytogenes 
NCIMB 13726 
B. subtilis 
NCIMB 
9118 
E. coli 
ATCC 
25922 
V. 
parahaemolyticus 
NCTC 10441 
Trans, trans-
sanguinamide A 
Not active  Not active  Not active  Not active  Not active 
Trans, cis-
sanguinamide A 
Not active  Not active  Not active  Not active  Not active 
D-Ile derivative 
1.75 
Not active  Not active  Not active  25  Not active 
Cys(tBu) 
compound 1.101 
Not active  Not active  Not active  11.3  Not active 
Sanguinamide B 
(1.130) 
Not active  Not active  Not active  12.7  Not active 
Table 1.6 : Minimum inhibitory concentrations in µM for different rotamers and derivatives of 
sanguinamides A and B 
 
1.6.2. Tyrosine kinase inhibitory activity 
 
The compounds were tested for their ability to inhibit the activity of tyrosine kinase. 
The inhibition of the epidermal growth factor receptor (EGFR) was evaluated with the 
activities of the compounds compared at the same concentration (100 µM) to the known 
tyrosine kinase inhibitor genistein. Mild to low inhibitory activity was obtained for all 
the tested compounds (Table 1.7). The rotamer trans, trans-sanguinamide A is the most 
active compound with 52.5% of inhibition.                    Proline-Containing Cyclic Peptide Natural Products 
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Compound  % Inhibition 
Trans, trans-sanguinamide A  52.5 
Trans, cis-sanguinamide A  27.5 
D-Ile derivative 1.75  32.5 
Cys(tBu) compound 1.101  25 
Sanguinamide B (1.130)  30 
Table 1.7 : Inhibition in percentage of tyrosine kinase by the different rotamers and derivatives of 
sanguinamides A and B at a concentration of 100 µM  
 
Unfortunately  no  biological  results  were  published  for  the  natural  products  and 
comparison between the biological activity of natural and synthetic compounds is not 
possible.                   Proline-Containing Cyclic Peptide Natural Products 
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1.7. SYNTHESIS OF STYLISSAMIDE A  
 
In collaboration with Professor Mark Hamann from the University of Mississippi we 
worked on the synthesis of stylissamide A. They isolated the natural product from the 
sponge Stylissa caribica and wanted to compare the isolated product to the synthetic 
compound. They were interested to verify that the biological activity of both natural and 
synthetic compound is the same.  
 
Stylissamide A was prepared by macrocyclisation from a commercial linear precursor 
1.131  followed  by  deprotection  with  TFA  treatment  of  the  Boc  and  tBu  protecting 
groups respectively present on lysine and tyrosine residues (Scheme 1.27). I purified the 
compound  by  flash  chromatography  and  sent  it  to  Hamann’s  group  for  HPLC 
purification.  
 
 
Scheme 1.27 : Synthesis of stylissamide A (1.20)                   Proline-Containing Cyclic Peptide Natural Products 
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The synthetic compound was a perfect match with the natural product displaying the 
same geometry for the proline residues (Figures 1.32 and 1.33). The structure of the 
heptapeptide  was  confirmed  as  cyclo(Pro
1-Tyr
2-Lys
3-Pro
4-Pro
5-Val
6-Tyr
7). 
13C  NMR 
data of stylissamide A indicated two proline peptide bonds are trans (Pro
1 ∆δβ = 3.4 
ppm, Pro
4 ∆δβ = 3.6 ppm) and one cis for Pro
5 (∆δβ = 9.5 ppm). Köck and co-workers 
reported the ∆δβ of Pro
1 and Pro
4 to be trans (∆δβ = 3.5 ppm) and Pro
5 to be cis with 
∆δβ = 9.5 ppm.
28 Adjacent cis and trans Pro residues were also found in a few other 
natural  products  such  as  phakellistatin  8  and  wainunuamide  and  were  found  to  be 
powerful β turn inducers.
53,54                   Proline-Containing Cyclic Peptide Natural Products 
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Figure 1.32 : Comparison of the 
1H NMR of natural (blue) and synthetic (red) stylissamide A in 
DMSO-d6
55 
 
 
 
Figure 1.33 : Co-injection on LC/MS of natural and synthetic stylissamide A in equal concentration 
ratio
55                   Proline-Containing Cyclic Peptide Natural Products 
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1.8. BIOLOGICAL ACTIVITY OF STYLISSAMIDE A 
 
Professor Mark Hamann and his group are interested in inhibitors of protein translation. 
Translation is extremely important in protein synthesis and is constituted of three main 
phases:  initiation,  elongation  and  termination.  Two  different  ways  of  initiating 
translation are possible; the most common process is the cap-dependent initiation and 
the  alternative  mechanism  known  as  cap-independent  initiation,  requires  the 
involvement of the internal  ribosomal entry sites  (IRES). During the  cap-dependent 
initiation step, messenger RNA is recognised at the 5’-end (5’-cap) by specific initiation 
factors  (IF)  such  as  eIF4E.  The  cap-independent  initiation  (IRES  method)  does  not 
require the interaction of eIF4E with the cap but occur through the internal ribosomal 
entry  sites  (IRES)  present  on  mRNA.  Several  protein  factors  regulating  the  cap-
dependent translation initiation are overexpressed and associated with cancers. 
 
The following work has been done by Anna J. Kochanowska, Amanda L. Waters and 
Professor Hamann. They discovered that the sponge Stylissa caribica is able to inhibit 
the protein translation.
55 They identified stylissamide A to  be the active component 
responsible for this inhibitory activity towards protein translation, even though it has 
been reported by Schmidt et al. that the compound had no antimicrobial or cytotoxic 
activity. They purified the active fractions of the sponge and isolated stylissamide A. 
They  showed  that  extracted  stylissamide  A  inhibits  HCV  IRES-dependent  and  cap-
dependent translation in Krebs extracts (Figure 1.34) and in rabbit reticulocytes lysate 
(Figure 1.35). It also inhibited the cap-dependent translation in the wheat germ extracts 
(Figure  1.36).  The translation  was  also  inhibited in  yeast  extract  by stylissamide A 
(Figure 1.37). The inhibition is dependent on the concentration. 
                   Proline-Containing Cyclic Peptide Natural Products 
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Figure 1.34 : Effect of stylissamide A on cap-dependent and HCV IRES-dependent translation in 
Krebs-2 cell extracts
55 
 
 
Figure 1.35 : Effect of stylissamide A on cap-dependent and HCV IRES-dependent translation in 
rabbit reticulocytes lysate
55 
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Figure 1.36 : Effect of stylissamide A on cap-dependent translation in wheat germ extract
55 
 
 
Figure 1.37 : Effect of stylissamide A on translation in yeast extract
55 
 
The Hamann group studied the mechanism of the translation inhibitory activity by the 
natural stylissamide A in order to determine which step is inhibited. They started with 
the initiation step and checked the influence of the inhibitor on the formation of the 
initiation complex (80S complex). Stylissamide A did not inhibit the translation during 
the initiation step as the 80S complex is formed (Figure 1.38).  
                   Proline-Containing Cyclic Peptide Natural Products 
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Figure 1.38 : Effect of stylissamide A on the assembly of initiation complex
55 
 
The natural stylissamide A was shown to block the translation at the elongation step. 
They  added  stylissamide  A  to  actively  translating  ribosomes  five  minutes  after  the 
initiation of translation and also ran the experiments with cycloheximide as positive and 
with  DMSO  as  negative  control.  These  experiments  showed  that  the  translation  is 
immediately stopped by the two compounds: stylissamide A and cycloheximide (Figure 
1.39). The latter is known to be a translation inhibitor during the elongation step. 
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Figure 1.39 : Effect of stylissamide A on actively translating ribosomes
55 
 
Natural stylissamide A showed very interesting results in in vitro studies but very poor 
results  were  obtained  in  vivo.  They  believe  that  the  membrane  crossing  of  this 
cyclopeptide  is  responsible  for  the  absence  of  inhibitory  activity  towards  protein 
translation in vivo as once injected into oocytes stylissamide A was active (Figure 1.40). 
 
 
Figure 1.40 : Effect of stylissamide A on the translation after injection into oocytes
55                   Proline-Containing Cyclic Peptide Natural Products 
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The synthetic stylissamide A which is identical to the natural product was also tested 
but  no  activity  in  oocytes  was  observed.  They  believed  that  another  metabolite  is 
responsible for the cell permeability of stylissamide A and their attempt to identify this 
compound was unsuccessful. Crude fractions containing the heptapeptide were tested 
for antimicrobial activity against Cryptococcus neoformans (IC50 0.79 to 10.51 µg/mL 
depending  on  fractions).  The  synthetic  purified  stylissamide  was  inactive  and  this 
supports the hypothesis that a potent metabolite is acting with stylissamide and helping 
its cell entrance. It is nevertheless possible that tertiary structural differences between 
the synthetic and natural product are responsible of this biological activity. Discovering 
the minor metabolite or other factor responsible for this biological activity is the focus 
of ongoing research in the Hamann group. 
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1.9. CONCLUSION 
 
Syntheses of sanguinamides gave different conformers to that of the natural products. 
Synthesis of sanguinamide A led to the formation of two conformers: the trans, trans 
and trans, cis that differed from the natural product which displayed a cis, cis geometry. 
We noticed that the position of the macrolactamisation led to the formation of different 
conformers. We checked that no epimerisation occurred at the ʱ-stereocentre next to the 
thiazoline ring. We also attempted to follow the likely biosynthesis of sanguinamide A 
in order to obtain the same geometry as in the natural product but with no success. 
Synthetic and natural sanguinamide B presented also opposite geometry in their proline 
peptide bonds. The synthetic trans, trans-sanguinamide B was obtained whereas the 
natural  product  has  both  cis  proline  peptide  linkage.  The  yields  for  the 
macrolactamisation are low due to the PyBOP impurity which is difficult to separate 
from the product. The synthetic conformers of sanguinamides along with the [D-Ile]-
sanguinamide A and the Cys(tBu) analogue of sanguinamide A were tested in different 
biological assays. [D-Ile]-Sanguinamide A, Cys(tBu) analogue of sanguinamide A and 
the  sanguinamide  B  showed  antibacterial  activity.  The  rotamer  trans,  trans-
sanguinamide A showed mild tyrosine kinase inhibitory activity.  
Our results show that NOE experiments are the most reliable in assigning the proline 
rotamer conformation. Rotamer assignment based on 
13C NMR chemical shift of proline 
β, CH2 carbons is not enough as several examples show smaller values for the cis 
peptide bond instead of trans.  
Attempts  to  interconvert  the  synthetic  conformers  to  the  natural  conformers  were 
performed  with  no  success.  Biosynthesis  or  prolonged  storage  may  well  produce  a 
different rotamer which is then apparently locked.  
The natural and synthetic stylissamide A displayed the same structural characteristics 
but different translation inhibitory activity.  
 
Cyclic peptides are important biologically active natural products. In this first part, we 
have seen some proline-rich cyclopeptides with various biological activities. In the next 
part, we will see the synthesis of a different type of cyclic peptide: cyclic depsipeptide 
natural products. They contain one ester bond and a specific biological activity.  
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2. HISTONE DEACETYLASE INHIBITORS 
 
2.1. INTRODUCTION 
 
2.1.1. Post translational modifications 
 
Within eukaryotic cells, DNA is condensed into a highly compact structure known as 
chromatin, which is a stainable material of interphase nuclei consisting of nucleic acids 
and associated histone proteins packed into nucleosomes. The fundamental repeating 
unit of chromatin is the nucleosome which is composed of 145-147 DNA base pairs. 
The DNA double helix is wrapped twice around a central core of eight histone protein 
molecules. The core consists of two of each of the four histone protein subunits: H2A, 
H2B,  H3  and  H4  as  represented  in  figure  2.1.  The  linker  histone  H1  allows  the 
condensation of this fundamental unit into structures of higher order.
56 
 
 
Figure 2.1 : Simplified representation of the nucleosome “Reprinted with permission from Access excellence the 
national health museum.” 
 
The basic N-terminal tails of these histones are exposed to different types of covalent 
modifications  such  as:  acetylation  occurring  on  lysine  residues;  ubiquitination  and 
sumoylation  on  lysine  residues;  methylation  on  lysine  or  arginine  residues  and 
phosphorylation on serine residues.
57 These post translational modifications are a major 
mechanism of regulation in gene expression, DNA replication and DNA damage repair. 
Such modifications also affect histone interactions with DNA and other proteins and are 
categorised as epigenetic marks which also include DNA methylation as well as histone Histone Deacetylase Inhibitors 
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modifications.  The  term  epigenetic  describes  the  heritable  changes  that  affect  gene 
expression without modifying the DNA sequence.
58 The accessibility of the DNA to the 
transcription machinery is determined by the state of modification of the N-terminal 
tails.  Alterations  of  histone  modifications  lead  to  errors  in  gene  transcription  or 
repression.  Since  most  human  diseases,  including  cancer,  involve  mis-timed 
transcription this suggests that the modulation of epigenetic events will be an attractive 
therapeutic strategy. 
 
2.1.2. Histone deacetylases 
 
Histone acetylation is one of the best understood histone modifications. It is a reversible 
modification: histone acetyltransferases (HATs) add acetyl  groups to lysine residues 
whereas  histone  deacetylases  (HDACs)  catalyse  the  removal  of  acetyl  groups  from 
acetylated  lysine  residues.  The  positively  charged  lysine  residues  interact  with  the 
negatively charged DNA; this strong interaction results in a closed chromatin structure 
which  prevents  transcription  from  occurring.
58  The  acetylation  of  lysine  by  HATs 
converts the charged lysine to a neutral acetamide, promoting a more relaxed chromatin 
structure which permits transcriptional activation.
58 The balance between acetylation 
and deacetylation  of histone residues, mediated by  HATs and HDACs, is  generally 
deregulated in cancer diseases. 
 
 
Figure 2.2 : Regulation of the transcription by acetylation/deacetylation Histone Deacetylase Inhibitors 
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To date, 18 HDACs have been identified in the human genome and are grouped into 
four classes based on their homology to yeast histone deacetylases. Class I HDACs, 
located in the nucleus, are homologous to yeast Rpd3 and comprises of HDAC1, -2, -3 
and -8.
59 The catalytic cycle of class II members share high similarity with that of yeast 
Hda1 and comprises of HDAC4, -5, -6, -7, -9 and -10; these HDACs shuttle between 
the nucleus and cytoplasm.
59 Class III is formed of seven sirtuins (SIRT1-7).
60,61 Class 
IV only contains HDAC11 which possesses a catalytic cycle which bears similarities to 
both Rpd3 and Hda1. Classes I, II and IV are zinc-dependent enzymes whereas class III 
enzymes  are  metal-free  and  require  nicotinamide  adenine  dinucleotide  (NAD
+)  as  a 
cofactor. As class III HDACs are not relevant to this work they will not be discussed 
further. 
 
As  deregulation  of  histone  modifications  is  implicated  in  many  diseases,  including 
cancer, the inhibition of enzymes which are able to catalyse the addition and removal of 
these epigenetic marks have therapeutic potential. Class I and II HDACs are mainly 
associated  with  haematological  and  solid  cancers.
62  In  addition  HDACs  are  usually 
over-expressed in multiple cancers: for example, HDAC1 is over-expressed in colon, 
prostate, gastric and breast cancers; high levels of HDAC2 are observed in colorectal, 
cervical and gastric cancers and over-expressed HDAC3 and -6 are detected in colon 
and breast cancers.
63 
 
Over-expression of HDACs can also be indicative of the outcome of the disease.
62 High 
levels of class I HDACs in colorectal cancer (HDAC1, -2 and -3) are associated with 
reduced survival rates whilst over-expression of HDAC6 in breast cancer is associated 
with improved survival rates.  
 
HDAC  inhibitors  are  also  able  to  regulate  p21,  which  is  a  cyclin-dependent  kinase 
(CDK)  inhibitor  responsible  for  the  inhibition  of  cell-cycle  progression.
62,64  Its 
expression is generally inactivated in tumour cells because of the deacetylation of the 
p21 promoter.
62 The up-regulation of p21 by HDAC led to tumour growth inhibition by 
apoptosis and cell cycle arrest.
63,64  
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In cancer, HDACs have an abnormal activity that leads to hyperacetylation and aberrant 
silencing  of  genes.
65  The  inhibition  mechanism  of  HDAC  inhibitors  has  different 
effects,  including  differentiation  and/or  apoptosis  of  transformed  cells.  Due  to  their 
pharmacological activity HDAC inhibitors have the potential to treat cancer, as they are 
able to reactivate gene expression and induce cancer cell death.  
 
2.1.3. Histone deacetylase inhibitors  
 
A variety of inhibitors of zinc-dependent HDACs have been discovered so far and they 
can  be  divided  into  different  classes  including  hydroxamates,  aliphatic  acids, 
benzamides and cyclic peptides.
66 
 
2.1.3.1. Acyclic inhibitors 
A) Hydroxamates  
Hydroxamate  HDAC  inhibitors  include  suberoylanilide  hydroxamic  acid  (SAHA, 
Zolinza or vorinostat, 2.1) and trichostatin A (TSA, 2.2). TSA was the first natural 
hydroxamate discovered to be an HDAC inhibitor.
67 SAHA, a synthetic compound, was 
the  first  FDA  approved  HDAC  inhibitor  for  the  treatment  of  cutaneous  T-cell 
lymphoma.
68 Both TSA and SAHA are nanomolar inhibitors and non selective as they 
target all zinc-dependent HDACs.  
 
 
Figure 2.3 : Structures of SAHA (2.1) and TSA (2.2) 
 
The first X-ray structure of a bacterial histone deacetylase-like protein (HDLP), which 
shares 35% sequence homology with human HDAC1, was solved by Finnin and co-
workers.
69 A solved X-ray structure of co-crystals of this HDAC-like protein and TSA 
has shown that the A. aeolicus HDLP active site contains a deep narrow pocket where 
TSA is bound (Figure 2.4). 
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Figure 2.4 : X-ray structure of TSA in the active site of HDLP
69
 “Reprinted by permission from Macmillan 
Publishers Ltd: [Nature] (Finnin, M. S. et al., 401, 1999, 188-193), copyright (1999).” 
 
A mechanism for the deacetylation of acetylated lysine by HDAC1 has been proposed 
based on the X-ray structure (Scheme 2.1).
66,69,70 The zinc atom coordinates to two 
asparagine residues, one histidine residue and a molecule of water. The latter, chelated 
by a histidine residue, attacks the carbonyl group of the acetylated lysine residue to 
form  an  intermediate  where  the  zinc  coordinates  to  two  asparagine  residues,  one 
histidine residue and two oxygens. The tetrahedral intermediate degrades to a molecule 
of acetic acid and the deacetylated lysine residue which had abstracted a proton from 
His132. 
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Scheme 2.1 : Proposed catalytic mechanism of lysine deacetylation
69 
 
The classic pharmacophore for HDAC inhibitors is deduced from the transition state 
existing  between  the  acetylated  lysine  residue  and  an  HDAC.  An  HDAC  inhibitor 
consists of three distinct domains: a metal binding domain which chelates the zinc; a 
linker which occupies the channel and a hydrophobic cap which interacts with residues 
present  on  the  rim  of  the  active  site.  The  HDAC  inhibitor  binds  directly  and 
competitively to the HDAC active site blocking the substrate access.  
In hydroxamates, the hydroxamic acid moiety chelates the zinc in a bidentate manner 
through its carbonyl and hydroxyl functions. Histone Deacetylase Inhibitors 
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B) Aliphatics 
Some short chain aliphatic carboxylic acids are able to inhibit class I and II HDACs. For 
example, valproic acid (2.3), previously used as an anticonvulsant drug, is in clinical 
trials for cancer as a HDAC inhibitor and additionally phenylbutyrate and its derivatives 
also exhibit activity (Figure 2.5). Nevertheless, these compounds are relatively weak 
inhibitors and not very selective. 
 
 
Figure 2.5 : Structures of valproic acid (2.3) and sodium phenylbutyrate (2.4) 
 
C) Benzamides  
Benzamides are sub-micromolar HDAC inhibitors in which the benzamide function is 
the  zinc-binding  group.  Entinostat  (MS-275,  SNDX-275,  figure  2.6)  is  a  synthetic 
benzamide  with  micromolar  inhibition  activity  for  class  I  HDAC1,  2  and  3  and  is 
undergoing clinical trials for various cancers.
63 
 
 
Figure 2.6 : Structure of Entinostat (2.5) 
 
2.1.3.2. Cyclic peptides  
A  number  of  cyclic  peptides  are  known  to  be  HDAC  inhibitors;  they  all  contain  a 
macrocycle and a side chain arm containing a zinc-binding warhead.  
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A) Cyclic peptides containing an epoxyketone  
Cyclic peptides containing the (S)-2-amino-9,10-epoxy-8-oxodecanoic acid moiety (L-
Aoe moiety) are known to be HDAC inhibitors.
71 The zinc binding site in these cyclic 
peptides  is  the  ʱ-epoxy  ketone  which  coordinates  irreversibly  to  the  zinc  ion.  The 
following figure represents a selection of HDAC inhibitors with an L-Aoe side chain 
arm: HC-toxin, trapoxin B and chlamydocin.  
 
 
Figure 2.7: Structures of HC-toxin (2.6), trapoxin B (2.7) and chlamydocin (2.8) 
 
B) Azumamides 
Azumamides  A-E,  isolated  from  the  marine  sponge  Mycale  izuensis,  are  cyclic 
tetrapeptides with three D-amino acid residues and one β-amino acid (Figure 2.8).
72  
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Figure 2.8 : Structures of azumamides A-E 
 
Azumamides A, B and D possess a carboxamide warhead whereas azumamides C and E 
contain a carboxylic acid warhead. As expected azumamide E, bearing the carboxylic 
acid function as the zinc-binding group, displays a better inhibition activity (IC50 1.22 
µM against HDAC1) than azumamide A with the carboxamide (IC50 > 50 µM against 
HDAC1).
73 Azumamide E is much more potent than the simple aliphatic acids, such as 
valproic acid, indicating that interactions of the macrocycle with the rim of the enzyme 
contribute to HDAC binding. Nevertheless, the carboxylic acid or carboxamide present 
in the natural products are weaker zinc-binding groups when compared to hydroxamic 
acids. The Ganesan group prepared the hydroxamic acid derivative of azumamide E and 
showed that it is significantly more potent than both natural products azumamides A or 
E  (IC50  7  nM  total  HDACs  versus  5800  nM  for  azumamide  A  and  110  nM  for 
azumamide E).
73 
 
C) Cyclic depsipetides 
a) FK228, FR901375, spiruchostatins and largazole 
FK228, FR901375, spiruchostatins and largazole are natural product cyclic depsipetides 
known to be HDAC inhibitors (Figure 2.9). A depsipeptide is a peptide where at least Histone Deacetylase Inhibitors 
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one internal, secondary amide has been replaced by an ester. These cyclic depsipetides 
all contain only one ester bond in their macrocycle and the β-hydroxy acid, (3S, 4E)-3-
hydroxy-7-mercaptohept-4-enoic  acid.  FK228,  FR901375  and  spiruchostatins  are 
bicyclic depsipeptide molecules which contain a disulfide bridge which is not present in 
largazole. All the members of this depsipeptide family have been isolated from extracts 
of  bacterial  fermentation.  There  are  however  several  differences  between  FK228, 
FR901375 and spiruchostatins within their caps.  
FK228, also known as romidepsin or FR901228, was isolated in the culture broth of 
Chromobacterium violaceum by Fujisawa Pharmaceutical Company.
74,75 Its structure 
was  elucidated  by  spectroscopic  analysis,  chiral  chromatography  and  X-ray 
crystallographic analysis. FK228 contains the β-hydroxy acid, a D-cysteine, a D-valine 
and L-valine residues and a (Z)-dehydrobutyrine residue which is a potential site for 
covalent modifications by Michael addition.  
FR901375 was discovered in the fermentation broth of Pseudomonas chloroaphis and 
also  in  Chromobacterium  violaceum  by  Fujisawa  Pharmaceutical  Company.
76  In 
addition to the β-hydroxy acid, FR901375 contains a L-threonine, a D-cysteine and two 
D-valine residues. Despite the similarity to FK228, the HDAC inhibitory activity of 
FR901375 has not been reported. 
Spiruchostatins were isolated from a Pseudomonas extract in 2001 by Shin-ya et al.
77 
They  determined  the  structure  using  spectroscopic  analysis  which  showed  that  the 
spiruchostatins include the β-hydroxy acid,  a statine unit and three amino acids (D-
alanine,  D-cysteine,  D-valine/D-allo-isoleucine).  Spiruchostatins  differ  by  the  amino 
acid  next  to  the  statine  subunit:  spiruchostatin A  contains  a  valine  residue  whereas 
spiruchostatin B contains an isoleucine residue. The stereochemistry of the alanine and 
cysteine residues was determined by chemical degradation. The stereochemistry of the 
statine and the 3-hydroxy-7-mercaptohept-4-enoic acid has not been assigned in the 
isolation paper but was elucidated only later by total synthesis of spiruchostatins A and 
B.
78,79 
Largazole was isolated from the marine cyanobacterium Symploca species collected in 
the Florida Keys.
80 H. Luesch and co-workers elucidated the structure by a combination 
of chemical degradation, chiral chromatography and spectroscopic analysis. Largazole 
is  a  flat  16-membered  macrocycle  with  a  side  chain  arm.  It  possesses  a  4-Histone Deacetylase Inhibitors 
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methylthiazoline linearly fused to a thiazole in its cyclic core, a L-valine residue and a 
thioester of the β-hydroxy acid unit. 
 
 
Figure 2.9 : Structures of FR901375 (2.14), FK228 (2.15), spiruchostatins (2.16-2.17) and largazole 
(2.18) 
 
The complexity of their cap is responsible for their high potency (nanomolar order) and 
isoform selectivity towards class I HDACs. FK228 was FDA approved in 2009 for the 
treatment  of  peripheral  and  cutaneous  T-cell  lymphoma  (CTCL)  and  is  the  most 
thoroughly studied among the depsipeptides. Cheng and co-workers have managed to 
identify the gene cluster responsible for the biosynthesis of FK228 (Figure 2.10).
81 
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Figure 2.10 : Proposed biosynthesis of FK228
81 “Reprinted from Applied and Environmental Microbiology, 73, Cheng, 
Y.-Q.; Matter A. M., Characterization of a Gene Cluster Responsible for the Biosynthesis of Anticancer Agent FK228 in Chromobacterium 
violaceum No. 968, 3460-3469, Copyright (2007), with permission from American Society for Microbiology.” 
 
Spiruchostatins  are  also  very  potent  HDAC  inhibitors  (nanomolar).
78,82  Largazole 
presents  potent  antiproliferative  activity  (nanomolar)  and  an  excellent  selectivity  at 
targeting  cancer  cells  over  non-transformed  cells.  As  reported  by  Luesch  and  co-
workers,  the  growth  inhibitory  activity  against  the  transformed  mammary  epithelial 
cells (MDA-MB-231, GI50 7.7 nM) is considerably higher than against non-transformed 
mammary epithelial cells (NMuMG, 122 nM).
80 This natural product shows strong class 
I HDAC selectivity.  
 
The warhead in these natural products is the sulfur containing β-hydroxy acid (3S, 4E)-
3-hydroxy-7-mercaptohept-4-enoic acid. FR901375, FK228 and spiruchostatins contain 
an identical disulfide bridge which is reduced intracellularly to provide the free thiol as 
shown for FK228 in scheme 2.2.
81 FR901375, FK228 and spiruchostatins are prodrugs 
and their reduced forms are the active metabolites in which the thiol is able to chelate 
the  active-site  Zn
2+  residue  of  the  HDACs  and  by  doing  so  inhibit  the  enzymes. 
Although the thiols are weaker zinc-binding groups than the hydroxamic acids, the caps 
of these cyclic depsipeptides are able to interact strongly with the enzyme rim and are Histone Deacetylase Inhibitors 
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responsible for the high potency of these natural products. Largazole was also believed 
to be a prodrug as the octanoic thioester would be metabolised in vivo into an active 
metabolite.  As  predicted,  the  thioester  function  is  rapidly  hydrolysed  under 
physiological  conditions  and  the  thiol  residue  coordinates  to  Zn
2+  as  shown  in  the 
following scheme.  
 
 
Scheme 2.2 : Cellular metabolism and mechanisms of HDAC inhibition of FK228 (2.15) and 
largazole (2.18)  
 
b) Thailandepsins 
In  2008,  Cheng  et  al.  initially  reported  in  a  patent  the  following  structures  of  new 
depsipeptide HDAC inhibitors: the natural products thailandepsins A, B and C (Figure 
2.11).
83 They also contain the (3S, 4E)-3-hydroxy-7-mercaptohept-4-enoic acid moiety 
and the disulfide bridge present in FK228 and spiruchostatins. Thailandepsins A and B 
contain a hemiaminal function, whilst thailandepsin C includes an imine. They differ 
from  spiruchostatins  by  the  phenylalanine  and  imine  or  hemiaminal  function.  The 
structures were deduced by analysis of the biosynthesis gene cluster of thailandepsins.
83 
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Figure 2.11 : Structures of thailandepsins A (2.21), B (2.22) and C (2.23) 
 
In 2010, Cheng presented revised structures for thailandepsins A and B, which are very 
similar  to  spiruchostatins;  however  their  stereochemistry  was  only  predicted  and  is 
shown in figure 2.12. The hemiaminal function and imine are replaced by the statine 
moiety  in  the  revised  structures  of  thailandepsins.  Thailandepsin  A  contains  a 
methionine residue, whereas thailandepsin B has a norleucine residue. 
 
 
Figure 2.12 : Structures of thailandepsins A (2.24) and B (2.25)  
 
c) Burkholdacs 
Burkholdacs  A  and  B  were  isolated  by  Brady  and  co-workers  from  Burkholderia 
thailandensis E264 in 2011.
84 Their structures were elucidated by spectroscopic analysis 
(HRMS and NMR) and confirmed by the biosynthetic gene cluster. Burkholdacs A and 
B are also bicyclic depsipetides containing a statine unit like the spiruchostatins, from 
which  they  only  differ  by  the  replacement  of  the  valine  residue  with  a  methionine 
residue.  
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Figure 2.13 : Structures of Burkholdacs 
 
We believed that burkholdacs and spiruchostatins are the same molecules as they were 
isolated from the same bacterial strain. 
The stereochemistry of these natural products has not been definitively assigned, only 
predicted from the gene cluster and biosynthesis of burkholdacs (Figure 2.14). Only one 
epimerase domain is present in the gene cluster in the cysteine incorporating module. 
According to this result, the stereochemistry was predicted by Brady to be the following 
L-Val or L-Ile, D-Cys and L-Met (Figure 2.15).  
 
 
Figure 2.14 : Gene cluster and proposed biosynthesis of burkholdacs
84 “Reprinted with permission from 
Biggins, J. B.; Gleber, C. D.; Brady, S. F. Org. Lett. 2011, 13, 1536-1539, copyright (2011) American Chemical Society.” 
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Figure 2.15 : Predicted stereochemistry of burkholdacs A (2.28) and B (2.29) 
 
d) New thailandepsins structures 
Finally, very recently during the writing of this thesis, Cheng published new structures 
for  the  thailandepsins  isolated  from  the  same  bacterial  strain:  Burkholderia 
thailandensis E264 (Figure 2.16).
85 Thailandepsin A is identical to burkholdac B but 
thailandepsin  B  is  different  to  burkholdac  A.  Instead  of  the  methionine  residue, 
thailandepsin B possesses a norleucine residue, NMR and MS have confirmed their 
structures. The stereochemistry is the same as in spiruchostatins. 
 
 
Figure 2.16 : Final structures of thailandepsins A (2.30) and B (2.31) 
 
2.1.4. The syntheses of depsipeptides  
 
Whilst  no  syntheses  have  been  reported  for  thailandepsins  or  burkholdacs,  several 
syntheses are described in the literature for the other depsipeptides.
42,78,79,82,86-92 
 
2.1.4.1. Preparation of the β-hydroxy acid moiety 
Different strategies were employed to prepare the (3S, 4E)-3-hydroxy-7-mercaptohept-
4-enoic acid moiety 2.32 (Figure 2.17).  
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Figure 2.17 : Structure of the β-hydroxy acid 2.32 
 
In the first synthesis of FK228, Simon prepared the β-hydroxy acid in five steps and 
employed  the  Carreira  catalytic  asymmetric  aldol  reaction  (Scheme  2.3).
86  They 
required the enantiomer of the β-hydroxy acid fragment as a Mitsunobu reaction is later 
employed for their macrolactonisation. Cesium triphenylmethylthiolate anion was added 
to methyl 2,4-pentadienoate 2.33 by conjugate addition to afford the α,β-unsaturated 
methyl ester. Reduction with DIBAL followed by Swern oxidation afforded the α,β-
unsaturated aldehyde 2.34 which then underwent an aldol reaction using a chiral Ti-
catalyst prepared in situ from Ti(O-iPr)4 and ligands di-tert-butyl salicylaldehyde and 
the Schiff base derived from (R)-(+)-binaphthyl amino alcohol. The aldol adduct was 
obtained in 98%  yield and 99% enantiomeric excess. The benzyl  ester of  2.35 was 
hydrolysed  by  LiOH  in  a  mixture  of  methanol/water  to  afford  the  β-hydroxy  acid. 
However several  groups failed to reproduce this Carreira catalytic asymmetric aldol 
reaction.
78,88  
 
 
Scheme 2.3 : Simon’s synthesis of the β-hydroxy acid 2.36 with the (R) stereochemistry via Carreira 
catalytic asymmetric aldol reaction 
 
For the preparation of FR901375, Wentworth and Janda also required the enantiomer of 
the β-hydroxy acid as the Mitsunobu strategy was chosen for their macrolactonisation.
88 
They prepared the α,β-unsaturated aldehyde 2.38 in 2 steps by 1,4-addition of trityl Histone Deacetylase Inhibitors 
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mercaptan to acrolein, followed by Wittig reaction using the commercially available 
(triphenylphosphoranylidene)-acetaldehyde in benzene (Scheme 2.4).  
 
 
Scheme 2.4 : Wentworth and Janda’s synthesis of ʱ,β-unsaturated aldehyde 2.38 
 
They attempted the aldol reaction using oxazolidinethione auxiliary reported by Phillips 
but the obtained yield was low (35%).
93 
 
 
Scheme 2.5 : Attempt of aldol reaction using oxazolidinethione auxiliary 
 
It is known that acetate aldol reactions have poor diastereoselectivity when using the 
classical  Evans’  oxazolidin-2-one  auxiliary;  an  alternative  approach  is  to  use 
haloacetyloxazolidinones.
94  Wentworth  and  Janda  decided  to  use  a 
chloroacetyloxazolidinone auxiliary to perform the Evans’ aldol reaction which would 
be followed by dechlorination (Scheme 2.6).
88 The aldol reaction of the dibutylboron 
enolate derivative of chloroacetyloxazolidinone 2.41 with the aldehyde 2.38 produced 
compound  2.42  in  good  yield  (69%)  and  high  diastereoselectivity  (>90%). 
Dechlorination,  performed  by  treatment  with  aluminium  amalgam,  followed  by 
hydrolysis, using LiOH and H2O2 in THF, afforded the β-hydroxy acid. The latter was 
obtained in a total of five steps.  
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Scheme 2.6 : Wentworth and Janda’s synthesis of the β-hydroxy acid 2.36 with the (R) 
stereochemistry  
 
Doi and Takahashi studied the stereoselectivity of different enolates with Seebach’s N-
acetyl-oxazolidin-2-one auxiliary (Scheme 2.7).
90 They looked at the lithium enolate, 
the titanium enolate obtained by addition of TiCl(Oi-Pr)3 and the zirconium enolate 
obtained with Cp2ZrCl2.
90 The zirconium enolate obtained by transmetallation gave the 
best  results  whereas  the  lithium  and  titanium  enolates  only  gave  moderate 
diastereoselectivity.  They  also  used  Seebach’s  bromoacetyloxazolidinone  auxiliary, 
followed by a samarium-Reformatsky reaction to compare the influence of the bromo 
group on the diastereoselectivity. Better results were obtained using Seebach’s N-acetyl-
oxazolidin-2-one auxiliary with Cp2ZrCl2 as additive.
90 
 
 
Scheme 2.7 : Stereoselectivity of different enolates with 2.38 
 
To prepare the β-hydroxy acid for their synthesis of spiruchostatin A, Ganesan and co-
workers  used  an  aldol  reaction  between  aldehyde  2.38  and  Nagao’s  chiral  N-
acetylthiazolidine-2 thione 2.46 under Vilarrasa’s conditions (Scheme 2.8).
78 The aldol 
reaction gave a good yield (84%) and a high diastereoselectivity (95%). Aldehyde 2.38 
was prepared in two steps from acrolein as described previously by Wentworth and 
Janda.
88 The reaction sequence is scalable and the β-hydroxy acid is obtained in only 
three steps as they directly used compound 2.47 in their synthesis of spiruchostatin A. Histone Deacetylase Inhibitors 
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This method was employed by several other groups for the synthesis of the β-hydroxy 
acid fragment.
95-98  
 
 
Scheme 2.8 : Ganesan’s synthesis of the β-hydroxy acid derivative 2.47 
 
Williams’ preparation of the β-hydroxy acid involved a different approach using an 
enantioselective synthesis.
87 The key step is a Noyori asymmetric hydrogen transfer 
reaction performed on compound 2.50, which was obtained in two steps from methyl 
3,3-dimethoxypropionate 2.48 via formation of Weinreb amide 2.49 (Scheme 2.9).
99 
Noyori’s asymmetric transfer hydrogenation using 2.51 as a catalyst gave a good yield 
(71%) and excellent enantioselectivity (99%). The alkyne was reduced by Red-Al to the 
(E)-alkene 2.52 prior to conversion of the silyl ether to the tosylate. Hydrolysis of the 
acetal to the aldehyde followed by oxidation using the Pinnick conditions afforded the 
carboxylic acid 2.36. The tosylate was displaced by trityl mercaptan to afford the β-
hydroxy acid in an overall yield of 13%. This method is slightly longer than the others 
(nine steps) but it is scalable.  
 
 
Scheme 2.9 : Williams’ synthesis of the β-hydroxy acid 2.36 with the (R) stereochemistry via Noyori 
asymmetric hydrogen transfer reaction Histone Deacetylase Inhibitors 
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Katoh and co-workers used a Julia-Kocienski olefination of sulfone 2.56 with aldehyde 
2.57 prepared from maleic acid (Scheme 2.10).
79,82 The sulfone 2.56 was obtained from 
mono-protected 1,3-propanediol: a Mitsunobu reaction to introduce the S-tetrazole was 
followed  by  molybdenum-mediated  oxidation,  deprotection  of  the  PMB  group  and 
finally  another  Mitsunobu  reaction  to  insert  the  S-trityl  group.  The  Julia-Kocienski 
olefination of sulfone 2.56 with aldehyde 2.57 led to the inseparable mixture of E/Z-
stereoisomers 2.59 and 2.60 (5:1) in good yield (66%). The mixture was treated by 
DIBAL to regioselectively open the acetal to form the separable E and Z isomers. The 
primary alcohol group was converted into the carboxylic acid in two steps. The PMB 
protected seco-acid was obtained in eight steps and used as such in their synthesis of 
spiruchostatin B. 
 
 
Scheme 2.10 : Katoh’s synthesis of the β-hydroxy acid 2.61 via Julia-Kocienski olefination 
 
Several groups used kinetic resolution to prepare the β-hydroxy acid for their synthesis 
of largazole (Scheme 2.11).
100-103 The racemic β-hydroxy ester 2.63 is obtained by aldol 
reaction between the lithium enolate of tert-butyl-acetate and acrolein. The enzymatic 
resolution of the racemic mixture 2.63, using PS-Amano Lipase, led to the formation of 
the  (S)-acetate  only.  The  yield  of  the  enzymatic  resolution  is  almost  50%  and  the 
enantiomeric  excess  is  excellent.  The  (S)-acetate  is  then  hydrolysed  to  give  the  β-Histone Deacetylase Inhibitors 
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hydroxy ester. Metathesis is then used to introduce the thiol containing side chain at a 
later stage, such as in the total synthesis of largazole. 
 
 
Scheme 2.11 : Synthesis of the β-hydroxy ester 2.66 via enzymatic resolution 
 
2.1.4.2. Macrolactonisation in the cyclic depsipeptides  
Simon’s  synthesis  of  FK228  is  the  first  synthesis  of  a  member  of  this  class  of 
depsipeptides  to  be  described  in  the  literature  (Scheme  2.12).
86  Synthesis  of  the 
tetrapeptide  2.69,  constituting  of  valine,  cysteine,  threonine  and  valine,  involved  a 
standard sequence of couplings. Tosylation of the alcohol followed by elimination after 
treatment  with  DABCO  formed  the  dehydrobutyrine  residue;  diethylamine  was  also 
used in the same step in order to remove the Fmoc protecting group. The tetrapeptide 
2.70  was  then  coupled  to  the  β-hydroxy  acid  2.36.  Ester  hydrolysis  followed  by 
macrolactonisation  was  performed  by  the  Mitsunobu  reaction.  Finally  the  disulfide 
bridge was formed by treatment with iodine and methanol.  
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Scheme 2.12 : First synthesis of FK228 (2.15) 
 
Macrolactonisation appeared to be very difficult in the synthesis of FK228. Simon and 
co-workers  attempted  the  esterification  using  acid  activation  with  various  coupling 
reagents were unsuccessful.
86 The Keck modification of the Steglich esterification gave 
the product with a very low yield (<5%). They then resorted to alcohol activation by 
Mitsunobu reaction to form the product in 62% yield following reaction optimisation. 
They noticed that the use of TsOH was essential to reduce the β-elimination occurring 
on  the  β-hydroxy  acid.  Since  the  Mitsunobu  reaction  proceeds  with  stereochemical 
inversion, the total synthesis required the enantiomer of the β-hydroxy acid prior to 
macrolactonisation.  Katoh  et  al.  managed  to  reproduce  the  62%  yield  for  their 
macrolactonisation in their synthesis of spiruchostatins.
82 The Mitsunobu reaction was 
also tried by Williams et al. who reported 24% yield, and by Ganesan who also reported 
a  low  yield  (10-20%).
42,87  This  shows  that  this  Mitsunobu  macrolactonisation  is 
complex and not easily reproducible.  
 
Wentworth and Janda were the only group who prepared FR901375 (Scheme 2.13).
88 
They used the same Mitsunobu conditions described by Simon and obtained a yield of 
59%.
86 Firstly they prepared the tetrapeptide 2.75, constituting of threonine, cysteine 
and two valine residues, which was then coupled to the β-hydroxy acid 2.36 with the 
(R)-stereochemistry.  After  ester  deprotection,  they  performed  the  macrolactonisation 
under Mitsunobu conditions and then formed the disulfide bond. The final step was the Histone Deacetylase Inhibitors 
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deprotection of the hydroxyl group of the threonine residue; the protecting group was 
necessary earlier in the synthesis in order to avoid side reactions occurring during the 
Mitsunobu macrolactamisation. 
 
 
Scheme 2.13 : Wentworth and Janda’s synthesis of FR901375 (2.14) 
 
In the synthesis of spiruchostatin, the macrolactonisation by carbonyl activation rather 
than  Mitsunobu  reaction  is  possible  as  the  carboxylic  acid  is  unhindered  at  the  ʱ-
position. This was first realised by Yamaguchi esterification (53%) in the total synthesis 
of  spiruchostatin  A  performed  in  2004  by  Ganesan  et  al.  (Scheme  2.14).
78  They 
performed a condensation of Boc-D-valine pentafluorophenyl ester with methyl acetate 
followed  by  diastereoselective  reduction  to  obtain  the  valine  statine  fragment.  The 
methyl ester has to be deprotected and reprotected with a Tce protecting group which is 
compatible with acidic and basic conditions. The valine statine derivative was coupled 
with Fmoc-D-Cys-OH, then with Fmoc-D-Ala-OH and finally with the β-hydroxy acid. 
The  Yamaguchi  esterification  was  used  to  form  the  macrocycle.  Formation  of  the 
disulfide bridge by treatment with iodine in a mixture of MeOH and CH2Cl2, followed 
by deprotection of the hydroxyl group afforded spiruchostatin A.  
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Scheme 2.14 : First synthesis of spiruchostatin A (2.16) 
 
However, improved yields (67 and 90% respectively) for the macrolactonisation were 
later obtained by Doi and Takahashi followed by Katoh with the use of 2-methyl-6-
nitrobenzoic  anhydride  (MNBA,  figure  2.18).
82,90  This  reagent,  also  known  as  the 
Shiina  reagent,  is  an  effective  condensation  reagent  for  the  DMAP-promoted 
lactonisation of seco-hydroxycarboxylic acids, as reported by Shiina et al.
41 These mild 
conditions do not require a protecting group on the hydroxyl group of the statine and 
also reduce the formation of side products.  
 
 
Figure 2.18 : Structure of MNBA (2.84)  
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Doi and Takahashi also showed that the order of reaction between macrolactonisation 
and disulfide formation is important as attempted macrolactonisation after the disulfide 
bond formation failed.
90 
 
Ganesan  et  al.  tried  to  perform  the  macrolactonisation  of  FK228  using  the  Shiina 
reagent but no product was formed.
42 They also tried several coupling reagents and the 
best results were obtained with MSNT in a low 34% yield. These low yields for the 
macrolactonisation are due not only to the presence of valine in the ʱ-position, but also 
due to the rest of the peptide. They decided to change their strategy and to perform the 
macrocyclisation by forming an amide bond instead of the ester bond. They started with 
the high yielding coupling of Fmoc-Val-OH with the β-hydroxy acid derivative 2.85 
that they obtained in two steps from compound 2.47 (Scheme 2.15).  
 
 
Scheme 2.15 : Synthesis of fragment 2.86 
 
This confirmed that not only is the hindrance of the valine responsible for the low yield 
of the macrolactonisation, but also the rest of the peptide. The tripeptide 2.89 formed of 
valine, cysteine and threonine is prepared by standard couplings (Scheme 2.16). The 
dehydrobutyrine 2.90 is formed by dehydration using DABCO and is then coupled to 
2.86 after ester hydrolysis. The macrolactamisation is performed after deprotection of 
both sides of the linear peptide 2.92 and is followed by the disulfide bridge formation.  
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Scheme 2.16 : Macrolactamisation strategy for FK228 preparation 
 
During the course of my PhD, several total syntheses of largazole were published. To 
form the macrocycle of largazole, the possible disconnections are the two amide bonds 
and  the  ester  bond.  Several  groups  performed  the  macrolactamisation  between  the 
thiazole ring and the β-hydroxy acid (Figure 2.19).
96,97,100-102,104 It is interesting to notice 
that  Luesch  et  al.  successfully  performed  the  macrolactamisation  between  the  4-
methylthiazoline ring and the valine residue with good yield despite the position being 
relatively hindered.
105 Several other groups also prepared the macrocycle by forming 
this bond.
95,103 
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Figure 2.19 : Different strategies employed for the preparation of largazole 
 
Many groups mentioned their attempts to perform the macrocyclisation by forming the 
ester bond. Forsyth mentioned that they tried the Yamaguchi, Keck, Mukaiyama and 
Mitsunobu procedures.
104 The macrolactonisation is not possible for the synthesis of 
largazole due to the hindrance of the valine and the rest of the peptide as observed in the 
synthesis of FK228.  
Xu and Tao used OTBS as precursor for the thiol but their macrolactamisation was 
unsuccessful (Figure 2.20).
97 They proposed that the homoallylic alcohol is involved in 
protecting group migration or intramolecular cyclisation and it is necessary to insert the 
S-trityl group before the macrolactamisation.  
 
 
Figure 2.20 : Macrolactamisation failed because of the presence of –OTBS group 
 
2.1.4.3. Statine unit of spiruchostatins 
Spiruchostatins contain an isoleucine statine derivative (Figure 2.21). 
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Figure 2.21 : Structure of the statine subunit 
 
Several natural products contain this moiety including tamandarins, melleumin A and 
miraziridine  A  (Figure  2.22).
106-108  Tamandarins  and  melleumin  A  are  also  cyclic 
depsipeptides. 
 
 
Figure 2.22 : Structures of tamandarins A and B, melleumin A and miraziridine A 
 
The  syn-stereochemistry  of  the  statine  present  in  spiruchostatin  was  not  originally 
assigned  and  was  elucidated  by  synthesis.
77,78  The  statine  unit  can  undergo  β-
elimination  and  form  a  similar  function  to  the  dehydrobutyrine  moiety  present  in 
FK228.  
 
Ganesan et al. performed a Claisen condensation of Boc-D-valine pentafluorophenyl 
ester with methyl acetate, followed by diastereoselective reduction to obtain the  syn 
diastereomer  (Scheme  2.17).
78,106  The  methyl  ester  has  to  be  deprotected  and Histone Deacetylase Inhibitors 
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reprotected  with  a  Tce  protecting  group  which  is  compatible  with  acidic  and  basic 
conditions.  
 
 
Scheme 2.17 : Formation of the statine unit 2.80 
 
Katoh investigated the best conditions for the reduction by comparing different reducing 
agents (LiBH4, NaBH4 and KBH4); it was determined that KBH4 at low temperature (–
40 °C) gave the best yield and diastereomeric ratio.
82 
 
2.1.4.4. Metathesis in largazole synthesis 
Several  groups  used  the  cross-metathesis  reaction  to  insert  the  side  chain  (Scheme 
2.18).
101-103,105  This  method  is  interesting  as  it  allowed  the  rapid  preparation  of 
analogues. Most of the groups used Grubbs’ second generation catalyst. Optimisation of 
this step was undertaken by Cramer et al. and Grela’s catalyst 2.98 appeared to give the 
best results.
102 Largazole is obtained with a good yield (75%) with a trans/cis ratio 4:1.  
 
 
Scheme 2.18 : Incorporation of the side chain on largazole 
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2.1.4.5. Thiazoline formation in largazole synthesis 
Most of the groups used basic conditions to form the thiazoline ring by condensation of 
the  nitrile  derivative  2.100  and  (R)-methylcysteine  hydrochloride  2.99,  using  either 
triethylamine as a base
 or sodium hydrogenocarbonate and a phosphate buffer solution
 
(Scheme 2.19).
96,97,101,102,105 
 
 
Scheme 2.19 : Thiazoline formation via basic condensation  
 
Xie used the Charette conditions to form the thiazoline moiety by condensation between 
the thiazolyl amide 2.103 and the (R)-methylcysteine methyl ester hydrochloride 2.102 
by treatment with triflic anhydride and pyridine in good yield (Scheme 2.20).
95,109 
 
 
Scheme 2.20 : Thiazoline formation using Charette conditions 
 
Forsyth employed a Staudinger reduction to obtain the thiazoline ring (Scheme 2.21).
104 
The  azido  thioester  2.105  was  treated  with  triphenylphosphine  in  acetonitrile  under 
microwave irradiation to form 2.106.  
 
 
Scheme 2.21 : Thiazoline formation using Staudinger reduction Histone Deacetylase Inhibitors 
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Kelly’s method was employed on 2.107 by both Ghosh and Doi to form the thiazoline 
in excellent yield (Scheme 2.22).
44,100,110  
 
 
Scheme 2.22 : Thiazoline formation by Kelly’s method 
 
Zhou and Jiang performed the simultaneous formation of the thiazole and thiazoline by 
treatment of the tripeptide, which was prepared by solid phase synthesis using 2-chloro-
trityl chloride resin, with TiCl4 (Scheme 2.23).
111 The thiazoline ring was then oxidised 
to the thiazole using activated manganese dioxide.  
 
 
Scheme 2.23 : Simultaneous formation of the thiazole and thiazoline rings 
 
2.1.5. Analogues of the cyclic depsipetides 
 
2.1.5.1. FK228 analogues 
Ganesan and co-workers prepared several analogues of FK228 (Figure 2.23).
112 They 
made  hybrids  of  FK228  and  spiruchostatin  A  that  contain  in  position  1:  a  glycine 
residue, in position 2: a valine residue and in position 3: an alanine or a valine residues. 
FK228 possesses instead in position 1: a valine residue, in position 2: a dehydrobutyrine Histone Deacetylase Inhibitors 
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residue (Dhb) and in position 3: a valine residue and spiruchostatin A comprises in 
position 1: the statine moiety, in position 2: a valine and an alanine residue in position 
3. Both the analogues 2.110 and 2.111 are potent HDAC inhibitors with similar activity 
to FK228. It is important to highlight the fact that the Dhb residue is not an essential 
element for the activity of FK228 and can be replaced, for example by a valine residue. 
Similarly, in spiruchostatin the presence of the statine functional unit is not necessary 
for biological activity. Biological activities of analogues 2.110 and 2.111 have shown 
that a bulky group in position 3 is favourable. The linear compound 2.112 was found to 
be  totally  inactive  as  an  HDAC  inhibitor,  demonstrating  the  importance  of  the 
macrocycle in the activity of the compounds. They decided to make analogues 2.113 
and 2.114, where the cysteine is replaced by an alanine residue, to check the importance 
of the disulfide bridge. They tested compound 2.114 and found it to give a good result 
in growth inhibition but poor result in HDAC inhibition. Compound 2.113 gave the 
opposite results: poor growth inhibition but potent as an HDAC inhibitor. This showed 
the importance of both thiols, one binds the zinc and the other is involved in the cellular 
uptake.  
 
 
Figure 2.23 : Reported analogues of FK228 
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2.1.5.2. Spiruchostatin analogues 
Epi-Spiruchostatin A (2.115) was prepared by Ganesan with the (R)-stereochemistry for 
the β-hydroxy acid.
78 Biological activity showed that the stereochemistry (S) at this 
position is essential as the epi-spiruchostatin lost considerable activity. The inhibition 
activity  against  growth  of  breast  cancer  cell  lines  dropped  from  10  nM  for 
spiruchostatin A to 10 µM for epi-spiruchostatin A.
78  
5’’-epi-Spiruchostatin  B  (2.116)  was  prepared  by  Katoh  et  al.  with  the  biological 
activity showing that the stereochemistry at this position can be either (R) or (S).
82 The 
5’’-epi-spiruchostatin B appeared to show even greater selectivity towards HDAC1 than 
HDAC6, than spiruchostatin B (1625-fold to 636-fold).  
 
 
Figure 2.24 : Spiruchostatins and epimers 
 
2.1.5.3. Largazole analogues prepared by other groups 
According to Luesch and Cramer, a
 four-atom linker, between the macrocycle and the 
octanoyl group in the side chain, is optimal for HDAC inhibitory activity to be a good 
mimic of the lysine side chain of substrate.
98,102 Studies showed the necessity of the 
thiobutenyl group for the antiproliferative activity of the molecule, as a shorter or longer 
spacer resulted in a loss of inhibitory activity. Zhou and Jiang confirmed the essential 
(E)-geometry for the alkene; (Z)-alkenes are inactive as HDAC inhibitors.
111 
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Analogues  bearing  S-acetyl  2.118  or  disulfide  derivative  2.119  present  a  similar 
inhibition  activity  against  HDAC  when  compared  to  largazole  with  its  S-octanoyl 
chain.
110  Phillips  was  able  to  confirm  that  the  thiol  is  a  zinc  chelating  group  by 
preparing inactive derivatives with an ester or ketone function instead of the thioester 
(2.120  and  2.121).
101  Williams  replaced  the  zinc-binding  group  of  largazole  by  a 
carboxylic acid function to form analogue 2.122, such as in azumamide.
113 As expected 
the thiol is a better zinc-binding group than the carboxylic acid function. Williams also 
prepared analogues with benzamide and thioamide as the zinc binding group (2.123, 
2.124, 2.125 and 2.126).
113 All these analogues are potent inhibitors, but a decrease of 
activity is nonetheless observed.  
 
 
Figure 2.26 : Reported analogues of largazole with variation in the side chain 
 
Luesch et al. demonstrated that the (S)-configuration at the C17-position is crucial as 
the 17-epi-largazole exhibited a more than 500-fold loss in activity.
98 Williams and co-
workers modified the thiazoline ring.
113 They prepared the C-7 epimer, the cysteine 
analogue 2.128 and the thiazole-thiazole derivative 2.131. These analogues are potent 
HDAC inhibitors but their activities are lower than largazole. The oxazoline-oxazole 
2.132 and pyridine-thiazole 2.133 analogues were also synthesised. They both displayed 
greater  inhibitory  activity  than  largazole,  especially  the  pyridine-thiazole  derivative 
2.133. De Lera prepared analogues with a substituent in C-7 position (H, Et, Bn) and the 
same  thiazole-thiazole  derivative  2.131.
103  The  C7-benzyl  and  the  thiazole-thiazole Histone Deacetylase Inhibitors 
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derivative were more potent inhibitors than largazole, however the biological result for 
the thiazole-thiazole analogue differed from that previously reported by Williams.
113 
Williams and co-workers prepared the enantiomer of largazole which was found to be 
less potent as an HDAC inhibitor than largazole (100-fold decrease).
113 
 
 
Figure 2.27 : Reported analogues of largazole with variation in the macrocycle 
 
Luesch et al.
 showed that it is possible to replace the valine residue with an alanine 
residue  with  little  alteration  to  the  inhibition  activity.
98  Williams  and  co-workers 
replaced the valine with a proline to add more rigidity in the macrocycle and observed a 
significant decrease in activity.
113 Zhou and Jiang showed that replacing valine by a 
tyrosine resulted in a slightly lower activity but an increase of selectivity towards cancer 
cell lines over normal cell lines of more than 100-fold.
111  
 
The linear compound 2.134 prepared by Phillips and co-workers presented no biological 
activity as an HDAC inhibitor and emphasised the importance of the macrolide ring 
(Figure 2.28).
101  
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Figure 2.28 : Structure of linear compound 2.134 
 
Bradner decided to make the amide isosteres of the depsipeptides FK228 and largazole 
(Figure  2.29).
114  These  compounds  should  be  more  stable  with  more  rigid 
conformations. 
 
 
Figure 2.29 : Amide isosteres of FK228 and largazole 
 
Having  prepared  the  compound  2.138  from  N-Boc(Asp)-OtBu-OH  (2.137)  in  seven 
steps they  coupled it to  the tetrapeptide  2.139. However, in  the case  of the FK228 
analogue,  the  macrolactamisation  was  unsuccessful.  They  reversed  the  order  of  the 
steps, forming the disulfide bridge followed by the macrolactamisation in 53% yield. 
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Scheme 2.24 : Synthesis of the amide isostere of FK228 
 
Concerning  the  preparation  of  largazole  analogue  2.136,  the  macrolactamisation 
between the thiazole ring and the β-hydroxy acid worked well following neutralization 
of the TFA  salt obtained after  Boc deprotection of the linear precursor. The amide 
isostere of FK228 lost considerable inhibition activity when compared to FK228 with a 
50-fold less in potency. The amide isostere of largazole also showed a loss in inhibition 
activity, but only a decrease of 9-fold when compared to largazole. The replacement of 
the ester function by an amide modifies the accessible conformational space.  
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2.2. AIMS 
 
HDAC  depsipeptide  inhibitors  are  molecules  of  interest  in  our  group  and  we  had 
previously prepared FK228, spiruchostatin A and analogues of these natural products. 
 
We decided to prepare largazole as it was an attractive target as an HDAC inhibitor. We 
also planned to prepare some related analogues in order to study the structure-activity 
relationships (SAR) of largazole.  
 
During the course of my PhD, the thailandepsins/burkholdacs were disclosed by Cheng 
and Brady. These natural products were also targeted for total synthesis. We started 
with  Cheng’s  originally  reported  hemiaminal  structure  for  thailandepsins  as  target 
molecules, followed later by his revised structures. Later, Brady’s burkholdac B became 
our target as we believed it was identical to Cheng’s revised structure for thailandepsin 
A.  Since  neither  Cheng  nor  Brady  determined  the  stereochemistry  of  the  natural 
products, this would need to be deduced and confirmed by comparison of synthetic and 
naturally isolated material. 
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2.3. SYNTHESIS AND BIOLOGICAL ACTIVITY OF LARGAZOLE 
AND ANALOGUES 
 
2.3.1. Total synthesis of largazole 
 
2.3.1.1. Retrosynthesis of largazole 
The strategy proposed to prepare largazole is to synthesise the following two fragments: 
the thiazole-thiazoline fragment 2.109 and the -hydroxy acid derivative 2.143 (Scheme 
2.25).  A  convergent  synthesis  is  to  be  employed  that  will  make  the  synthesis  of 
analogues easier. The macrolactamisation can be performed between the thiazole and 
the carboxylic acid of the -hydroxy acid (position 1) and between the thiazoline and 
valine (position 2). We decided to perform the macrolactamisation between the thiazole 
and the carboxylic acid of the -hydroxy acid because this position is less hindered than 
the position between the thiazoline and valine. Amide bond formation will be performed 
in  position  2  prior  to  the  macrolactamisation.  The  fragment  containing  the  4-
methylthiazoline  linearly  fused  to  the  thiazole  2.109,  can  be  prepared  from  (R)-
methylcysteine and glycine. The -hydroxy acid derivative 2.143 will be synthesised 
using the method previously employed in our group to prepare spiruchostatin A and 
FK228. The thioester will be formed in the last step as thioesters are known to be easily 
hydrolysed.  
 
 
Scheme 2.25 : Retrosynthetic analysis of largazole (2.18) Histone Deacetylase Inhibitors 
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2.3.1.2. Synthesis of the -hydroxy acid derivative  
The Fujita-Nagao auxiliary was obtained in two steps from D-valine (Scheme 2.26). The 
reduction of valine, using a mixture of sodium borohydride and iodine in THF, yielded 
(R)-valinol in good yield.
115 The alcohol is then condensed with carbon disulfide in 
excellent yield.
116 Treatment of 2.145 with sodium hydride and acetyl chloride gave the 
desired acetylated Fujita-Nagao auxiliary 2.46 (89%).
117 
 
 
Scheme 2.26 : Synthesis of acetylated Fujita-Nagao auxiliary 2.46 
 
The aldehyde 2.38 was prepared in two steps, 1,4-addition and Wittig reaction, from 
acrolein 2.37 as described in the Wentworth-Janda synthesis.
88 Reaction of the aldehyde 
2.38  with  the  N-acetylthiazolidinethione  Nagao  auxiliary  2.46,  under  Vilarrasa’s 
conditions, gives the desired diastereomer 2.47 in moderate yield. The chiral auxiliary is 
then removed and replaced by a trimethylsilyl ethyl protecting group (TMSE) in one 
step. The fragment 2.86 is finally prepared by esterification of N-Fmoc-L-valine with 
the seco-acid 2.85 (Scheme 2.27). 
 
 
Scheme 2.27 : Synthesis of -hydroxy acid derivative 2.86 
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2.3.1.3. Synthesis of the thiazole-thiazoline fragment  
In order to prepare the thiazole-thiazoline fragment 2.104, we planned to prepare the 
thiazole fragment 2.147 from the thioamide 2.149, methyl bromopyruvate and (R)-2-
methylcysteine. The thiazoline ring will be prepared via formation of the amide 2.146. 
 
 
Scheme 2.28 : Retrosynthetic analysis of fragment 2.104 
 
The commercially available thioamide 2.149 was treated with methyl bromopyruvate to 
give the thiazole derivative 2.151 in moderate yield (50%).
33 Saponification of 2.151 
with lithium hydroxide in a mixture of water/THF at 0 °C generated the carboxylic acid 
2.147 in excellent yield (Scheme 2.29). In this case, we do not need to use epimerisation 
free conditions for the thiazole formation as a glycine derivative is used. 
 
 
Scheme 2.29 : Synthesis of fragment 2.147 
 
Amide  2.146  was  prepared  by  coupling  of  2.147  with  (R)-2-methylcysteine  methyl 
ester,  although  protection  of  the  thiol  would  have  avoided  side  reactions  such  as 
dimerisation. Formation of the thiazoline was attempted using TiCl4 but with no success 
(Scheme 2.30).
44 
 Histone Deacetylase Inhibitors 
 
107 
 
 
Scheme 2.30 : Attempt to synthesise fragment 2.104 
 
We proposed that the lack of success was due to loss of the Boc group during this step. 
We decided to use a different protecting group: the allyloxycarbonyl (Alloc) protecting 
group.  
 
The synthesis of the Alloc fragment 2.156 is slightly different as the thioamide is not 
commercially available (Scheme 2.31). The first step is to convert the amine function of 
glycinamide 2.152 to its N-Alloc derivative 2.153 using allyl chloroformate and Hünig’s 
base in the presence of DMAP as a catalyst (Scheme 2.31).
118 The amide 2.153 is then 
transformed into the thioamide 2.154 using Lawesson’s reagent.
119 The thiazole ring is 
formed using the conditions described previously and finally the ester 2.155 hydrolysed 
to afford 2.156.
33 
 
 
Scheme 2.31 : Synthesis of fragment 2.156 
 
The  thiol  function  of  commercial  (R)-2-methylcysteine  hydrochloride  was  first 
protected with a trityl group by using triphenylmethanol and boron trifluoride diethyl 
etherate  in  acetic  acid  (Scheme  2.32).
120  Esterification  of  the  S-triphenylmethyl 
thioether 2.158 with thionyl chloride in methanol provided the methyl ester 2.159.
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Scheme 2.32 : Protection of (R)-2-methylcysteine 
 
We prepared amide 2.160 and attempted to form the thiazoline ring using the Kelly 
method  (triphenylphosphine  oxide  and  triflic  anhydride),  however  no  product  was 
obtained (Scheme 2.33). We thought that this method was not suitable for 4-methyl 
thiazolines as no examples were described in the literature. However Doi and Gosh later 
published their syntheses of largazole where they employed the Kelly method to form 
the  4-methylthiazoline  ring,  respectively  using  the  azide  and  Fmoc  protecting 
group.
100,110 We hoped that the Alloc protecting group should be compatible with the 
Kelly conditions, however the reaction was unsuccessful. It is possible that the failed 
reaction  was  due  to  the  use  of  an  open  bottle  of  triflic  anhydride.  After  trityl 
deprotection of 2.160, we tried to cyclise 2.161 with TiCl4 but obtained a mixture of 
starting material and product that was difficult to separate. 
 
 
Scheme 2.33 : Attempt to synthesise fragment 2.162 
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As  difficulties  were  encountered  in  the  formation  of  the  thiazoline  ring,  some 
modifications were necessary to the previous pathway. Conversion of the carboxylic 
acid 2.156 into the amide 2.163, followed by dehydration with trifluoroacetic anhydride 
and  triethylamine,  resulted  in  the  cyano-  compound  2.164  in  two  steps  (Scheme 
2.34).
73,101  The  latter  was  directly  coupled  to  (R)-2-methylcysteine  under  mild 
conditions (phosphate buffer solution pH 6, methanol, 70 ºC, 2 h).
122 This procedure 
allowed  the  direct  use  of  (R)-methylcysteine  hydrochloride  without  addition  of  any 
protecting groups.  
 
 
Scheme 2.34 : Synthesis of thiazole-thiazoline fragment 2.165 
 
Removal of the Fmoc protecting group on the fragment 2.86, using diethylamine, and 
PyBOP-mediated coupling to the thiazoline-thiazole carboxylic acid 2.165 provided the 
acyclic precursor 2.166 (Scheme 2.35). The Alloc protecting group was then removed 
using tetrakis(triphenylphosphine)palladium, with morpholine as a scavenger, in poor 
yield (30%). The TMSE group was deprotected to form the carboxylic acid using TFA, 
after  which  the  macrolactonisation,  using  HATU  under  highly  diluted  conditions  in 
order to avoid intermolecular reactions, was performed to give 2.168. The quantity of 
final product obtained was very low. 
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Scheme 2.35 : Attempts to synthesise largazole 
 
Using  compound  2.169  as  a  model,  an  undergraduate  student,  Emma  Packard, 
attempted  to  deprotect  the  Alloc  group.  However,  the  reaction  yielded  a  multi-
component  crude  product  from  which  low  yields  of  desired  product  were  obtained 
(Scheme 2.36). We believe that this is due to interference in the reaction by the -
hydroxy acid moiety and a different amine protecting group would be more effective. 
 
 
Scheme 2.36 : Removal of Alloc protecting group 
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As  a  result  of  changing  our  strategy  to  form  the  thiazoline  ring,  by  using  basic 
conditions, the Boc group became a suitable protecting group. We started the synthesis 
from  the  cheap  starting  material  glycinamide  hydrochloride  instead  of  the  more 
expensive, commercially available thioamide 2.149. Glycinamide hydrochloride 2.152 
was  protected  with  a  Boc  group  and  the  resulting  amide  2.171  converted  into  a 
thioamide 2.149 at rt using Lawesson’s reagent (Scheme 2.37).
123 Initial attempts to 
convert  to  the  thioamide  in  refluxing  toluene  and  then  in  refluxing  THF  were 
unsuccessful  with  decomposition  observed  in  both  cases.  Classic  thiazole  formation 
followed by hydrolysis of the ester yielded the desired product 2.147. 
 
 
Scheme 2.37 : Synthesis of thiazole fragment 2.147 
 
Due to the high costs of (R)-2-methylcysteine hydrochloride (£200 for 1 g) we decided 
to  prepare  it  ourselves  from  commercially  available  starting  materials.  (R)-2-
Methylcysteine hydrochloride 2.157 was prepared in four steps from cysteine using the 
Pattenden method (Scheme 2.38).
124,125 Condensation of (R)-cysteine methyl ester 2.172 
with pivaldehyde yielded the thiazolidine 2.173 with a mixture of (2R, 4R) and (2S, 4R) 
diastereomers in a 1.9:1 ratio. N-Formylation of the thiazolidine 2.173 using sodium 
formate in the presence of formic acid led to a single (2R, 4R) syn-diastereomer 2.174 in 
79% yield. Treatment of a solution of 2.174 in tetrahydrofuran at –90 ºC with lithium 
diisopropylamide in the presence of the additive 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-
pyrimidinone  (DMPU),  followed  by  quenching  of  the  resulting  enolate  with 
iodomethane at –90 ºC produced the corresponding 4-methylthiazolidine 2.175 in 51% 
yield.  Methylation  occurred  anti-  to  the  bulky  t-butyl  group  with  excellent 
diastereoselectivity observed. Hydrolysis of 2.175 in the presence of 5 M HCl solution Histone Deacetylase Inhibitors 
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produced  the  desired  product  (R)-2-methylcysteine  hydrochloride  2.157  in  excellent 
yield. 
 
 
Scheme 2.38 : Preparation of (R)-2-methylcysteine hydrochloride (2.157) 
 
The nitrile derivative 2.100 was prepared as previously described from the carboxylic 
acid 2.147 via the amide 2.176, and then directly coupled to the (R)-methylcysteine 
under basic conditions to form the thiazole-thiazoline fragment 2.109 in excellent yield 
(Scheme 2.39).
122  
 
 
Scheme 2.39 : Synthesis of thiazole-thiazoline fragment 2.109 
 
2.3.1.4. Coupling of the fragments 
Fragment 2.86 was Fmoc deprotected and coupled to the carboxylic acid 2.109 using 
PyBOP as the coupling reagent (Scheme 2.40). TFA treatment removed the Boc and Histone Deacetylase Inhibitors 
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TMSE  protecting  groups  on  the  linear  fragment  of  largazole.
96  It  was  necessary  to 
extend the reaction times as the TMSE protecting group proved to be more difficult to 
remove than the Boc protecting group. The macrolactamisation was then performed 
under high dilution using HATU and HOBt (65% over 2 steps).
96 The S-trityl protecting 
group  was  removed  using  TFA  and  triethylsilane  as  scavenger  to  afford  the  active 
metabolite:  largazole  thiol  in  good  yield  (79%).  Formation  of  the  thioester  using 
octanoyl chloride and triethylamine completed the total synthesis of largazole.
96  
 
 
Scheme 2.40 : Synthesis of largazole (2.18) 
 
Largazole  was  obtained  in  2.4%  overall  yield  in  the  longest  linear  sequence  (11 
steps).
126 The structure was confirmed by comparison of the 
1H and 
13C NMR data of 
the  synthetic  compound  with  that  reported  in  the  literature  for  the  natural  product 
(Figure 2.30, table 2.1).
80 
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Figure 2.30 : Atom numbering used for largazole Histone Deacetylase Inhibitors 
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#  ʴ
1H and mult. 
Reported
80  
1H and mult. 
ʴ
13C and mult. 
Reported
80 
ʴ
13C and 
mult. 
1 
   
168.8, C  168.9, C 
2  4.61, dd (9.3, 3.3)  4.61, dd (9.2, 3.3)  57.8, CH  57.7, CH 
3  2.11, td (6.8, 3.5)  2.10, m  34.2, CH  34.2, CH 
4  0.69, d (7.0)  0.68, d (7.2)  18.8, CH3  18.9, CH3 
5  0.53, d (7.0)  0.50, d (7.2)  16.7, CH3  16.6, CH3 
NH  7.17, d (9.0)  7.15, d (9.2)     
6 
   
173.5, C  173.5, C 
7 
   
84.4, C  84.4, C 
8a  4.05, d (11.5)  4.04, d (11.4)  43.3, CH2  43.3, CH2 
8b  3.28, d (11.5)  3.27, d (11.4)     
9  1.88, s  1.87, br s  24.1, CH2  24.2, CH3 
10 
   
164.3, C  164.6, C 
11 
   
147.4, C  147.4, C 
12  7.77, s  7.76, s  124.2, CH  124.2, CH 
13 
   
167.9, C  167.9, C 
14a  5.29, dd (17.8, 9.3)  5.29, dd (17.4, 9.6)  41.1, CH2  41.1, CH2 
14b  4.28, dd (17.6, 3.0)  4.27, dd (17.4, 2.5)     
NH  6.44, dd (9.3, 2.8)  6.45, dd (9.6, 2.5)     
15 
   
169.4, C  169.4, C 
16a  2.84, dd (16.6, 10.5)  2.86, dd (16.5, 10.5)  40.5, CH2  40.5, CH2 
16b  2.69, dd (16.1, 2.5)  2.68, dd (16.5, 1.8)     
17  5.68, m  5.66, ddd (10.5, 7.2, 1.8)  72.0, CH  72.0, CH 
18  5.52, dd (15.6, 7.0)  5.51, dd (15.6, 7.2)  128.4, CH  128.4, CH 
19  5.84, m  5.82, dt (15.6, 7.2)  132.7, CH  132.7, CH 
20  2.32, q (6.5)  2.31, br q (7.2)  32.3, CH2  32.3, CH2 
21  2.91, t (7.5)  2.90, t (7.2)  27.9, CH2  27.9, CH2 
22 
   
199.4, C  199.4, C 
23  2.54, t (7.5)  2.52, t (7.5)  44.1, CH2  44.1, CH2 
24  1.63, m  1.64, m  25.6, CH2  25.6, CH2 
25  1.28, m  1.29, m  28.9 or 29.0, CH2  28.9, CH2 
26  1.28, m  1.25, m  28.9 or 29.0, CH2  28.9, CH2 
27  1.28, m  1.26, m  31.6, CH2  31.6, CH2 
28  1.28, m  1.28, m  22.6, CH2  22.6, CH2 
29  0.88, t (6.8)  0.87, br t (6.9)  14.0, CH3  14.0, CH3 
Table 2.1 : Collected and reported
80 
1H and 
13C NMR data in ppm for largazole in CDCl3  Histone Deacetylase Inhibitors 
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2.3.2. Synthesis of largazole analogues 
 
To study the structure-activity relationships of largazole, several modifications were 
envisaged, such as simplification of largazole or increasing its lipophilicity.  
We decided to simplify the structure by replacing the valine with a glycine and also a β-
alanine  residue,  which  would  increase  the  size  of  the  macrocycle  by  one  carbon. 
Replacing the 4-methyl thiazoline by the achiral Aib (aminoisobutyric acid) moiety was 
also  envisaged  to  determine  the  influence  of  the  thiazoline  ring  on  the  inhibition 
activity. Comparison of the glycine position in largazole with the other depsipeptides 
shows  that  they  possess  bigger  substituents  (alanine  or  valine).  In  addition,  the 
phenylalanine derivative has been prepared by Sabrina Marie in order to incorporate a 
large substituent at this position and to increase the lipophilicity of the compound. It 
was proposed that it would be possible to improve the inhibition activity in a cell assay 
by modifying the thioester function of largazole through insertion of a valine subunit 
that can be recognised by a transporter. 
 
 
Figure 2.31 : Structures of FR901375, FK228, spiruchostatins and largazole 
 
We were planning to prepare a total of five analogues (Figure 2.32). 
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Figure 2.32 : Structures of largazole thiol and the proposed analogues  
 
2.3.2.1. Synthesis of glycine and the β-alanine analogues 
In order to  make the  glycine and the β-alanine derivatives  2.179 and  2.180, it was 
necessary to prepare the fragments 2.184 and 2.185 by esterification of N-Fmoc-glycine 
or  N-Fmoc-β-alanine  with  the  previously  prepared  -hydroxy  acid  derivative  2.85 
(Scheme  2.41).  The  following  steps  were  undertaken  in  the  same  way  as  those 
undertaken in the synthesis of largazole. The yield obtained for the 18-membered ring 
formation with the β-alanine residue is lower than that obtained for either of the 17-
membered ring formations of largazole or the glycine analogue (18% yield versus 65% 
or 53% respectively). 
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Scheme 2.41 : Synthesis of largazole analogues 2.179 and 2.180 
 
2.3.2.2. Synthesis of the Aib analogue 
The previously prepared carboxylic acid 2.147 was coupled to 2-aminoisobutyric acid to 
form the methyl ester 2.190, which was then hydrolysed to afford the carboxylic acid 
2.191 (Scheme 2.42). The Fmoc deprotected -hydroxy acid derivative was coupled to 
the carboxylic acid 2.191 using PyBOP as a coupling reagent (62% over 2 steps). The 
following steps to obtain the Aib analogue 2.181 are repeated as above. 
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Scheme 2.42 : Synthesis of largazole analogue 2.181 
 
2.3.2.3. Attempt to synthesise the valine thioester analogue 
We coupled largazole thiol 2.178 with Boc-L-valine to form 2.194 and then removed the 
Boc group to afford the desired largazole analogue 2.183 (Scheme 2.43).  
 
 
Scheme 2.43 : Attempt to synthesise the valine thioester analogue 
 
The thioester 2.183 was found to be unstable over time as partial hydrolysis occurred 
despite the compound being stored in the freezer. Further quantities of this analogue 
were  not  prepared  due  to  the  cell  assay  showing  similar  inhibition  activity  to  the 
largazole thiol. 
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2.3.3. Biological results and metabolic studies of largazole and its analogues 
 
A Western blot experiment was performed by Annette Hayden at the Cancer Research 
UK centre in Southampton using an antibody which binds only to the acetylated form of 
histone 4 lysine 8 (acH4K8) (Figure 2.33). This experiment measures acetylated histone 
proteins levels in protein extracts from three different breast cancer cell lines: MCF7, 
MDA-MB-231 and SKBr3. These cancer cell lines are representative of three major 
subtypes of breast cancer cell lines. MCF7 are estrogen receptor positive cancer cell 
lines; MDA-MB-231 are triple negative and SKBr3 are HER2 positive cancer cell lines. 
Largazole and largazole thiol were tested in comparison with untreated cells. The strong 
bands correspond to the presence of acetylated H4K8. This experiment shows that in the 
presence  of  inhibitor,  the  deacetylation  activity  of  HDACs  decreases  for  the  three 
cancer cell lines as shown by enhancement of the level of the acetylated form of H4K8. 
As expected largazole, which is more cell permeable, has a more intense band than 
largazole thiol. 
 
 
Figure 2.33 : Western blotting of acH4K8 in MCF7, MDA-MB-231 and SKBr3 cell lines with 
DMSO control, largazole and largazole thiol 
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The compounds were tested in both enzyme and cell assays by Annette Hayden. The 
cell assay involves the measurement of growth inhibition activity of the compounds 
against the breast cancer cell line MCF7. 
 
The  Fluor  de  Lys®  (Fluorescent  deacetylation  of  lysine)  assay  system  is  used  to 
measure  the  inhibition  of  histone  deacetylase  activity  in  HeLa  cell  extracts. 
Deacetylation of a Fluor de Lys® substrate by a deacetylase sensitizes the substrate 
which then produces a fluorophore after treatment with the Fluor de Lys® developer. 
The fluorophore is excited with light (wavelength 360 nm) and the emitted light (460 
nm) is detected on a fluorometric plate reader.  
 
 
Scheme 2.44 : Simplified reaction scheme of the Fluor de Lys® fluorometric assay  
 
Largazole and largazole thiol were first tested in the Fluor-de-Lys® HDAC enzyme 
assay and the cell line growth inhibition assay  in the breast  cancer cell line MCF7 
(Figure 2.34). Largazole thiol gives excellent inhibition activity in the enzyme assay (43 
pM) and largazole had potent antiproliferative activity. Largazole is hydrolysed to its 
active metabolite, largazole thiol, under physiological conditions. Nevertheless, we are 
surprised to see that largazole thiol is such a potent HDAC inhibitor in the enzyme 
assay but it is not so good in the cell assay, as we expected a picomolar inhibitor to give 
better results in the cell assay (5 nM for largazole versus 0.8 nM for FK228). 
 
 
Figure 2.34 : HDAC inhibition and growth inhibition of largazole thiol (2.178) and largazole (2.18) Histone Deacetylase Inhibitors 
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The largazole analogues were tested in a similar manner in comparison with largazole 
thiol (Table 2.2). The glycine analogue 2.179 is a subnanomolar HDAC inhibitor which 
suggests that the valine is not indispensable to the activity and can be replaced by a 
glycine residue. The β-alanine analogue 2.180 is also a nanomolar HDAC inhibitor and 
shows that an increase in the size of the macrocycle is tolerated. The Aib derivative 
2.181 exhibits a nanomolar inhibition activity. Nevertheless, the cell assay results are 
very poor for these three compounds which was as expected since they are free thiols 
and not prodrugs. On the contrary, the phenylalanine analogue 2.182 is a weaker HDAC 
inhibitor  in  the  enzyme  assay  (a  400  fold  reduction)  even  though  it  has  a  similar 
antiproliferative activity to largazole thiol.  
 
Compound  HDAC inhibition (nM)  MCF7 inhibition (nM) 
Largazole (2.18)  572 ± 29  5 ± 1 
Largazole thiol (2.178)  0.043 ± 0.026  277 ± 130 
Bn analogue 2.182  17.2 ± 0.05  377 ± 62 
Glycine analogue 2.179  0.17 ± 0.35  2458 ± 1135 
β-alanine analogue 2.180  3.15 ± 0.07  >10,000 
Aib analogue 2.181  0.99 ± 0.07  5902 ± 1698 
Table 2.2 : HDAC inhibition and growth inhibition of largazole and related analogues 
 
Our results show that some modifications in the structure of largazole are possible and 
tolerated. From the data, we observed that the lipophilicity is a very important factor in 
cell assay. In fact, incorporating a phenylalanine residue increased the activity in cells 
and simplification of the valine residue with glycine or β-alanine decreased this activity. 
In the Aib and β-alanine analogues, the rigidity of the macrocycle is also modified and 
this might explain the difference in activity.  
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We were interested in the pharmacokinetic properties of largazole and related analogues 
and decided to investigate their stability in the presence of mouse liver homogenate. 
These  studies  were  carried  out  by  Prof  Paul  Loadman  and  Jason  Lyle  from  the 
University of Bradford. Largazole was found to be unstable, with a half-life of less than 
5 min, undergoing rapid thioester hydrolysis to largazole thiol (Table 2.3). Largazole 
thiol itself is relatively stable in liver homogenate with a half-life of 51 min at 37 ºC. 
The glycine analogue 2.179 has similar stability with a half-life of 32 min. A major 
metabolite of unknown structure is formed in the case of largazole thiol 2.178 and the 
glycine analogue 2.179. The β-alanine and Aib analogues are highly unstable with a 
half-life of less than 5 min with a complex metabolism which could not be elucidated. 
 
Compound  Half life (min) 
Largazole (2.18)  <5 
Largazole thiol (2.178)  51 
Glycine analogue 2.179  32 
β-alanine analogue 2.180  <5 
AIB analogue 2.181  <5 
Table 2.3 : Half-life of largazole and related analogues 
 
This  study  showed  that  the  thioester  prodrug  is  metabolised  too  quickly  and  the 
disulfide depsipeptides are more stable than largazole. Studies to find a more stable 
thioester  would  be  necessary  for  future  in  vivo  applications  of  largazole  or  related 
thioesters.  Histone Deacetylase Inhibitors 
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2.4. SYNTHESIS  AND  BIOLOGICAL  ACTIVITY  OF 
THAILANDEPSINS AND BURKHOLDACS 
 
2.4.1. Synthesis of thailandepsins 
 
2.4.1.1. First structures of thailandepsins 
The first structures of thailandepsins A, B and C were published by Cheng and co-
workers (Figure 2.35).
83 The structures were elucidated by study of the biosynthesis 
gene cluster of thailandepsins but no stereochemistry was assigned. Thailandepsins A 
and B were found to possess an unusual hemiaminal function only rarely encountered in 
cyclic peptide natural products (for example, tyrocidine A).
127 Thailandepsin C contains 
an imine function resulting from the loss of water from the hemiaminal 2.22.  
 
 
Figure 2.35 : Structures of thailandepsins A (2.21), B (2.22) and C (2.23) 
 
We predicted the stereochemistry by analogy to the other depsipeptides assuming that 
the  stereochemistry  of  the  β-hydroxy  acid  would  be  the  same  as  in  the  other 
depsipeptides. We thought that D-cysteine, D-alanine and D-phenylalanine are the most 
plausible stereochemistry for thailandepsins by analogy to spiruchostatins and FK228 
(Figure 2.36).  
 
 
Figure 2.36 : Suggested stereochemistry of thailandepsins A (2.195), B (2.196) and C (2.197) Histone Deacetylase Inhibitors 
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Investigation into the total synthesis of thailandepsins reveals a starting point from the 
β-hydroxy acid derivative and several amino acids such as alanine, glycine, cysteine and 
phenylalanine. This is highlighted in the retrosynthetic analysis of thailandepsins A and 
B (Scheme 2.45). Thailandepsin C can be obtained from thailandepsin B. 
 
 
Scheme 2.45 : Retrosynthetic analysis of thailandepsins A (2.195) and B (2.196) 
 
Thailandepsins can be prepared by a convergent synthesis from fragment 2.198 and the 
β-hydroxy acid derivative 2.199 or 2.200 (Scheme 2.46).  
 
 
Scheme 2.46 : Retrosynthetic analysis of thailandepsins A (2.195) and B (2.196) 
 
Our first target was the synthesis of the amine fragment 2.198 (Scheme 2.47). Coupling 
of Fmoc-D-Cys(Tr)-OH and (R)-phenylalaninol, using PyBOP and HOBt as coupling 
reagents and N-methylmorpholine as a base, led to the formation of 2.201 without the 
need for protection of the alcohol.
128 Removal of the Fmoc group yielded 2.202 which Histone Deacetylase Inhibitors 
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was then coupled to Fmoc-D-Ala-OH. The desired fragment 2.198 was obtained after 
Fmoc deprotection of 2.203. 
 
 
Scheme 2.47 : Synthesis of fragment 2.198 
 
Fragment  2.204  had  already  been  used  in  the  synthesis  of  the  glycine  largazole 
analogue. The treatment of 2.204 with TFA gave an excellent yield with no deprotection 
of the trityl group (Scheme 2.48). 
 
 
Scheme 2.48 : Synthesis of the carboxylic acid 2.200 
 
The next step in the synthesis was to couple the two fragments 2.200 and 2.198 and to 
then form the disulfide bond prior to the challenging cyclisation.  Histone Deacetylase Inhibitors 
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We  worked  on  the  model  amide  2.201  in  order  to  find  suitable  conditions  for  the 
oxidation of the alcohol and Fmoc deprotection (Scheme 2.49). Two routes are possible: 
oxidation followed by Fmoc deprotection or Fmoc removal and then oxidation. 
 
 
Scheme 2.49 : Attempts to obtain compound 2.206 from model amide 2.201 
 
We first tried different oxidation conditions on substrate 2.201 including IBX, TEMPO, 
Dess-Martin  periodinane  and  Parikh-Doering.
129-132  IBX,  TEMPO  and  Dess-Martin 
oxidation  were  unsuccessful,  however  the  Parikh-Doering  conditions  allowed  us  to 
convert  the  hydroxyl  function  into  the  aldehyde.  Fmoc  deprotection  with  a  non-
nucleophilic base, such as DBU, is necessary due to the presence of the aldehyde. In the 
alternate pathway, the Fmoc group was removed with diethylamine and the primary 
alcohol oxidised with Parikh-Doering conditions. Both pathways seemed to lead to the 
formation  of  a  cyclic  compound  which  we  proposed  was  the  6-membered  ring 
containing  an  imine  function.  We  would  prefer  to  remove  the  Fmoc  group  before 
oxidation of the alcohol as the free amine will not cause problems in the oxidation step. 
 
The amine 2.198 was coupled to the -hydroxy acid derivative 2.200, using the same 
coupling conditions as previously reported, to afford 2.207 (Scheme 2.50). An oxidative 
disulfide bond formation was then performed using iodine and MeOH in CH2Cl2 to give 
2.208.
78 Firstly, Fmoc was removed using diethylamine and the alcohol 2.209 was then 
oxidised to the aldehyde. No trace of product was found by NMR or mass spectrometric 
analysis. We then attempted the oxidation of the hydroxyl group using Parikh-Doering 
conditions  followed  by  the  Fmoc  deprotection  using  diethylamine  but  were  again 
unsuccessful. One of the major problems encountered in this synthesis is the solubility 
of  the  compounds.  Whilst  mass  spectrometric  analysis  shows  the  formation  of  the Histone Deacetylase Inhibitors 
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compounds 2.207, 2.208, 2.209 and 2.210, NMR characterisation is problematic as the 
peaks are not well defined.  
 
 
Scheme 2.50 : Attempts to synthesise thailandepsin B 
 
We proposed that a way of solving the oxidation step would be to oxidise the alcohol 
2.203, and then protect as an acetal using Noyori’s conditions, earlier in the synthesis.
133 
After the protection the reaction sequence is similar to that described previously with 
the last step being deprotection of the acetal group of 2.216 (Scheme 2.51). 
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Scheme 2.51 : Attempts to synthesise thailandepsin via aldehyde protection 
 
Unfortunately, we encountered a different problem in this sequence with epimerisation, 
detected by TLC and NMR spectroscopy, occurring during the protection step of the 
aldehyde. Separation of these diastereomers was very difficult by flash chromatography. 
We tried to  protect  the aldehyde  at  a lower temperature (–78 °C) but only starting 
material  was  recovered.  The  synthesis  was  continued  using  the  mixture  of  the  two 
diastereomers  but  due  to  low  yields  the  synthesis  could  not  be  finished.  Whilst 
researching alternative literature procedures for the protection of the aldehyde, which 
would avoid  epimerisation (ethylene  glycol,  pyridinium  p-toluenesulfonate, toluene), 
we  realised  that  there  were  mistakes  in  the  structures  published  by  Cheng.
134  The 
molecular weights and structures that Cheng published in his patent do not match the Histone Deacetylase Inhibitors 
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data deduced from the structures (Table 2.4).
83 We contacted Cheng and although he 
acknowledged  that  the  structures  in  the  patent  were  incorrect,  he  refused  to  share 
additional information about the natural products. 
 
Compound 
Formula and Mw deduced 
from structures 
Formula and Mw given 
on the patent
83 
Thailandepsin A 
Formula: C25H34N4O6S2 
Mw: 550.69 g/mol 
Formula: C25H31N4O6S2 
Mw: 547.68 g/mol 
Thailandepsin B 
Formula: C24H32N4O6S2 
Mw: 536.66 g/mol 
Formula: C24H29N4O6S2 
Mw: 533.65 g/mol 
Thailandepsin C 
Formula: C24H30N4O5S2 
Mw: 518.65 g/mol 
Formula: C24H27N4O5S2 
Mw: 515.63 g/mol 
Table 2.4 : Comparative table of reported
83 and corrected formula and molecular weight (Mw) for 
the different thailandepsins 
 
2.4.1.2.   Revised structures of thailandepsins  
In a later presentation to the NCI, Cheng reported revised structures for thailandepsins 
A and B (Figure 2.37). There are only two thailandepsins and not three as he postulated 
earlier. Their structures, which were elucidated by biosynthesis, are very similar to the 
spiruchostatins. The stereochemistry was predicted to be L-Met/Nle, D-Cys and L-Ile.  
 
 
Figure 2.37 : Revised structures of thailandepsins A (2.24) and B (2.25)  
 
Although  the  structures  were  not  published  in  the  literature  but  only  viewed  in  a 
presentation, synthesizing these compounds is still of interest as they are analogues of 
the  potent  HDAC  inhibitor,  depsipeptide  spiruchostatin.  We  decided  to  prepare 
thailandepsin A, which contains the methionine residue, and believe that the most likely Histone Deacetylase Inhibitors 
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stereochemistry would be the D- amino acids by analogy to spiruchostatins. We chose to 
prepare thailandepsin A over B because of the methionine residue, as we believe that 
the sulfur containing compound is more interesting than the carbon chain compound. 
Nevertheless, there is uncertainty regarding the β-chiral centre of the isoleucine residue 
as during the biosynthesis of the natural product one or two of the chiral centres of 
isoleucine  could  be  epimerised.  To  resolve  this  issue,  both  diastereomers  of  D-
isoleucine  would  need  to  be  incorporated  in  the  synthesis.  The  first  compound  we 
prepared contains the β-hydroxy acid, D-methionine statine derivative, D-cysteine and 
D-isoleucine components (Scheme 2.52). 
 
 
Scheme 2.52 : Retrosynthesis of thailandepsin A (2.217) with our suggested stereochemistry 
 
Our  synthesis  route  will  be  inspired  by  the  synthesis  of  spiruchostatin,  previously 
undertaken  by  our  group,  with  some  modifications.
78  We  decided  to  use  an  allyl 
protecting  group  on  the  statine  to  avoid  deprotection  of  the  methyl  ester  and  its 
reprotection  with  Tce.
135  We  will  prepare  compound  2.218  and  couple  it  to  the  -
hydroxy  acid  derivative  2.219  (Scheme  2.53).  After  allyl  deprotection,  the 
macrolactonisation will be performed using Shiina reagent which has been shown to 
give the best yield for this cyclisation.
90 The disulfide bond formation will be the last 
step of the synthesis. 
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Scheme 2.53 : Retrosynthesis of thailandepsin A (2.217) with our suggested stereochemistry 
 
The  statine  2.222  was  obtained  by  Claisen  condensation  of  Boc-D-Met-OH 
pentafluorophenyl  ester  2.220  with  allyl  acetate,  followed  by  diastereoselective 
reduction  of  2.221  (Scheme  2.54).
106  It  was  observed  that  the  reaction  time  of  the 
reduction step is very important. A longer reaction time of 135 min resulted in the 
additional reduction of the allyl ester with a reaction yield of 6%; with a shorter reaction 
time  of  50  min  the  yield  increased  to  81%.  The  Boc  group  was  then  removed  by 
treatment with TFA and the free amine was coupled to Fmoc-D-Cys(Tr)-OH to give 
2.223. After Fmoc deprotection of 2.223, the free amine was coupled with Fmoc-D-Ile-
OH to afford the fragment 2.224. 
 
 
Scheme 2.54 : Synthesis of the tetrapeptide fragment 2.224 Histone Deacetylase Inhibitors 
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The -hydroxy acid previously used in the synthesis of largazole was hydrolysed in 
order to obtain the carboxylic acid 2.219 (Scheme 2.55). 
 
 
Scheme 2.55 : Synthesis of 2.219 by hydrolysis of 2.47 
 
Fragment 2.224 is Fmoc deprotected and coupled to 2.219. Removal of the allyl group 
by  palladium-catalysed  reaction  with  morpholine  provided  the  deprotected  linear 
precursor which then underwent macrolactonisation to give 2.226 (Scheme 2.56). We 
decided  to  use  2-methyl-6-nitrobenzoic  anhydride  (MNBA)  as  the  reagent  for  the 
macrocyclisation as it gave the best yield for the macrocyclisation of spiruchostatin A, 
as reported by Doi and Takahashi.
90 An oxidative disulfide bond formation was then 
performed using iodine and MeOH in CH2Cl2 to afford 2.217. 
 
 
Scheme 2.56 : Synthesis of thailandepsin A (2.217) 
 
No further information was available to us to compare the compound made with the 
natural product. We asked Cheng once again for further details but with no success. We 
planned nevertheless to test the biological activity of this spiruchostatin analogue. 
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2.4.2. Elucidation of the stereochemistry of burkholdacs 
 
2.4.2.1. Synthesis of Brady’s proposed diastereomer (L-Ile, D-Cys and L-Met) 
Later on the structures of burkholdacs A and B, isolated by Brady and co-workers, were 
published  and  found  to  be  surprisingly  similar  to  Cheng’s  revised  structures  of  the 
thailandepsins (Figure 2.38).
84 We started to think that the natural products isolated by 
Cheng and Brady are the same compounds as they were all isolated from the same 
bacterial  strain.  The  structures  of  the  burkholdacs  were  elucidated  by  spectroscopic 
analysis and analysis of the biosynthetic gene cluster. 
 
 
Figure 2.38 : Structures of burkholdacs 
 
We decided to prepare burkholdac A, containing the methionine and the isoleucine, as it 
is an isomeric compound to the previously synthesised thailandepsin A. In fact, the only 
difference  between  the  two  compounds  is  that  the  position  of  the  methionine  and 
isoleucine are inverted. According to the biosynthesis of burkholdacs, Brady predicted 
the stereochemistry of the natural product to be L-Ile, D-Cys and L-Met. We are able to 
prepare  this  compound  from  the  β-hydroxy  acid,  L-isoleucine  statine  derivative,  D-
cysteine and L-methionine (Scheme 2.57). 
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Scheme 2.57 : Retrosynthesis of burkholdac B (2.29) with Brady’s predicted stereochemistry 
 
We  prepared  the  L-isoleucine  statine  derivative  2.228  in  a  similar  manner  to  the 
previously described method. Subsequent couplings with Fmoc-D-Cys(Tr)-OH, Fmoc-
D-Met-OH  and  the  -hydroxy  acid  afforded  compound  2.231  (Scheme  2.58).  Allyl 
deprotection  followed  by  macrolactonisation  and  disulfide  bond  formation  yielded 
Brady’s proposed diastereomer 2.29.  
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Scheme 2.58 : Synthesis of Brady’s predicted diastereomer 2.29 (L-Ile, D-Cys and L-Met) 
 
Comparison of the 
1H NMR and 
13C NMR spectra of the synthetic compound with the 
natural product shows that the stereochemistry assigned by Brady is incorrect as several 
differences are observed (Figures 2.39 and 2.40).
84 
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Figure 2.39 : 
1H NMR spectra of burkholdac B published by Brady
84 in CD2Cl2 (600 MHz) “Reprinted 
with permission from Biggins, J. B.; Gleber, C. D.; Brady, S. F. Org. Lett. 2011, 13, 1536-1539, copyright (2011) American Chemical Society.” 
 
 
Figure 2.40 : 
1H NMR spectra of Brady’s proposed diastereomer 2.29 in CD2Cl2 (400 MHz) 
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By analogy to spiruchostatin, we decided to prepare the diastereomer with all the amino 
acids  in  the  D-series.  The statine  is likely  to  be the  syn diastereomer  but  the same 
ambiguity resides for the stereochemistry of the isoleucine, which could be D- or D-allo- 
depending on the degree of epimerisation in the biosynthesis. 
 
2.4.2.2. Synthesis of the diastereomer 2.237 (D-Ile, D-Cys and D-Met) 
The diastereomer 2.237 is prepared as described previously, starting from D-isoleucine, 
D-cysteine and D-methionine (Scheme 2.59). 
 
 
Scheme 2.59 : Synthesis of the diastereomer 2.237 (D-Ile, D-Cys and D-Met) 
 
The 
1H NMR spectra of this diastereomer is very similar to that of the natural product 
(Figures  2.39  and  2.41).
84  We  can  see  a  difference  in  the  chemical  shifts  of  the Histone Deacetylase Inhibitors 
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isoleucine residue signals which suggests that the stereochemistry of the isoleucine is 
probably not D- but D-allo, as present in spiruchostatin B.  
 
 
Figure 2.41 : 
1H NMR spectra of diastereomer 2.237 (D-Ile, D-Cys and D-Met) in CD2Cl2 (400 MHz) 
 
2.4.2.3. Synthesis of burkholdac B (D-allo-Ile, D-Cys and D-Met) 
The  prior  synthesis  is  this  time  repeated  with  D-allo-isoleucine,  D-cysteine  and  D-
methionine residues to obtain the diastereomer 2.243 (Scheme 2.60). 
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Scheme 2.60 : Synthesis of the burkholdac B (D-allo-Ile, D-Cys and D-Met) 
 
The 
1H and 
13C NMR spectra matched perfectly with that reported in the literature for 
the natural product (Figures 2.39 and 2.42).
84 Thus, the stereochemistry of the natural 
product is D-allo-isoleucine, D-cysteine and D-methionine. We successfully assigned the 
stereochemistry of burkholdac B by synthesis.
136  
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Figure 2.42 : 
1H NMR spectra of diastereomer (D-allo-Ile, D-Cys and D-Met) in CD2Cl2 (400 MHz) 
 
No optical rotation value was reported for burkholdac B in Brady’s paper. The NMR 
assignment  is  the  only  available  information  and  matched  with  that  of  the  last 
diastereomer. Collected 
1H and 
13C NMR data for the three diastereomers 2.29, 2.237 
and 2.243 were compared to that reported in the literature (Figure 2.43 and Table 2.5). 
This comparison has confirmed the fact that the correct diastereomer possesses D-allo-
Ile, D-Cys and D-Met stereochemistry. We can observe larger chemical shift differences 
(Δδ) for the other diastereomers, particularly for compound 2.29.  
 
 
Figure 2.43 : Atom numbering used for burkholdac BHistone Deacetylase Inhibitors 
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# 
1H Δʴ for 
2.29 
13C Δʴ for 
2.29 
1H Δʴ for 
2.237 
13C Δʴ for 
2.237 
1H Δʴ for 
2.243 
13C Δʴ for 
2.243 
1  /  0.1  /  0.1  /  0.2 
2  -0.32  -3  -0.01  0.2  -0.01  0 
3 
 
0.28  -1.5  0.02  0.2  0.01  0.2 
0.21  /  -0.04  /  -0.01  / 
4 
0.01  -0.1  0.04  0.1  -0.01  0.1 
-0.11    -0.08  /  -0.02  / 
5  -0.09  -0.5  0.05  1.2  -0.01  0.1 
NH  -0.74  /  0.02  /  0.02  / 
6  /  -1.2  /  0.3  /  0.2 
7 
0.36  -0.5  0.08  -0.1  0.03  -0.1 
-0.3  /  0.01  /  -0.02  / 
8  0.11  -1.4  0.01  0.3  0.01  0.2 
9  /  -0.7  /  0.2  /  0.1 
10  -0.2  1.4  0.02  0.3  -0.03  0.2 
11  -0.38  1.1  -0.07  1.5  -0.01  0.1 
12  0.92  -1.8  -0.18  0.8  0.01  0 
13  -0.22  -0.7  0.17  -0.4  -0.02  0.1 
14 
-0.19  -4.1  -0.13  -1  -0.01  0.2 
0.09  /  0.04  /  -0.01  / 
15  -0.02  0.3  -0.06  -0.7  0  0.1 
16  0  1.1  0.11  0.2  -0.01  0.2 
NH  -0.24  /  0.17  /  0  / 
OH  /  /  /  /  /  / 
17  /  1  /  0  /  0.2 
18  0.01  1.9  -0.03  0.4  0  0.2 
19 
-0.04  -0.9  0.04  0  0  0.2 
0  /  -0.09  /  -0.02  / 
NH  0.27  /  0.01  /  0.01  / 
20 
-0.09  1.4  -0.06  -0.1  0  0.1 
0.15  /  0.06  /  0.03  / 
21 
-0.39  -1.4  0  0  -0.05  0.1 
0.01  /  0  /  0.01  / 
22  -0.45  -1.5  -0.08  0.1  -0.04  0.1 
23  -0.01  1  0.03  0.4  0.03  0.2 
Table 2.5 : Difference between collected 
1H and 
13C NMR data for the three diastereomers 2.29, 
2.237 and 2.243 with that
84 of reported in the literature (values in ppm are written in red if 
1H Δʴ > 
0.1 ppm and if 
13C Δʴ > 1 ppm) Histone Deacetylase Inhibitors 
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Cheng published later on the isolation of thailandepsin A which is the equivalent of 
burkholdac B.
85 Optical rotation was available and values collected and reported are 
close  ([]
25
D  collected  –23.3  (c  0.08,  CH3CN),  []
24
D  reported  –22.8  (c  1.00, 
CH3CN)).
85 
Only one epimerase is present in the biosynthesis gene cluster of burkholdac B, but 
surprisingly a total of three chiral centres are epimerised. We believe that the single 
epimerase  present  might  be  responsible  for  the  multiple  epimerisations.  It  is  also 
possible that D-amino acid residues are incorporated in the biosynthesis. Either way, our 
results show that looking at the biosynthesis gene cluster is not completely reliable for 
the  assignment  of  stereochemistry  in  peptide  natural  products.  The  synthesis  of  the 
compounds is extremely important to confirm the structures and their stereochemistry. 
 
2.4.3. Biological results for thailandepsin A, burkholdac B and other diastereomers 
 
We were now in a position to compare the biological activity of these four compounds: 
Cheng’s  revised  structure  of  thailandepsin  A  (2.217),  Brady’s  burkholdac  B 
diastereomer 2.29, the diastereomer with all the amino acids with  D-stereochemistry 
2.237,  which  is  an  epimer  of  burkholdac  B  (epi-burkholdac  B),  and  burkholdac  B 
(2.243).  
 
 
Figure 2.44 : Structures of the different synthesised compounds 
 Histone Deacetylase Inhibitors 
 
144 
 
Alison Donlevy, at the Cancer Research UK centre in Southampton, tested the four 
compounds in the Fluor-de-Lys HDAC enzyme assay and growth inhibition against the 
cancer cell line MCF7, such as performed for largazole and related analogues (Table 
2.6).
136 The Brady diastereomer with two L-amino acids appeared to be the least potent 
inhibitor in both assays, which suggests that  L-amino acids are unfavourable for the 
HDAC inhibition activity. Thailandepsin A, epi-burkholdac B and burkholdac B are all 
nanomolar  HDAC  inhibitors  in  both  assays.  The  potency  of  burkholdac  B  and  its 
epimer,  epi-burkholdac  B,  in  cell  assay  towards  the  cancer  cell  line  MCF7  is 
particularly  remarkable  (subnanomolar).  Burkholdac  B  is  the  most  potent  of  all  the 
depsipeptides in cell assay with an increase of 13-fold compared to FK228 which had 
been, until now, the best depsipeptide and a clinically approved drug. 
 
Compound  HDAC inhibition (nM)  MCF7 inhibition (nM) 
FK228 (2.15)  24 ± 4  0.8 ± 0.2 
Spiruchostatin A (2.16)  5.3 ± 3.3  5.7 ± 0.7 
Largazole (2.18)  572 ± 29  5 ± 1 
Largazole thiol 2.182  0.04 ± 0.3  277 ± 130 
2.217  8.3 ± 2.4  10.5 ± 1.8 
2.29  3312 ± 2472  410 ± 82 
2.237 (epi-burkholdac B)  3.1  0.25 ± 0.05 
2.243 (burkholdac B)  5.0 ± 3.0  0.06 ± 0.04 
Table 2.6 : HDAC inhibition and cell growth inhibition for the different isomers prepared 
 
The main difference between burkholdac and the other depsipetides is the bigger and 
more lipophilic methionine amino acid. We believe that the methionine is responsible 
for the high potency of burkholdac B in cell assay. The poorer potency in the enzyme 
assay could be explained by the degradation of the product in the enzyme assay. Histone Deacetylase Inhibitors 
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2.5. CONCLUSION 
 
The total synthesis of largazole was achieved by a convergent synthesis. Largazole thiol 
exhibited remarkable activity in the enzyme assay (picomolar). Unfortunately, the cell 
assay results for largazole were disappointing when compared to its outstanding enzyme 
activity. The convergent strategy used for largazole synthesis allowed us to prepare four 
analogues  in  order  to  study  the  structure-activity  relationships  of  largazole.  All  the 
modifications  made  to  the  compounds  were  tolerated  and  we  determined  that 
simplification of largazole is possible with conservation of the biological activity. A 
correlation between lipophilicity and growth inhibition activity was also observed. The 
stability of largazole as a prodrug has to be improved. 
 
The thailandepsins/burkholdacs story illustrates the importance of synthesis in structure 
elucidation. Elucidation of compounds by study of biosynthesis pathways can lead to 
errors  in  the  structures.  In  fact,  the  first  reported  structures  of  thailandepsins  were 
completely  wrong,  which  led  to  us  spending  some  time  trying  to  form  an  unusual 
hemiaminal function which was not present in the molecule. We then worked on the 
second revised structures of thailandepsins and discovered that they were also incorrect. 
The compound prepared was however a spiruchostatin analogue and worth testing for 
biological activity. The structures of burkholdacs were then published with a predicted 
stereochemistry from the biosynthesis and their structures confirmed by MS and NMR. 
We  decided  to  prepare  burkholdac  B  with  their  predicted  stereochemistry,  however 
discovered that it was not correct. After preparation of two other diastereomers, we 
elucidated the stereochemistry of burkholdac B to be as in spiruchostatin B (D-allo-Ile, 
D-Cys and D-Met). Burkholdac B showed excellent cell growth inhibition activity. The 
L-series  amino  acids  appeared  unfavourable  in  HDAC  inhibition  activity  for 
burkholdacs whereas the D-series gave better results. The natural product gave the best 
results out of all the compounds prepared. 
 
At  the  time  of  writing,  largazole  thiol  is  the  most  potent  among  this  class  of 
depsipeptide natural products in HDAC enzyme inhibition. Meanwhile, burkholdac B is 
the most potent depsipeptide in terms of cell growth inhibition.    
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3. HISTONE DEMETHYLASE INHIBITORS 
 
3.1. INTRODUCTION 
 
As  discussed  previously,  acetylation  is  an  important  histone  post-translational 
modification that influences the state of the chromatin but it is not the only modification 
to occur; methylation is also an essential key element. Histone methylation regulates 
diverse  chromatin-templated  processes  including  transcription.  This  modification  is 
catalysed  by  histone  methyltransferases  (HMTs)  which  use  S-adenosylmethionine 
(SAM) as a methyl group donor.
137 The major methylation sites on histone tails are the 
basic amino acid chains of lysine and arginine residues with methylation catalysed by 
histone  lysine  methyltransferases  (HKMTs)  and  histone  arginine  methyltransferases 
(HRMTs) respectively. Lysine residues can be mono-, di-, or trimethylated on the ε-
nitrogen, and arginine residues are mono- or dimethylated on the guanidinium group.
138-
140 Histone acetylation only occurs on lysine residues, whereas histone methylation can 
take  place  on  both  lysine  and  arginine  residues.  Methylation  is  a  distinctive  post-
translational modification as it can occur in both DNA (C-5 position of cytosine that 
precedes guanines, CpG) and histone proteins.
141 
 
3.1.1. Lysine-specific demethylase 1 (LSD1) 
 
Lysine methylation was viewed as a permanent epigenetic mark until recently, most 
likely because of the thermodynamic stability of the bond N-CH3. The discovery of the 
first  histone lysine-specific demethylase 1 (LSD1), also  called KDM1  (or AOF2 or 
BHC110),  showed  that  methylation  is  also  a  reversible  process;  a  dynamic  protein 
modification  like  all  the  other  known  histone  modifications.
142  LSD1  demethylates 
mainly mono- and dimethylated lysine 4 and 9 on histone 3 (H3K4 and H3K9). This 
enzyme belongs to the amine oxidase family of flavin adenine dinucleotide (FAD)-
dependent enzymes. By reducing FAD to FADH2, LSD1 oxidises the methyl ε-amine of 
the methylated lysine 3.1 to generate the corresponding imine 3.2 which is subsequently 
hydrolysed to produce a carbinolamine 3.3 (Scheme 3.1).
142 This unstable species 3.3 
degrades, releasing formaldehyde 3.5 and the demethylated lysine 3.4. This reaction     Histone Demethylase Inhibitors
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results in a hydride transfer with reduction of FAD to FADH2 that is regenerated to its 
oxidised  form  by  molecular  oxygen  producing  hydrogen  peroxide.  This  mechanism 
explains why LSD1 is not able to demethylate trimethylated lysine residues as a lone 
pair  on  the  nitrogen  is  required  for  electron  transfer  in  order  to  form  the  imine 
intermediate 3.2.  
 
 
Scheme 3.1 : Mechanism of demethylation by LSD1 on H3K4 
 
The  mechanism  of  the  oxidative  conversion  of  the  amine  to  the  imine  is  however 
controversial and may involve either hydride transfer or single electron mechanisms.
143 
 
LSD1 is a protein of around 100 kDa and contains three domains: SWIRM domain, 
amine oxidase domain and the tower domain.
142,144 The amine oxidase domain of LSD1 
shares  sequence  and  structural  similarities  with  the  catalytic  domain  of  the  amine 
oxidases. LSD1 often forms a complex with the corepressor protein (CoREST). The X-
ray crystal structure of the LSD1-CoREST complex has been resolved (Figure 3.1) and 
shows that the tower domain of LSD1 binds to CoREST.
145-147 
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Figure 3.1 : X-Ray structure of the complex LSD1 (in blue) and CoREST (red)
147 “Reprinted from Trends 
in Biochemical Sciences, 33, Forneris, F.; Binda, C.; Battaglioli E.; Mattevi A., LSD1: oxidative chemistry for multifaceted functions in 
chromatin regulation, 181-189 Copyright (2008), with permission from Elsevier.” 
 
3.1.1.1. Transcription 
Lysine  methylation  has  different  effects  that  are  dependent  on  which  residue  is 
methylated and the degree of modifications. It can activate or repress gene transcription; 
for  example,  methylation  on  H3K9  or  on  H3K27  is  a  transcriptionally  repressive 
modification whereas on H3K4 it is a transcriptionally activating modification.
148 
LSD1  can  also  be  a  transcriptional  repressor  or  activator  depending  on  its  binding 
partner.  LSD1  is  a  transcriptional  repressor  when  it  catalyses  the  demethylation  of 
H3K4.
148 The complex LSD1-CoREST is found binding HDAC1 or HDAC2 forming 
complexes which are transcriptional repressors.
149 By itself, LSD1 is able to remove 
methyl on H3K4 but it cannot demethylate H3K4 in the nucleosome; in order to do so, 
it requires the corepressor CoREST.
146,149 NMR spectroscopy shows that the CoREST 
SANT2 domain binds to DNA and this binding was established to be crucial for the 
demethylation of nucleosomal H3K4.
146 LSD1 is also a transcriptional activator in the 
presence  of  androgen  receptor  (AR)  as  the  complex  removes  methyl  groups  from 
H3K9.
150  
 
3.1.1.2. LSD2  
LSD2  also  called  KDM2  (or  KDM1b  or  AOF1)  is  the  only  known  mammalian 
homologue of LSD1.
151 To date, the LSD family consists of LSD1 and LSD2; they both 
share a similar catalytic domain (around 31% homology) but differ in the N-terminal     Histone Demethylase Inhibitors
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region.
152  Like  LSD1,  LSD2  can  only  demethylate  mono-  and  dimethylated  H3K4. 
LSD2 does not bind to CoREST and is believed to possess different biological functions 
compared to LSD1. LSD2 is able to demethylate nucleosomal H3K4 by itself unlike 
LSD1 which requires CoREST to do so.
152 
 
3.1.1.3. Cancer 
Aberrant expression of LSD1 has been detected in several types of cancer, with over-
expression being observed in prostate cancer.
150,153,154 LSD1 is also highly expressed in 
neuroblastoma, breast and bladder cancers.
155 This suggests that the inhibition of LSD is 
a potential target for chemotherapy. 
 
According  to  a  statistical  study  led  by  Cancer  Research  UK,  prostate  cancer  is  the 
second leading cause of cancer mortality for men in the UK after lung cancer.
156 The 
androgen receptor (AR), a nuclear hormone and transcription factor, is a therapeutic 
target in prostate cancer. An experiment carried out by Metzger showed that the LSD1-
AR complex is responsible for the inhibition of tumour growth.
150 In prostate cancer cell 
lines, small interfering RNA (siRNA) induces LSD1 knockdown and therefore reduces 
the LSD1-AR complex formation. The demethylation of the repressing histone marks, 
mono- and dimethyl H3K9, by the LSD1-AR complex is no longer possible. This leads 
to a decrease of the AR mediated transcription and cell proliferation is observed. This 
experiment confirmed that the LSD1-AR complex allows the derepression of the AR 
and promotes gene activation.
150,154 Inhibition of LSD1 by pargyline was also shown to 
block the demethylation of H3K9 by the complexation of LSD1 and the AR.
150,154 Over-
expression of LSD1 in prostate tumours is a predictive mark for aggressive tumours and 
correlates significantly with relapse during therapy.
150,154  
Over-expression  of  the  tumour  suppressor  p53  is  also  a  sign  of  relapse  in  prostate 
cancer.
18  LSD1  can  control  the  tumour  suppressor  activity  of  p53  by  directly 
demethylating  a specific p53 lysine (Lys370me2 and  Lys370me1).
157 Therefore, the 
transcriptional activation mediated by p53 is repressed and p53-promoted apoptosis is 
inhibited.
157  
 
It is possible that LSD1 and HDACs cooperate to repress the transcription of genes. 
Inhibitors of LSD1 exhibit antitumor activities and it might be possible to use them in     Histone Demethylase Inhibitors
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combination with HDAC inhibitors.
65,158 In a recent study, treatment of breast cancer 
cells  with  zinc-dependent  HDAC  inhibitors  (class  I  and  II)  reduced  the  activity  of 
LSD1,  thus  leading  to  an  increase  of  the  LSD1  substrate  H3K4me2  known  as  a 
transcriptionally active modification.
65 On the other hand, they observed that inhibition 
of  LSD1 resulted in  an  enhanced level  of AcH3K9 also  known  as  a mark of  gene 
activation.
65 Simultaneous treatment with HDAC and LSD1 inhibitors led to the growth 
inhibition of breast cancer cells.
65 
 
3.1.2. Inhibitors of LSD1 
 
As LSD1 belongs to the family of flavin adenine dinucleotide (FAD)-dependent amine 
oxidases, certain inhibitors of monoamine oxidases (MAOs), which belong to the same 
family,  are  also  capable  of  inhibiting  LSD1.
159  MAOs  are  responsible  for  the 
deamination  of  neurotransmitters  such  as  serotonin  or  dopamine.  According  to 
Shiekhattar  and  McCafferty,  tranylcypromine  presents  the  highest  inhibition  activity 
towards LSD1 when compared to other MAO inhibitors such as nialamide, phenelzine, 
deprenyl, chlorgyline and pargyline.
138,159 So far, only a few LSD1 inhibitors have been 
described  in  the  literature:  tranylcypromine,  pargyline,  phenelzine  and  polyamines 
(Figure 3.2).  
 
Figure 3.2 : Structures of tranylcypromine (3.6), nialamide (3.7), phenelzine (3.8), deprenyl (3.9), 
chlorgyline (3.10) and pargyline (3.11) 
 
3.1.2.1. Pargyline and propargyl derivatives 
Pargyline (3.11) is a known MAO inhibitor and was first proposed to inhibit LSD1 by 
Metzger  et  al.
150  Cole and  co-workers  designed  a  propargyl-Lys-derivatised  peptide     Histone Demethylase Inhibitors
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3.12 as a potent LSD1 inactivator.
160,161 The inhibitor irreversibly inactivates LSD1; the 
mechanism  was  elucidated  by  MS,  NMR  and  absorbance  spectrometric  analysis 
(Scheme 3.2).
161 The amine is oxidised to the propargylic iminium ion which undergoes 
Michael addition with N
5 of the flavin.  
 
 
Scheme 3.2 : Mechanism of inactivation of LSD1 by 3.12 
 
3.1.2.2. Tranylcypromine 
Tranylcypromine (3.6, PCPA or trans-2-phenylcyclopropylamine or Parnate) is a MAO 
inhibitor, a clinically used antidepressant, and has also been shown to inhibit LSD1. The 
value of the IC50 found in the literature for the LSD1 inhibition by tranylcypromine, 
varies  depending  on  the  assay  performed  (micromolar  order).  Tranylcypromine  is 
accepted as a substrate by LSD1. This is followed by rapid opening of the cyclopropyl 
ring and formation of a covalent adduct with the cofactor FAD 3.15 (Scheme 3.3).
162 
The  FAD-PCPA  adduct  3.19  is  a  five-membered  ring.  Tranylcypromine  is  an 
irreversible inhibitor with the active part functionalities being the cyclopropyl ring and 
the amine group.      Histone Demethylase Inhibitors
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Scheme 3.3 : Mechanism of inactivation of LSD1 by tranylcypromine 
 
The crystal structure of LSD1 inhibited by tranylcypromine was first solved by Yu et 
al.
162  It  provided  evidence  supporting  the  mechanism  of  LSD1  inactivation  by 
tranylcypromine and the formation of the FAD-PCPA adduct 3.19. Yokoyama and co-
workers  solved  this  complex  with  an  improved  resolution  and  suggested  that  the 
covalent adduct 3.19 is the major adduct formed but also observed the N
5 adduct 3.20 
(Figure 3.3).
163 
 
 
Figure 3.3 : Structure of the N
5 adduct (3.20) 
 
The mechanism of inactivation of LSD1 by tranylcypromine is different to that of the 
MAO  inhibition  (Scheme  3.4).  In  fact,  the  FAD-PCPA  adduct  obtained  in  MAO 
inactivation is not the same as 3.19, which is formed in LSD1 inactivation. The covalent 
adduct  FAD-PCPA,  formed  in  the  inactivation  of  MAO  B,  is  believed  to  be  the 
aldehyde 3.21. Depending on the opening of the cyclopropane another adduct can be     Histone Demethylase Inhibitors
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obtained.
138,162 The site of modification of MAO by tranylcypromine has not yet been 
identified without ambiguities.  
 
 
Scheme 3.4 : Mechanism of inactivation of MAOB by tranylcypromine 
 
According to Yu et al., the phenyl group of the FAD-PCPA adduct 3.19 is located in a 
large hydrophobic pocket in the active site of LSD1.
162 The model showed that the 
cavity  space  is  not  completely  filled  (Figure  3.4).
162  There  is  potential  that 
tranylcypromine analogues with hydrophobic substituents on the phenyl ring might be 
more potent inhibitors of LSD1.  
 
 
Figure 3.4 : FAD-PCPA adduct in LSD1
162 “Reprinted with permission from Yang, M. et al.. Biochemistry 2007, 46, 8058-
8065, copyright (2007) American Chemical Society.” 
 
McCafferty  et  al.  believed  that  substituents  on  the  para-position  should  make  the 
analogues more selective towards LSD1 than MAO.
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Tranylcypromine, used as a drug in the treatment of depression, is administered as the 
racemate. It appeared that the (–)-enantiomer had the same therapeutic effect as the 
racemate with fewer side effects.
165 One of the two enantiomers should also be more 
appropriate in the inhibition of LSD1.  
Mai et al. synthesised the enantiomers (+) and (–)-tranylcypromine.
166 The difference in 
LSD1 inhibition activity found for the two distinct enantiomers was small, with the (+)-
enantiomer found to be the most potent inhibitor. Crystallographic studies showed that 
the FAD-PCPA adducts in LSD1 differed for the two enantiomers.  
 
During  the  course  of  this  work,  several  groups  reported  the  preparation  of 
tranylcypromine analogues. 
 
McCafferty’s tranylcypromine analogues (Figure 3.5) were prepared by two different 
cyclopropanation  methods:  either  cyclopropanation  of  trans-cinnamate  with  a  diazo 
compound or Michael-initiated ring closure with a sulfur ylide.
164 The compounds were 
tested against LSD1, MAOA and MAOB and inhibition kinetics were reported. The 
para-bromo- derivative was the only analogue with greater LSD1 inhibition compared 
to  tranylcypromine,  while  the  analogues  with  trifluoromethyl-  and  methoxy- 
substituents  exhibited  a  decreased  inhibition.  The  thienyl-,  naphthyl-  and  biphenyl- 
compounds were found to be inactive. 
 
 
Figure 3.5 : Tranylcypromine analogues prepared by McCafferty 
 
In  2009,  Miyata  published  tranylcypromine-lysine  hybrid  analogues  3.29  and  3.30 
(Figure 3.6).
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structures of FAD-PCPA adduct 3.19 and the FAD-N-propargyl lysine peptide adduct 
3.14. The cyclopropanation was performed by Michael-initiated ring closure with the 
sulfur ylide on trans cinnamate derivatives. Amino acid side chains were linked by an 
ether bond on the aromatic ring at the meta or para positions. Benzylamino and benzoyl 
groups were used in order to increase hydrophobic interactions with residues in the 
active site. These compounds are active in enzyme and cell growth inhibition assay with 
the  para  compound  3.30  showing  slightly  better  biological  activity  than  the  meta 
derivative 3.29.  
 
 
Figure 3.6 : Tranylcypromine analogues prepared by Miyata 
 
In 2010, Mai et al. meanwhile prepared a series of tranylcypromine analogues in order 
to increase the selectivity of the analogues towards LSD1 versus MAO (Figure 3.7).
166 
They performed the cyclopropanation of styrene using diazoester with copper triflate. 
Their compounds are similar to that reported by Myata but instead of ether linkage, 
amide linkage is  employed to  incorporate the side chain  containing phenyl  rings.
167 
Good  inhibition  activity  and  selectivity  were  obtained  for  the  linear  and  branched 
analogues. 
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Figure 3.7 : Selection of tranylcypromine analogues prepared by Mai 
 
In 2010, Yokoyama published some fluoro- tranylcypromine analogues (Figure 3.8).
168 
They  performed  the  cyclopropanation  of  styrene  using  a  diazoester  and  rhodium 
catalyst, followed by epimerisation with sodium hydroxide solution in ethanol. They 
first made compound 3.34 and realised that the fluoro- groups were beneficial for LSD1 
inhibition  activity.  From  the  crystal  structure  analysis  of  FAD-3.34  in  LSD1,  they 
discovered that a phenyl ring in ortho position of the cyclopropyl group would enhance 
the biological activity. Some modifications were performed on the phenyl ring in the 
ortho position and gave interesting LSD1 inhibitors (3.36, 3.37 and 3.38). 
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Figure 3.8 : Selection of tranylcypromine analogues prepared by Yokoyama 
 
It  is  important  to  highlight  that the  IC50  of the analogues  prepared by the different 
groups  are  not  comparable  due  to  differences  in  assay  conditions.  The  IC50  of 
tranylcypromine is the reference required to compare the compounds. 
 
3.1.2.3. Peptide derivatives and phenelzine 
The  study  led  by  Cole  and  co-workers  was  a  comparison  of  peptides  versus  small 
molecules.
169 The chlorovinyl-containing compounds 3.39 and 3.40 and the hydrazine 
peptide  derivative  3.41  presented  respectively  similar  and  greater  LSD1  inhibition 
activity than the propargyl- peptide derivative 3.12 (Figure 3.9). 
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Figure 3.9 : Structures of peptide derivatives 
 
They  stated  that  phenelzine  (3.8)  is  a  more  potent  LSD1  inhibitor  than  previously 
reported.
169  According  to  their  research,  this  inhibitor  is  35-fold  more  potent  than 
tranylcypromine in enzyme assay. The mechanism of LSD1 inactivation by phenelzine 
is proposed to involve oxidations to afford 3.43 via the formation of the diazene 3.42 
(Scheme  3.5).  Nucleophilic  attack  of  the  flavin  on  the  electrophilic  carbon  of  3.43 
formed the covalent adduct 3.44 after loss of nitrogen. 
 
 
Scheme 3.5 : Proposed mechanism of LSD1 inactivation by phenelzine 
 
They  also  tested  this  compound  in  cell  assay  and  determined  that  it  blocked  the 
demethylation of H3K4Me in cells.
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3.1.2.4. Polyamines 
Some  polyamines  were  found  to  exhibit  LSD1  inhibition,  such  as  biguanide  and 
bisguanidine  polyamine  analogues  (Figure  3.10).
170  These  polyamine  analogues  are 
LSD1 inhibitors with an IC50 lower than 2.5 μM. They are able to re-express several 
aberrantly silenced tumour suppressor genes.
170,171 These biguanide and bisguanidine 
polyamine  analogues  were  shown  to  reactivate  aberrantly  silenced  genes  in  colon 
cancer.
170 A later study also showed that 3.46 was also able to alter gene expression in 
ER-negative human breast cancer cell lines.
172 
 
 
Figure 3.10 : Structures of biguanide 3.45 and bisguanidine 3.46 inhibitors of LSD1  
 
3.1.3. Jumonji-containing histone demethylases  
 
Other  histone  demethylases  recently  discovered  include
  Jumonji-containing  histone 
demethylases (JHDMs).
143 The demethylase activity of these enzymes requires Fe(II) 
and  ʱ-ketoglutarate  as  cofactors.  The  Jumonji  family  of  iron(II)-ʱ-ketoglutarate-
dependent demethylases are able to demethylate different sites on a lysine substrate with 
different  degrees  of  methylation.
143  Unlike  LSD1,  these  enzymes  are  able  to 
demethylate trimethyl- lysine. This demethylation proceeds with a different mechanism 
than  that  of  LSDs:  hydroxylation  of  the  methyl  group  followed  by  elimination  of 
formaldehyde (Scheme 3.6).  
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Scheme 3.6 : Demethylation of trimethyl-lysine by the Jumonji proteins 
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3.2. AIMS 
 
We focused on LSD1 enzyme and envisaged preparing inhibitors of LSD1 as they are 
potential antitumor therapeutic agents. 
 
We planned to study the SAR of tranylcypromine. As a large hydrophobic pocket was 
clearly  observed  in  the  crystal  structure  of  FAD-PCPA  in  LSD1,  analogues  of 
tranylcypromine with substituents on the phenyl ring were interesting targets. We were 
also  planning  to  set  up  the  LSD1  assay  in  order  to  be  able  to  test  the  compounds 
ourselves.  
We also wanted to prepare some phenelzine analogues and investigate their biological 
activity as Cole et al. mentioned the potency of phenelzine in inhibiting LSD1 but no 
phenelzine analogues were evaluated.
169 
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3.3. SYNTHESIS OF TRANYLCYPROMINE ANALOGUES 
 
Different  strategies  are  conceivable  to  prepare  analogues  of  tranylcypromine.  As 
cyclopropane rings are found in a variety of natural products and biologically active 
compounds,  methods  to  construct  those  rings  are  highly  developed  in  racemic  and 
asymmetric series.
173 Several cyclopropanation methods are reported in the literature 
such  as  cyclopropanation  of  styrene  derivatives  or  trans-cinnamates  with  diazo 
compounds, or Simmons-Smith cyclopropanation of trans-cinnamates.
173,174 Action of 
the sulfur ylide initiated by Michael addition on trans-cinnamate is also a possible way 
to prepare cyclopropane rings.
175 
As the transition-metal catalysed cyclopropanation of olefins, using diazo compounds as 
a  carbene  source,  is  a  major  and  convenient  method  for  the  preparation  of 
cyclopropanes, we chose to perform the cyclopropanation on terminal activated olefins 
using this strategy. 
We first decided to prepare derivatives of tranylcypromine bearing substituents, such as 
halogens,  aryl  or  alkyls  groups,  on  the  para  position  of  the  phenyl  ring.  The 
retrosynthetic analysis of the target molecules 3.50 indicates they will be obtained from 
styrene derivatives 3.52 via formation of the intermediate esters 3.51 (Scheme 3.7).  
 
 
Scheme 3.7 : Retrosynthetic analysis of tranylcypromine derivatives 
 
3.3.1. First strategy in racemic series 
 
Firstly, cyclopropanation was performed in racemic series (Scheme 3.8). The reaction of 
ethyl diazoacetate in the presence of para-fluoro- or para-methoxy- styrene 3.53, using 
rhodium  catalysis  at  reflux  in  toluene,  afforded  a  mixture  of  trans-  and  cis-ethyl 
cyclopropanecarboxylates  3.54  (63/37  for  para-fluoro-;  75/25  for  para-methoxy- 
compound).
176  An  epimerisation  using  sodium  methoxide  as  a  base  gave  the 
thermodynamic diastereomer, trans-ester and the trans-acid 3.55 as major compound.
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Then, the hydrolysis of this trans-ester by action of lithium hydroxide in a mixture of 
methanol and water gave the carboxylic acid 3.55. Treatment with diphenylphosphoryl 
azide and triethylamine at reflux in tert-butanol gave the carbamate 3.56 with a yield 
ranging from 22 to 53%.
176 The Curtius rearrangement is a relatively slow step as it 
required 48 h. The reaction is carried out in tert-butanol which scavenged the isocyanate 
intermediate to lead to the carbamate 3.56. Subsequent acidic treatment should provide 
the amine 3.57. 
 
 
Scheme 3.8 : Attempts to prepare tranylcypromine analogues via rhodium catalysed 
cyclopropanation 
 
Problems  were  encountered  during  the  epimerisation  which  was  not  found  to  be 
reproducible.  Many  trials  were  performed  to  repeat  the  epimerisation  but  all 
unsuccessfully: a mixture of cis- and trans-ester and -acid was obtained. Hydrolysis of 
the ester took place during the work-up and the quantity of ester obtained was low. The 
source of sodium methoxide bottle and the concentration of the reaction were changed. 
In  addition  the  reaction  was  performed  under  anhydrous  conditions.  We  decided  to 
change the strategy in order to avoid the epimerisation step. We should have changed 
the  base  and  use  sodium  hydroxide  solution  in  ethanol  as  Yokoyama  did  for  the 
synthesis of his fluoro- tranylcypromine analogues.  
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3.3.2. Second strategy using an asymmetric cyclopropanation 
 
As we believed that one of the trans enantiomers might be a better LSD1 inhibitor, we 
decided to attempt to prepare analogues using an asymmetric strategy. The most active 
enantiomer  for  MAO  inhibition  is  the  (–)-tranylcypromine  with  the  (1S,  2R) 
stereochemistry.  We  decided  to  prepare  the  same  enantiomer  in  the  belief  that  the 
homologous LSD1 enzyme would exhibit the same stereochemical preference.  
A cationic copper complex, formed in situ from chiral bis(oxazolines) 3.58 and copper 
triflate,  was  used  as  catalyst  to  perform  the  asymmetric  cyclopropanation  on  the 
monosubstituted  olefin  3.53  with  an  achiral  diazo  ester  (tert-butyl  diazoacetate)  at 
ambient  temperature  (Scheme  3.9).
164,177  The  products  were  isolated  as  trans/cis 
mixtures of the cyclopropyl esters (83/17 for the fluoro- derivative). The trans isomer 
3.59 (1S, 2S) is the major compound and its absolute configuration was deduced by 
analogy  from  previous  work.  We  used  tert-butyl  diazoacetate  instead  of  ethyl 
diazoacetate  in  order  to  obtain  higher  enantioselectivity.  The  trans-tert-butyl 
cyclopropanecarboxylate  3.59  was  then  hydrolysed  using  trifluoroacetic  acid  and 
triethylsilane in dichloromethane.
178 The carboxylic acid obtained 3.60 was converted 
into a carbamate 3.61 by Curtius rearrangement and finally HCl gas was employed to 
remove  the  Boc  protecting  group.
176  The  fluoro-  and  methoxy-  derivatives  were 
prepared. 
 
 
Scheme 3.9 : Asymmetric synthesis of tranylcypromine analogues with (1S, 2R) stereochemistry 
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Resolution of the tranylcypromine racemic mixture 
A resolution of the racemic mixture of tranylcypromine was carried out by forming 
diastereomeric tartrates (Scheme 3.10).
165 Recrystallisation allowed the isolation of one 
diastereomeric tartrate and therefore the corresponding enantiomer after hydrolysis (e.g. 
3.63 with L-tartaric acid). 
 
 
Scheme 3.10 : Resolution of (±) racemic tranylcypromine 
 
The  LSD1  enzyme  assay  of  the  racemic  mixture  of  tranylcypromine  and  the  two 
enantiomers was performed. The assay will be described in detail at a later stage. The 
racemic mixture gave the best enzyme assay result with 25 µM for the Ki. The Ki of 
(+)-enantiomer  was  26.6 µM  and the (–)-enantiomer was  28.1 µM.  Based on these 
results, we decided to prepare the (+)-enantiomer as it showed slightly better activity 
than the (–)-enantiomer. Asymmetric cyclopropanation on styrene derivatives 3.65 was 
performed using tert-butyl diazoacetate at ambient temperature and a catalyst formed in 
situ from chiral bis(oxazolines) 3.66 and copper triflate (Scheme 3.11). We used the 
same  procedure  described  earlier,  but  used  ligand  3.66,  with  the  opposite 
stereochemistry to that of ligand 3.58, in order to obtain the (1R, 2S) tranylcypromine 
analogue instead of the (1S, 2R) as described in scheme 3.9. Using this pathway, we 
prepared several analogues in four steps: para-fluoro-, para-methoxy-, para-bromo-, 
meta-bromo-  and  ortho-bromo-  tranylcypromine  derivatives.  Four  of  them  were 
prepared by Christopher Hodgkinson, an undergraduate student under my supervision. 
Cu(OTf)2 instead of CuOTf was used by mistake for the synthesis of all the derivatives 
however,  as  Cu(OTf)2  must  be  reduced  to  CuOTf  during  the  reaction,  the 
cyclopropanation worked quite well. This mistake may explain the wide range of yield 
obtained for the different analogues (30-77%).     Histone Demethylase Inhibitors
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Scheme 3.11 : Asymmetric synthesis of tranylcypromine analogues with (1R, 2S) stereochemistry 
 
In  addition  to  being  interested  in  the  bromo-  derivatives  LSD1  inhibition  activity 
(3.70c-e), we chose the bromo  substituent  in  order to  be  able to  prepare  additional 
analogues, by diverse palladium catalysed crosscoupling reactions, with ease. Suzuki 
couplings were performed on the bromo- carbamate derivatives in order to incorporate 
phenyl groups. Initial work on the Suzuki was performed by a student but he was unable 
to obtain the purified carbamates (3.69c-e), due to reactions not going to completion and 
difficulty separating the product from the starting material, during his placement. By 
increasing the number of equivalents of the reagents we were able to force the reactions 
to completion and successfully prepare the derivatives 3.69f-h. The final step is the Boc 
removal (Scheme 3.12). Suzuki coupling enabled us to prepare the para-, meta- and 
ortho- phenyl tranylcypromine derivatives (3.70f-h) in a total of five steps.  
 
 
Scheme 3.12 : Synthesis of the biphenyl tranylcypromine analogues via Suzuki coupling 
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We attempted to prepare the furyl-, thienyl- and pyridyl- analogues (Figure 3.11).  
 
 
Figure 3.11 : Bicyclic compound carbamates 
 
We successfully obtained the meta- and para- furyl- derivatives along with the para- 
pyridyl-  compound  but  did  not  manage  to  obtain  the  thienyl-  compound.  HCl 
deprotection was unsuccessful and no product was obtained, probably due to sensitivity 
of the furan and pyridine rings to acidic conditions. No further work was carried out for 
these compounds. Different Boc deprotection methods could be tried in the future as the 
biological activity of these compounds is potentially interesting.  
We are going to test the tranylcypromine analogues prepared as LSD1 inhibitors (Figure 
3.12). 
 
Figure 3.12 : Structures of the prepared tranylcypromine analogues (3.70a-h) 
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3.4. BIOLOGY TESTING OF TRANYLCYPROMINE ANALOGUES 
 
3.4.1. Expression and purification of full length human LSD1  
 
Dr Patrick Duriez, a collaborator at the Cancer Research UK centre in Southampton, 
performed all the work to prepare the enzyme. 
 
3.4.1.1. Cloning of LSD1 in pET15b and protein expression principles 
The  human  recombinant  protein  LSD1  was  produced  in  bacteria  using  molecular 
biology techniques. First, the DNA coding for the LSD1 protein was inserted in the 
plasmid pET15b to create the construct pET15b-LSD1 (generous gift from Dr. Yang 
Shi, Harvard Medical School, Boston). A plasmid is a small circular DNA that  can 
replicate  independently  of  the  chromosomal  DNA  once  incorporated  into  bacteria. 
Among other features, the plasmid carries an antibiotic resistant gene that allows the 
selection of the bacteria that contain the plasmid. The bacterial strain used was E. coli 
BL21 CodonPlus-RIPL. 
The pET plasmids have been engineered to allow the production of protein upon the 
addition  of  a  chemical  inducer,  IPTG  (isopropyl-β-D-thiogalactopyranoside),  to  the 
bacterial  culture. The construct  pET15b-LSD1  also  includes  a stretch  of 6 histidine 
residues at the N-terminus of the LSD1 protein for purification purposes. 
 
3.4.1.2. Protein expression 
The induction of the expression of the protein LSD1 was carried out by adding IPTG to 
exponentially  growing  bacteria.  Following  the  protein  induction,  the  bacteria  were 
centrifuged.  The  supernatant  was  removed  and  the  bacteria  pellet  was  kept  in  the 
freezer. 
 
3.4.1.3. Protein extraction 
The bacteria pellet was lysed in a mixture of Tris-HCl, NaCl, Triton X100, glycerol, 
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degradation of the protein of interest by bacterial enzymes. The detergent Triton X100 
helps the lysis of the bacteria while the DNase I is an enzyme that breaks down the 
DNA which is released during the lysis of the bacteria and will make the sample very 
viscous otherwise. The supernatant containing the soluble proteins was kept and will be 
purified. 
 
3.4.1.4. Protein purification 
The expressed protein His6-LSD1 was subjected to successive chromatography steps 
due to the presence of contaminant proteins to obtain a protein which was as pure as 
possible.  The  first  chromatography  separation  relied  on  the  binding  of  the  His6  tag 
present at the N-terminus of the protein on a Nickel column. The second purification 
step used a gel filtration, or size exclusion column to separate LSD1 from other proteins 
according  to  its  molecular  weight.  Finally,  the  last  chromatography  used  an  anion 
exchanger (Q-sepharose column) to separate LSD1 from other proteins according to its 
isoelectric point or pI (pI of LSD1 ~ 6). The fractions containing LSD1 were combined, 
aliquoted and stored at –80 ºC. This purified enzyme will be used in the enzyme assay. 
 
3.4.2. Mass spectrometric analysis  
 
This analysis was performed by Dr P. Duriez with the help of Dr B. Zeidan and Prof P. 
Townsend. 
Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-
TOF) was used to control the demethylation activity of LSD1 on the substrate. This 
method  employs  chromatographic  surfaces  coupled  to  a  time-of-flight  mass 
spectrometry.
179 In SELDI-TOF, samples are spotted on ProteinChip® arrays (surface 
modified  with  a  chemical  functionality)  then,  the  matrix  that  absorbs  laser  energy 
(energy absorbing molecule or EAM) is added and co-crystallised with the sample. The 
mass-to-charge ratios are deduced from the time required by the ionised proteins to 
reach the detector.  
The  enzyme  was  incubated  with  the  peptide  fragment  of  H3K4me2: 
ARTK(me2)QTARKSTGGKAPRKQLA. SELDI-TOF mass spectrometric analysis of 
the substrate presented a peak with a molecular weight equal to 2283 (Figure 3.13). The 
mass spectrometer presented a calibration error responsible for an additional 5 units in     Histone Demethylase Inhibitors
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all the detected mass. SELDI-TOF mass spectrometric analysis of the reaction mixture 
showed the peaks of the methylated (MW 2269) and non-methylated substrate (MW 
2255).  Addition  of  tranylcypromine  resulted  in  the  enhancement  of  the  peak 
corresponding to the dimethyllysine (MW 2283). This experiment confirmed the fact 
that the prepared enzyme is able to demethylate H3K4 and that tranylcypromine is an 
inhibitor of LSD1. 
 
 
Figure 3.13 : Mass spectrometric analysis of LSD1 activity with the substrate H3K4me2: top graph 
MS of peptide alone, middle graph: peptide with LSD1 and bottom graph: peptide with LSD1 and 
tranylcypromine 
 
3.4.3. Fluorescence based LSD1 enzyme assay 
 
Our collaborator Dr Patrick Duriez first attempted to use a colorimetric assay in which 
the formaldehyde is converted by formaldehyde dehydrogenase to formic acid with the 
reduction of NAD
+ to NADH. The latter is detected spectrophotometrically at 340 nM. 
Unfortunately, this method did not detect any enzyme activity in our hands.  
We then decided to detect hydrogen peroxide, the other by-product formed during the 
demethylation  of  lysine  by  LSD1.  For  the  enzymatic  determination  of  hydrogen 
peroxide, we decided to use a method based on the peroxidase catalysed oxidation of N-
acetyl-3,7-dihydroxyphenoxazine  3.75  (Amplex®  Red)  to  the  fluorescent  product 
resorufin  3.76  (Scheme  3.13).
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derivative  of  dihydroresorufin,  is  oxidised  to  the  fluorescent  resorufin.  This  highly 
sensitive method gave reliable and reproducible results. 
 
 
Scheme 3.13 : Oxidation of Amplex® Red (3.75) to resorufin (3.76) by hydrogen peroxide and HRP 
 
From that point, I performed the enzyme assay after receiving help and explanations 
from Patrick Duriez, our co-worker.  
The experiments were performed in a 96-well microplate. LSD1 was incubated with the 
commercial  peptide  substrate  which  consists  of  the  first  21  amino  acids  of  human 
histone 3 dimethylated on lysine 4 ARTK(me2)QTARKSTGGKAPRKQLA for 20 min. 
Amplex® Red and horseradish peroxidise (HRP) were then added in order to detect 
subsequent hydrogen peroxide formation. After 30 min, Amplex® Red stop reagent was 
added in order to stop the reaction. It is essential to stop the reaction to measure the 
fluorescence after a certain time period for all the experiments as the fluorescence is 
time-dependent. The fluorescence was read on a microplate reader with excitation at 
530 nm wavelength and emission at 590 nm wavelength. The value read represents the 
relative fluorescence unit (RFU).  
For determining the effect of the inhibitors on the enzyme, the analogues were pre-
incubated with LSD1 for 10 min prior to performing the assay. 
 
In order to find the optimum conditions, we had to look into the enzyme kinetics and to 
determine the Michaelis constant Km of the enzyme.
181 For three fixed concentrations of 
the enzyme, the concentration of the substrate was varied and the assay was carried out 
(Figure 3.14).  
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Figure 3.14 : Effect of substrate concentration on the rate of an enzyme catalysed reaction for three 
different concentrations of the enzyme 
 
Linear transformation of the Michaelis-Menten equation allowed us to determine the 
value of Km (Figure 3.15). The determination of the Km could have been obtained from 
the first graph but higher accuracy is obtained with the Lineweaver-Burk plot. 
 
 
Figure 3.15 : Lineweaver-Burk plot: effect of substrate concentration on the initial rate of an 
enzyme-catalysed reaction 
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To determine the Km, we decided to use the two lines obtained for the concentration of 
the enzyme equal to 20 and 40 ng/µL, as there is a point which is an outlier in the line 
obtained for the concentration equal to 10 ng/µL. The lines have an intercept of –1/Km 
on the 1/[S] axis. Km was found to be around 21 µM for the peptide substrate.  
We  would  usually  perform  a  screening  of  the  analogues  we  prepared  at  a  certain 
concentration (25 µM or 50 µM).  
If  the  analogues  presented  a  greater  activity  than  tranylcypromine  a  dose-response 
experiment would be performed. The Ki was obtained from five to eight concentrations 
points performed in duplicate or triplicate, fitted by a representative sigmoidal dose 
response curve (e.g. figure 3.16 for racemic tranylcypromine and for both enantiomers). 
The  LSD1  inhibition  profile  experiment  was  then  repeated  once  or  twice  for  each 
compound in order to obtain the Ki(inact) for the inhibitors (Table 3.1). 
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Figure 3.16 : Dose response experiments for racemic tranylcypromine, (+)-tranylcypromine and    
(–)-tranylcypromine 
 
The 4-methoxy-, 4-fluoro- and 4-bromo- analogues (3.70a-c) were made in order to 
study  the  influence  on  the  LSD1  inhibition  activity  of  the  electronic  effects  on  the 
substituents in the phenyl ring. The bromo- analogue 3.70c was found to be a greater 
LSD1 inhibitor than tranylcypromine with a Ki(inact) of 3.7 µM, whereas the methoxy- 
and fluoro- analogues (3.70a and 3.70b) were weaker LSD1 inhibitors with respective 
Ki(inact) of 41.8 and 79.6 µM. We can see that strong electron-withdrawing and electron-
donating substituents on the phenyl ring are unfavourable for the LSD1 activity. The 
encouraging  result  of  the  bromo-  derivative  led  us  to  prepare  the  meta-  and  ortho-     Histone Demethylase Inhibitors
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bromo-  analogues  (3.70d and  3.70e). These compounds were also  more active than 
tranylcypromine, displaying Ki(inact) of 8.9 µM for the meta- derivative 3.70d and 11.7 
µM for the ortho- analogue 3.70e, the para- analogue 3.70c being the most potent LSD1 
inhibitor. It is likely that the para- bromo- analogue is the best inhibitor because the 
bromo- group in para position has a better fit within the hydrophobic pocket. The para- 
phenyl analogue 3.70f was also a greater LSD1 inhibitor than tranylcypromine whereas 
the meta- and ortho- phenyl derivatives (3.70g and 3.70h) were poorer inhibitors in 
enzyme assay.  
 
3.4.4. LNCaP cell growth inhibition assay 
 
As explained earlier, LSD1 is able to form a complex with the AR and to demethylate 
the repressive marks of mono- and dimethyllysine 9 on histone 3. The LSD1 inhibitors 
are able to block this demethylation. We tested our tranylcypromine analogues against 
the LNCaP prostate adenocarcinoma cell line. A six-day dose response was performed 
by our collaborators for each derivative in order to obtain IC50 (Table 3.1).  
Tranylcypromine showed very poor results in cell growth inhibition (IC50 174 mM). 
The  methoxy-  and  fluoro-  compounds  (3.70a  and  3.70b)  were,  as  expected,  poor 
inhibitors  of the cell line  whilst the methoxy- compound  3.70a was  better than the 
fluoro-  analogue  3.70b  in  accordance  with  the  enzyme  assay  result.  The  para-  and 
meta-  bromo-  analogues  (3.70c  and  3.70d)  were  much  more  potent  than 
tranylcypromine  with  respective  IC50  of  111  and  129  µM  (1000  fold  compared  to 
tranylcypromine).  The  ortho-  bromo-  compound  3.70e  showed  a  good  activity  in 
enzyme assay but was relatively poor in  cell growth inhibition. We are not able to 
explain the weak result of the ortho- bromo- analogue 3.70e in cell assay. The phenyl 
analogues (3.70f-h) were all quite potent inhibitors of the cell line LNCaP whereas in 
enzyme  assay  only  the  para- phenyl  analogue  3.70f  showed interesting  results. We 
believed  that  the  cell  assay  result  is  highly  correlated  to  the  permeability  of  the 
compounds. The lipophilicity is responsible for the cell permeability of the compounds, 
thus  lipophilic  compounds,  such  as  the  phenyl  analogues,  are  able  to  penetrate  the 
membrane and cause growth inhibition (Figure 3.17). 
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Figure 3.17 : Predicted lipophilicity of the different analogues 3.77, 3.78, 3.79 and 3.80 using 
ChemDraw     Histone Demethylase Inhibitors
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Compound  Structure 
LSD1 
inhibition 
Ki(inact) (µM) 
LNCaP 
inhibition IC50 
(µM) 
(±)-
Tranylcypromine   
25.0 ± 9.5  >100,000 
(+)-
Tranylcypromine   
26.6 ± 12.2  >100,000 
(–)-
Tranylcypromine   
28.1 ± 12.9  >100,000 
3.70a 
 
41.8 ± 1.0  1706 ± 120 
3.70b 
 
79.6 ± 1.0  >100,000 
3.70c 
 
3.7 ± 0.5  111 ± 103 
3.70d 
 
8.9 ± 3.2  129 ± 3 
3.70e 
 
11.7 ± 0.9  5869 ± 470 
3.70f 
 
6.8 ± 0.3  110 ± 31 
3.70g 
 
>100  226 ± 72 
3.70h 
 
>100  181 ± 6 
Table 3.1 :Activity of the tranylcypromine derivatives in LSD1 enzyme assay and LNCaP growth 
inhibition 
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3.4.5. PSA expression 
 
Another experiment was performed by our collaborators at the Cancer Research UK 
centre in Southampton: Dr Simon Crabb, Dr Annette Hayden and Rosemary Bulleid. 
The AR induces prostate-specific antigen (PSA) gene expression, and our collaborators 
are looking at the influence of the inhibitors on PSA expression (Figures 3.18 and 3.19). 
The experiment was done with different concentrations of the compounds which makes 
the comparison of the compounds relatively difficult. They determined that pargyline 
3.11, the para- phenyl and the para- bromo- analogues (3.70g, 3.70f and 3.70c) are the 
most potent inhibitors of PSA expression with the most promising compounds being the 
para- phenyl and the para- bromo- derivatives (3.70f and 3.70c). Further testing of 
these two compounds is ongoing. 
 
 
Figure 3.18 : PSA expression following treatment with the different analogues 
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Figure 3.19 : PSA expression following treatment with different analogues 
 
3.4.6. Screening of compounds 
 
3.4.6.1. Screening of Taiwanese compounds 
We  performed  a  screening  of  tranylcypromine  analogue  MAO  inhibitors  that  we 
obtained, from Weir-Torn Jiaang, Yu-Sheng Chao and Ting-Yueh Tsai from Taiwan, 
and performed the dose-response experiment of the analogues with greater inhibition 
activity  than  tranylcypromine  (Table  3.2).  We  are  trying  to  understand  the  SAR  of 
tranylcypromine and discovered some interesting compounds. Chloro- groups in either 
the meta- or para- position gave, in both cases, active inhibitors (3.81, 3.82 and 3.83). 
Donors  group  in  the  meta-position,  such  as  -OCF3  and  –OEt,  gave  good  LSD1 
inhibition activity. The phenyl ring was replaced by a methyl thiazole ring and this 
analogue 3.85 is a good LSD1 inhibitor.     Histone Demethylase Inhibitors
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Compound  Structure  LSD inhibition 
Ki(inact) (µM) 
3.81 
 
2.38 ± 1.5 
3.82 
 
6.30 ± 2.2 
3.83 
 
6.68 ± 3.4 
3.84 
 
11.31 ± 2.9 
3.85 
 
13.39 ± 2.5  
3.86 
 
16.73 ± 5.8 
Table 3.2 : Ki(inact) table of potent Taiwanese compounds 
 
Only three compounds from the screening were not tested and this was because their 
inhibition activity was much weaker than tranylcypromine (Figure 3.20). The phenyl 
ring replaced by 3,5-disubstituted-1,2,4-oxadiazole gave a poor LSD1 inhibitor (3.87). 
The  screening  also  showed  us  that  substituting  both  ortho  positions  with  chlorine 
groups is unfavourable for the biology activity of the compounds, as well as when there 
are two donor groups (methoxy) on the meta positions. 
 
 
Figure 3.20 : Analogues less active than tranylcypromine in LSD1 enzyme assay     Histone Demethylase Inhibitors
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3.4.6.2. Screening of German compounds 
A) LSD1 enzyme assay  
We  tested  eighteen  fluorinated  phenylcyclopropylamines  obtained  from  Professor 
Günter Haufe from the University of Münster. They were first tested in the enzyme 
assay at a single concentration and amongst them, four compounds were more potent 
than tranylcypromine. The compounds displaying higher activity were then tested in the 
enzyme assay at different concentrations to obtain Ki(inact) from dose-response curves 
(Table 3.3). Compound 3.90 with F5S- substituent in para position is the best analogue 
obtained so far from all the analogues tested (Ki(inact)lower than 1 µM). Compound 3.91 
with two phenyl rings attached to the cyclopropyl ring and derivative 3.92 containing 
F3C- group in  para position  also  showed  good activity  (Ki(inact)  around 2 µM). The 
chloro-  compound  3.93  showed  good activity, even though  the stereochemistry  was 
different to the other analogues (trans vs. cis for the previous ones).  
 
Compound  Structure  LSD inhibition Ki(inact) 
(µM) 
3.90 
 
0.77 ± 0.2 
3.91 
 
2.06 ± 0.8 
3.92 
 
2.13 ± 0.2 
3.93 
 
6.70 ± 0.5 
Table 3.3 : Ki(inact) values of the potent fluorinated phenylcyclopropylamine analogues 
 
Several  fluorinated  phenylcyclopropylamines  were  less  active  than  tranylcypromine 
(Figure 3.21). Compounds 3.94 and 3.95, differing from tranylcypromine by the fluoro 
group in the cyclopropyl ring, are less active than tranylcypromine. The compounds 
3.96, 3.97, 3.98 and 3.99, with a strong donor group (-F and -OMe), are not very active     Histone Demethylase Inhibitors
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as  has  also  been  observed  for  our  analogues.  We  were  not  surprised  to  see  that 
derivatives  3.100  and  3.101,  with  extra  carbons  between  the  amino  group  and  the 
cyclopropyl ring, are not active as this part is responsible for the LSD1 inhibition. Trans 
compounds 3.102 and 3.103, with -CF3 and F5S-, and cis compound 3.104, with the two 
phenyl substituents on the cyclopropyl ring, are less active than tranylcypromine and 
their  respective  cis  isomers  3.92,  3.90  and  3.91.  The  cis  derivative  3.105,  with  the 
chloro- group, is less active than tranylcypromine and its trans isomer 3.93. Cis and 
trans compounds 3.106 and 3.107, with a methyl substituent in the 4- position on the 
aromatic ring, are less active than tranylcypromine.  
 
 
Figure 3.21 : Fluorinated phenylcyclopropylamine analogues less active than tranylcypromine in 
LSD1 enzyme assay     Histone Demethylase Inhibitors
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B) LNCaP cell growth inhibition assay 
The compounds are very potent in cell growth inhibition (Table 3.4).  
 
Compound 
LNCaP inhibition IC50 
(µM) 
Tranylcypromine  1132 ± 72 
3.90  6.67 ± 4.5 
3.91  1.53 ± 0.4 
3.92  23.23 ± 12.5 
3.93  2.76 ± 0.3 
Table 3.4 : Activity of the fluorinated phenylcyclopropylamines in LNCaP growth inhibition 
 
C) PSA expression 
Tranylcypromine and pargyline reduced significantly PSA expression while the German 
compounds 3.93 (equivalent to GC6), 3.90 (equivalent to GC8) and 3.91 (equivalent to 
GC14) failed to show reduction in PSA expression even at high concentrations (Figure 
3.22).  Compound  3.92  (equivalent  to  GC11)  showed  minimal  reduction  of  PSA 
expression. It is difficult to explain why these compounds are very active in the enzyme 
and the cell assay but not able to reduce PSA expression. It is possible that the fluoro- 
group on the cyclopropyl ring is involved in other biological process.  
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Figure 3.22 : PSA expression following treatment with the fluorinated phenylcyclopropylamines 
 
These four compounds displayed potent activity in enzyme assay and in cell growth 
inhibition. Nevertheless they were not able to reduce PSA expression.  
The facts that derivatives 3.94 and 3.95 are less potent than tranylcypromine and that 
poor  results  are  also  obtained  for  PSA  expression,  has  encouraged  us  to  prepare 
analogues without the fluoro group on the cyclopropyl ring. Thus, we are planning to 
prepare the tranylcypromine derivative 3.108 with F5S- in para position and the cis and 
trans derivatives 3.109 and 3.110 with the two phenyl substituents on the cyclopropyl 
ring.  We  have  already  tested  compound  3.83,  with  the  chloro-  substituents  in  para 
position, and McCafferty tested the compound 3.23 with -CF3 in para position.  
 
 
Figure 3.23 : Tranylcypromine derivatives to prepare in the future     Histone Demethylase Inhibitors
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3.5. SYNTHESIS OF PHENELZINE ANALOGUES 
 
3.5.1. Route 1 
 
We were planning to prepare some analogues of phenelzine as it has been mentioned 
that phenelzine was more potent than tranylcypromine in enzyme assay.
169 They also 
showed that phenelzine was an inhibitor of LSD1 in cells. We decided to prepare the 
para-  bromo-  and  phenyl-  phenelzine  derivatives  due  to  the  encouraging  biological 
activity  results  we  obtained  for  the  two  corresponding  tranylcypromine  derivatives 
(3.70c and 3.70f).  
First,  we decided to  prepare the phenelzine analogues  via formation  of the tosylate 
derivative 3.112 obtained from the carboxylic acid 3.113 (Scheme 3.14).  
 
 
Scheme 3.14 : Retrosynthetic analysis of para- bromo- and phenyl- phenelzine derivatives 
 
The  commercial  4-bromophenylacetic  acid  3.113  was  reduced  to  the  alcohol  3.114 
followed by protection of the hydroxyl group with a tosyl group. We then attempted to 
displace the tosylate with Boc hydrazine but were unsuccessful. The final product 3.116 
would  have  been  obtained  after  Boc  deprotection.  We  were  planning  to  perform 
palladium coupling to insert the phenyl ring followed by Boc deprotection to obtain 
3.118.  
As this strategy was unsuccessful we decided to change our method. From previous 
work performed in our laboratory by former PhD student Sally Radford, we proposed 
that we could use the reductive alkylation of Boc hydrazine that she developed.
182 
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Scheme 3.15 : Attempts to synthesise phenelzine analogues 
 
3.5.2. Route 2 
 
The synthesis of the following phenelzine analogues was performed by two students 
(Charlotte Poillion and Sebastian Schwenk). We decided to form the aldehyde 3.119 
and then condense it with Boc hydrazine to form the hydrazine derivative 3.111. 
 
 
Scheme 3.16 : New retrosynthesis of para- bromo- and phenyl- phenelzine derivatives 
 
Oxidization of alcohol 3.114 to the aldehyde 3.119 was performed by Dess-Martin-
periodinane in CH2Cl2.
183 Washes with solutions of Na2S2O3 and NaHCO3 during the 
work-up are important to obtain a high yield and clean reaction. The aldehyde 3.119 
was treated with tert-butyl carbazate in dry toluene at 50 °C to form the Boc-protected 
hydrazone 3.120 in 76%.
182 The hydrazone 3.120 was reduced to the corresponding 
hydrazine  3.115  using  NaBH(OAc)3  in  good  yield  (84%).
184,185  We  initially  used 
NaBH3CN as described by Sally Radford, but decided instead to use NaBH(OAc)3 for 
safety reasons.
182 The Boc group was successfully removed using HCl in dioxane to 
afford 3.121.
186     Histone Demethylase Inhibitors
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Scheme 3.17 : Synthesis of the bromo- phenelzine derivative 
 
In order to prepare the para phenyl phenelzine analogue 3.122 Suzuki coupling was 
employed. We used the same conditions that were successful for the tranylcypromine 
analogues (entry 1) but the yield obtained was very low (10%). 
 
 
Scheme 3.18: Synthesis of the phenyl- phenelzine derivative 
 
Optimization  of  the  reaction  was  attempted  by  changing  solvent,  base  and  reaction 
conditions (Table 3.5). Potassium carbonate and acetonitrile were used (entry 2) and 
gave the compound 3.117 with low yield 18%.
187 Microwave reaction was tried but with 
no success (entry 3). The purification of this compound was complicated as several by-
products were also formed.      Histone Demethylase Inhibitors
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Entry  Chemicals  Solvents  Conditions  Yield (%) 
1
 
4 equiv PhB(OH)2 
0.2 equiv Pd(PPh3)4 
2 equiv Na2CO3 
Toluene/MeOH/H2O  120 °C,18 h  10 
2
 
1 equiv PhB(OH)2 
0.04 equiv Pd(PPh3)4  
K2CO3 
MeCN/H2O 
 
90 °C, 16 h  18 
3 
1.2 equiv PhB(OH)2 
0.09 equiv  
PEPPSI-iPr 
2.1 eq. Cs2CO3 
Dioxane 
120 °C,  
Microwave  
150 psi,  
250 W, 40 min 
0 
Table 3.5 : Optimisation of the Suzuki coupling reaction 
 
Boc removal was performed by treatment with HCl in dioxane to afford 3.122 in 94%. 
Sebastian Schwenk prepared the bromo- and phenyl- analogues.     Histone Demethylase Inhibitors
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3.6. PRELIMINARY STUDIES ON THE BIOLOGY ACTIVITY OF 
THE PHENELZINE ANALOGUES 
 
Phenelzine sulfate 3.123 was tested in growth inhibition by Annette Hayden and we 
obtained a potent inhibitor (IC50 121.7 ± 0.1 µM). 
LSD1 enzyme assays were performed on the prepared phenelzine analogues 3.121 and 
3.122 along with some commercial hydrazine compounds available in our laboratory 
(3.123 to 3.127).  
 
 
Figure 3.24 : Synthetic phenelzine and commercially available hydrazine derivatives tested 
 
We performed a screening of the inhibitors at high concentration (200 µM instead of 25 
or 50 µM) using tranylcypromine as the reference. Unfortunately we discovered that 
none  of  the  compounds  were  biologically  active  against  LSD1  while  Cole  and  co-
workers obtained a Ki(inact) of 17.6 ± 2.8 µM for phenelzine.
169 These results are difficult 
to explain as Cole et al. used the same detection method as us (Amplex® Red coupled 
assay).
169 We decided to test these compounds in the cell assay and these experiments 
are currently ongoing. 
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3.7. CONCLUSION 
 
We decided to prepare the most active enantiomer after studying the LSD1 inhibition 
activity of both enantiomers after resolution of tranylcypromine racemic mixture. We 
prepared  a  series  of  tranylcypromine  analogues  in  four  to  five  steps  using  an 
asymmetric  synthesis.  We  tested  the  compounds  in  LSD1  enzyme  assay  using  a 
fluorometric assay. Cell assay against prostate cancer cell line was then performed. We 
discovered  several  tranylcypromine  analogues  which  exhibited  greater  activity  than 
tranylcypromine itself in enzyme and cell assays. In cell assay, para- and meta- bromo 
derivatives are 1000 fold more potent than tranylcypromine. We determined that the 
size and electronic properties of the substituents are important with substituents in the 
para-  and  meta-  positions  appearing  to  be  more  favourable.  It  is  probable  that  the 
substituents  in  these  positions  have  a  better  fit  within  the  hydrophobic  pocket. 
Correlation between cell growth inhibition and lipophilicity was observed. 
We are planning to prepare other tranylcypromine derivatives.  For example, we are 
going to prepare derivatives starting from para-vinylbenzoic acid in order to be able to 
prepare several inhibitors by simple coupling steps. We are also planning to prepare the 
derivative with the -SF5 substitution in the para position and the derivatives with the 
two phenyl- groups on the cyclopropyl ring (cis and trans). Further development of 
tranylcypromine analogues as LSD1 inhibitors for the treatment of prostate cancer is 
ongoing. An interesting experiment would be to test the compounds as MAO inhibitors 
in order to determine their selectivity towards LSD1. 
Phenelzine was a potent inhibitor of the cell line LNCaP. Two phenelzine analogues 
were prepared and tested in LSD1 enzyme assay. Phenelzine and related derivatives 
were not found to be active as LSD1 inhibitors.  
So  far,  only  irreversible  LSD1  inhibitors  are  reported.  A  reversible  LSD1  inhibitor 
would be a better inhibitor. 
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4. CONCLUSIONS AND FUTURE WORK 
 
We prepared five different natural product cyclic peptides: sanguinamides A and B, 
stylissamide A, largazole and burkholdac B. These compounds were all of biological 
interests.  
Sanguinamides  and  stylissamide  A  are  proline-rich  containing  cyclopeptides.  We 
planned to prepare these cyclopeptides to evaluate their biological activities. The natural 
rotamers were not obtained synthetically. We prepared stylissamide A in order to study 
the translation inhibitory activity of the synthetic compound versus the natural product. 
The natural and synthetic stylissamide A displayed the same structural characteristics 
but different biological activity.  
Largazole  and  burkholdacs  are  cyclic  depsipetides  presenting  histone  deacetylase 
inhibitory activity. Largazole and a series of analogues were prepared in order to study 
the  SAR  of  this  potent  HDAC  inhibitor.  We  investigated  the  metabolic  stabilty  of 
largazole  and  analogues.  All  the  modifications  that  we  made  were  tolerated. 
Simplification of largazole is possible with conservation of the biological activity and a 
correlation  between  lipophilicity  and  growth  inhibition  activity  was  also  observed. 
Burkholdac  B  was  finally  prepared  after  synthesizing  several  compounds  such  as 
thailandepsins, revised structures of thailandepsins followed by two diastereomers of 
Burkholdac B. The first set of thailandepsins presented a synthetic challenge as they 
were containing an unusual cyclic hemiaminal function but we discovered that they 
were inaccurate structures of the natural products. It was also the case of the revised 
structures of thailandepsins. The synthesis of the diastereomers of burkholdac B allowed 
us to elucidate the stereochemistry of burkholdacs which was left unassigned by Brady. 
Potent HDAC inhibitors were discovered in these two projects. We are planning to 
synthesise second-generation HDAC inhibitors based on largazole and burkholdacs. 
On top of being interested on histone deacetylase inhibitors we were also attracted by 
histone demethylase inhibitors, especially LSD1 inhibitors. We started our investigation 
on this area by synthesizing synthetic compounds, analogues of tranylcypromine and 
phenelzine presenting LSD1 inhibition activity. We were pleased to identify several 
small molecules  with  higher activity than tranylcypromine in vitro and  in  vivo. We 
discovered by screening several compounds some possible modifications that could be 
made in order to continue our investigation on the SAR of tranylcypromine. We also set      
192 
 
up a high-throughput LSD1 assay. Further development of tranylcypromine analogues 
as LSD1 inhibitors for the treatment of prostate cancer is undergoing. 
     Experimental Procedures 
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5. EXPERIMENTAL PROCEDURES 
 
5.1. GENERAL PROCEDURES 
 
Glassware was dried in the oven prior to use if the reaction is water sensitive. The 
reactions were carried out under argon or nitrogen atmosphere unless otherwise noted. 
The term in vacuo is used to describe the evaporation under vacuum using a rotary 
evaporator. 
All  the reagents  were purchased from commercial suppliers  such as  Sigma-Aldrich, 
Alfa Aesar, Novabiochem. Anhydrous THF, dichloromethane and toluene were freshly 
distilled under argon from solvent purification system. All other anhydrous solvents 
were purchased as Aldrich® sure/seal bottles. 
The reactions were monitored by TLC using pre-coated aluminium backed sheets of 
silica coated with 0.14 mm of silica gel 60 with a fluorescence indicator at 254 nm 
(Merck, Kieselgel 60 F254). The spots were visualised by UV-light (λ 254 nm) and/or 
stained  with  cerium-ammonium  molybdate  or  potassium  permanganate  or  ninhydrin 
followed  by  heating.  Flash  chromatographies  are  performed  using  silica  gel  (MN 
Kieselgel 60, 40-63 µm, 230-400 mesh ASTM).  
Optical  rotations  were  determined  using  polarimeter  POLAAR  2001.  Solutions  of 
compounds mainly in CHCl3 or CH3OH were irradiated with D line of sodium lamp (λ 
589 nm) and the [ʱ]D values are given in deg.cm
3.g
-1. Prior to the measurement of the 
optical rotation of the compounds, calibration with the solvent used was performed. 
Some of the optical rotations were taken using polarimeter ADP220 (Bellingham and 
Stanley). Melting points were obtained using an Electrothermal melting point apparatus. 
Infrared spectra were collected using a Thermo Nicolet 380 FT-IR spectrometer with a 
Smart orbit Gate attachment. The software used is Omnic and the values are reported as 
absorptions as wavelengths in cm
-1.  
NMR spectra were recorded on a Bruker AV300 spectrometer or a Bruker DPX400 
spectrometer at 300 or 400 MHz respectively for 
1H and at 75 MHz or 100 MHz for 
13C. 
Spectral  data  were  reprocessed  using  ACD  labs  software  or  MESTRENOVA  and 
referenced to the residual solvent peak (CDCl3, CD3OD, CD2Cl2 or DMSO-d6). The 
1H 
NMR data are reported with the chemical shifts in ppm followed by brackets containing     Experimental Procedures 
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in this order the multiplicity (s: singlet, d: doublet, t: triplet, q: quartet, quin: quintet, 
sxt:  sextet,  spt:  septet,  m:  multiplet,  br:  broad),  coupling  constants  reported  in  Hz, 
number of protons (from integration) and the proton assignment if possible (i.e. H-4). 
The 
13C NMR data are reported with chemical shifts followed by the order of carbons 
(C, CH, CH2 or CH3) and the assignment if possible (i.e. CO for carbonyl or C-6) in 
parentheses. 
Mass spectra were done using ES or EI. Electrospray mass spectra were obtained using 
a  Thermoquest  Trace  MS  and  Micromass  Platform  II  single  quadrupole  mass 
spectrometer. High resolution mass spectra were collected by the School of Chemistry 
Mass  spectrometry  Service  of  Southampton  using  a  Bruker  Apex  III  FT-ICR  mass 
spectrometer fitted with an Appollo electrospray ionisation source. Some HRMS were 
acquired by the EPSRC National Mass Spectrometry Service Centre, Swansea. 
Intermediate  amines  or  acids  prepared  for  coupling  are  most  of  the  time  not 
characterised; the deprotection step is checked by TLC or mass spectrometry analysis. 
Complete characterisation is carried on the amide compound. 
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5.2. EXPERIMENTAL  PROCEDURES  FOR  CHAPTER  1: 
PROLINE-CONTAINING  CYCLIC  PEPTIDE  NATURAL 
PRODUCTS 
 
5.2.1. Sanguinamide A 
 
N-Boc-isoleucinamide (1.38)  
 
To a solution of di-tert butyl dicarbonate (1.31 g, 6 mmol, 1 equiv) in CH2Cl2 (30 mL) 
were added L-isoleucinamide hydrochloride (1 g, 6 mmol, 1 equiv) and triethylamine 
(1.73 mL, 12.4 mmol, 2.1 equiv). The reaction mixture was refluxed for 4 h under 
argon. Triethylamine salts  were extracted twice  with water (10 mL). The combined 
aqueous layers were extracted once with EtOAc. The combined organic layers were 
dried over MgSO4 and evaporated to provide 1.38 as a white solid (1.38 g, 100%).  
1H NMR (400 MHz, CD3OD) ʴ ppm 3.95 (d, J=6.5 Hz, 1H, CH), 1.90–1.70 (m, 1H, 
Me-CH-Et), 1.65–1.52 (m, 1H, CH2), 1.48 (s, 9H, CMe3), 1.20 (tt, J=14.2, 7.3 Hz, 1H, 
CH2), 0.98 (d, J=7.0 Hz, 3H, CH-CH3), 0.95 (t, J=7.5 Hz, 3H, CH2-CH3); ES
+ MS m/z 
253 ([M+Na]
+). 
The spectroscopic data are consistent with that
188 reported in the literature. 
 
 
N-Boc-isoleucine thioamide (1.39)  
 
To a solution of 1.38 (1.36 g, 5.8 mmol, 1 equiv) in dry THF (20 mL) was added 
Lawesson’s reagent (1.43 g, 3.5 mmol, 0.6 equiv) under argon. The reaction mixture     Experimental Procedures For Chapter 1 
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was stirred at 70 °C for 6 h. The solvent was evaporated and the residue purified by 
flash chromatography using EtOAc/CH2Cl2 (1:9) to give 1.39 as a white solid (730 mg, 
50%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.06 (br s, 1H, NH2), 7.66 (br s, 1H, NH2), 5.26 (d, 
J=9.0 Hz, 1H, NH), 4.23 (t, J=8.5 Hz, 1H, CH), 2.05–1.86 (m, 1H, Me-CH-Et), 1.75–
1.52 (m, 1H, CH2), 1.44 (s, 9H, CMe3), 1.24–1.04 (m, 1H, CH2), 1.04–0.81 (m, 6H, 
2CH3); ES
+ MS m/z 269 ([M+Na]
+). 
The spectroscopic data are consistent with that
189 reported in the literature. 
 
 
Boc-(Ile)Thz-OMe (1.40)  
 
Method 1 
To  a  solution  of  1.39  (620  mg,  2.5  mmol,  1  equiv)  in  ethanol  (10  mL),  methyl 
bromopyruvate (295 µL, 2.8 mmol, 1.1 equiv) and calcium carbonate (136 mg, 1.4 
mmol,  0.5  equiv)  were  added.  The  reaction  mixture  was  stirred  under  argon  at  rt 
overnight.  The  reaction  mixture  was  evaporated  under  reduced  pressure  and  the 
obtained residue was partitioned between CHCl3 and saturated NaHCO3 solution. The 
organic layer was then washed once with water. The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified 
by flash chromatography (hexane/EtOAc 7:3) to afford a mixture of diastereomers 1.40 
and 1.47 (326 mg, 39%).  
 
Method 2 
To a suspension of pulverised KHCO3 (2.37 g, 23.7 mmol, 8 equiv) in a solution of 1.39 
(730 mg, 3.0 mmol, 1 equiv) in DME (8 mL), methyl bromopyruvate (946 µL, 8.9 
mmol, 3 equiv) was added. The reaction mixture was stirred under argon at rt for 2 h. 
The suspension was then cooled to 0 °C and a solution of TFAA (1.65 mL, 11.9 mmol,     Experimental Procedures For Chapter 1 
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4  equiv)  and  pyridine  (2.04  mL,  25.2  mmol,  8.5  equiv)  in  DME  was  then  added. 
Solvents  were  evaporated  under  reduced  pressure.  The  residue  was  suspended  in 
chloroform and this solution was washed with water. The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified 
by flash chromatography (hexane/EtOAc 9:1) to afford 1.40 as a colourless oil (308 mg, 
32%). 
1H NMR (400 MHz, CDCl3) ʴ ppm 8.10 (s, 1H, H-3), 5.29 (br s, 1H, NH), 5.03–4.74 
(m, 1H, H-5), 3.95 (s, 3H, CO2Me), 2.28–2.06 (m, 1H, H-6), 1.44 (s, 10H, H-8; CMe3), 
1.15 (s, 1H, H-8), 1.02–0.79 (m, 6H, H-7; H-9); ES
+ MS m/z (351 [M+Na]
+). 
The spectroscopic data are consistent with that
190 reported in the literature. 
 
 
Boc-Pro-(Ile)Thz-OMe (1.42) 
 
1.40 (365 mg, 1.1 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 2.5 mL) for 1 
h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN and 
CHCl3 was performed to afford 1.41.  
To a solution of Boc-L-Pro-OH (390 mg, 1.8 mmol, 1.6 equiv) in CH2Cl2 (10 mL), 
PyBOP (1.07 g, 1.8 mmol, 1.6 equiv) and Hünig’s base (632 µL, 3.6 mmol, 3.2 equiv) 
were added. The reaction mixture was stirred for 5 min before the free amine 1.41 (253 
mg, 1.1 mmol, 1 equiv) was added. The reaction mixture was stirred at rt overnight and 
concentrated  in  vacuo.  The  crude  material  was  purified  by  flash  chromatography 
(hexane/EtOAc 8:2) to afford 1.42 as a colourless oil (320 mg, 62%). 
[ʱ]D
27 –86.9 (c 0.55, CH3OH); IR 3297, 2970, 2929, 2872, 1724, 1699, 1524, 1474, 
1389, 1356, 1242, 1213, 1152, 1123, 1095, 984 cm
–1;
 1H NMR (400 MHz, CDCl3) ʴ 
ppm 8.08 (s, 1H, H-3), 7.89 (br s, 1H, NH), 5.29–5.14 (m, 1H, H-5), 4.48–4.29 (m, 1H, 
H-11), 3.94 (s, 3H, CO2Me), 3.60–3.22 (m, 2H, H-14), 2.54–2.19 (m, 2H, H-12), 2.05–    Experimental Procedures For Chapter 1 
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1.70 (m, 3H, H-6; H-13), 1.59–1.25 (m, 10H, CMe3; H-8), 1.24–1.10 (m, 1H, H-8), 
0.99–0.78 (m, 6H, H-7; H-9); 
13C NMR (100 MHz, CDCl3) ʴ ppm 173.8 (C), 171.9 
(C), 161.9 (C), 156.3 (C), 147.1 (C, C-2), 127.0 (CH, C-3), 80.6 (C, CMe3), 59.7 (CH, 
C-5 or C-11), 56.4 (CH, C-5 or C-11), 52.3 (CH3, CO2Me), 47.1 (CH2, C-14), 39.2 (CH, 
C-6), 28.3 (3CH3, CMe3), 27.2 (CH2, C-8 or C-12 or C-13), 24.7 (CH2, C-8 or C-12 or 
C-13), 23.9 (CH2, C-8 or C-12 or C-13), 15.8 (CH3, C-7), 11.4 (CH3, C-9); ES
+ MS m/z 
448 ([M+Na]
+); HRMS (ESI) m/z calcd. for C20H31N3NaO5S (M+Na)
+ 448.1877, found 
448.1878. 
 
 
H-Pro-(Ile)Thz-OMe hydrochloride (1.33) 
 
1.42 (164 mg, 0.04 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 300 µL) for 1 
h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN and 
CHCl3  was  performed  to  afford  1.33.  The  compound  was  used  without  further 
purification. 
 
 
Methyl  2-((1S,2S)-2-methyl-1-((S)-1-(4-nitrobenzoyl)pyrrolidine-2-carboxami-do)-
butyl)-thiazole-4-carboxylate (1.48) 
 
To a solution of para-nitrobenzoic acid (7.1 mg, 42 µmol, 1.1 equiv) in CH2Cl2 (1 mL), 
Hünig’s base (24 µL, 134 µmol, 3.5 equiv), EDCI.HCl (9 mg, 46 µmol, 1.2 equiv),     Experimental Procedures For Chapter 1 
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HOBt (1 mg, 8 µmol, 0.2 equiv) were added at 0 °C. The reaction mixture was stirred 
for 5 min before 1.33 (12.5 mg, 38 µmol, 1 equiv) was added. The reaction mixture was 
stirred at rt overnight. The reaction mixture was washed twice with a saturated solution 
of NH4Cl. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. 
The  crude  material  was  purified  by  flash  chromatography  (CH2Cl2/MeOH  98:2)  to 
afford 1.48 as a yellow solid (16 mg, 87%). Crystalline needles were grown from a 
mixture acetonitrile/water. 
[]D
27 –78 (c 0.16, CH3OH); mp 62–64 °C; IR 3305, 2978, 1728, 1687, 1638, 1519, 
1433, 1348, 1217 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 8.32 (d, J=8.5 Hz, 2H, 
HAr), 8.11 (s, 1H, H-3), 7.70 (d, J=8.5 Hz, 2H, HAr), 7.53 (d, J=7.5 Hz, 1H, NH), 5.29 
(dd, J=8.5, 6.0 Hz, 1H, H-5), 4.80 (dd, J=7.3, 4.8 Hz, 1H, H-11), 3.95 (s, 3H, CO2Me), 
3.66–3.50 (m, 1H, H-14), 3.48–3.33 (m, 1H, H-14), 2.51–2.34 (m, 1H, H-12), 2.34–2.20 
(m, 1H, H-12 or H-13), 2.19–2.04 (m, 2H, H-12 or H-13), 1.99–1.84 (m, 1H, H-6), 
1.58–1.42 (m, 1H, H-8), 1.39–1.12 (m, 1H, H-8), 0.94 (d, J=7.0 Hz, 3H, H-7), 0.89 (t, 
J=7.5 Hz, 3H, H-9); 
13C NMR (100 MHz, CDCl3) ʴ ppm 172.1 (C), 170.5 (C), 168.8 
(C), 165.6 (C), 148.7 (C), 146.9 (C), 142.0 (C), 128.1 (2CH, HAr), 127.1 (CH, C-3), 
123.9  (2CH,  HAr),  60.2  (CH,  C-5  or  C-11),  56.3  (CH,  C-5  or  C-11),  52.4  (CH3, 
CO2Me), 50.3 (CH2, C-14), 39.5 (CH, C-6), 27.6 (CH2, C-8 or C-12 or C-13), 25.5 
(CH2, C-8 or C-12 or C-13), 24.5 (CH2, C-8 or C-12 or C-13), 15.8 (CH3, C-7), 11.5 
(CH3, C-9); ES
+ MS m/z 497 ([M+Na]
+); X-Ray: X-ray data available in Appendix 6.1. 
 
 
Boc-Pro-Ile-OMe (1.52)  
 
To  a  solution  of  Boc-L-Pro-OH  (539  mg,  2.5  mmol,  1  equiv)  in  CH2Cl2  (20  mL), 
EDCI.HCl (720 mg, 3.8 mmol, 1.5 equiv), HOBt (68 mg, 0.5 mmol, 0.2 equiv) and 
Hünig’s base (873 µL, 5.0 mmol, 2 equiv) were added. The reaction mixture was stirred 
for 5 min before the L-isoleucine methyl ester hydrochloride (500 mg, 2.8 mmol, 1.1 
equiv) was added. The reaction mixture was stirred at rt overnight. The reaction mixture     Experimental Procedures For Chapter 1 
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was washed twice with a saturated solution of NH4Cl. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (hexane/EtOAc 7:3) to afford 1.52 as a colourless oil (850 mg, 99%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.50 (br s, 0.5H, NH), 6.53 (br s, 0.5H, NH), 4.65–
4.45 (m, 1H, H-2), 4.43–4.17 (m, 1H, H-8), 3.73 (s, 3H, CO2Me), 3.58–3.24 (m, 2H, H-
11), 2.57–1.78 (m, 5H, H-3; H-9; H-10), 1.48 (s, 9H, CMe3), 1.47–1.36 (m, 1H, H-5), 
1.24–1.07 (m, 1H, H-5), 0.96–0.82 (m, 6H, H-4; H-6); ES
+ MS m/z 365 ([M+Na]
+). 
The spectroscopic data are consistent with that
191 reported in the literature. 
 
 
Boc-Phe-Pro-Ile-OMe (1.54) 
 
Boc-Pro-Ile-OCH3 1.52 (939 mg, 2.7 mmol, 1 equiv) was treated with HCl in dioxane 
(4 M, 8 mL) for 1 h. The reaction mixture was concentrated in vacuo, and coevaporation 
with CH3CN and CHCl3 was performed to afford 1.53 (765 mg, 100%).  
To a solution of Boc-L-Phe-OH (800 mg, 3.0 mmol, 1.1 equiv) in CH2Cl2 (20 mL), 
EDCI.HCl (789 mg, 4.1 mmol, 1.5 equiv), HOBt (74 mg, 0.6 mmol, 0.2 equiv) and 
Hünig’s base (1.67 mL, 9.6 mmol, 2 equiv) were added. The reaction mixture was 
stirred for 5 min before 1.53 previously prepared (765 mg, 2.7 mmol, 1 equiv) was 
added.  The  reaction  mixture  was  stirred  at  rt  overnight.  The  reaction  mixture  was 
washed twice with a saturated solution of NH4Cl. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography using a gradient hexane/EtOAc as eluent (7:3 to 1:1) to afford 1.54 as a 
colourless oil (Mixture of conformers) (1.02 g, 76%). 
[]D
27 –21.8 (c 0.30, CH3OH); IR 3313, 2962, 2925, 2872, 1740, 1691, 1638, 1523, 
1499,  1433,  1364,  1249,  1204,  1159,  1057,  1012,  869  cm
–1; 
1H  NMR  (400  MHz, 
CDCl3) ʴ ppm Major conformer: 7.37–7.13 (m, 5H, HAr), 5.31 (d, J=8.8 Hz, 1H, NH),     Experimental Procedures For Chapter 1 
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4.70–4.54 (m, 2H), 4.51 (dd, J=8.0, 4.9 Hz, 1H), 3.74 (s, 3H, CO2Me), 3.62–3.48 (m, 
1H, H-11), 3.14 (t, J=9.7 Hz, 1H, H-11), 3.06–2.93 (m, 1H, H-14), 2.92–2.82 (m, 1H, 
H-14), 2.37–2.24 (m, 1H, H-9), 2.10–1.81 (m, 4H, H-3, H-9; H-10), 1.57–1.42 (m, 1H, 
H-5), 1.37 (s, 9H, CMe3), 1.28–1.15 (m, 1H, H-5), 1.03–0.85 (m, 6H, H-4; H-6); 
13C 
NMR (100 MHz, CDCl3) ʴ ppm Major conformer: 172.1 (C), 172.0 (C), , 170.4 (C), 
155.1 (C), 136.2 (C, CAr), 129.3 (2CH, CAr), 128.5 (2CH, CAr), 126.9 (CH, CAr), 79.7 
(C, CMe3), 59.9 (CH, C-2 or C-8 or C-13), 56.8 (CH, C-2 or C-8 or C-13), 53.3 (CH, C-
2 or C-8 or C-13), 52.0 (CH3, CO2Me), 47.4 (CH2, C-11), 39.5 (CH2, C-14), 37.6 (CH, 
C-3), 28.2 (CH3, CMe3), 27.1 (CH2, C-9), 25.2; 25.1 (CH2, C-5, C-10), 15.5 (CH3, C-4), 
11.6  (CH3,  C-6);  ES
+  MS  m/z  512  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for 
C26H39N3NaO6 (M+Na)
+ 512.2731, found 512.2730. 
 
 
Boc-Ala-Phe-Pro-Ile-OMe (1.56) 
 
1.54 (943 mg, 1.93 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 6.2 mL) for 1 
h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN and 
CHCl3 was performed to afford 1.55 (813 mg, 99%).  
To a solution of Boc-Ala-OH (434 mg, 2.30 mmol, 1.2 equiv) in CH2Cl2 (25 mL), 
EDCI.HCl (600 mg, 3.13 mmol, 1.6 equiv), HOBt (56.4 mg, 0.42 mmol, 0.2 equiv) and 
Hünig’s base (1.27 mL, 7.30 mmol, 3.8 equiv) were added. The reaction mixture was 
stirred for 5 min before 1.55 previously prepared (813 mg, 1.93 mmol, 1 equiv) was 
added.  The  reaction  mixture  was  stirred  at  rt  overnight.  The  reaction  mixture  was 
washed twice with a saturated solution of NH4Cl. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography using a gradient hexane/EtOAc as eluent (1:1 to 1:2) to afford 1.56 as a 
white solid (832 mg, 71%).     Experimental Procedures For Chapter 1 
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[]D
27 –72.4 (c 0.29, CH3OH); mp 58–60 °C; IR 3314, 2966, 2937, 2872, 1748, 1679, 
1634, 1528, 1446, 1372, 1250, 1201, 1164 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 
Major conformer: 7.41–7.21 (m, 5H, HAr), 7.12 (br s, 1H, NH), 5.13–4.93 (m, 2H), 
4.65–4.54 (m, 2H), 4.37–4.19 (m, 1H), 3.80 (s, 3H, CO2Me), 3.65 (td, J=8.0, 7.0 Hz, 
1H, H-11), 3.28–3.16 (m, 1H, H-11), 3.11 (dd, J=13.6, 7.0 Hz, 1H, H-14), 3.00 (dd, 
J=13.6, 6.5 Hz, 1H, H-14), 2.34–2.22 (m, 1H, H-9), 2.14–1.88 (m, 4H, H-3; H-9; H-10), 
1.51 (s, 10H, CMe3; H-5), 1.32 (d, J=7.0 Hz, 3H, H-23), 1.29–1.23 (m, 1H, H-5), 1.06–
0.94 (m, 6H, H-4; H-6); 
13C NMR (100 MHz, CDCl3) ʴ ppm Major conformer: 172.2 
(C), 172.0 (C), 170.9 (C), 170.7 (C), 155.2 (C), 135.9 (C, CAr), 129.5 (2CH, CAr), 128.5 
(2CH, CAr), 127.0 (CH, CAr), 80.0 (C, CMe3), 59.9 (CH), 56.7 (CH), 52.0; 51.9 (CH3; 
2CH), 47.5 (CH2, C-11), 39.0 (CH2, C-14), 37.7 (CH, C-3), 28.3 (CH3, CMe3), 27.6 
(CH2, C-9), 25.2; 25.0 (CH2, C-5, C-10), 18.7 (CH3, C-23), 15.5 (CH3, C-4), 11.6 (CH3, 
C-6);  ES
+  MS  m/z  583  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for  C29H44N4NaO7 
(M+Na)
+ 583.3102, found 583.3096. 
 
 
Boc-Ala-Phe-Pro-Ile-OH (1.34) 
 
To a solution of Boc-Ala-Phe-Pro-Ile-OCH3 1.56 (300 mg, 0.5 mmol, 1 equiv) in 4 mL 
of a mixture THF/water (3:1) that had been cooled to 0 °C was added LiOH (38.5 mg, 
1.6 mmol, 3 equiv) and stirred at 0 °C overnight. The solution was diluted with water (5 
mL) and acidified to pH 1–2 with a saturated KHSO4 solution. This aqueous layer was 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with 
brine, dried over MgSO4 and concentrated in vacuo to provide 1.34 as a white solid 
(292 mg, 100%). 
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Linear precursor 1.58 
 
To a solution of 1.34 (189 mg, 0.35 mmol, 1.1 equiv) in CH2Cl2 (5 mL), PyBOP (242 
mg, 0.41 mmol, 1.3 equiv) and Hünig’s base (137 µL, 0.79 mmol, 2.5 equiv) were 
added. The reaction mixture was stirred for 5 min before the amine 1.33 previously 
prepared (103 mg, 0.31 mmol, 1 equiv) was added. The reaction mixture was stirred at 
rt overnight. The reaction mixture was concentrated in vacuo and the crude material was 
purified by flash chromatography using a gradient of MeOH in CH2Cl2 (0-5%) to afford 
1.58 as a white solid with PyBOP by-product (512 mg).  
ES
+ MS m/z 876 ([M+Na]
+). 
 
 
Trans, trans-Sanguinamide A (1.59) 
 
To a solution of 1.58 (269 mg, 0.3 mmol, 1 equiv) in 8 mL of a mixture THF/water 
(3:1) that had been cooled to 0 °C was added LiOH (22.6 mg, 0.9 mmol, 3 equiv) and 
stirred at 0 °C overnight. The solution was diluted with water (5 mL) and acidified to 
pH 1–2 with a saturated KHSO4 solution. This aqueous layer was extracted with EtOAc 
(3 x 20 mL). The combined organic layers were washed with brine, dried over MgSO4 
and  concentrated  in  vacuo  to  provide  the  carboxylic  acid  (180  mg,  68%).  The     Experimental Procedures For Chapter 1 
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carboxylic acid (180 mg, 0.2 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 5 
mL) for 1 h. The reaction mixture was concentrated in vacuo, and coevaporation with 
CH3CN and CHCl3 was performed to afford the linear precursor of sanguinamide A 
(158  mg,  100%).  Acyclic  precursor  (158  mg,  0.2  mmol,  1  equiv)  was  dissolved  in 
CH3CN/THF/CH2Cl2 (25 mL) and added dropwise to a vigorously stirred solution of 
Hünig’s base (112 µL, 0.6 mmol, 3 equiv) and HATU (163 mg, 0.4 mmol, 2 equiv) in 
CH3CN  (160  mL).  The  reaction  mixture  was  allowed  to  stir  overnight,  and  then 
concentrated in vacuo. The crude material was purified by flash chromatography with a 
gradient of MeOH in CH2Cl2 (0-5%) followed by several SCX-3. HPLC was performed 
to afford 1.59 as colorless oil (4 mg, 3%). 
[]D
24 –23 (c 0.08, CH3OH); IR 3285, 2964, 1646, 1534, 1454 cm
–1; 
1H NMR (600 
MHz, CDCl3) ʴ ppm 8.33 (d, J=9.4 Hz, 2H, NH), 7.94 (s, 1H, H-31), 7.30–7.25 (m, 
2H, H-22; H-24), 7.25–7.18 (m, 1H, H-23), 7.15 (d, J=7.6 Hz, 2H, H-21; H-25), 6.52 
(d, J=5.9 Hz, 1H, NH), 5.06 (t, J=9.7 Hz, 1H, H-33), 4.72 (d, J=7.6 Hz, 1H, H-7), 4.69–
4.65 (m, 2H, H-18; H-27), 4.44 (d, J=8.2 Hz, 2H, H-2), 3.85 (t, J=7.6 Hz, 1H, H-13), 
3.64 (t, J=8.5 Hz, 1H, H-16), 3.59 (t, J=9.1 Hz, 1H, H-5), 3.54–3.32 (m, 2H, H-5; H-
16), 3.17 (dd, J=13.8, 5.6 Hz, 1H, H-19), 2.93 (dd, J=13.5, 2.3 Hz, 1H, H-19), 2.31–
2.23 (m, 1H, H-34), 2.23–2.14 (m, 2H, H-3; H-14), 2.12–1.98 (m, 3H, H-3; H-4; H-15), 
1.98–1.67 (m, 3H, H-4; H-14; H-15), 1.57–1.54 (m, 1H, H-8), 1.53 (d, J=7.0 Hz, 3H, H-
28), 1.49–1.38 (m, 1H, H-35), 1.28 (spt, J=7.0 Hz, 1H, H-9), 1.21–1.02 (m, 2H, H-9; H-
35), 0.95 (t, J=7.6 Hz, 3H, H-10), 0.92 (d, J=6.5 Hz, 3H, H-37), 0.86 (t, J=7.6 Hz, 3H, 
H-36), 0.67 (d, J=6.5 Hz, 3H, H-11); 
13C NMR (150 MHz, CDCl3) ʴ ppm 171.4 (C, C-
1), 171.3 (C, C-12), 170.9 (C, C-26), 170.63 (C, C-6), 170.58 (C, C-32), 168.9 (C, C-
17), 160.8 (C, C-29), 146.6 (C, C-30), 135.3 (C, C-20), 131.1 (2CH, C-21; C-25), 128.0 
(2CH, C-22; C-24), 126.7 (CH, C-23), 125.6 (CH, C-31), 62.2 (CH, C-13), 61.4 (CH, 
C-2), 53.1 (CH, C-33), 53.0 (CH, C-7), 51.3 (CH, C-18), 48.9 (CH, C-27), 47.6 (CH2, 
C-16), 46.4 (CH2, C-5), 37.7 (CH, C-8), 35.8 (CH2, C-19), 34.1 (CH, C-34), 30.6 (CH2, 
C-3), 29.8 (CH2, C-14), 27.5 (CH2, C-9), 25.9 (CH2, C-15), 25.3 (CH2, C-35), 24.1 
(CH2, C-4), 18.3 (CH3, C-28), 17.0 (CH3, C-37), 13.8 (CH3, C-11), 12.2 (CH3, C-10), 
10.0  (CH3,  C-36);  ES
+  MS  m/z  744  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for 
C37H51N7NaO6S (M+Na)
+ 744.3514, found 744.6507, X-Ray: X-ray data available in 
Appendix 6.2. 
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Boc-Ala-Phe-OMe (1.69) 
 
To a solution of Boc-L-Ala-OH (580 mg, 3.1 mmol, 1.1 equiv) in CH2Cl2 (20 mL), 
PyBOP (1.81 g, 3.1 mmol, 1.1 equiv) and Hünig’s base (973 µL, 5.6 mmol, 2 equiv) 
were added. The reaction mixture was stirred for 5 min before the H-Phe-OMe (500 mg, 
2.8 mmol, 1 equiv) was added. The reaction mixture was stirred at rt overnight and 
concentrated  in  vacuo.  The  crude  material  was  purified  by  flash  chromatography 
(hexane/EtOAc 7:3) to afford 1.69 as a white solid (977 mg, 100%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.36–7.19 (m, 3H, HAr), 7.16–7.03 (m, 2H, HAr), 
6.50 (d, J=7.3 Hz, 1H, NH), 5.06–4.66 (m, 2H, NH; CHBn), 4.25–3.99 (m, 1H, CHMe), 
3.72 (s, 3H, CO2Me), 3.22–3.05 (m, 2H, CH2Ph), 1.44 (s, 9H, CMe3), 1.32 (d, J=7.3 Hz, 
3H, Me). 
The spectroscopic data are consistent with that
192 reported in the literature. 
 
 
H-Ala-Phe-OMe hydrochloride (1.70) 
 
1.69 (100 mg, 0.29 mmol) was treated with HCl in dioxane (4 M, 1 mL) for 1 h. The 
reaction mixture was concentrated in vacuo, and coevaporation with CH3CN and CHCl3 
was performed to afford 1.70 (81.8 mg, 100%).  
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Boc-Pro-(Ile)Thz-OH (1.61) 
 
To compound 1.42 in 8 mL of a mixture THF/water (3:1) at 0 °C was added LiOH (60 
mg, 2.5 mmol, 3 equiv) and stirred at 0 °C overnight. The solution was diluted with 
water (5 mL) and acidified to pH 1–2 with a saturated KHSO4 solution. This aqueous 
layer was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed 
with brine, dried over MgSO4 and concentrated in vacuo to provide 1.61 as a white solid 
(338 mg, 100%). 
 
 
Boc-Pro-(Ile)Thz-Ala-Phe-OMe (1.65) 
 
To a solution of 1.61 (123 mg, 0.30 mmol, 1.05 equiv) in CH2Cl2 (8 mL), PyBOP (352 
mg, 0.60 mmol, 2.1 equiv), and Hünig’s base (149 µL, 0.85 mmol, 3 equiv) were added. 
The reaction mixture was stirred for 5 min before 1.70 previously prepared (71 mg, 0.28 
mmol,  1  equiv)  was  added.  The  reaction  mixture  was  stirred  at  rt  overnight  and 
concentrated in vacuo. The crude material was purified by flash chromatography using a 
gradient hexane/EtOAc as eluent (1:2) to afford 1.65 as a white solid (150 mg, 78%). 
[]D
25 25.4 (c  0.11, CH3OH); 
1H  NMR (300 MHz, CDCl3/CD3OD)  ʴ ppm Major 
conformer: 7.89 (s, 1H, H-9), 7.05–6.93 (m, 5H, HAr), 4.98 (d, J=6.4 Hz, 1H, H-11), 
4.60 (t, J=6.4 Hz, 1H, H-2), 4.44 (q, J=6.8 Hz, 1H, H-5), 4.22–4.10 (m, 1H, H-17), 3.55 
(s, 3H, CO2Me), 3.37–3.13 (m, 2H, H-20), 2.99 (dd, J=13.8, 5.8 Hz, 1H, H-3), 2.87 (dd,     Experimental Procedures For Chapter 1 
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J=13.9, 7.5 Hz, 1H, H-3), 2.08–1.69 (m, 5H, H-12; H-18; H-19), 1.29 (br d, J=7.2 Hz, 
14H, H-6; H-13; CMe3), 0.76 (br d, J=6.8 Hz, 6H, H-14; H-15); 
13C NMR (100 MHz, 
CDCl3/CD3OD) ʴ ppm Major conformer: 175.6 (C), 174.4 (C), 173.3 (C), 169.8 (C), 
162.7 (C), 156.1 (C), 150.1 (C, C-8), 138.0 (C, CAr), 130.4 (2CH, CAr), 129.6 (2CH, 
CAr), 128.0 (CH, CAr), 125.4 (CH, C-9), 81.5 (C, CMe3), 61.2 (CH), 57.4 (CH), 55.4 
(CH or CH3), 52.9 (CH or CH3), 50.1 (CH), 47.7 (CH2), 40.6 (CH), 38.4 (CH2), 31.2 
(CH2), 28.8 (CH3, CMe3), 26.2 (CH2), 25.0 (CH2), 18.7 (CH3, C-6), 16.2 (CH3, C-15), 
11.7  (CH3,  C-14);  ES
+  MS  m/z  666  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for 
C32H45N5NaO7S (M+Na)
+ 666.2932, found 666.2930. 
 
 
Linear precursor 1.64 
 
1.65 (150 mg, 0.24 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 5 mL) for 1 
h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN and 
CHCl3 was performed to afford the deprotected amine (127 mg, 100%).  
To a solution of 1.66 (84 mg, 0.26 mmol, 1.1 equiv) in CH2Cl2 (5 mL), PyBOP (275 
mg, 0.47 mmol, 1.8 equiv), and Hünig’s base (122 µL, 0.70 mmol, 2.7 equiv) were 
added. The reaction mixture was stirred for 5 min before the previous deprotected amine 
(84 mg, 0.26 mmol, 1 equiv) was added. The reaction mixture was stirred at rt overnight 
and concentrated in vacuo. The crude material was purified by flash chromatography 
using EtOAc as eluent to afford 1.64 as a white solid with PyBOP by-product (165 mg, 
83%). 
ES
+ MS m/z 876 ([M+Na]
+). 
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Linear precursor 1.60 
 
To a solution of 1.61 (97 mg, 0.24 mmol, 1.3 equiv) in CH2Cl2 (10 mL), PyBOP (264 
mg, 0.45 mmol, 2.4 equiv), and Hünig’s base (117 µL, 0.67 mmol, 3.6 equiv) were 
added. The reaction mixture was stirred for 5 min before 1.62 (85 mg, 0.19 mmol, 1 
equiv) was added. 1.62 was obtained by treatment of 1.56 with HCl in dioxane followed 
by evaporation. The reaction mixture was stirred at rt overnight and concentrated in 
vacuo.  The  crude  material  was  purified  by  flash  chromatography  using  a  gradient 
CH2Cl2/MeOH as eluent (98:2) to afford 1.60 as a white solid (101 mg, 63%). 
ES
+ MS m/z 876 ([M+Na]
+). 
 
 
Trans, cis-Sanguinamide A (1.63) 
 
To a solution of 1.60 (101 mg, 0.12 mmol, 1 equiv) in 8 mL of a mixture THF/water 
(3:1) that had been cooled to 0 °C was added LiOH (26 mg, 1.1 mmol, 3 equiv) and 
stirred at 0 °C overnight. The solution was diluted with water (5 mL) and acidified to 
pH 1–2 with a saturated KHSO4 solution. This aqueous layer was extracted with EtOAc 
(3 x 20 mL). The combined organic layers were washed with brine, dried over MgSO4     Experimental Procedures For Chapter 1 
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and  concentrated  in  vacuo  to  provide  the  carboxylic  acid  (99  mg,  100%).  The 
carboxylic acid was treated with HCl in dioxane (4 M, 5 mL) for 1 h. The reaction 
mixture was concentrated in vacuo, and coevaporation with CH3CN and CHCl3 was 
performed to afford the linear precursor of sanguinamide A (88 mg, 100%). Deprotected 
acyclic precursor (87.5 mg, 0.12 mmol, 1 equiv) was dissolved in CH3CN/THF (25 mL) 
and added dropwise to a vigorously stirred solution of Hünig’s base (62 µL, 0.36 mmol, 
3 equiv) and HATU (90 mg, 0.24 mmol, 2 equiv) in CH3CN (90 mL). The reaction 
mixture  was  allowed  to  stir  overnight,  and  then  concentrated  in  vacuo.  The  crude 
material was purified by flash chromatography with EtOAc to afford 1.63 as a white 
solid (15 mg). HPLC was performed in order to remove HATU by-product to yield 1.63 
(2 mg, 2%).  
[]D
23 –140 (c 0.06, CH3OH); 
1H NMR (600 MHz, CDCl3) ʴ ppm 9.24 (d, J=7.6 Hz, 
1H, NH), 8.78 (d, J=7.0 Hz, 1H, NH), 8.13 (d, J=8.2 Hz, 1H, NH), 8.01 (s, 1H, H-31), 
7.29 (d, J=7.6 Hz, 2H, H-22; H-24), 7.27–7.24 (m, 1H, H-23), 7.17 (d, J=6.5 Hz, 2H, 
H-21; H-25), 6.60 (br s, 1H, NH), 5.10 (dd, J=7.3, 6.2 Hz, 1H, H-33), 4.77 (ddd, J=7.6, 
6.5, 6.5 Hz, 1H, H-27), 4.69 (d, J=8.2 Hz, 1H, H-2), 4.28 (dd, J=10.6, 7.6 Hz, 1H, H-7), 
4.25 (ddd, J=11.2, 5.3, 1.8 Hz, 1H, H-18), 4.00 (td, J=10.1, 6.7 Hz, 1H, H-5), 3.63 (t, 
J=8.2 Hz, 1H, H-5), 3.54 (td, J=11.4, 7.6 Hz, 1H, H-16), 3.50–3.44 (m, 1H, H-16), 3.41 
(d, J=7.6 Hz, 1H, H-13), 3.11 (t, J=11.7 Hz, 1H, H-19), 3.02 (dd, J=12.3, 5.3 Hz, 1H, 
H-19), 2.69 (dd, J=12.3, 5.9 Hz, 1H, H-3), 2.36–2.21 (m, 1H, H-8), 2.11 (dd, J=12.3, 
6.5 Hz, 1H, H-14), 2.06–1.98 (m, 1H, H-4), 1.97–1.86 (m, 2H, H-3; H-4), 1.86–1.77 (m, 
2H, H-9; H-15), 1.76–1.62 (m, 2H, H-15; H-34), 1.57–1.50 (m, 1H, H-35), 1.48 (d, 
J=6.5 Hz, 3H, H-28), 1.38–1.23 (m, 1H, H-9), 1.23–1.10 (m, 1H, H-35), 1.03 (d, J=6.5 
Hz, 3H, H-11), 0.99–0.94 (m, 1H, H-14), 0.93 (t, J=7.3 Hz, 3H, H-36), 0.92 (t, J=8.2 
Hz, 3H, H-10), 0.78 (d, J=7.0 Hz, 3H, H-37); 
13C NMR (150 MHz, CDCl3) ʴ ppm 
174.4 (C, C-6), 171.4 (C, C-12), 171.3 (C, C-26), 170.7 (C, C-1), 169.9 (C, C-17), 168.2 
(C, C-32), 160.5 (C, C-29), 148.5 (C, C-30), 134.7 (C, C-20), 129.4 (2CH, C-21; C-25), 
129.1 (2CH, C-22; C-24), 127.7 (CH, C-23), 123.1 (CH, C-31), 61.1 (CH, C-13), 60.9 
(CH, C-2), 56.4 (CH, C-7), 56.3 (CH, C-33), 54.6 (CH, C-18), 49.2 (CH, C-27), 48.3 
(CH2, C-5), 46.4 (CH2, C-16), 41.0 (CH, C-34), 37.8 (CH2, C-19), 35.5 (CH, C-8), 30.4 
(CH2, C-14), 25.8 (2CH2, C-3; C-35), 25.5 (CH2, C-9), 25.0 (CH2, C-4), 21.9 (CH2, C-
15), 18.0 (CH3, C-28), 15.2 (CH3, C-11), 15.1 (CH3, C-37), 11.5 (CH3, C-36), 10.4     Experimental Procedures For Chapter 1 
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(CH3, C-10); ES
+ MS m/z 744 ([M+Na]
+); HRMS (ESI) m/z calcd. for C37H52N7O6S 
(M+H)
+ 722.3694, found 722.3687. 
 
 
N-Boc-D-isoleucinamide (1.133)  
 
Boc-D-Ile-OH  (500 mg, 2.16 mmol,  1 equiv)  was  dissolved in  CH2Cl2 (5 mL)  and 
HOBt (876 mg, 6.48 mmol, 3 equiv), EDCI (1.24 g, 6.48 mmol, 3 equiv) and Hünig’s 
base (1.5 mL, 8.65 mmol, 4 equiv), were added at 0 °C. After stirring for 5 min, NH3 in 
dioxane (0.5 M, 43 mL, 21.60 mmol, 10 equiv) was added. The reaction mixture was 
stirred  at  rt  overnight.  HCl  solution  (0.1  M)  was  added  with  cooling  to  adjust  the 
reaction mixture to pH 4–5. The aqueous layer was extracted with CH2Cl2 (3 times). 
The combined organic layers were dried and concentrated in vacuo. The residue was 
purified by flash chromatography using CH2Cl2 then 3% MeOH in CH2Cl2 to afford 
1.133 as a white solid (361 mg, 73%). 
1H NMR (300 MHz, CD3OD) ʴ ppm 3.92 (d, J=6.8 Hz, 1H, CH), 1.91–1.66 (m, 1H, 
CH-Et), 1.63–1.35 (m, 10H, CH2; CMe3), 1.30–1.08 (m, 1H, CH2), 0.97–0.83 (m, 6H, 
2Me). 
The spectroscopic data are consistent with that
188 reported in the literature. 
 
 
N-Boc-D-isoleucine thioamide (1.134) 
 
To a solution of 1.133 (541 mg, 2.35 mmol, 1 equiv) in dry THF (14 mL) was added 
Lawesson’s reagent (570 mg, 1.41 mmol, 0.6 equiv) under argon. The reaction mixture 
was stirred overnight at rt. Lawesson’s reagent (285 mg, 0.7 mmol, 0.3 equiv) was     Experimental Procedures For Chapter 1 
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added and the reaction mixture was stirred overnight at rt. The solvent was evaporated 
and the residue purified by flash chromatography using EtOAc/CH2Cl2 (1:9) to give 
1.134 as a white solid (223 mg, 39%). 
1H NMR (400 MHz, CD3OD) ʴ ppm 4.14 (d, J=6.8 Hz, 1H, CH), 1.96-1.76 (m, 1H, 
CH-Et), 1.72-1.54 (m, 1H, CH2), 1.46 (s, 9H, CMe3), 1.16 (s, 1H, CH2), 0.99-0.87 (m, 
6H, 2Me). 
The spectroscopic data are consistent with that
189 reported in the literature. 
 
 
N-Boc-(D-Ile)Thz-OMe (1.72)  
 
To a suspension of pulverised KHCO3 (714 mg, 7.13 mmol, 8 equiv) in a solution of 
1.134 (219.5 mg, 0.89 mmol, 1 equiv) in DME (2.5 mL), methyl-3-bromopyruvate (484 
µL, 2.67 mmol, 3 equiv) was added. The reaction mixture was stirred under argon at rt 
for 2 h. The suspension was then cooled to 0 °C and a solution of TFAA (496 µL, 3.56 
mmol, 4 equiv) and pyridine (612 µL, 7.57 mmol, 8.5 equiv) in DME (2 mL) was then 
added. Solvents were evaporated under reduced pressure. The residue was suspended in 
chloroform  and  this  solution  was  washed  with  HCl  (1  M).  The  aqueous  layer  was 
extracted once with chloroform. The combined organic layers were dried over MgSO4, 
filtered  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography (hexane/EtOAc 9:1) to afford 1.72 as a colourless oil (136 mg, 47%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.02 (s, 1H, H-3), 5.23 (br d, J=8.1 Hz, 1H, NH), 
4.86 (t, J=6.6 Hz, 1H, H-5), 3.87 (s, 3H, CO2Me), 2.25–1.92 (m, 1H, H-6), 1.37 (br s, 
10H, H-8; CMe3), 1.20–0.99 (m, 1H, H-8), 0.95-0.69 (m, 6H, H-7; H-9). 
The spectroscopic data are consistent with that
190 reported in the literature. 
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Boc-Pro-(D-Ile)Thz-OMe (1.135) 
 
1.134 (127 mg, 0.39 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 5 mL) for 
1.5 h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN 
and CHCl3 was performed to afford the deprotected amine.  
To a solution of Boc-L-Pro-OH (125 mg, 0.58 mmol, 1.5 equiv) in CH2Cl2 (6 mL), 
PyBOP (343 mg, 0.58 mmol, 1.5 equiv) and Hünig’s base (202 µL, 1.16 mmol, 3 equiv) 
were added. The reaction mixture was stirred for 5 min before the previous deprotected 
amine was added. The reaction mixture was stirred at rt overnight. The organic layer 
was dried over MgSO4, filtered and concentrated in  vacuo. The crude material was 
purified by flash chromatography (hexane/EtOAc 8:2) to afford 1.135 as a colourless oil 
(137 mg, 83%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.07 (s, 1H, H-3), 7.83 (br s, 1H, NH), 5.25 (dd, 
J=8.7, 5.7 Hz, 1H, H-5), 4.51–4.24 (m, 1H, H-11), 3.94 (s, 3H, CO2Me), 3.60–3.30 (m, 
2H, H-14), 2.55–2.13 (m, 2H, H-12), 1.97–1.75 (m, 3H, H-13; H-6), 1.47 (br s, 10H, 
CMe3; H-8), 1.33–1.07 (m, 1H, H-8), 0.96 (d, J=6.8 Hz, 3H, H-7), 0.88 (t, J=7.3 Hz, 
1H, H-9).  
 
 
Linear precursor 1.74 
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1.135 (125 mg, 0.38 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 8 mL) for 1 
h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN and 
CHCl3 was performed to afford the deprotected amine 1.73.  
To a solution of 1.34 (156 mg, 0.28 mmol, 1.1 equiv) in CH2Cl2 (8 mL), EDCI.HCl (68 
mg, 0.36 mmol, 1.5 equiv), HOBt (6.4 mg, 0.04 mmol, 0.2 equiv) and Hünig’s base 
(124 µL, 0.71 mmol, 3 equiv) were added. The reaction mixture was stirred for 5 min 
before the previous deprotected amine 1.73 was added. The reaction mixture was stirred 
at rt overnight. The reaction mixture was washed twice with a saturated solution of 
NH4Cl. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. 
The crude material was purified by flash chromatography using a gradient of MeOH in 
CH2Cl2 (0-5%) to afford 1.74 as a colourless oil (162.5 mg, 65%).  
ES
+ MS m/z 876 ([M+Na]
+); HRMS (ESI) m/z calcd. for C43H63N7NaO9S (M+Na)
+ 
876.4300, found 876.4295. 
 
 
Trans, cis-[D-Ile]-Sanguinamide A (1.75) 
 
To a solution of 1.74 (145.8 mg, 0.17 mmol, 1 equiv) in 8 mL of a mixture THF/water 
(3:1) that had been cooled to 0 °C was added LiOH (12.3 mg, 0.51 mmol, 3 equiv) and 
stirred at 0 °C overnight. The solution was diluted with water and acidified to pH 1–2 
with a saturated KHSO4 solution. This aqueous layer was extracted with EtOAc (3 x 7 
mL). The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated in vacuo to provide the carboxylic acid (143 mg, 100%). The carboxylic 
acid (143 mg, 0.17 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 5 mL) for 1 
h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN and     Experimental Procedures For Chapter 1 
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CHCl3 was performed to afford the linear precursor of [D-Ile]-sanguinamide A (126 mg, 
100%). Acyclic precursor (126 mg, 0.17 mmol, 1 equiv) was dissolved in CH3CN/THF 
(25 mL) and added dropwise to a vigorously stirred solution of Hünig’s base (89 µL, 
0.51 mmol, 3 equiv) and HATU (130 mg, 0.34 mmol, 2 equiv) in CH3CN (160 mL). 
The reaction mixture was allowed to stir overnight, and then concentrated in vacuo. The 
crude material was purified by flash chromatography with a gradient of EtOAc. HPLC 
was also performed (14 mg, 11%). 
1H NMR (600 MHz, DMSO-d6) ʴ ppm 8.78 (d, J=8.8 Hz, 1H, NH), 8.55 (d, J=9.4 Hz, 
1H, NH), 8.25 (s, 1H, H-31), 7.78 (d, J=8.8 Hz, 1H, NH), 7.71 (d, J=8.8 Hz, 1H, NH), 
7.31 (d, J=7.6 Hz, 2H, H-21; H-25), 7.25 (t, J=7.3 Hz, 2H, H-22; H-24), 7.19 (t, J=7.0 
Hz, 1H, H-23), 5.18 (t, J=9.7 Hz, 1H, H-33), 4.68 (dd, J=9.1, 2.6 Hz, 1H, H-7), 4.53 (td, 
J=8.8, 3.5 Hz, 1H, H-18), 4.38 (d, J=8.2 Hz, 1H, H-2), 4.34–4.25 (m, 2H, H-13; H-27), 
3.67 (t, J=7.3 Hz, 1H, H-16), 3.59 (t, J=8.8 Hz, 1H, H-5), 3.50 (dd, J=16.4, 7.6 Hz, 1H, 
H-5), 3.32 (dd, J=15.9, 9.4 Hz, 1H, H-16), 3.01 (dd, J=13.5, 2.9 Hz, 1H, H-19), 2.68 
(dd, J=13.2, 9.7 Hz, 1H, H-19), 2.54 (s, 1H, H-34), 2.29–2.10 (m, 1H, H-4), 2.09–1.88 
(m, 5H, H-3; H-4; H-14; H-15; H-35), 1.87–1.78 (m, 2H, H-3; H-14), 1.78–1.68 (m, 
2H, H-15; H-35), 1.67–1.58 (m, 1H, H-8), 1.24 (d, J=7.6 Hz, 3H, H-28), 1.22–1.11 (m, 
1H, H-9), 1.07 (dt, J=13.6, 7.0 Hz, 1H, H-9), 0.87 (app q, J=7.0 Hz, 6H, H-11; H-37), 
0.73 (d, J=5.3 Hz, 6H, H-10; H-36); 
13C NMR (100 MHz, DMSO-d6) ʴ ppm 171.9 (C, 
C-32), 171.4 (C, C-12), 171.1 (C, C-26), 171.0 (C, C-1), 169.1 (C, C-6), 168.0 (C, C-
17), 160.2 (C, C-29), 148.0 (C, C-30), 137.4 (C, C-20), 129.6 (2CH, C-21; C-25), 127.9 
(2CH, C-22; C-24), 126.3 (CH, C-23), 125.7 (CH, C-31), 60.5 (CH, C-13), 59.3 (CH, 
C-2), 55.0 (CH, C-33), 51.7 (CH, C-18), 51.6 (CH, C-7), 50.1 (CH, C-27), 46.7 (CH2, 
C-16), 46.3 (CH2, C-5), 40.4 (CH, C-8 or C-34), 36.8 (CH2, C-19), 36.1 (CH, C-8 or C-
34), 29.2 (CH2, C-14), 28.7 (CH2, C-3), 26.3 (CH2, C-9 or C-35), 25.5 (CH2, C-15), 
25.0 (CH2, C-9 or C-35), 24.5 (CH2, C-4), 17.3 (CH3, C-28), 15.6 (CH3, C-11 or C-37), 
14.2 (CH3, C-11 or C-37), 11.7 (CH3, C-10 or C -36), 10.2 (CH3, C-10 or C -36); ES
+ 
MS m/z 744 ([M+Na]
+). 
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Boc-D-allo-Ile-OH (1.136) 
 
To a suspension of D-allo-isoleucine (500 mg, 3.8 mmol, 1 equiv) in dioxane (8 mL) 
and NaOH (1 M, 4 mL) was slowly added Boc2O (915 mg, 4.2 mmol, 1.1 equiv). The 
reaction mixture was stirred at rt for 5 h and then acidified with a dilute solution of 
KHSO4. After addition of EtOAc, the organic layer was separated and the aqueous layer 
extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered 
and concentrated in vacuo to provide 1.136 as a colourless oil (880 mg, 100%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 9.16 (br s, 1H, CO2H), 5.88 (br s, 4/5H, NH), 4.90 
(d, J=9.0 Hz, 1/5H, NH), 4.34 (dd, J=9.2, 3.6 Hz, 4/5H, CH), 4.14 (br s, 1/5H, CH), 
1.91 (d, J=3.4 Hz, 1H, CH-Et), 1.48–1.33 (m, 10H, CH2; CMe3), 1.28–1.10 (m, 1H, 
CH2), 1.01–0.74 (m, 6H, 2CH3). 
The spectroscopic data are consistent with that
193 reported in the literature. 
 
 
N-Boc-D-allo-isoleucinamide (1.137)  
 
Boc-D-Ile-OH (1.76 g, 7.6 mmol, 1 equiv) was dissolved in CH2Cl2 (5 mL) and HOBt 
(3.08 g, 22.8 mmol, 3 equiv), EDCI (4.33 g, 22.8 mmol, 3 equiv) and Hünig’s base (5.3 
mL, 30.4 mmol, 4 equiv), were added at 0 °C. After stirring for 5 min, NH3 in dioxane 
(0.5 M, 152 mL, 76.0 mmol, 10 equiv) was added. The reaction mixture was stirred at rt 
overnight. HCl solution (0.1 M) was added with cooling to adjust the reaction mixture 
to pH 4–5. The aqueous layer was extracted with CH2Cl2 (3 times). The combined 
organic layers were dried and concentrated in vacuo. The residue was purified by flash 
chromatography using CH2Cl2 then 3% MeOH in CH2Cl2 to afford 1.137 as a white 
solid (1.31 g, 85%).     Experimental Procedures For Chapter 1 
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1H NMR (300 MHz, CD3OD) ʴ ppm 4.09 (d, J=4.3 Hz, 1H, CH), 1.96–1.77 (m, 1H, 
CH-Et), 1.46 (s, 10H, CH2; CMe3), 1.32–1.09 (m, 1H, CH2), 0.95 (t, J=7.2 Hz, 3H, 
CH3-CH2), 0.88 (d, J=6.5 Hz, 3H, CH3-CH). 
The spectroscopic data are consistent with that
194 reported in the literature. 
 
 
N-Boc-D-allo-isoleucine thioamide (1.138) 
 
To a solution of 1.137 (1.27 g, 5.5 mmol, 1 equiv) in dry THF (15 mL) was added 
Lawesson’s reagent (1.34 g, 3.3 mmol, 0.6 equiv) under argon. The reaction mixture 
was stirred overnight at rt. The solvent was evaporated and the residue purified by flash 
chromatography using EtOAc/CH2Cl2 (1:9) to give 1.138 as a white solid (800 mg, 
59%).  
1H NMR (400 MHz, CD3OD) ʴ ppm 4.42–4.20 (m, 1H, CH), 2.18–1.95 (m, 1H, CH-
Et), 1.47 (br s, 10H, CH2; CMe3), 1.37–1.14 (m, 1H, CH2), 0.97 (t, J=7.4 Hz, 3H, CH3-
CH2), 0.90 (d, J=6.3 Hz, 3H, CH3-CH); ES
+ MS m/z 269 ([M+Na]
+). 
 
 
N-Boc-(D-allo-Ile)Thz-OMe (1.77)  
 
To a suspension of pulverised KHCO3 (2.64 g, 26.4 mmol, 8 equiv) in a solution of 
1.138 (800 mg, 3.3 mmol, 1 equiv) in DME (9 mL), ethyl-3-bromopyruvate (1.24 mL, 
9.9 mmol, 3 equiv) was added. The reaction mixture was stirred under argon at rt for 2 
h. The suspension was then cooled to 0 °C and a solution of TFAA (1.83 mL, 13.2 
mmol, 4 equiv) and pyridine (2.27 mL, 28.0 mmol, 8.5 equiv) in DME (4.3 mL) was     Experimental Procedures For Chapter 1 
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then  added.  Solvents  were  evaporated  under  reduced  pressure.  The  residue  was 
suspended in chloroform and this solution was washed with HCl (1 M). The aqueous 
layer was extracted once with chloroform. The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (hexane/EtOAc 9:1) to afford 1.77 as a colourless oil (598 mg, 53%). 
[]D
23 11 (c 0.99, CH3OH); IR 3346, 2968, 1702, 1499, 1366, 1235, 1206, 1164, 1094 
cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 8.07 (s, 1H, H-3), 5.24–5.17 (d, J=7.1 Hz, 
1H, NH), 5.16–4.98 (m, 1H, H-5), 4.42 (q, J=7.1 Hz, 2H, CO2CH2-CH3), 2.40–2.13 (m, 
1H, H-6), 1.57–1.32 (m, 13H, H-8; CO2CH2-CH3; CMe3), 1.32–1.16 (m, 1H, H-8), 0.96 
(t, J=7.3 Hz, 3H, H-9), 0.83 (d, J=6.5 Hz, 3H, H-7); 
13C NMR (100 MHz, CDCl3) ʴ 
ppm 174.2 (C), 161.3 (C), 155.4 (C, CO), 147.5 (C), 126.7 (CH, C-3), 80.0 (C, CMe3), 
61.3 (CH2, CO2CH2-CH3), 56.5 (CH, C-5), 39.5 (CH, C-6), 28.2 (3CH3, CMe3), 26.5 
(CH2, C-8), 14.3 (CH3), 13.8 (CH3), 11.5 (CH3); ES
+ MS m/z 365 ([M+Na]
+). 
 
 
N-Boc-Pro-(D-allo-Ile)Thz-OMe (1.139) 
 
1.77 (523 mg, 1.53 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 5 mL) for 1.5 
h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN and 
CHCl3 was performed to afford the deprotected amine.  
To a solution  of Boc-L-Pro-OH (493 mg, 2.3  mmol,  1.5 equiv) in  CH2Cl2 (6 mL), 
PyBOP (1.35 mg, 2.3 mmol, 1.5 equiv) and Hünig’s base (800 µL, 4.6 mmol, 3 equiv) 
were added. The reaction mixture was stirred for 5 min before the previous amine was 
added. The reaction mixture was stirred at rt overnight. The organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. The crude material was purified by 
flash chromatography (hexane/EtOAc 8:2) to afford 1.139 as a colourless oil (661 mg, 
93%).     Experimental Procedures For Chapter 1 
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[]D
23 16.1 (c 0.62, CH3OH); IR 2972, 1690, 1479, 1391, 1366, 1235, 1206, 1162, 
1121, 1090 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 8.04 (br s, 1H, H-3), 5.38 (dd, 
J=8.7, 3.4 Hz, 1H, H-5), 4.40 (q, J=7.0 Hz, 2H, H-11; CO2CH2CH3), 3.61–3.26 (m, 2H, 
H-14), 2.52–2.25 (m, 2H, H-12), 1.97–1.80 (m, 3H, H-6; H-13), 1.47 (br s, 9H, CMe3), 
1.38 (t, J=7.2 Hz, 3H, CO2CH2CH3), 1.34–1.18 (m, 2H, H-8), 0.96 (t, J=7.3 Hz, 3H, H-
9), 0.83 (d, J=6.5 Hz, 3H, H-7); 
13C NMR (100 MHz, CDCl3) ʴ ppm 172.6 (C), 172.3 
(C), 161.4 (C, CO), 156.2 (C, CO), 147.6 (C, C-2), 126.6 (CH, C-3), 80.8 (C, CMe3), 
61.4 (CH2, CO2CH2-CH3), 59.8 (CH, C-5 or C-11), 54.9 (CH, C-5 or C-11), 47.2 (CH2, 
C-14), 39.1 (CH, C-6), 29.7 (CH2), 28.4 (3CH3, CMe3), 27.7 (CH2), 26.7 (CH2), 14.4 
(CH3, CO2CH2-CH3), 13.6 (CH3, C-7), 11.6 (CH3, C-9); ES
+ MS m/z 462 ([M+Na]
+). 
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Fmoc-Pro-Ile-Cys(tBu)-Ala-Phe-Pro-Ile-OH (1.100) 
 
Swelling of the Wang resin  
The  dry  Wang  resin  (600  mg,  loading  1.7  mmol/g)  placed  in  an  appropriate  SPPS 
reaction vessel was covered with CH2Cl2 and the reaction vessel was shaken for 5 min. 
The resin was dried by application of vacuum. This operation was repeated twice with 
CH2Cl2 and twice with DMF.  
 
DIC coupling (used for the coupling of the first amino acid) 
Fmoc-Ile-OH (3.6 g, 10.2 mmol, 10 equiv) was dissolved in a mixture of CH2Cl2 (30 
mL) and DMF (1 mL). DIC (790 µL, 5.1 mmol, 5 equiv) was added at 0 °C and the 
reaction mixture was stirred for 30 min. CH2Cl2 was removed by evaporation under 
reduced  pressure.  A  minimum  volume  of  DMF,  CH2Cl2  and  NMP  was  added  to 
dissolve the symmetrical anhydride. The solution and DMAP (0.01 equiv) were added 
to the Wang resin, the reaction vessel was shaken for 1 h. The resin  was dried by 
application  of  vacuum,  DMF  was  added  and  the  solvent  was  drained  off.  This  last 
operation was repeated once with CH2Cl2 and then with DMF. 
 
Fmoc deprotection 
A solution of 20% piperidine in DMF (v/v) was added to cover the beads. The reaction 
vessel was shaken for 5 min. The reagent was washed from the resin with DMF. The 
deprotection step was repeated once for 15 min. The resin was washed several times 
with DMF.  
 
PyBOP coupling 
To a solution of Fmoc protected amino acid (5.1 mmol, 5 equiv) in a mixture of CH2Cl2 
and DMF, were added PyBOP (2.65 g, 5.1 mmol, 5 equiv) and Hünig’s base (1.78 mL, 
10.2 mmol, 10 equiv). The solution was added to the resin and the reaction vessel was 
shaken for 1 h. The reagents were washed from the resin with CH2Cl2 (twice) and DMF 
(twice).      Experimental Procedures For Chapter 1 
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Monitoring of the coupling and deprotection steps  
The deprotection and coupling steps were monitored by ESI-MS or monitored using a 
qualitative ninhydrin assay (Kaiser test).  
Preparation of the Kaiser test solutions 
In  a  vial,  phenol  (8  g)  was  dissolve  in  absolute  ethanol  (2  mL).  In  another  vial, 
potassium cyanide (13 mg) was dissolved in water (20 mL). To pyridine (980 µL), were 
added aqueous KCN solution (20 µL) followed by phenol solution in ethanol (100 µL) 
to form the Kaiser solution A. Ninhydrin (1 g) was dissolve in absolute ethanol (20 mL) 
and thus forming the solution B.  
Some dried beads were removed and solution A (20 µL) was added followed by of 
solution B (40 µL). In the presence of unprotected amine, the solution turns blue in 
colour (positive Kaiser test) while if no free amine is present the solution will be yellow 
in colour (negative Kaiser test).  
In the case of incomplete couplings, the coupling step was repeated a maximum of two 
times. The peptide was capped by N-acetylation if necessary. 
 
Acetylation of the N-terminus 
A solution of acetic anhydride (5 drops), pyridine (100 µL) and DMF was added to 
cover the resin. The reaction vessel  was shaken for 15 min. The resin  was washed 
several times with DMF. 
 
Cleavage of the resin 
A solution of ethane dithiol (200 µL), anisole (200 µL), TIPS (200 µL), water (200 µL), 
TFA (3 mL) and CH2Cl2 (2 mL) was prepared and added to the resin in a flask. The 
resin was filtered off and washed twice with TFA. The filtrate was evaporated. Cold 
diethyl ether was added and the precipitate was filtered to afford 1.100 as a pink solid 
(605 mg, 59%). 
ES
+ MS m/z 1060 ([M+Na]
+). 
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Cyclo[Pro-Ile-Cys(tBu)-Ala-Phe-Pro-Ile] (1.101) 
 
To heptapeptide 1.100 (200 mg, 0.19 mmol) in DMF (4 mL) was added piperidine (1 
mL). The reaction mixture was stirred for 1 h at rt. The solvents were removed by 
evaporation under reduced pressure to afford the deprotected linear precursor.  
Unprotected  acyclic  precursor  (140  mg,  0.17  mmol,  1  equiv)  was  dissolved  in 
CH3CN/THF  (40  mL)  and  was  added  dropwise  to  a  vigorously  stirred  solution  of 
Hünig’s base (88 µL, 0.51 mmol, 3 equiv) and HATU (131 mg, 0.34 mmol, 2 equiv) in 
CH3CN (150 mL). The reaction mixture was stirred overnight, and then concentrated in 
vacuo. The crude material was purified by flash chromatography using as eluent EtOAc 
then  with  2  to  5%  MeOH  in  CH2Cl2  to  afford  1.101  (120  mg,  87%).  HPLC  was 
performed on 60 mg of this product (2 mg, 3%). 
1H NMR (600 MHz, CDCl3) ʴ ppm 7.86 (br d, J=2.9 Hz, 1H, NH), 7.36 (d, J=6.7 Hz, 
1H, NH), 7.29 (t, J=7.0 Hz, 2H, H-22; H-24), 7.24 (t, J=7.0 Hz, 1H, H-23), 7.20 (d, 
J=7.0 Hz, 2H, H-21; H-25), 6.10–5.96 (br m, 1H, NH), 4.70 (td, J=7.9, 6.2 Hz, 1H, H-
30), 4.52 (t, J=8.4 Hz, 1H, H-7), 4.30 (quin, J=5.1 Hz, 1H, H-18), 4.24 (t, J=7.8 Hz, 1H, 
H-2), 4.16 (br t, J=5.9 Hz, 1H, H-35), 4.11–3.96 (m, 2H, H-5; H-27), 3.63 (dt, J=9.6, 
7.1 Hz, 1H, H-5), 3.54–3.42 (m, 2H, H-16), 3.34 (d, J=7.9 Hz, 1H, H-13), 3.18 (dd, 
J=13.1, 5.1 Hz, 1H, H-31), 3.11 (dd, J=12.6, 5.0 Hz, 1H, H-19), 2.95 (t, J=10.9 Hz, 1H, 
H-19), 2.79 (dd, J=13.1, 8.1 Hz, 1H, H-31), 2.40 (dd, J=13.8, 5.9 Hz, 1H, H-3), 2.19–
2.06 (m, 2H, H-4; H-36), 2.06–1.89 (m, 4H, H-3; H-4; H-8; H-14), 1.77–1.67 (m, 1H, 
H-15), 1.63 (d, J=7.0 Hz, 3H, H-28), 1.61–1.53 (m, 1H, H-37), 1.46–1.38 (m, 2H, H-9; 
H-15), 1.33 (s, 9H, CMe3), 1.16–1.01 (m, 2H, H-9; H-14), 0.97 (d, J=6.7 Hz, 3H, H-39), 
0.94 (d, J=6.7 Hz, 3H, H-11), 0.93–0.91 (m, 1H, H-37),0.91 (t, J=7.0 Hz, 3H, H-38), 
0.86 (t, J=7.3 Hz, 3H, H-10); 
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172.9 (C, C-1), 172.7 (C, C-26), 171.34 (C, C-29), 171.30 (C, C-12), 170.7 (C, C-34), 
170.4 (C, C-17), 135.9 (C, C-20), 129.6 (2CH, C-21; C-25), 129.0 (2CH, C-22; C-24), 
127.5 (CH, C-23), 62.3 (CH, C-2), 61.1 (CH, C-13), 59.9 (CH, C-35), 55.3 (CH, C-7), 
53.9 (CH, C-30), 53.8 (CH, C-18), 53.7 (CH, C-27), 48.5 (CH2, C-5), 46.6 (CH2, C-16), 
42.7 (C, C-32), 39.7 (CH2, C-19), 36.6 (CH, C-8), 35.4 (CH, C-36), 31.1 (3CH3, C-33), 
31.0 (CH2, C-14), 30.7 (CH2, C-31), 30.0 (CH2, C-3), 25.4 (CH2, C-4), 25.3 (CH2, C-
37), 24.9 (CH2, C-9), 22.2 (CH2, C-15), 16.9 (CH3, C-28), 16.5 (CH3, C-39), 16.1 (CH3, 
C-11), 11.8 (CH3, C-38), 10.9 (CH3, C-10); ES
+ MS m/z 820 ([M+Na]
+). 
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223 
 
5.2.2. Sanguinamide B 
 
N-Boc-Pro-Val-OMe (1.112) 
 
To a solution  of Boc-L-Pro-OH (1.55  g, 7.2 mmol,  1.1 equiv) in  CH2Cl2 (30 mL), 
EDCI.HCl (1.7 g, 9.0 mmol, 1.5 equiv), HOBt (161 mg, 1.19 mmol, 0.2 equiv) and 
Hünig’s base (3.64 mL, 20.9 mmol, 2 equiv) were added. The reaction mixture was 
stirred for 5 min before L-Val-OMe hydrochloride (1 g, 6.0 mmol, 1 equiv) was added. 
The reaction mixture was stirred at rt overnight. The reaction mixture was washed twice 
with a saturated solution of NH4Cl. The organic layer was dried over MgSO4, filtered 
and concentrated in vacuo. The crude material was purified by flash chromatography 
using a gradient hexane/EtOAc as eluent (7:3) to afford 1.112 as a white solid (1.96 g, 
100%). 
1H NMR (300 MHz, CDCl3) ʴ ppm (mixture of conformers) 7.50 (br s, 0.5H, NH), 
6.53 (br s, 0.5H, NH), 4.56–4.44 (m, 1H, H-1 or H-5), 4.39–4.24 (m, 1H, H-1 or H-5), 
3.73 (s, 3H, CO2Me), 3.54–3.30 (m, 2H, H-8), 2.45–2.30 (m, 0.5H, H-6), 2.21–2.11 (m, 
1.5H, H-6), 1.99–1.83 (m, 3H, H-2; H-7), 1.48 (s, 9H, CMe3), 0.91 (t, J=7.3 Hz, 6H, H-
3; H-4); ES
+ MS m/z 329 ([M+H]
+), 351 ([M+Na]
+), 392 ([M+Na+CH3CN]
+). 
The spectroscopic data are consistent with that
195 reported in the literature. 
 
 
N-Boc-alaninamide (1.115) 
 
To a solution of di-tert butyl dicarbonate (1.75 g, 8.0 mmol, 1 equiv) in CH2Cl2 (40 mL) 
were added  L-alaninamide hydrochloride (1 g, 8.0 mmol, 1 equiv) and triethylamine 
(2.32  mL,  16.6  mmol,  2.3  equiv).  The  reaction  mixture  was  refluxed  for  5  h.     Experimental Procedures For Chapter 1 
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Triethylamine salts were extracted twice with water (10 mL) and the combined aqueous 
layers were extracted once with EtOAc. The combined organic layers were dried over 
MgSO4 and evaporated to provide 1.115 as a white solid (926 mg, 61%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 6.23 (br s, 1H, NH2), 5.61 (br s, 1H, NH2), 5.07 
(br d, J=6.8 Hz, 1H, NH), 4.38–4.09 (m, 1H, CH), 1.45 (s, 9H, CMe3), 1.38 (d, J=7.2 
Hz, 3H, Me); ES
+ MS m/z 211 ([M+Na+CH3CN]
+), 252 ([M+Na+CH3CN]
+). 
The spectroscopic data are consistent with that
196 reported in the literature. 
 
 
N-Boc-alanine thioamide (1.116) 
 
To a solution of N-Boc-alaninamide 1.115 (926 mg, 4.92 mmol, 1 equiv) in dry THF (7 
mL) was added Lawesson’s reagent (1.19 g, 2.95 mmol, 0.6 equiv) under argon. The 
reaction mixture was stirred at rt overnight. The solvent was evaporated and the residue 
purified by flash chromatography using EtOAc/CH2Cl2 (1:9) to give 1.116 as a white 
solid (947 mg, 94%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.09 (br s, 0.5H, NH2), 7.71 (br s, 0.5H, NH2), 
5.34 (d, J=7.2 Hz, 1H, NH), 4.53 (quin, J=7.1 Hz, 1H, CH), 1.82 (br s, 1H, SH or NH2), 
1.47 (d, J=7.2 Hz, 3H, CH3), 1.44 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
196 reported in the literature. 
 
 
(S)-Methyl 2-(1-(tert-butoxycarbonylamino)ethyl)thiazole-4-carboxylate (1.117)  
 
To a suspension of pulverised KHCO3 (3.34 g, 33.4 mmol, 8 equiv) in a solution of N-
Boc-alanine thioamide 1.116 (853 mg, 4.2 mmol, 1 equiv) in DME (20 mL), methyl     Experimental Procedures For Chapter 1 
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bromopyruvate (1.33 mL, 12.5 mmol, 3 equiv) was added. The reaction mixture was 
stirred under argon at rt for 2 h. The suspension was then cooled to 0 °C and a solution 
of TFAA (2.32 mL, 16.7 mmol, 4 equiv) and pyridine (2.87 mL, 35.5 mmol, 8.5 equiv) 
was then added. The reaction mixture was stirred 30 min at 0 °C and  stirred at rt. 
Solvents were evaporated under reduced pressure. The residue was separated between 
CHCl3 (100 mL) and HCl solution (1 M, 100 mL). The aqueous layer was extracted 
with CHCl3 (50 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated  in  vacuo.  The  crude  material  was  purified  by  flash  chromatography 
(hexane/EtOAc 7:3) to afford 1.117 as a yellow oil (940 mg, 79%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.11 (s, 1H, HAr), 5.33–4.97 (m, 2H, NH; CH-
Me), 3.95 (s, 3H, CO2Me), 1.63 (d, J=7.0 Hz, 3H, CH3), 1.45 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
190 reported in the literature. 
 
 
(S)-2-(1-(Tert-Butoxycarbonylamino)ethyl)thiazole-4-carboxylic acid (1.118)  
 
To a solution of 1.117 (933 mg, 3.3 mmol, 1 equiv) in 16 mL of a mixture THF/water 
(3:1) at 0 °C was added LiOH (234 mg, 9.8 mmol, 3 equiv) and the reaction mixture 
was stirred at rt overnight. The solution was diluted with water (10 mL) and acidified to 
pH 1–2 with a saturated KHSO4 solution. The aqueous layer was extracted 3 times with 
EtOAc. The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated in vacuo to provide the carboxylic acid 1.118 (745 mg, 84%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.22 (s, 1H, HAr), 5.26 (br s, 1H, NH), 5.19–4.96 
(br s, 1H, CH-Me), 1.64 (d, J=6.8 Hz, 3H, CH3), 1.45 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
197 reported in the literature. 
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(S)-Methyl  2-(2-((S)-1-(tert-butoxycarbonylamino)ethyl)thiazole-4-carboxami-do)-
4-methylpentanoate (1.119) 
 
To a solution of Boc-L-(Ala)Thz-OH (1.118) (737 mg, 2.7 mmol, 1 equiv) in CH2Cl2 
(30 mL), PyBOP (1.97 g, 3.8 mmol, 1.4 equiv) and Hünig’s base (1.4 mL, 8.1 mmol, 3 
equiv)  were  added.  The  reaction  mixture  was  stirred  for  5  min  before  H-L-Leu-
OMe.HCl (541 mg, 3.0 mmol, 1.1 equiv) was added. The reaction mixture was stirred at 
rt  overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography (hexane/EtOAc 1:1) to afford 1.119 as a yellow oil (817 mg, 76%). 
[]D
23 –20.9 (c 1.13, CH3OH); IR 3301, 2966, 2860, 1748, 1712, 1654, 1552, 1515, 
1491, 1454, 1356, 1246, 1209, 1160, 1062, 1001 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ 
ppm 8.00 (s, 1H, H-4), 7.63 (d, J=8.7 Hz, 1H, NH), 5.20 (br s, 1H, NH), 5.14–5.01 (m, 
1H, H-1 or H-7), 4.88–4.71 (m, 1H, H-1 or H-7), 3.76 (s, 3H, H-13), 1.85–1.66 (m, 3H, 
H-8; H-9), 1.61 (d, J=6.8 Hz, 3H, H-2), 1.46 (s, 9H, CMe3), 1.10–0.87 (m, 6H, H-10; H-
11); 
13C NMR (100 MHz, CDCl3) ʴ ppm 174.3 (C), 173.3 (C), 160.8 (C), 154.9 (C), 
149.2 (C, C-5), 123.5 (CH, C-4), 80.3 (C, CMe3), 52.3 (CH3, C-13), 50.6 (CH, C-1 or 
C-7), 48.7 (CH, C-1 or C-7), 41.6 (CH2, C-8), 28.3 (CH3, CMe3), 24.9 (CH, C-9), 22.8; 
21.8 (2CH3, C-10; C-11), 21.3 (CH3, C-2); ES
+ MS m/z 422 ([M+Na]
+); HRMS (ESI) 
m/z calcd. for C18H29N3NaO5S1 (M+Na)
+ 422.1720, found 422.1722. 
 
 
N-Boc-prolinamide (1.120)  
 
Boc-Pro-OH (1.08 mg, 5 mmol, 1 equiv) was dissolved in CH2Cl2 (15 mL) and HOBt 
(2 g, 15 mmol, 3 equiv), EDCI.HCl (2.87 g, 15 mmol, 3 equiv) and Hünig’s base (3.48 
mL, 20 mmol, 4 equiv), were added at 0 °C. After stirring for 5 min, NH3 in dioxane     Experimental Procedures For Chapter 1 
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(0.5 M, 100 mL, 50 mmol, 10 equiv) was added. The reaction mixture was stirred at rt 
overnight. HCl solution (0.1 M) was added with cooling to adjust the reaction mixture 
to pH 4–5. The aqueous layer was extracted with CH2Cl2 (3 x 100 mL). The combined 
organic layers were dried and concentrated in vacuo. The residue was purified by flash 
chromatography using 100% of CH2Cl2 then 3 to 4% MeOH in CH2Cl2 to afford 1.120 
as a white solid (1.15 g, 100%). 
1H NMR (400 MHz, CDCl3) ʴ ppm (mixture of rotamers) 6.9 (br s, 0.5H, NH2), 6.05 
(br s, 0.5H, NH2), 5.78–5.45 (m, 1H, NH2), 4.45–4.15 (m, 1H, CHʱ), 3.55–3.30 (m, 2H, 
CH2δ), 2.55–2.09 (m, 2H, CH2), 2.02–1.83 (m, 2H, CH2γ), 1.47 (s, 9H, CMe3); ES
+ 
MS m/z 278 ([M+Na+CH3CN]
+). 
The spectroscopic data are consistent with that
198 reported in the literature. 
 
 
N-Boc-proline thioamide (1.121)  
 
To a solution of N-Boc-prolinamide 1.120 (1.19 g, 5.55 mmol, 1 equiv) in dry THF (7 
mL) was added Lawesson’s reagent (1.35 g, 3.33 mmol, 0.6 equiv) under argon. The 
reaction mixture was stirred at rt overnight. The solvent was evaporated and the residue 
purified by flash chromatography using EtOAc/CH2Cl2 (1:9) to give 1.121 as a white 
solid (716 mg, 56%). 
1H NMR (300 MHz, CDCl3) ʴ ppm (mixture of conformers) 7.50 (br s, 1H, NH2), 
4.77–4.54 (m, 1H, CHʱ), 3.68–3.38 (m, 2H, CH2δ), 2.46–2.18 (m, 2H, CH2), 2.07–
1.80 (m, 2H, CH2γ), 1.60 (s, 1H, SH or NH2), 1.47 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
199 reported in the literature. 
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(S)-Methyl 2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)thiazole-4-carboxylate 
(1.122)  
 
To a suspension of pulverised KHCO3 (2.47 g, 24.7 mmol, 8 equiv) in a solution of N-
Boc-alanine thioamide 1.121 (710 mg, 3.1 mmol, 1 equiv) in DME (17 mL), methyl 
bromopyruvate  (984  µL,  9.3  mmol,  3  equiv)  was  added.  The  reaction  mixture  was 
stirred under argon at rt for 2 h. The suspension was then cooled to 0 °C and a solution 
of TFAA (1.71 mL, 12.3 mmol, 4 equiv) and pyridine (2.12 mL, 26.2 mmol, 8.5 equiv) 
was slowly added. The reaction mixture was stirred 30 min at 0 °C and stirred at rt. 
Solvents were evaporated under reduced pressure. The residue was separated between 
chloroform (100 mL) and HCl solution (1 M, 100 mL). The aqueous was extracted with 
CHCl3 (50 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated  in  vacuo.  The  crude  material  was  purified  by  flash  chromatography 
(hexane/EtOAc 7:3) to afford 1.122 as a yellow oil (560 mg, 58%). 
1H NMR (300 MHz, CDCl3) ʴ ppm (mixture of conformers) 8.09 (s, 1H, HAr), 5.30–
5.16 (m, 1H, CHʱ), 3.95 (s, 3H, CO2Me), 3.76–3.24 (m, 2H, CH2δ), 2.71–2.10 (m, 2H, 
CH2),  2.10–1.81  (m,  2H,  CH2γ),  1.55–1.28  (m,  9H,  CMe3);  ES
+  MS  m/z  335 
([M+Na]
+). 
The spectroscopic data are consistent with that
200 reported in the literature. 
 
 
(S)-2-(1-(Tert-Butoxycarbonyl)pyrrolidin-2-yl)thiazole-4-carboxylic acid (1.123)  
 
To a solution of 1.122 (550 mg, 1.76 mmol, 1 equiv) in 8 mL of a mixture THF/water 
(3:1) that had been cooled to 0 °C was added LiOH (127 mg, 5.28 mmol, 3 equiv) and 
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pH 1–2 with a saturated KHSO4 solution. This aqueous layer was extracted 3 times with 
EtOAc. The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated in vacuo to provide the carboxylic acid 1.123 (493 mg, 94%). 
1H NMR (300 MHz, CDCl3) ʴ ppm (mixture of conformers) 8.20 (s, 1H, HAr), 5.33–
5.15 (m, 1H, CHʱ), 3.74–3.36 (m, 2H, CH2δ), 2.51–2.21 (m, 2H, CH2), 2.11–1.82 (m, 
2H, CH2γ), 1.59–1.28 (m, 9H, CMe3). 
The spectroscopic data are consistent with that
201 reported in the literature. 
 
 
N-Boc-(Pro)Thz-Ser-OMe (1.124) 
 
To a solution of Boc-L-(Ile)Thz-OH (1.123) (737 mg, 2.7 mmol, 1 equiv) in CH2Cl2 (30 
mL), PyBOP (1.97 g, 3.8 mmol, 1.4 equiv) and Hünig’s base (1.4 mL, 8.1 mmol, 3 
equiv) were added. The reaction mixture was stirred for 5 min before H-Ser-OMe (541 
mg, 3.0 mmol, 1.1 equiv) was added. The reaction mixture was stirred at rt overnight 
and concentrated in vacuo. The crude material was purified by flash chromatography 
(hexane/EtOAc 1:1) to afford 1.124 as a colourless oil (817 mg, 76.4%). 
[]D
23 –49.5 (c 0.21, CH3OH); IR 3391, 2974, 2876, 2357, 2341, 1744, 1695, 1667, 
1544, 1491, 1458, 1389, 1209, 1168, 1111 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ ppm 
(mixture of rotamers) 8.13 (br d, J=16.5 Hz, 1H, NH), 8.03 (s, 1H, HAr), 5.30–4.97 (m, 
1H, CHʱ), 4.90–4.73 (m, 1H, CH-CH2OH), 4.18–3.96 (m, 2H, CH2OH), 3.82 (s, 3H, 
CO2Me),  3.70–3.37  (m,  2H,  CH2δ),  2.47–2.11  (m,  2H,  CH2),  2.08–1.79  (m,  2H, 
CH2γ), 1.60–1.25 (m, 9H, CMe3); ES
+ MS m/z 422 ([M+Na]
+). 
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(S)-Methyl  2-(2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)thiazol-4-yl)oxazole-4-
carboxylate (1.126) 
 
To a solution of N-Boc-(Pro)Thz-Ser-OMe (1.124) (100 mg, 0.25 mmol, 1 equiv) in dry 
CH2Cl2, DAST (40 µL, 0.30 mmol, 1.2 equiv) was added at –78 °C under argon. After 
stirring the reaction mixture for 1 h at –78 °C, anhydrous K2CO3 (52.0 mg, 0.38 mmol, 
1.5 equiv) was added in one portion and the mixture was warmed to rt. The reaction 
mixture was poured into saturated NaHCO3 and extracted with CH2Cl2. The combined 
organic phases were dried over MgSO4, filtered and concentrated in vacuo to give the 
oxazoline intermediate 1.125 (95 mg, 100%).  
To 1.125 (95 mg, 0.24 mmol, 1 equiv) in CH2Cl2 (4 mL), DBU (41 µL, 0.27 mmol, 1.2 
equiv) was added dropwise followed by BrCCl3 (32 µL, 0.32 mmol, 1.4 equiv) at –10 
°C. The mixture was stirred overnight at rt. The mixture was washed with saturated 
NH4Cl (2 x 5 mL), and the combined aqueous layers were extracted once with EtOAc. 
The  combined  organic  layers  were  dried  over  MgSO4,  filtered  and  concentrated  in 
vacuo. The crude material was purified by flash chromatography (hexane/EtOAc 3:1 to 
1:1) to afford 1.126 as a white solid (58 mg, 64%).  
[]D
23 –89.2 (c 0.17, CH3OH); mp 146–148 °C; IR 3130, 2983, 2946, 1732, 1704, 
1589,  1565,  1401,  1315,  1176,  1156,  1115,  1005,  952  cm
–1; 
1H  NMR  (400  MHz, 
CDCl3) ʴ ppm (mixture of conformers) 8.26 (s, 1H, H-6), 8.04 (s, 1H, H-9), 5.40–5.09 
(m, 1H, H-1), 3.91 (s, 3H, H-12), 3.72–3.37 (m, 2H, H-4), 2.45–2.16 (m, 2H, H-2), 
2.06–1.80 (m, 2H, H-3), 1.51–1.21 (m, 9H, CMe3); 
13C NMR (100 MHz, CDCl3) ʴ 
ppm (mixture of conformers) 177.8 (C), 161.4 (C), 157.7 (C), 154.0 (C), 143.5 (CH, C-
9), 142.3 (C, C-7), 134.2 (C, C-10), 120.8 (CH, C-6), 80.4 (C, CMe3), 59.5 (CH, C-1), 
52.1 (CH3, C-12), 46.6 (CH2, C-4), 34.1 (CH2, C-2), 28.1 (CH3, CMe3), 23.1 (CH2, C-
3). 
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Methyl  2-(2-((S)-1-((S)-2-(2-((S)-1-(tert-butoxycarbonylamino)ethyl)thiazole-4-
carboxamido)-4-methylpentanoyl)pyrrolidin-2-yl)thiazol-4-yl)oxazole-4-
carboxylate (1.128) 
 
To  N-Boc-(Ala)Thz-Leu-OMe  (1.119)  (380  mg,  0.95  mmol,  1  equiv)  in  8  mL  of 
THF/water (3:1) at 0 °C was added LiOH (68 mg, 2.85 mmol, 3 equiv). The reaction 
mixture was stirred at rt overnight and was diluted with water and acidified to pH 1–2 
with a saturated KHSO4 solution. This aqueous layer was extracted 3 times with EtOAc. 
The  combined  organic  layers  were  washed  with  brine,  dried  over  MgSO4  and 
concentrated in vacuo to provide the carboxylic acid (357 mg, 97%). 
1.126 (243.7 mg, 0.64 mmol, 1 equiv) was treated with HCl in dioxane (4 M, 7 mL) for 
1 h. The reaction mixture was concentrated in vacuo, and coevaporation with CH3CN 
and CHCl3 was performed to afford the free amine as hydrochloride salt 1.127 (203 mg, 
100%).  
To a solution of the previous carboxylic acid (84 mg, 0.26 mmol, 1.1 equiv) in CH2Cl2 
(20 mL), PyBOP (501.4 mg, 0.96 mmol, 1.5 equiv), and Hünig’s base (336 µL, 1.93 
mmol, 3 equiv) were added. The reaction mixture was stirred for 5 min before the amine 
1.127 (203 mg, 0.64 mmol, 1 equiv) was added. The reaction mixture was stirred at rt 
overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography using EtOAc/hexane (1:1 to 7:3) as eluent to afford 1.128 as a colorless 
oil (280 mg, 67%). 
[]D
23 –39.7 (c 0.21, CH3OH); IR 2957, 1709, 1641, 1536, 1440, 1250, 1167, 824; 
1H 
NMR (400 MHz, CDCl3/CD3OD) ʴ ppm (Mixture of conformers) 8.32–8.17 (m, 1H, 
HAr), 8.03 (s, 1H, HAr), 7.94 (d, J=7.6 Hz, 1H, HAr), 5.55–5.29 (m, 1H, H-16), 5.04–4.80 
(m, 2H, H-1; H-7), 3.95–3.82 (m, 4H, CO2Me; H-13), 3.81–3.53 (m, 1H, H-13), 2.41–
2.21 (m, 2H, H-15), 2.20–2.04 (m, 2H, H-14), 1.75-1.60 (m, 2H, H-8), 1.59–1.45 (m, 
4H, H-2; H-9), 1.35 (br s, 9H, CMe3), 0.98–0.79 (m, 6H, H-10; H-11); ES
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([M+Na]
+); HRMS (ESI) m/z calcd. for C29H38N6NaO7S2 (M+Na)
+ 669.2136, found 
669.2132. 
 
 
(S)-Methyl2-((S)-1-(2-(2-((S)-1-((S)-2-(2-((S)-1-(tert-butoxycarbonylamino)-
ethyl)thiazole  -4-carboxamido)-4-methylpentanoyl)pyrrolidin-2-yl)thiazol-4-yl)-
oxazole-4-carbonyl) pyrrolidine -2-carboxamido)-3-methylbutanoate (1.129) 
 
To 1.128 (277 mg, 0.43 mmol, 1 equiv) in 8 mL of THF/water (3:1) was added LiOH 
(31 mg, 1.28 mmol, 3 equiv) at 0 °C and stirred at rt overnight. The solution was diluted 
with water and acidified to pH 1–2 with a saturated KHSO4 solution. This aqueous layer 
was extracted 3 times with EtOAc. The combined organic layers were washed with 
brine, dried over MgSO4 and concentrated in vacuo to provide the carboxylic acid (271 
mg, 100%). 
The dipeptide Boc-Pro-Val-OMe (1.112) (500 mg, 2.19 mmol, 1 equiv) was treated 
with HCl in dioxane (4 M, 5 mL) for 1 h. The reaction mixture was concentrated in 
vacuo, and coevaporation with CH3CN and CHCl3 was performed to afford the free 
amine as hydrochloride salt 1.113 (403 mg, 100%).  
To a solution of carboxylic acid (271 mg, 0.43 mmol, 1 equiv) in CH2Cl2 (5 mL), 
PyBOP (334 mg, 0.64 mmol, 1.5 equiv), and  Hünig’s base (224 µL, 1.28 mmol, 3 
equiv) were added. The reaction mixture was stirred for 5 min before the amine 1.113 
(170  mg,  0.64  mmol,  1.5  equiv)  was  added.  The  reaction  mixture  was  stirred  at  rt 
overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography using EtOAc as eluent to afford 1.129 as a white solid (209 mg, 58%). 
ES
+ MS m/z 865 ([M+Na]
+); HRMS (ESI) m/z calcd. for C39H54N8NaO9S2 (M+Na)
+ 
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233 
 
Trans, trans-Sanguinamide B (1.130) 
 
To a solution of 1.129 (189 mg, 0.22 mmol, 1 equiv) in 4 mL of a mixture THF/water 
(3:1) that had been cooled to 0 °C was added LiOH (54 mg, 2.20 mmol, 10 equiv) and 
stirred at 0 °C overnight. The solution was diluted with water and acidified to pH 1–2 
with a saturated KHSO4 solution. This aqueous layer was extracted 3 times with EtOAc. 
The  combined  organic  layers  were  washed  with  brine,  dried  over  MgSO4  and 
concentrated in vacuo to provide the carboxylic acid. The carboxylic acid was treated 
with HCl in dioxane (4 M, 5 mL) for 1 h. The reaction mixture was concentrated in 
vacuo, and coevaporation with CH3CN and CHCl3 was performed to afford the linear 
precursor of sanguinamide B (171.5 mg, 100%). Acyclic precursor (171 mg, 0.22 mmol, 
1 equiv) was dissolved in CH3CN/THF (100 mL) and added dropwise to a vigorously 
stirred solution of Hünig’s base (117 µL, 0.67 mmol, 3 equiv) and HATU (170 mg, 0.45 
mmol,  2  equiv)  in  CH3CN  (170  mL).  The  reaction  mixture  was  allowed  to  stir 
overnight, and then concentrated in vacuo. The crude material was purified by flash 
chromatography with 3% MeOH in CH2Cl2 to afford sanguinamide B and an impurity. 
HPLC was performed to afford trans, trans-sanguinamide B (1.130) (4 mg, 3%). 
1H NMR (600 MHz, CDCl3) ʴ ppm 8.37 (s, 1H, H-13), 7.92 (s, 1H, H-30), 7.43 (s, 1H, 
H-16), 7.24 (d, J=8.2 Hz, 1H, NH), 7.02 (d, J=10.9 Hz, 1H, NH), 6.27 (d, J=10.6 Hz, 
1H, NH), 5.43 (d, J=7.0 Hz, 1H, H-18), 5.13–4.97 (m, 2H, H-23;  H-32), 4.78 (dd, 
J=10.6, 2.6 Hz, 1H, H-2), 4.72 (dd, J=8.7, 1.3 Hz, 1H, H-7), 3.91–3.74 (m, 4H, H-10; 
H-21), 2.88 (dq, J=6.8, 4.1 Hz, 1H, H-3), 2.36–2.20 (m, 3H, H-8; H-19), 2.20–2.06 (m, 
1H, H-9), 2.06–1.98 (m, 1H, H-9), 1.98–1.88 (m, 3H, H-19; H-20; H-24), 1.83–1.71 (m, 
1H, H-20), 1.69–1.51 (m, 2H, H-24; H-25), 1.08–0.95 (m, 9H, H-5; H-26; H-33), 0.92 
(d, J=6.5 Hz, 3H, H-27), 0.86 (d, J=6.7 Hz, 3H, H-4); 
13C NMR (100 MHz, CDCl3) ʴ 
ppm 173.6 (C, C-6), 172.8 (C, C-17), 171.02 (C, C-31), 170.96 (C, C-1), 168.9 (C, C-    Experimental Procedures For Chapter 1 
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22), 162.1 (C, C-11), 160.0 (C, C-28), 157.7 (C, C-14), 146.7 (C, C-29), 143.7 (CH, C-
13), 140.7 (C, C-15), 136.7 (C, C-12), 125.7 (CH, C-30), 122.6 (CH, C-16), 64.3 (CH, 
C-7), 59.0 (CH, C-18), 56.9 (CH, C-2), 49.1 (CH, C-23), 48.1 (CH2, C-10), 46.7 (CH2, 
C-21), 45.9 (CH, C-32), 41.6 (CH2, C-24), 35.8 (CH2, C-19), 32.0 (CH2, C-8), 28.4 
(CH, C-3), 24.4 (CH, C-25), 23.5 (CH3, C-27), 22.7 (CH2, C-9), 22.3 (CH3, C-26), 20.3 
(CH2, C-20), 19.9 (CH3, C-5), 16.5 (CH3, C-4), 16.3 (CH3, C-33); ES
+ MS m/z 711 
([M+H]
+),  733  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for  C33H42N8NaO6S2  (M+Na)
+ 
733.2561, found 733.2582.     Experimental Procedures For Chapter 1 
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5.2.3. Stylissamide A 
 
Protected stylissamide A (1.132) 
 
Acyclic precursor 1.131 (98.7 mg, 0.09 mmol, 1 equiv) was then taken up in CH2Cl2 
(20 mL) and added dropwise to a vigorously stirred solution of Hünig’s base (97 µL, 
0.56 mmol, 6 equiv), HOBt (25 mg, 0.19 mmol, 2 equiv) and HATU (71 mg, 0.19 
mmol, 2 equiv) in CH3CN (65 mL). The reaction mixture was allowed to stir overnight, 
and  then  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography (5 to 10% MeOH in CH2Cl2) to afford 1.132 as a pale yellow solid (60 
mg, 62%). 
ES
+ MS m/z: 1079 ([M+Na]
+). 
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Stylissamide A (1.20) 
 
1.132 (50 mg, 47 µmol) was dissolved in a mixture of TFA (3 mL), triisopropylsilane 
(100 µL) and water (100 µL) at 0 ºC. The mixture was stirred for 3 h, before being 
concentrated. The solid was triturated with  ether (25 mg). HPLC was  performed to 
obtain a compound as pure as possible and afforded 1.20 (10 mg, 25%). 
1H NMR (600 MHz, DMSO-d6) ʴ ppm 7.83 (br s, 2H, NH2), 7.73–7.69 (d, 1H, NH), 
7.62 (d, J=8.1 Hz, 1H, NH), 7.33–7.29 (m, 1H, NH), 7.25 (d, J=9.5 Hz, 1H, NH), 7.06 
(d, J=7.7 Hz, 2H, H-9; H-13), 6.99 (d, J=8.1 Hz, 2H, H-39; H-43), 6.64 (d, J=7.7 Hz, 
2H, H-40; H-42), 6.63 (d, J=7.7 Hz, 1H, H-10; H-12), 4.90 (t, J=10.8 Hz, 1H, H-36), 
4.41 (d, J=7.0 Hz, 2H, H-15; H-29), 4.36–4.27 (m, 2H, H-6; H-24), 3.97 (t, J=8.1 Hz, 
1H, H-4), 3.79–3.60 (m, 3H, H-1; H-31), 3.47–3.38 (m, 3H, H-21; H-26), 3.33 (dd, 
J=15.6, 6.8 Hz, 1H, H-21), 3.27 (d, J=12.8 Hz, 1H, H-37), 3.17 (d, J=12.1 Hz, 1H, H-
7), 2.86 (t, J=12.6 Hz, 1H, H-7), 2.81–2.71 (m, 2H, H-19), 2.38 (t, J=12.1 Hz, 1H, H-
37), 2.19–2.11 (m, 2H, H-23; H-28), 2.10–1.97 (m, 4H, H-2; H-3; H-28), 1.96–1.69 (m, 
7H, H-16; H-22; H-23; H-27; H-32), 1.63–1.43 (m, 5H, H-3; H-16; H-18; H-27), 1.37–
1.26 (m, 2H, H-17), 0.77 (d, J=6.2 Hz, 3H, H-33 or H-34), 0.43 (d, J=6.2 Hz, 3H, H-33 
or H-34); ES
+ MS m/z: 845 ([M+H]
+), 867 ([M+Na]
+). 
The spectroscopic data are consistent with that
28 reported in the literature. 
 
     Experimental Procedures For Chapter 2 
237 
 
5.3. EXPERIMENTAL  DATA  FOR  CHAPTER  2  :  HISTONE 
DEACETYLASE INHIBITORS 
 
5.3.1. Experimental procedures for largazole and analogues 
 
D-Valinol (2.144)  
 
To a solution of sodium borohydride (7.76 g, 205 mmol, 2.4 equiv) in THF (200 mL) 
was added in one portion D-valine (10 g, 86 mmol, 1 equiv). The reaction mixture was 
cooled to 0 °C and a solution of iodine (21.7 g, 86 mmol, 1 equiv) in THF (55 mL) was 
added dropwise resulting in the formation of hydrogen. After the hydrogen formation 
stopped, the reaction mixture was refluxed overnight, then, cooled to rt, and neutralised 
by cautious addition of methanol until the mixture became clear. After stirring 30 min, 
the solvent  was removed  in  vacuo affording a  white paste  which was  dissolved by 
addition of KOH solution (20%, 150 mL). The solution was stirred for 4 h and extracted 
with CH2Cl2 (3 x 150 mL). The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo to form 2.144 as a white solid (7.7 g, 87%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 3.65 (dd, J=10.6, 4.0 Hz, 1H, CH2OH), 3.29 (dd, 
J=10.6, 8.8 Hz, 1H, CH2OH), 2.56 (ddd, J=8.8, 6.2, 4.0 Hz, 1H, CHNH2), 1.98 (br s, 
3H, NH2, OH), 1.58 (qd, J=13.5, 6.7 Hz, 1H, CH(CH3)2), 0.92 (app dd, J=6.8, 4.6 Hz, 
6H, CH3).  
The spectroscopic data are consistent with that
115 reported in the literature. 
 
 
(R)-4-Isopropylthiazolidine-2-thione (2.145)  
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To  a  stirred  solution  of  D-valinol  2.144  (7.7  g,  75  mmol,  1.0  equiv)  in  potassium 
hydroxide solution (1 M, 380 mL), carbon disulfide (23 mL, 380 mmol, 5.0 equiv) was 
added. The reaction mixture was stirred at 100 C for 24 h. After cooling to rt, the 
reaction mixture was extracted with CH2Cl2 (2 x 300 mL). The combined organic layers 
were dried over MgSO4 and then evaporated under reduced pressure to afford 2.145 as a 
yellow solid (11.2 g, 93%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 7.61 (br s, 1H, NH), 4.10–4.00 (m, 1H, CHNH), 
3.52 (dd, J=11.1, 8.1 Hz, 1H, CH2), 3.34 (dd, J=11.1, 8.5 Hz, 1H, CH2), 1.98 (octet, 
J=6.8 Hz, 1H, CH(CH3)2), 1.05 (d, J=6.6 Hz, 3H, CH3), 1.01 (d, J=6.6 Hz, 3H, CH3). 
The spectroscopic data are consistent with that
116 reported in the literature. 
 
 
(R)-1-(4-Isopropyl-2-thioxothiazolidin-3-yl)ethanone (2.46)  
 
To a suspension of 60% NaH (3.05 g, 76.4 mmol, 1.1 equiv) in dry THF (65 mL) was 
added a solution of 2.145 (11.2 g, 69.4 mmol, 1 equiv) in THF (65 mL). The mixture 
was stirred at 0 °C for 10 min. Acetyl chloride (5.43 mL, 76.4 mmol, 1.1 equiv) was 
added to the reaction mixture which was stirred at 0 °C to rt overnight. HCl solution 
(5%) was added and the aqueous layer was extracted with EtOAc (3 x 300 mL). The 
combined  organic  extracts  were  dried  over  MgSO4  and  concentrated  in  vacuo.  The 
crude material was purified by flash chromatography (EtOAc/hexane 5:95) to give 2.46 
as a yellow oil (12.6 g, 89%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 5.16 (ddd, J=7.7, 6.2, 1.1 Hz, 1H, CHNH), 3.51 
(dd, J=11.5, 8.1 Hz, 1H, CH2), 3.03 (dd, J=11.7, 1.1 Hz, 1H, CH2), 2.78 (s, 3H, CH3), 
2.38 (octet, J=6.8 Hz, 1H, CH(CH3)2), 1.07 (d, J=6.8 Hz, 3H, CH3), 0.99 (d, J=7.2 Hz, 
3H, CH3). 
The spectroscopic data are consistent with that
117 reported in the literature. 
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(E)-5-(Tritylthio)pent-2-enal (2.38)  
 
To a solution of triphenylmethanethiol (3.5 g, 12.7 mmol, 1 equiv) in CH2Cl2 (70 mL) 
was added NEt3 (2.5 mL, 18.1 mmol, 1.43 equiv) followed by acrolein (1.20 mL, 17.7 
mmol, 1.4 equiv) at rt under argon with stirring. After 2 h, the reaction mixture was 
concentrated in vacuo and the solid was dried.  
The crude intermediate and formylmethene triphenylphosphorane (3.85 g, 12.7 mmol, 1 
equiv) were dissolved in toluene (70 mL). The reaction mixture was heated at 80 °C 
overnight. The reaction was allowed to reach rt and pass through a silica plug (eluent 
EtOAc/hexane 1:4). The solvent was then removed and the residue purified by flash 
chromatography (5-10% EtOAc in hexane) to give 2.38 as a beige solid (3.0 g, 65%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 9.41 (d, J=7.5 Hz, 1H, H-1), 7.50–7.11 (m, 15H, 
HAr), 6.60 (dt, J=15.7, 6.3 Hz, 1H, H-3), 5.96 (dd, J=15.8, 7.9 Hz, 1H, H-2), 2.38–2.22 
(m, 4H, H-4; H-5). 
The spectroscopic data are consistent with that
88 reported in the literature. 
 
 
(3S)-Hydroxy-1-(4R-isopropyl-2-thioxo-thiazolidin-3-yl)-7-tritylsulfanyl-hept-4E-
en-1-one (2.47)  
 
To a stirred solution of the acetylated Nagao chiral auxiliary 2.46 (2.73 g, 13.4 mmol, 
1.7 equiv) in CH2Cl2 (110 mL) at 0 ºC was added TiCl4 (1.67 mL, 15.2 mmol, 1.9 
equiv). The reaction mixture was stirred for 5 min, cooled to –78 ºC before the addition 
of Hünig’s base (2.65 ml, 15.2 mmol, 1.9 equiv) and stirred for 2 h. The aldehyde 2.38 
(2.92 g, 8.1 mmol, 1 equiv) in CH2Cl2 (17 mL) was added dropwise and the reaction 
mixture  stirred  for  30  min.  Saturated  NH4Cl  (100  mL)  was  added  to  the  reaction 
mixture which was diluted with CH2Cl2 (60 mL) and allowed to reach rt. The aqueous 
layer was extracted with CH2Cl2 (3 x 60 mL), washed with saturated NaCl (50 mL) and     Experimental Procedures For Chapter 2 
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dried weith Na2SO4. The solvent was then removed and the residue purified by flash 
chromatography (10-25% EtOAc in hexane) to give the major isomer 2.47 as a yellow 
solid (1.9 g, 42%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 7.49–7.13 (m, 15H, HAr), 5.69–5.53 (m, 1H, H-3), 
5.47 (dd, J=15.6, 6.0 Hz, 1H, H-4), 5.14 (t, J=6.8 Hz, 1H, H-10), 4.68–4.50 (m, 1H, H-
5), 3.57 (dd, J=17.6, 3.0 Hz, 1H, H-6), 3.48 (dd, J=11.5, 8.0 Hz, 1H, H-9), 3.29 (dd, 
J=17.6, 8.5 Hz, 1H, H-6), 3.01 (d, J=11.5 Hz, 1H, H-9), 2.74 (br s, 1H, OH), 2.36 (dq, 
J=13.4, 6.8 Hz, 1H, H-11), 2.22 (t, J=7.5 Hz, 2H, H-1), 2.10 (q, J=7.0 Hz, 2H, H-2), 
1.06 (d, J=6.5 Hz, 3H, H-12 or H-13), 0.98 (d, J=7.0 Hz, 3H, H-12 or H-13). 
The spectroscopic data are consistent with that
78 reported in the literature. 
 
 
(3S,4E)-3-Hydroxy-7-[(triphenylmethyl)thio]-4-heptenoic  acid  (2-trimethyl-silyl)-
ethyl ester (2.85)  
 
Compound 2.47 (800 mg, 1.42 mmol, 1 equiv) was dissolved in CH2Cl2 (20 mL) and 2-
trimethylsilyethanol (2.04 mL, 14.24 mmol, 10 equiv) was added, followed by DMAP 
(17.4  mg,  0.14  mmol,  0.1  equiv).  The  reaction  mixture  was  stirred  overnight  and 
concentrated in vacuo. The crude was purified by flash chromatography (EtOAc/hexane 
2:8) to give 2.85 as a clear oil (384 mg, 52%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.56–7.16 (m, 15H, HAr), 5.73–5.50 (m, 1H, H-3), 
5.50–5.30 (m, 1H, H-4), 4.60–4.35 (m, 1H, H-5), 4.29–4.07 (m, 2H, H-8), 2.56–2.36 
(m, 2H, H-6), 2.31–2.15 (m, 2H, H-1), 2.08 (q, J=6.9 Hz, 2H, H-2), 1.11–0.85 (m, 2H, 
H-9), 0.05 (s, 9H, SiMe3). 
The spectroscopic data are consistent with that
42 reported in the literature. 
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(S,E)-2-(Trimethylsilyl)ethyl3-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl-amino)-
3-methylbutanoyloxy)-7-(tritylthio)hept-4-enoate (2.86)  
 
Compound 2.85 (156 mg, 0.30 mmol, 1 equiv) and N-Fmoc-L-valine (112 mg, 0.33 
mmol, 1.1 equiv) were dissolved in CH2Cl2 (5 mL). The reaction was cooled to 0º C. 
DCC (74 mg, 0.36 mmol, 1.2 equiv) and DMAP (4 mg, 0.03 mmol, 0.1 equiv) were 
added. The reaction mixture was stirred overnight and concentrated in vacuo. The crude 
was purified by flash chromatography (EtOAc/hexane 5:95) to give 2.86 as a white 
solid (238 mg, 94%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 7.78 (d, J=7.7 Hz, 2H, HAr), 7.61 (d, J=6.6 Hz, 
2H, HAr), 7.52–7.17 (m, 19H, HAr), 5.89–5.56 (m, 2H), 5.48–5.13 (m, 2H), 4.47–4.08 
(m, 6H, H-8; H-11; H-16; H-17), 2.78–2.50 (m, 2H, H-6), 2.31–1.92 (m, 5H, H-1; H-2; 
H-12), 1.06–0.68 (m, 8H, H-9; H-13; H-14), 0.03 (s, 9H, SiMe3); ES
+ MS m/z 862 
([M+Na]
+). 
The spectroscopic data are consistent with that
42 reported in the literature. 
 
 
Allyl carbamoylmethylcarbamate (2.153) 
 
To a solution of glycinamide hydrochloride (3 g, 27.1 mmol, 1 equiv) in THF (65 mL) 
at rt was added Hünig’s base (23.6 mL, 135.7 mmol, 5 equiv), allylchloroformate (8.7 
mL, 81.4 mmol, 3 equiv), and DMAP (332 mg, 2.7 mmol, 0.1 equiv). The reaction 
mixture was stirred for 3 h at rt and diluted with ethyl acetate. The organic layer was 
washed  with  KHSO4  solution  (0.05  M),  saturated  NaHCO3  solution  and  brine.  The 
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The  crude  material  was  purified  by  flash  chromatography  using  0-10%  MeOH  in 
CH2Cl2 with to afford 2.153 as a white solid (1.65 g, 37%). 
mp 104–106 ºC; IR 3334, 3198, 1678, 1652, 1550, 1546, 1300, 1270 cm
–1; 
1H NMR 
(300  MHz,  CD3OD)  ʴ  ppm  5.98  (ddd,  J=22.7,  10.6,  5.5  Hz,  1H,  H-2),  5.35  (dq, 
J=17.3, 1.8 Hz, 1H, H-1), 5.22 (dq, J=10.5, 1.4 Hz, 1H, H-1), 4.59 (br d, J=5.5 Hz, 2H, 
H-3), 3.79 (s, 2H, H-6); 
13C NMR (75 MHz, CD3OD) ʴ ppm 175.2 (C, CO), 159.0 (C, 
CO), 134.4 (CH, C-2), 117.8 (CH2, C-1), 66.9 (CH2, C-3), 44.6 (CH2, C-5); ES
+ MS 
m/z 181 ([M+Na]
+). 
 
 
Allyl thiocarbamoylmethylcarbamate (2.154) 
 
To a solution of 2.153 (1.65 g, 10.5 mmol, 1 equiv) in toluene (25 mL) was added the 
Lawesson’s reagent (2.5 g, 6.3 mmol, 0.6 equiv). The reaction mixture was refluxed for 
24 h. The reaction mixture was purified by flash chromatography using 0-3% MeOH in 
CH2Cl2 to afford 2.154 as a yellow solid (1.44 g, 79%). 
mp 78–80 ºC; IR 3330, 3160, 2926, 1690, 1610, 1527, 1448, 1399, 1361, 1251, 1149, 
1047, 990, 945 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.87 (br s, 2H, NH2), 6.04–
5.81 (m, 1H, H-2), 5.71 (br s, 1H, NH), 5.33 (dd, J=17.2, 1.1 Hz,1H, H-1), 5.25 (dd, 
J=10.2, 1.1 Hz, 1H, H-1), 4.61 (d, J=5.9 Hz, 2H, H-3), 4.21 (d, J=5.9 Hz, 2H, H-5); 
13C 
NMR (75 MHz, CDCl3) ʴ ppm 204.4 (C, C=S), 156.7 (C, C=O), 132.1 (CH, C-2), 
118.3 (CH2, C-1), 66.4 (CH2, C-3), 51.4 (CH2, C-5); ES
+ MS m/z 197 ([M+Na]
+). 
 
 
Allyl (4-(methoxycarbonyl)thiazol-2-yl)methylcarbamate (2.155) 
 
To  a  solution  of  2.154  (2.1  g,  12.16  mmol,  1  equiv)  in  ethanol  (28  mL),  methyl 
bromopyruvate (1.42 mL, 3.15 mmol, 1.1 equiv) and calcium carbonate (657 mg, 1.55     Experimental Procedures For Chapter 2 
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mmol,  0.5  equiv)  were  added.  The  reaction  mixture  was  stirred  under  argon  at  rt 
overnight.  The  reaction  mixture  was  filtered  and  the  filtrate  was  evaporated  under 
reduced  pressure.  The  residue  was  partitioned  between  chloroform  and  saturated 
NaHCO3 solution. The organic layer was then washed once with water. The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (hexane/EtOAc 7:3) to afford 2.155 as a 
yellow oil (2 g, 64%). 
IR 3330, 3115, 2952, 1712, 1523, 1440, 1240, 1142, 1092, 987, 926 cm
–1; 
1H NMR 
(300 MHz, CDCl3) ʴ ppm 8.15 (s, 1H, H-7), 6.03–5.84 (m, 1H, H-2), 6.02–5.54 (br s, 
1H, NH), 5.32 (d, J=16.6 Hz, 1H, H-1), 5.24 (dd, J=10.5, 1.0 Hz, 1H, H-1), 4.72 (d, 
J=6.5 Hz, 2H, H-5), 4.63 (d, J=5.5 Hz, 2H, H-3), 3.96 (s, 3H, Me); 
13C NMR (75 MHz, 
CDCl3) ʴ ppm 169.3 (C), 161.3 (C), 155.9 (C), 146.1 (C, C-8), 132.1 (CH, C-2), 127.8 
(CH, C-7), 117.7 (CH2, C-1), 65.8 (CH2, C-3), 52.1 (CH3, Me), 42.3 (CH2, C-5); ES
+ 
MS m/z 279 ([M+Na]
+). 
 
 
Allyl (4-(carboxylic acid)thiazol-2-yl)methylcarbamate (2.156) 
 
To a solution of 2.155 (2 g, 7.8 mmol, 1 equiv) in 40 mL of a mixture THF/water (3:1) 
was added LiOH (560 mg, 23.4 mmol, 3 equiv) at 0 °C. The reaction mixture was 
stirred at rt overnight. The solution was diluted with water and acidified to pH 1–2 with 
a  saturated  KHSO4.  The  aqueous  layer  was  extracted  with  EtOAc.  The  combined 
organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo to 
provide 2.156 as a yellow solid (1.5 g, 79%). 
mp 137–138 ºC; IR 3312, 3119, 2922, 1712, 1516, 1251, 1110, 1039, 983, 934 cm
–1; 
1H NMR (300 MHz, CD3OD) ʴ ppm 8.29 (s, 1H, H-7), 6.34–6.12 (m, 1H, H-2), 5.32 
(d, J=17.2 Hz, 1H, H-1), 5.20 (d, J=10.6 Hz, 1H, H-1), 4.65–4.44 (m, 4H, H-3; H-5);
 
13C NMR (75 MHz, CD3OD) ʴ ppm 173.2 (C, CO2H), 164.0 (C), 159.8 (C), 148.3 (C, 
C-8), 134.3 (CH, C-2), 129.5 (CH, C-7), 117.9 (CH2, C-1), 67.0 (CH2, C-3), 43.5 (CH2, 
C-5); ES
– MS m/z 242 ([M-H]
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(R)-2-Amino-2-methyl-3-(tritylthio)propanoic acid (2.158) 
 
A mixture of (R)-2-methylcysteine hydrochloride (100 mg, 0.58 mmol, 1 equiv) and 
glacial acetic acid (1.8 mL) was warmed at 60 ºC. Triphenylmethanol (152 mg, 0.58 
mmol, 1 equiv) was added at rt and the temperature is raised again to 60 ºC before 
boron trifluoride diethyl etherate (152 mg, 0.58 mmol) was added. The reaction mixture 
was heated at 80 ºC for 30 min and stirred at rt for 45 min. To the reaction mixture, 
EtOH (800 µL), water (300 µL) and sodium acetate (16 mg) were added. Water was 
added and the reaction mixture was cooled. The precipitated was filtered and washed 
with diethyl ether to provide 2.158 as a white solid (124 mg, 96%). 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.52–7.17 (m, 15H, HAr), 2.72 (d, J=12.1 Hz, 1H, 
CH2), 2.48 (d, J=12.1 Hz, 1H, CH2), 1.40 (s, 3H, Me); ES
+ MS m/z 243 ([CPh3]
+), 400 
([M+Na]
+). 
The spectroscopic data are consistent with that
202 reported in the literature. 
 
 
(R)-2-Amino-2-methyl 3-tritylsulfanyl-propionic acid methyl ester (2.159) 
 
To a solution of thionyl chloride (93 µL, 1.27 mmol, 5 equiv) in dry methanol (5mL), 
compound 2.158 (96 mg, 0.25 mmol, 1 equiv) was added at 0 ºC. This solution was 
refluxed overnight under argon. The reaction mixture was concentrated in vacuo and the 
crude material purified by flash chromatography (hexane/EtOAc 1:1) to afford 2.159 as 
a white solid (67 mg, 67%).     Experimental Procedures For Chapter 2 
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1H NMR (300 MHz, CDCl3) ʴ ppm 7.43–7.05 (m, 15H, HAr), 3.69 (s, 3H, CO2Me), 
2.95 (d, J=12.1 Hz, 1H, CH2), 2.54 (d, J=12.1 Hz, 1H, CH2), 1.96 (br s, 2H, NH2), 1.62 
(s, 3H, Me); ES
+ MS m/z 243 ([CPh3]
+), 413 ([M+Na]
+). 
The spectroscopic data are consistent with that
203 reported in the literature. 
 
 
(R)-Methyl 2-(2-((allyloxycarbonylamino)methyl)thiazole-4-carboxamido)-2-
methyl-3-(tritylthio)propanoate (2.160) 
 
To a solution of 2.156 (283 mg, 1.17 mmol, 1.1 equiv) in MeCN (17 mL) cooled at 0 
°C, PyBOP (688 mg, 1.17 mmol, 1.1 equiv) and Hünig’s base (462 µL, 2.65 mmol, 2.5 
equiv) were added. After 10 min, 2.159 (400 mg, 1.06 mmol, 1 equiv) in solution in 
CH2Cl2 (17 mL) was added dropwise. The reaction mixture was stirred at rt overnight 
and concentrated in vacuo. The crude material was purified by flash chromatography 
(EtOAc/hexane 1:1) to afford 2.160 as a white solid (650 mg, 100%). 
[]D
26 –4.3 (c 0.22, CHCl3); mp 76–80 ºC; IR 3361, 2949, 2930, 1735, 1675, 1538, 
1493, 1448, 1251 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.04 (s, 1H, H-7), 7.94 (s, 
1H, NH), 7.48–7.13 (m, 15H, HAr), 6.03–5.84 (m, 1H, H-2), 5.55 (br t, J=5.7 Hz, 1H, 
NH), 5.33 (dd, J=17.0, 0.6 Hz, 1H, H-1), 5.28–5.20 (m, 1H, H-1), 4.68 (d, J=6.2 Hz, 
2H, H-5), 4.64 (dt, J=5.6, 1.4 Hz, 2H, H-3), 3.71 (s, 3H, CO2Me), 3.06 (d, J=11.8 Hz, 
1H, H-13), 2.89 (d, J=11.8 Hz, 1H, H-13), 1.51 (s, 3H, H-11); 
13C NMR (75 MHz, 
CDCl3) ʴ ppm 173.1 (C, CO), 168.2 (C), 159.9 (C), 156.1 (C), 149.7 (C, C-8), 144.5 
(3C, CAr), 132.4 (CH, C-2), 129.6 (6CH, CAr), 127.9 (6CH, CAr), 126.7 (3CH, CAr), 
123.9 (CH, C-7), 118.1 (CH2, C-1), 66.5 (C, CPh3), 66.2 (CH2, C-3), 59.2 (C, C-10), 
52.9 (CH3, CO2Me), 42.6 (CH2, C-5), 37.9 (CH2, C-13), 23.1 (CH3, C-11); ES
+ MS m/z 
638 ([M+Na]
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Allyl (4-carbamoylthiazol-2-yl)methylcarbamate (2.163) 
 
Carboxylic acid 2.156 (200 mg, 0.83 mmol, 1 equiv) was dissolved in dry CH2Cl2 and 
HOBt (335 mg, 2.48 mmol, 3 equiv), EDCI.HCl (475 mg, 2.48 mmol, 3 equiv) and 
Hünig’s base (575 µL, 3.30 mmol, 4 equiv) were added. After stirring for 10 min, NH3 
in  dioxane  (0.5  M,  16.5  mL,  8.26  mmol,  4  equiv)  was  added.  After  stirring  at  rt 
overnight, HCl solution (0.1 M) was added with cooling to adjust the reaction mixture 
to  pH  4–5.  The  aqueous  layer  was  extracted  3  times  with  CH2Cl2.  The  combined 
organic layers were dried and concentrated in vacuo. The residue was purified by flash 
chromatography using 5% MeOH in CH2Cl2 to afford 2.163 as a white solid (144 mg, 
72%). 
mp 128–130 °C; IR 3323, 3100, 2930, 1724, 1701, 1652, 1520, 1414, 1278, 1244, 
1172, 979 cm
–1; 
1H NMR (300 MHz, CD3OD/CDCl3) ʴ ppm 8.44 (s, 1H, H-7), 6.44 
(br s, 1H, NH), 5.96–5.77 (m, 1H, H-2), 5.28 (dd, J=16.1, 1.1 Hz, 1H, H-1), 5.18 (dd, 
J=10.4, 0.4 Hz, 1H, H-1), 4.61–4.54 (m, 4H, H-3; H-5), 2.75 (br s, 2H, NH2); 
13C NMR 
(75 MHz, CD3OD/CDCl3) ʴ ppm 169.0 (C), 163.4 (C), 156.4 (C), 148.9 (C), 132.3 
(CH, C-2), 124.8 (CH, C-7), 117.9 (CH2, C-1), 66.0 (CH2, C-3), 42.3 (CH2, C-5); ES
+ 
MS m/z 264 ([M+Na]
+). 
 
 
Allyl (4-cyanothiazol-2-yl)methylcarbamate (2.164) 
 
Amide  2.163  (370  mg,  1.53  mmol,  1  equiv)  was  dissolved  in  CH2Cl2  (8  mL). 
Triethylamine (291 µL, 2.08 mmol, 2.1 equiv) was added to the reaction mixture at 0 °C 
following by the addition of TFAA  (145 µL, 1.04 mmol, 1.05 equiv). The reaction 
mixture was stirred at rt overnight, the solvent removed and the crude mixture purified 
by flash chromatography using EtOAc/hexane (3:7) to afford 2.164 as a yellow solid 
(318 mg, 93%).     Experimental Procedures For Chapter 2 
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mp 46–48 ºC; IR 3327, 3107, 2945, 1712, 1527, 1247, 1153, 1123, 990, 941 cm
–1; 
1H 
NMR (300 MHz, CDCl3) ʴ ppm 7.97 (s, 1H, H-7), 6.02–5.84 (m, 1H, H-2), 5.59 (br s, 
1H, NH), 5.33 (dt, J=16.4, 1.0 Hz, 1H, H-1), 5.25 (dq, J=10.4, 1.3 Hz, 1H, H-1), 4.69 
(d, J=6.3 Hz, 2H, H-5), 4.63 (dt, J=5.7, 1.4 Hz, 2H, H-3); 
13C NMR (75 MHz, CDCl3) 
ʴ ppm 170.5 (C), 156.2 (C), 132.2 (CH, C-2 or C-7), 130.9 (CH, C-2 or C-7), 126.5 (C, 
C-8), 118.3 (CH2, C-1), 113.7 (C, CN), 66.3 (CH2, C-3), 42.5 (CH2, C-5); ES
+ MS m/z 
246 ([M+Na]
+). 
 
 
(4R)-4-Methyl-2'-({[(prop-2-en-1-yloxy)carbonyl]aminomethyl)-4,5-dihydro-2,4'-
bi-1,3-thiazole-4-carboxylic acid (2.165) 
 
To a solution of nitrile 2.164 (142 mg, 0.63 mmol, 1 equiv) and (R)-methylcysteine 
hydrochloride (207 mg, 1.21 mmol, 1.9 equiv) in MeOH (7.9 mL), were added solid 
NaHCO3 (266 mg, 3.17 mmol, 5 equiv) and phosphate buffer solution pH = 6 (0.1 M, 4 
mL). The reaction mixture was heated 2 h at 70 °C. To the cold reaction mixture were 
added water (10 mL) and saturated NaHCO3 solution (5 mL). The mixture was washed 
with EtOAc (2 x 10 mL). The aqueous layer was acidified (pH = 1–2) with KHSO4 
solution and extracted 3 times with EtOAc. The combined organic layers were dried and 
concentrated in vacuo to afford 2.165 as a white solid (208 mg, 96%). 
mp 48–50 ºC; IR 3312, 3058, 2930, 1724, 1523, 1417, 1274, 896 cm
–1; 
1H NMR (300 
MHz, CDCl3) ʴ ppm 7.98 (s, 1H, H-7), 6.00–5.87 (m, 1H, H-2), 5.84 (br s, 1H, NH), 
5.32 (d, J=17.3 Hz, 1H, H-1), 5.23 (dt, J=10.4, 0.7 Hz, 1H, H-1), 4.68 (d, J=6.3 Hz, 2H, 
H-3 or H-5), 4.62 (d, J=5.9 Hz, 2H, H-3 or H-5), 3.90 (d, J=11.5 Hz, 1H, H-10), 3.33 
(d, J=11.5 Hz, 1H, H-10), 1.68 (s, 3H, Me); 
13C NMR (75 MHz, CDCl3) ʴ ppm 174.5 
(C, CO2H), 168.3 (C), 163.5 (C), 155.3 (C), 146.8 (C), 131.4 (CH, C-2), 122.1 (CH, C-
7), 117.2 (CH2, C-1), 83.2 (C, C-11), 65.2 (CH2, C-3), 41.5 (CH2, C-5 or C-10), 40.2 
(CH2, C-5 or C-10), 23.2 (CH3, Me); ES
+ MS m/z 364 ([M+Na]
+).     Experimental Procedures For Chapter 2 
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(3S,4E)-2-(Trimethylsilyl)ethyl-3-[(S)-2-((R)-2-[2-[(Allyloxycarbonyl)methyl]-
thiazol-4-yl]-4-methyl-4,5-dihydrothiazole-4-carboxamido)-3-methylbutanoyl-oxy]-
7-(tritylthio) hept-4-enoate (2.166) 
 
Compound 2.86 was dissolved in MeCN and diethylamine was added to the reaction 
mixture. After stirring for 2 h, the reaction mixture was concentrated in vacuo. The free 
amine was dried under high vacuum.  
To a solution of 2.165 (113 mg, 0.33 mmol, 1.1 equiv) in MeCN (5 mL) cooled at 0 °C, 
PyBOP (212 mg, 0.36 mmol, 1.1 equiv) and Hünig’s base (157 µL, 0.90 mmol, 3 equiv) 
were added. After 15 min, the previously deprotected amine (185 mg, 0.30 mmol, 1 
equiv) in solution in CH2Cl2 (5 mL) was added dropwise. The reaction mixture was 
stirred at rt overnight and concentrated in vacuo. The crude material was purified by 
flash  chromatography  (EtOAc/hexane,  gradient  9:1  to  5:5)  to  afford  2.166  as  a 
colourless oil (220 mg, 78%). 
[]D
26 –30.1 (c 0.42, CHCl3); IR 3383, 2956, 2926, 1731, 1675, 1512, 1247, 1176, 979, 
869, 835 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.92 (d, J=1.1 Hz, 1H, H-13), 
7.44–7.34 (m, 6H, HAr), 7.32–7.13 (m, 9H, HAr), 6.00–5.86 (m, 1H, H-2), 5.77–5.58 (m, 
2H, H-5; H-21), 5.47 (br s, 1H, NH), 5.42–5.33 (m, 2H, H-1), 5.25 (dq, J=10.3, 1.2 Hz, 
1H, H-20), 4.67 (dd, J=19.4, 5.9 Hz, 4H, H-15; H-17), 4.50 (dd, J=9.0, 4.6 Hz, 1H, H-
7), 4.23–4.11 (m, 2H, H-2), 3.79 (dd, J=11.5, 1.1 Hz, 1H, H-10), 3.33 (dd, J=11.5, 1.1 
Hz, 1H, H-10), 2.70 (dd, J=15.7, 7.7 Hz, 1H, H-4), 2.56 (dd, J=15.7, 5.5 Hz, 1H, H-4), 
2.24–1.99 (m, 5H, H-22; H-23; H-24), 1.59 (s, 3H, Me), 1.03–0.92 (m, 2H, H-1), 0.83 
(dt, J=6.9, 0.5 Hz, 3H, H-25 or H-26), 0.76 (d, J=6.9 Hz, 3H, H-25 or H-26), 0.04 (s, 
9H, SiMe3); 
13C NMR (75 MHz, CDCl3) ʴ ppm 174.4 (C), 170.5 (C), 170.3 (C), 169.6 
(C), 163.0 (C), 156.1 (C), 148.8 (C), 144.8 (3C, CAr), 133.9 (CH, C-18 or C-21), 132.4 
(CH, C-18 or C-21), 129.5 (6CH, CAr), 127.8 (CH, C-20), 127.8 (6CH, CAr), 126.6 
(3CH, CAr), 121.4 (CH, C-13), 118.1 (CH2, C-19), 85.2 (C, C-9), 71.8 (CH, C-5), 66.6 
(C, CPh3), 66.2 (CH2), 63.1 (CH2), 56.8 (CH, C-7), 42.6 (CH2), 41.5 (CH2), 39.7 (CH2),     Experimental Procedures For Chapter 2 
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31.3 (CH2), 31.2 (CH, C-24), 31.1 (CH2), 24.7 (CH3, Me), 19.0 (CH3, C-25 or C-26), 
17.5 (CH3, C-25 or C-26), 17.3 (CH2, C-1), -1.5 (3CH3, SiMe3);  ES
+ MS  m/z  964 
([M+Na]
+). 
 
 
N-Boc-glycinamide (2.171)  
 
To a solution of di-tert butyl dicarbonate (21.7 g, 100 mmol, 1 equiv) in CH2Cl2 (500 
mL)  were  added  glycinamide  hydrochloride  (11  g,  100  mmol,  1  equiv)  and 
triethylamine (29 mL, 207 mmol, 2.1 equiv). The reaction mixture was refluxed for 3 h. 
Triethylamine salts were extracted twice with water (100 mL) and the organic layer, 
dried over MgSO4, was evaporated to provide 2.171 as a white solid (8.15 g, 47%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 6.16 (br s, 1H, NH2), 5.73 (br s, 1H, NH2), 5.24 
(br s, 1H, NH), 3.82 (s, 2H, CH2), 1.46 (s, 9H, CMe3); ES
+ MS m/z 197 ([M+Na]
+). 
The spectroscopic data are consistent with that
204 reported in the literature. 
 
 
N-Boc-glycine thioamide (2.149)  
 
To a solution of N-Boc-glycinamide (2.5 g, 14.3 mmol, 1 equiv) in anhydrous THF (20 
mL)  was  added  Lawesson’s  reagent  (3.5  g,  8.6  mmol,  1  equiv)  under  argon.  The 
reaction mixture was stirred at rt overnight. The solvent was evaporated and the residue 
purified by flash chromatography using EtOAc/CH2Cl2 (1:9) to give 2.149 as a white 
solid (1.4 g, 51%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.89 (br s, 1H, NH2), 7.63 (br s, 1H, NH2), 5.32 
(br s, 1H, NH), 4.16 (d, J=4.9 Hz, 2H, CH2), 1.47 (s, 9H, CMe3); ES
+ MS m/z 213 
([M+Na]
+).     Experimental Procedures For Chapter 2 
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The spectroscopic data are consistent with that
204 reported in the literature. 
 
 
Methyl 2-Boc-aminomethyl-thiazole-4-carboxylate (2.151)
 
 
To  a  solution  of  2.149  (666  mg,  3.5  mmol,  1  equiv)  in  ethanol  (10  mL),  methyl 
bromopyruvate (410 µL, 3.9 mmol, 1.1 equiv) and calcium carbonate (189 mg, 1.9 
mmol,  0.5  equiv)  were  added.  The  reaction  mixture  was  stirred  under  argon  at  rt 
overnight. The reaction mixture was evaporated under reduced pressure. The residue 
was partitioned between CHCl3 and saturated NaHCO3 solution. The organic layer was 
then washed once with water. The combined organic layers were dried over MgSO4, 
filtered  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography (hexane/EtOAc 7:3) to afford 2.151 as a yellow solid (585 mg, 56%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.14 (s, 1H, H-3), 5.31 (br s, 1H, NH), 4.65 (d, 
J=6.3 Hz, 2H, H-1), 3.95 (s, 3H, Me), 1.47 (s, 9H, CMe3); ES
+ MS m/z 295 ([M+Na]
+). 
The spectroscopic data are consistent with that
205 reported in the literature. 
 
 
2-Boc-aminomethyl-thiazole-4-carboxylic acid (2.147)
  
 
To a solution of 2.151 (575 mg, 2.11 mmol, 1 equiv) in 20 mL of THF/water (3:1) was 
added LiOH (152 mg, 6.33 mmol, 3 equiv) at 0 °C. The reaction mixture was left at rt 
overnight. The solution was diluted with water (6 mL) and acidified to pH 1–2 with 
saturated KHSO4 solution. The aqueous layer was extracted twice with EtOAc (20 mL). 
The  combined  organic  layers  were  washed  with  brine,  dried  over  MgSO4  and 
concentrated in vacuo to provide 2.147 as a yellow solid (545 mg, 100%).      Experimental Procedures For Chapter 2 
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1H NMR (300 MHz, CD3OD) ʴ ppm 8.17 (s, 1H, H-3), 4.63 (s, 2H, H-1), 1.46 (s, 9H, 
CMe3); ES
+ MS m/z 281 ([M+Na]
+). 
The spectroscopic data are consistent with that
204 reported in the literature. 
 
 
Boc-2-aminomethylthiazole-4-carboxamide (2.176)  
 
Carboxylic acid 2.147 (705 mg, 2.6 mmol, 1 equiv) was dissolved in anhydrous CH2Cl2 
(10 mL) and THF (4 mL). HOBt (1.05 g, 7.8 mmol, 3 equiv), EDCI.HCl (1.5 g, 7.8 
mmol, 3 equiv) and Hünig’s base (1.8 mL, 10.4 mmol, 4 equiv) were added. After 
stirring for 10 min, NH3 in dioxane (0.5 M, 52 mL, 26.0 mmol, 10 equiv) was then 
added. The reaction mixture was stirred overnight and HCl (0.1 M) was added with 
cooling to adjust the pH to 4–5. The aqueous layer was extracted 3 times with CH2Cl2. 
The combined organic layers were dried and concentrated in vacuo. The residue was 
purified by flash chromatography using 5% MeOH in CH2Cl2 to afford 2.176 as a white 
solid (583 mg, 88%).  
1H NMR (300 MHz, CD3OD/CDCl3) ʴ ppm 8.10 (s, 1H, H-3), 7.11 (br s, 1H, NH), 
5.69 (br s, 1H, NH), 5.24 (br s, 1H, NH), 4.59 (s, 2H, H-1), 1.47 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
102 reported in the literature. 
 
 
2-(N-Boc-aminomethyl)thiazole-4-carbonitrile (2.100)
 
 
Amide 2.176 (583 mg, 2.42 mmol, 1 equiv) was dissolved in anhydrous CH2Cl2 (15 
mL). Triethylamine (707 µL, 5.07 mmol, 2.1 equiv) was added to the reaction mixture     Experimental Procedures For Chapter 2 
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at 0 °C followed by TFAA (353 µL, 2.54 mmol, 1.05 equiv). The reaction mixture was 
stirred  overnight,  the  solvent  removed  and  the  crude  product  purified  by  flash 
chromatography using EtOAc/hexane (3:7) to afford 2.100 as a yellow solid (478 mg, 
83%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 7.95 (s, 1H, H-3), 5.31 (br s, 1H, NH), 4.62 (d, 
J=6.0 Hz, 2H, H-1), 1.48 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
102 reported in the literature. 
 
 
Methyl 2-tert-butyl-1,3-thiazolidine-4-carboxylate (2.173a) and (2.173b)  
 
A  mixture  of  (R)-cysteine  methyl  ester  hydrochloride  (8.6  g,  50  mmol,  1  equiv), 
pivaldehyde (10.9 mL, 100 mmol, 2 equiv) and triethylamine (7.7 mL, 55 mmol, 1.1 
equiv) in pentane (80 mL) was refluxed for 9 h with continual removal of water using a 
Dean-Stark trap. The mixture was cooled and the resulting suspension was filtered. The 
residue  was  washed  with  ether  and  the  filtrate  was  concentrated  in  vacuo  to  give 
2.173a-b as a mixture of (2R, 4R) and (2S, 4R) diastereomers 1.9:1 (10.74 g, 100%). 
1H NMR (300 MHz, CDCl3) ʴ ppm Major isomer 4.46 (s, 1H, CHCMe3), 3.81 (dd, 
J=9.7, 6.6 Hz, 1H, CHCO2Me), 3.78 (s, 3H, CO2Me), 3.26 (dd, J=10.2, 6.8 Hz, 1H, 
CH2), 2.68 (t, J=9.9 Hz, 1H, CH2), 1.07 (s, 9H, CMe3); minor isomer 4.53 (s, 1H, 
CHCMe3), 4.14 (t, J=6.0 Hz, 1H, CHCO2Me), 3.76 (s, 3H, CO2Me), 3.15–2.97 (m, 2H, 
CH2), 0.98 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
124 reported in the literature. 
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(2R,4R)-Methyl 2-tert-butyl-1,3-thiazolidine-3-formyl-4-carboxylate (2.174)  
 
Acetic anhydride (15 mL, 162.9 mmol, 3.1 equiv) was added dropwise to a solution of 
formic acid (50 mL), diastereomers 2.173 (10.74 g, 52.8 mmol, 1 equiv) and sodium 
formate  (4.02  g,  59.1  mmol,  1.1  equiv)  at  0-5  °C.  The  solution  was  stirred  at  rt 
overnight. The solvents were removed and the residue was cautiously neutralised with 
NaHCO3 solution and extracted with ether. The combined ether extracts were dried and 
evaporated in vacuo to afford a white solid which after recrystallisation from petroleum 
ether gave the thiazolidine 2.174 as white crystals (6.7:1 mixture of conformers) (9.7 g, 
79%).  
1H NMR (300 MHz, CDCl3) ʴ ppm Major conformer 8.36 (s, 1H, CHO), 4.90 (t, J=8.7 
Hz, 1H, CHCO2Me), 4.75 (s, 1H, CHCMe3), 3.78 (s, 3H, CO2Me), 3.35–3.26 (m, 2H, 
CH2), 1.04 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
125 reported in the literature. 
 
 
(2R,4R)-Methyl 2-tert-butyl-1,3-thiazolidine-3-formyl-4-methyl-4-carboxylate 
(2.175)  
 
A solution of BuLi in hexanes (1.6 M, 12.2 mL, 19.5 mmol, 1.05 equiv) was added 
dropwise to a stirred solution of diisopropylamine (3.9 mL, 27.8 mmol, 1.5 equiv) in 
dry  THF  (86  mL)  at  –90  °C  under  argon.  1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-
pyrimidinone (DMPU) (13 mL, 107.5 mmol, 5.8 equiv) was added in one portion, and 
the mixture was then stirred at –90 °C for 1 h. A solution of 2.174 (4.3 g, 18.6 mmol, 1 
equiv) in dry THF (5 mL) was added over 15 min at –95 °C. The resulting solution was 
stirred for 45 min at –90 °C and iodomethane (1.4 mL, 22.3 mmol, 1.2 equiv) was then 
slowly added over 5 min. The reaction mixture was stirred for 2 h at –90 °C and then     Experimental Procedures For Chapter 2 
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warmed to rt. Solvents were removed resulting an oily residue. Brine (200 mL) and 
ether (300 mL) were added to the oil and then the layers were separated. The separated 
aqueous layer was extracted with ether (3 x 300 mL), and the combined organic layers 
were dried and evaporated in vacuo to leave an oil. The resulting oil was purified by 
flash chromatography using 5-10% EtOAc in light petroleum ether as eluent to afford 
2.175 as a mixture of conformers 2.3:1 (2.3 g, 51%).  
1H NMR (300 MHz, CDCl3) ʴ ppm Major conformer 8.29 (s, 1H, CHO), 4.67 (s, 1H, 
CH), 3.78 (s, 3H, OMe), 3.33 (d, J=11.5 Hz, 1H, CH2), 2.73 (d, J=11.6 Hz, 1H, CH2), 
1.77 (s, 3H, Me), 1.08 (s, 9H, CMe3); minor conformer 8.42 (s, 1H, CHO), 5.31 (s, 1H, 
CH), 3.83 (s, 3H, OMe), 3.65 (d, J=12.2 Hz, 1H, CH2), 2.87 (d, J=12.3 Hz, 1H, CH2), 
1.79 (s, 3H, Me), 0.97 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
125 reported in the literature. 
 
 
(R)-2-Methyl cysteine hydrochloride (2.157) 
 
 
Hydrochlorydric acid (5 M, 35.5 mL) was added to 2.175 (2.3 g, 9.4 mmol) and the 
solution  was  then  refluxed  under  argon  for  3  days.  The  solution  was  washed  with 
EtOAc (3 x 20 mL) and then the aqueous layer was concentrated in vacuo to afford 
2.157 as a yellow oil (1.3 g, 81%).  
1H NMR (300 MHz, D2O) ʴ ppm 3.16 (d, J=15.0 Hz, 1H, CH2), 2.87 (d, J=15.1 Hz, 
1H, CH2), 1.58 (s, 3H, Me). 
The spectroscopic data are consistent with that
125 reported in the literature. 
 
 
(R)-2-(2-((tert-Butoxycarbonylamino)methyl)thiazol-4-yl)-4-methyl-4,5-dihydro-
thiazole-4-carboxylic acid (2.109)     Experimental Procedures For Chapter 2 
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To a solution  of nitrile  2.100  (445 mg, 1.9 mmol,  1 equiv) and (R)-methylcysteine 
hydrochloride (2.157) (606 mg, 3.5 mmol, 1.9 equiv) in MeOH (25 mL), were added 
solid NaHCO3 (781 mg, 9.3 mmol, 5 equiv) and phosphate buffer solution pH = 6 (0.1 
M, 12.7 mL). The reaction mixture was heated for 2 h at 70 °C. To the cold reaction 
mixture were added water (10 mL) and saturated NaHCO3 solution (5 mL). The mixture 
was washed twice with EtOAc (10 mL). The aqueous layer was acidified (pH = 1–2) 
with KHSO4 solution and extracted 3 times with EtOAc. The combined organic layers 
were dried and concentrated in vacuo to afford 2.109 as a white solid (663 mg, 99%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 8.01 (s, 1H, H-3), 5.33 (br s, 1H, NH), 4.67–4.59 
(m, 2H, H-1), 3.89 (d, J=11.7 Hz, 1H, H-6), 3.38 (d, J=11.7 Hz, 1H, H-6), 1.69 (s, 3H, 
H-8), 1.48 (s, 9H, CMe3); ES
+ MS m/z 373 ([M+NH4]
+). 
The spectroscopic data are consistent with that
102 reported in the literature. 
 
 
(3S,4E)-2-(Trimethylsilyl)ethyl-3-[(S)-2-((R)-2-[2-[(tert-butoxycarbonyl)methyl]-
thiazol-4-yl]-4-methyl-4,5-dihydrothiazole-4-carboxamido)-3-methylbutanoyl-oxy]-
7-(tritylthio) hept-4-enoate (2.177)  
 
Amine 2.86 was prepared by deprotection of the Fmoc derivative: the Fmoc carbamate 
(422  mg,  0.50  mmol,  1  equiv)  was  dissolved  in  anhydrous  acetonitrile  (4  mL)  and 
diethylamine (260 µl, 2.51 mmol, 5 equiv) was added. After stirring for 2 h, the reaction     Experimental Procedures For Chapter 2 
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mixture was concentrated in vacuo and the free amine purified by flash chromatography 
(EtOAc/hexane 1:1). 
To a solution of thiazole-thiazoline compound 2.109 (191 mg, 0.54 mmol, 1.1 equiv) in 
anhydrous CH2Cl2 (10 mL) cooled at 0 °C, were added PyBOP (345 mg, 0.58 mmol, 
1.1  equiv)  and  Hünig’s  base  (254  µL,  1.46  mmol,  3  equiv).  After  10  min,  amine 
previously deprotected (300 mg, 0.49 mmol, 1 equiv) in solution in CH2Cl2 (10 mL) 
was added dropwise. The reaction mixture was stirred at rt overnight and concentrated 
in vacuo. The crude material was purified by flash chromatography (EtOAc/hexane 3:7) 
to afford 2.177 as a white solid (351 mg, 77%).  
1H NMR (400 MHz, CDCl3) ʴ ppm 7.95 (s, 1H, H-13), 7.44–7.33 (m, 6H, HAr), 7.33–
7.12 (m, 9H, HAr), 5.74–5.55 (m, 2H, H-5; H-18), 5.38 (dd, J=15.6, 7.5 Hz, 1H, H-17), 
5.25 (br s, 1H, NH), 4.63 (d, J=6.0 Hz, 2H, H-15), 4.48 (dd, J=9.0, 5.0 Hz, 1H, H-7), 
4.25–4.06 (m, 2H, H-2), 3.80 (d, J=11.5 Hz, 1H, H-10), 3.33 (d, J=11.5 Hz, 1H, H-10), 
2.69 (dd, J=15.8, 7.8 Hz, 1H, H-4), 2.56 (dd, J=15.6, 5.5, Hz, 1H, H-4), 2.24–1.96 (m, 
5H, H-19; H-20; H-21), 1.59 (s, 3H, Me), 1.48 (s, 9H, CMe3), 1.01–0.93 (m, 2H, H-1), 
0.83 (d, J=7.0 Hz, 3H, H-22 or H-23), 0.76 (d, J=7.0 Hz, 3H, H-22 or H-23), 0.04 (s, 
9H, SiMe3); ES
+ MS m/z 979 ([M+Na]
+). 
The spectroscopic data are consistent with that
96 reported in the literature. 
 
 
S-Trityl macrocycle 2.168  
 
To a solution of the acyclic precursor 2.177 (338 mg, 0.35 mmol) in CH2Cl2 (17 mL) 
was added TFA (3.4 mL) at 0 ºC. The reaction mixture was warmed to rt and stirred 
overnight. The reaction mixture was concentrated in vacuo and then coevaporated with 
toluene to remove residual TFA. The crude amino acid (267 mg, 0.35 mmol, 1 equiv) 
was  then  dissolved  in  CH2Cl2  (20  mL)  and  added  dropwise  to  a  vigorously  stirred 
solution of Hünig’s base (369 µL, 2.12 mmol, 6 equiv), HOBt (95 mg, 0.71 mmol, 2     Experimental Procedures For Chapter 2 
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equiv) and HATU (269 mg, 0.71 mmol, 2 equiv) in anhydrous acetonitrile (250 mL). 
The reaction mixture was stirred overnight, and then concentrated in vacuo. The crude 
material was purified by flash chromatography (hexane/EtOAc 10:1 then 100% EtOAc) 
to afford 2.168 as a pale yellow solid (170 mg, 65%).  
1H NMR (400 MHz, CDCl3/CD3OD) ʴ ppm 7.80 (s, 1H, H-12), 7.51–7.14 (m, 15H, 
HAr), 7.11 (d, J=9.5 Hz, 1H, NH), 5.69 (dt, J=15.4, 6.6 Hz, 1H, H-19), 5.58 (t, J=7.5 
Hz, 1H, H-17), 5.39 (dd, J=15.6, 7.0 Hz, 1H, H-18), 5.19 (d, J=17.6 Hz, 1H, H-14), 
4.55 (dd, J=9.3, 3.3 Hz, 1H, H-2), 4.17 (d, J=17.6 Hz, 1H, H-14), 4.00 (d, J=11.5 Hz, 
1H, H-8), 3.30 (d, J=11.5 Hz, 1H, H-8), 2.90 (dd, J=16.3, 10.8 Hz, 1H, H-16), 2.59 (dd, 
J=16.1, 2.5 Hz, 1H, H-16), 2.26–2.14 (m, 2H, H-21), 2.14–1.96 (m, 3H, H-3; H-20), 
1.84 (s, 3H, H-9), 0.67 (d J=7.0 Hz, 3H, H-4 or H-5), 0.45 (d, J=6.5 Hz, 3H, H-4 or H-
5); ES
+ MS m/z 761 ([M+Na]
+). 
The spectroscopic data are consistent with that
96 reported in the literature. 
 
 
Largazole thiol (2.178) 
 
Macrocycle 2.168 (77.2 mg, 0.10 mmol, 1 equiv) was dissolved in anhydrous CH2Cl2 
(13 mL) and cooled to 0 ºC. The mixture was treated with Et3SiH (33 µL, 0.21 mmol, 2 
equiv) followed by TFA (515 µL, 6.93 mmol, 69 equiv). The reaction mixture was 
warmed  to  rt  and  stirred  for  2  h,  concentrated  in  vacuo  and  purified  by  flash 
chromatography with EtOAc as eluent to provide largazole thiol (2.178) as a white solid 
(41.2 mg, 79%).  
1H NMR (400 MHz, CDCl3) ʴ ppm 7.77 (s, 1H, H-12), 7.19 (d, J=9.5 Hz, 1H, NH), 
6.50 (d, J=7.0 Hz, 1H, NH), 5.92–5.77 (m, 1H, H-19), 5.69 (t, J=7.0 Hz, 1H, H-17), 
5.55 (dd, J=15.6, 7.0 Hz, 1H, H-18), 5.28 (dd, J=17.6, 9.5 Hz, 1H, H-14), 4.61 (dd, 
J=9.5, 3.5 Hz, 1H, H-2), 4.28 (dd, J=17.6, 3.0 Hz, 1H, H-14), 4.05 (d, J=11.0 Hz, 1H,     Experimental Procedures For Chapter 2 
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H-8), 3.29 (d, J=11.0 Hz, 1H, H-8), 2.87 (dd, J=16.6, 10.0 Hz, 1H, H-16), 2.71 (dd, 
J=16.3, 2.8 Hz, 1H, H-16), 2.57 (q, J=7.4 Hz, 2H, H-21), 2.45–2.29 (m, 2H, H-20), 
2.19–2.02 (m, 1H, H-3), 1.87 (s, 3H, H-9), 1.43 (t, J=7.8 Hz, 1H, SH), 0.70 (d, J=6.5 
Hz, 3H, H-4 or H-5), 0.54 (d, J=6.5 Hz, 3H, H-4 or H-5); ES
+ MS m/z 519 ([M+Na]
+).  
The spectroscopic data are consistent with that
96 reported in the literature. 
 
 
Largazole (2.18) 
 
To largazole thiol (20.6 mg, 42 µmol, 1 equiv) in CH2Cl2 (4 mL), was added Et3N (12 
µL, 83 µmol, 2 equiv) followed by octanoyl chloride (35.5 µL, 207 µmol, 5 equiv) at 0 
ºC. The reaction mixture was warmed to rt and stirred for 3 h. The reaction mixture was 
then quenched with CH3OH (5 mL) at 0 ºC, concentrated in vacuo and purified by flash 
chromatography using EtOAc as eluent to provide largazole (2.18) as a clear oil (16 mg, 
62%). 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.77 (s, 1H, H-12), 7.17 (d, J=9.0 Hz, 1H, NH), 
6.44 (dd, J=9.3, 2.8 Hz, 1H, NH), 5.90–5.77 (m, 1H, H-19), 5.72–5.64 (m, 1H, H-17), 
5.52 (dd, J=15.6, 7.0 Hz, 1H, H-18), 5.29 (dd, J=17.8, 9.3 Hz, 1H, H-14), 4.61 (dd, 
J=9.3, 3.3 Hz, 1H, H-2), 4.28 (dd, J=17.6, 3.0 Hz, 1H, H-14), 4.05 (d, J=11.5 Hz, 1H, 
H-8), 3.28 (d, J=11.5 Hz, 1H, H-8), 2.91 (t, J=7.5 Hz, 2H, H-21), 2.84 (dd, J=16.6, 10.5 
Hz, 1 H, H-16), 2.69 (dd, J=16.1, 2.5 Hz, 1H, H-16), 2.54 (t, J=7.5 Hz, 2H, H-23), 2.32 
(q, J=6.5 Hz, 2H, H-20), 2.11 (td, J=6.8, 3.5 Hz, 1H, H-3), 1.88 (s, 3H, H-9), 1.71–1.55 
(m, 2H, H-24), 1.37–1.19 (m, 8H, H-25; H-26; H-27; H-28), 0.88 (t, J=6.8 Hz, 3H, H-
29), 0.69 (d, J=7.0 Hz, 3H, H-4 or H-5), 0.53 (d, J=7.0 Hz, 3H, H-4 or H-5); 
13C NMR 
(100 MHz, CDCl3) ʴ ppm 199.4 (C, C-22), 173.5 (C, C-6), 169.4 (C, C-15), 168.8 (C, 
C-1), 167.9 (C, C-13), 164.3 (C, C-10), 147.4 (C, C-11), 132.7 (CH, C-19), 128.4 (CH, 
C-18), 124.2 (CH, C-12), 84.4 (C, C-7), 72.0 (CH, C-17), 57.8 (CH, C-2), 44.1 (CH2, C-
23), 43.3 (CH2, C-8), 41.1 (CH2, C-14), 40.5 (CH2, C-16), 34.2 (CH, C-3), 32.3 (CH2,     Experimental Procedures For Chapter 2 
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C-20), 31.6 (CH2, C-27), 29.0; 28.9 (2CH2, C-25;C-26), 27.9 (CH2, C-21), 25.6 (CH2, 
C-24), 24.1 (CH2, C-9), 22.6 (CH2, C-28), 18.8 (CH3, C-4 or C-5), 16.7 (CH3, C-4 or C-
5), 14.0 (CH3, C-29); ES
+ MS m/z 645 ([M+Na]
+), 686 ([M+Na+CH3CN]
+). 
The spectroscopic data are consistent with that
80 reported in the literature.     Experimental Procedures For Chapter 2 
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Synthesis of largazole analogues 
 
(S,E)-2-(Trimethylsilyl)ethyl  3-(2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-
acetoxy)-7-(tritylthio)hept-4-enoate (2.184) 
 
The protected β-hydroxy ester 2.85 (200 mg, 0.39 mmol, 1 equiv) and N-Fmoc-glycine 
(126 mg, 0.42 mmol, 1.1 equiv) were dissolved in anhydrous CH2Cl2 (7 mL). DCC (96 
mg, 0.46 mmol, 1.2 equiv) and DMAP (4.7 mg, 0.04 mmol, 0.1 equiv) were added to 
the reaction mixture cooled to 0 ºC. The reaction mixture was stirred overnight. The 
precipitate was filtered and solvents were evaporated. The crude was purified by flash 
chromatography (EtOAc/hexane 5:95) to give 2.184 as a colourless oil (180 mg, 59%).  
[]D
23 –9.9 (c 0.54, CHCl3); IR 3368, 2964, 2918, 2843, 1735, 1520, 1448, 1247, 1172, 
1051, 858, 839 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.78 (d, J=7.5 Hz, 2H, HAr), 
7.60 (d, J=7.0 Hz, 2H, HAr), 7.46–7.15 (m, 19H, HAr), 5.76–5.57 (m, 2H, H-3; H-5), 
5.39 (dd, J=15.6, 7.0 Hz, 1H, H-4), 5.24 (br s, 1H, NH), 4.39 (d, J=7.0 Hz, 2H, H-13), 
4.24 (t, J=7.0 Hz, 1H, H-14), 4.16 (t, J=8.5 Hz, 2H, H-8), 3.96 (d, J=5.5 Hz, 2H, H-11), 
2.67 (dd, J=15.8, 8.3 Hz, 1H, H-6), 2.55 (dd, J=15.8, 5.3 Hz, 1H, H-6), 2.20 (t, J=7.5 
Hz, 2H, H-1), 2.08 (t, J=7.0 Hz, 2H, H-2), 0.97 (t, J=8.5 Hz, 2H, H-9), 0.04 (s, 9H, 
SiMe3); 
13C NMR (100 MHz, CDCl3) ʴ ppm 169.7 (C, CO), 168.9 (C, CO), 156.1 (C, 
CO), 144.8 (3C, CAr), 143.8 (2C, CAr), 141.3 (2C, CAr), 133.6 (CH, C-3), 129.6 (6CH, 
CAr), 127.9 (6CH, CAr), 127.7 (2CH, CAr), 127.6 (CH, C-4), 127.1 (2CH, CAr), 126.6 
(3CH, CAr), 125.1 (2CH, CAr), 120.0 (2CH, CAr), 71.9 (CH, C-5), 67.2 (CH2, C-13), 
66.6 (C, CPh3), 63.1 (CH2, C-8), 47.1 (CH, C-14), 42.8 (CH2, C-11), 39.6 (CH2, C-6), 
31.3; 31.1 (2CH2, C-1; C-2), 17.3 (CH2, C-9), –1.5 (3CH3, SiMe3); ES
+ MS m/z 820 
([M+Na]
+); HRMS (ESI) m/z calcd. for C48H51NNaO6SSi (M+Na)
+ 820.3099, found 
820.3090.  
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(S,E)-2-(Trimethylsilyl)ethyl  3-(2-((R)-2-(2-((tert-butoxycarbonylamino)methyl)-
thiazol-4-yl)-4-methyl-4,5-dihydrothiazole-4-carboxamido)acetoxy)-7-
(tritylthio)hept-4-enoate (2.186) 
 
Carbamate 2.184 (170 mg, 0.21 mmol, 1 equiv) was deprotected by stirring for 2 h in 
anhydrous acetonitrile (5 mL) and diethylamine (110 µl, 1.07 mmol, 5 equiv) followed 
by concentration in vacuo. To a solution of 2.109 (84 mg, 0.24 mmol, 1.1 equiv) in 
anhydrous CH2Cl2 (5 mL) cooled at 0 °C, PyBOP (151 mg, 0.26 mmol, 1.2 equiv) and 
Hünig’s base (112 µL, 0.64 mmol, 3 equiv) were added. After 10 min, the previous 
deprotected amine (123 mg, 0.21 mmol, 1 equiv) in solution in anhydrous CH2Cl2 (5 
mL)  was  added  dropwise.  The  reaction  mixture  was  stirred  at  rt  overnight  and 
concentrated  in  vacuo.  The  crude  material  was  purified  by  flash  chromatography 
(EtOAc/hexane 3:7) to afford 2.186 as a colourless oil (153 mg, 78%).  
[]D
24 –40.3 (c 0.27, CHCl3); IR 3342, 2971, 2952, 1727, 1671, 1599, 1512, 1444, 
1365, 1244, 1168, 858, 835 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.91 (s, 1H, H-
13), 7.47–7.34 (m, 6H, HAr), 7.34–7.12 (m, 9H, HAr), 5.73–5.54 (m, 2H, H-5; H-18), 
5.36 (dd, J=15.6, 7.0 Hz, 1H, H-17), 5.26 (br s, 1H, NH), 4.64 (d, J=6.0 Hz, 2H, H-15), 
4.22–4.09 (m, 2H, H-2), 4.02 (dd, J=7.5, 5.5 Hz, 2H, H-7), 3.76 (d, J=11.5 Hz, 1H, H-
10), 3.34 (d,  J=11.5  Hz, 1H, H-10), 2.66 (dd,  J=15.8, 8.3  Hz, 1H, H-4), 2.53 (dd, 
J=15.8, 5.3 Hz, 1H, H-4), 2.18 (t, J=7.0 Hz, 2H, H-20), 2.12–1.96 (m, 2H, H-19), 1.60 
(s, 3H, Me), 1.48 (s, 9H, CMe3), 1.07–0.88 (m, 2H, H-1), 0.04 (s, 9H, SiMe3); ES
+ MS 
m/z  937  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for  C47H58N4NaO7S3Si  (M+Na)
+ 
937.3129, found 937.3136.  
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(5R,11S)-5-Methyl-11-((E)-4-(tritylthio)but-1-en-1-yl)-10-oxa-3,17-dithia-
7,14,19,20-tetraazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione 
(2.188) 
 
Acyclic precursor 2.186 (138 mg, 0.15 mmol) was dissolved in CH2Cl2 (7 mL), cooled 
to 0 ºC and treated with TFA (1.5 mL). The reaction mixture was warmed to rt and 
stirred  overnight.  The  reaction  mixture  was  concentrated  in  vacuo  and  then 
coevaporated with toluene to remove residual TFA. The crude amino acid (108 mg, 0.15 
mmol, 1 equiv) was taken up in anhydrous CH2Cl2 (13 mL) and added dropwise to a 
vigorously stirred solution of Hünig’s base (158 µL, 0.90 mmol, 6 equiv), HOBt (41 
mg,  0.30  mmol,  2  equiv)  and  HATU  (115  mg,  0.30  mmol,  2  equiv)  in  anhydrous 
acetonitrile (110 mL). The reaction mixture was stirred overnight, and then concentrated 
in vacuo. The crude material was purified by flash chromatography (hexane/EtOAc 10:1 
then 100% EtOAc) to afford 2.188 as a pale yellow solid (55.4 mg, 53%).  
[]D
24 –51.2 (c 0.22, CH3OH); mp 136–138 ºC; IR 3628, 2923, 1734, 1670, 1541, 
1507, 1262, 840 cm
–1; 
1H NMR (400 MHz, CD3OD) ʴ ppm 8.02 (s, 1H, H-9), 7.40–
7.29 (m, 6H, HAr), 7.29–7.10 (m, 9H, HAr), 5.74–5.53 (m, 2H, H-14; H-16), 5.41 (dd, 
J=15.6, 7.0 Hz, 1H, H-15), 4.97 (d, J=17.6 Hz, 1H, H-11), 4.34 (d, J=17.6 Hz, 1H, H-
11), 4.06 (d, J=18.1 Hz, 1H, H-2), 3.97 (d, J=11.5 Hz, 1H, H-5), 3.73 (d, J=18.1 Hz, 
1H, H-2), 3.31 (d, J=11.5 Hz, 1H, H-5), 2.97 (dd, J=17.3, 11.3 Hz, 1H, H-13), 2.63 (dd, 
J=17.1, 2.0 Hz, 1H, H-13), 2.17 (t, J=6.0 Hz, 2H, H-18), 2.02 (q, J=6.5 Hz, 2H, H-17), 
1.74 (s, 3H, H-6); 
13C NMR (100 MHz, CD3OD) ʴ ppm 176.2 (C, CO), 172.8 (C, CO), 
169.7 (C, CO), 168.0 (C, C-10), 166.8 (C, C-7), 148.4 (C, C-8), 146.5 (3C, CAr), 134.4 
(CH, C-16), 130.9 (6CH, CAr), 129.5 (CH, C-15), 129.0 (6CH, CAr), 127.9 (3CH, CAr), 
126.7 (CH, C-9), 85.4 (C, C-4), 73.8 (CH, C-14), 67.9 (C, CPh3), 44.6 (CH2), 42.7 
(CH2), 42.3 (CH2), 40.2 (CH2), 32.5 (CH2), 32.4 (CH2), 25.5 (CH3, C-6); ES
+ MS m/z 
719  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for  C37H36N4NaO4S3  (M+Na)
+  719.1791, 
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(5R,11S)-11-((E)-4-Mercaptobut-1-en-1-yl)-5-methyl-10-oxa-3,17-dithia-7,14,19,20-
tetra-azatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione (2.179) 
 
S-Trityl macrocycle 2.188 (45.3 mg, 65 µmol, 1 equiv) was dissolved in CH2Cl2 (8 mL) 
and cooled to 0 ºC and successively treated with Et3SiH (21 µL, 130 µmol, 2 equiv) and 
TFA (320 µL, 6.93 mmol, 64 equiv). The reaction mixture was warmed to rt and stirred 
for 2 h, before being concentrated and purified by flash chromatography with EtOAc as 
eluent to provide 2.179 as a white solid (6 mg, 20%).  
[]D
24 +9.7 (c 0.24, CH3OH); mp 102–104 ºC; IR 3380, 2964, 2930, 2843, 1750, 1678, 
1591, 1512, 1262, 1187, 1043 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.74 (s, 1H, 
H-9), 7.09 (br s, 1H, NH), 6.41 (br s, 1H, NH), 5.94–5.71 (m, 2H, H-14; H-16), 5.52 
(dd, J=15.5, 7.3 Hz, 1H, H-15), 5.23 (dd, J=17.4, 8.9 Hz, 1H, H-11), 4.27 (dd, J=17.3, 
4.0 Hz, 1H, H-11), 4.21–4.07 (m, 2H, H-2; H-5), 3.88 (dd, J=18.8, 3.1 Hz, 1H, H-2), 
3.25 (d, J=11.3 Hz, 1H, H-5), 2.92 (dd, J=16.7, 11.0 Hz, 1H, H-13), 2.69 (d, J=15.2 Hz, 
1H, H-13), 2.58 (q, J=7.4 Hz, 2H, H-18), 2.37 (q, J=6.7 Hz, 2H, H-17), 1.84 (s, 3H, H-
6), 1.39 (t, J=7.8 Hz, 1H, SH); 
13C NMR (100 MHz, CDCl3) ʴ ppm 173.8 (C, CO), 
169.5 (C, CO), 167.7 (C, CO), 167.5 (C, C-10), 166.2 (C, C-7), 135.4 (C, C-8), 133.1 
(CH, C-16), 128.8 (CH, C-15), 124.6 (CH, C-9), 84.3 (C, C-4), 72.5 (CH, C-14), 43.7 
(CH2), 42.2 (CH2), 41.3 (CH2), 40.2 (CH2), 36.2 (CH2), 25.3 (CH3, C-6), 23.8 (CH2); 
ES
+ MS m/z 477 ([M+Na]
+); HRMS (ESI) m/z calcd. for C18H22N4NaO4S3 (M+Na)
+ 
477.0695, found 477.0702.  
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(S,E)-2-(Trimethylsilyl)ethyl  3-(3-(((9H-fluoren-9-yl)methoxy)  carbonylamino)-
propa-noy-loxy)-7-(tritylthio)hept-4-enoate (2.185) 
 
The  protected  β-hydroxy  ester  2.85  (208  mg,  0.40  mmol,  1  equiv)  and  N-Fmoc--
alanine (137 mg, 0.44 mmol, 1.1 equiv) were dissolved in anhydrous CH2Cl2 (8 mL), 
cooled to 0º C and DCC (99 mg, 0.48 mmol, 1.2 equiv) and DMAP (4.9 mg, 0.04 
mmol, 0.1 equiv) were then added. The reaction mixture was stirred overnight. The 
precipitate was filtered and solvents were evaporated. The crude was purified by flash 
chromatography (EtOAc/hexane 5:95) to give 2.185 as a colourless oil (207 mg, 64%).  
[]D
23 –9.9 (c 0.56, CHCl3); IR 3376, 3058, 2949, 1724, 1504, 1455, 1244, 1164, 1081, 
1066, 1036, 990, 975, 862, 835 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.75 (d, 
J=7.5 Hz, 2H, HAr), 7.59 (d, J=7.0 Hz, 2H, HAr), 7.52–7.34 (m, 19H, HAr), 5.70–5.53 
(m, 2H, H-3; H-5), 5.48 (br s, 1H, NH), 5.38 (dd, J=15.6, 7.0 Hz, 1H, H-4), 4.34 (d, 
J=7.0 Hz, 2H, H-14), 4.28–4.07 (m, 3H, H-8; H-15), 3.50–3.40 (m, 2H, H-12), 2.69–
2.46 (m, 4H, H-6; H-11), 2.19 (t, J=7.0 Hz, 2H, H-1), 2.07 (t, J=6.5 Hz, 2H, H-2), 0.95 
(t, J=8.5 Hz, 2H, H-9), 0.01 (s, 9H, SiMe3); 
13C NMR (100 MHz, CDCl3) ʴ ppm 171.2 
(C, CO), 170.1 (C, CO), 156.3 (C, CO), 144.8 (3C, CAr), 144.0 (2C, CAr), 141.3 (2C, 
CAr), 133.1 (CH, C-3), 129.6 (6CH, CAr), 128.0 (CH, C-4), 127.9 (6CH, CAr), 127.7 
(2CH, CAr), 127.0 (2CH, CAr), 126.6 (3CH, CAr), 125.1 (2CH, CAr), 119.9 (2CH, CAr), 
70.9 (CH, C-5), 66.8 (CH2, C-14), 66.6 (C, CPh3), 63.1 (CH2, C-8), 47.2 (CH, C-15), 
39.7 (CH2, C-6), 36.7 (CH2, C-12), 34.8 (CH2, C-11), 31.3, 31.2 (2CH2, C-1; C-2), 17.3 
(CH2, C-9), –1.5 (3CH3, SiMe3); ES
+ MS m/z 834 ([M+Na]
+). HRMS (ESI) m/z calcd. 
for C49H53NNaO6SSi (M+Na)
+ 834.3255, found 834.3270.  
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(S,E)-2-(Trimethylsilyl)ethyl  3-(3-((R)-2-(2-((tert-butoxycarbonylamino)methyl)-
thiazol-4-yl)-4-methyl-4,5-dihydrothiazole-4-carboxamido)propanoyloxy)-7-
(tritylthio)hept-4-enoate (2.187) 
 
Carbamate 2.185 (185 mg, 0.23 mmol, 1 equiv) was dissolved in anhydrous acetonitrile 
(5  mL)  and  diethylamine  (118  µl,  1.14  mmol,  5  equiv)  was  added  to  the  reaction 
mixture. After stirring for 2 h, the reaction mixture was concentrated in vacuo.  
To a solution of 2.109 (90 mg, 0.25 mmol, 1.1 equiv) in anhydrous CH2Cl2 (5 mL) 
cooled at 0 °C, PyBOP (162 mg, 0.28 mmol, 1.2 equiv) and Hünig’s base (120 µL, 0.69 
mmol, 3 equiv) were added. After 15 min, the previous deprotected amine (135 mg, 
0.23 mmol, 1 equiv) in anhydrous CH2Cl2 (5 mL) was added dropwise. The reaction 
mixture was stirred at rt overnight and concentrated in vacuo. The crude material was 
purified by flash chromatography (EtOAc/hexane 3:7) to afford 2.187 as a colourless oil 
(175 mg, 82%).  
[]D
25 –39.8 (c 0.61, CHCl3); IR 3361, 2967, 2941, 2926, 1724, 1659, 1520, 1440, 
1368, 1259, 1168, 1032, 866, 835 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.97 (br s, 
1H, H-14), 7.39 (d, J=7.5 Hz, 6H, HAr), 7.33–7.12 (m, 9H, HAr), 5.57 (dt, J=14.6, 7.5 
Hz, 2H, H-5; H-19), 5.35 (dd, J=15.1, 7.0 Hz, 1H, H-18), 5.28 (br s, 1H, NH), 4.63 (d, 
J=5.5 Hz, 2H, H-16), 4.21–4.06 (m, 2H, H-2), 3.76 (d, J=11.5 Hz, 1H, H-11), 3.59–3.43 
(m, 2H, H-8), 3.33 (d, J=11.5 Hz, 1H, H-11), 2.62 (dd, J=15.8, 7.8 Hz, 1H, H-4), 2.51 
(dt, J=10.3, 5.5 Hz, 3H, H-4; H-7), 2.18 (t, J=7.5 Hz, 2H, H-21), 2.08–1.95 (m, 2H, H-
20), 1.57 (s, 3H, Me), 1.48 (s, 9H, CMe3), 1.04–0.87 (m, 2H, H-1), 0.03 (s, 9H, SiMe3); 
13C NMR (100 MHz, CDCl3) ʴ ppm 174.5 (C), 170.8 (C), 169.9 (2C), 165.5 (C), 154.3 
(C), 144.8 (3C, CAr), 132.9 (CH, C-19), 129.6 (6CH, CAr), 128.1 (CH, C-18), 127.9 
(6CH, CAr), 126.6 (3CH, CAr), 122.1 (CH, C-14), 85.0 (C, C-10), 70.8 (CH, C-5), 66.6 
(C, CPh3), 63.0 (CH2), 42.3 (CH2), 41.3 (CH2), 39.7 (CH2), 34.9 (CH2), 34.2 (CH2), 
31.3 (CH2), 31.2 (CH2), 28.3 (3CH3, CMe3), 24.8 (CH3, Me), 17.3 (CH2, C-1), –1.5     Experimental Procedures For Chapter 2 
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(3CH3,  SiMe3);  ES
+  MS  m/z  951  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for 
C48H60N4NaO7S3Si (M+Na)
+ 951.3286, found 951.3287.  
 
 
(5R,12S)-5-Methyl-12-((E)-4-(tritylthio)but-1-en-1-yl)-11-oxa-3,18-dithia-
7,15,20,21-tetraazatricyclo[15.2.1.12,5]henicosa-1(19),2(21),17(20)-triene-6,10,14-
trione (2.189) 
 
Acyclic  precursor  2.187  (152  mg,  0.16  mmol)  was  dissolved  in  CH2Cl2  (7.6  mL), 
cooled to 0 ºC and treated with TFA (1.6 mL). The reaction mixture was warmed to rt, 
stirred overnight, concentrated in vacuo and then coevaporated with toluene to remove 
residual TFA. The crude amino acid (120 mg, 0.17 mmol, 1 equiv) was then taken up in 
anhydrous  CH2Cl2  (14  mL)  and  added  dropwise  to  a  vigorously  stirred  solution  of 
Hünig’s base (172 µL, 0.99 mmol, 6 equiv), HOBt (45 mg, 0.33 mmol, 2 equiv) and 
HATU (125 mg, 0.33 mmol, 2 equiv) in anhydrous acetonitrile (120 mL). The reaction 
mixture  was  stirred  overnight,  concentrated  in  vacuo  and  the  crude  material  was 
purified by flash chromatography (hexane/EtOAc 10:1 then 100% EtOAc) to afford 
2.189 as a colourless oil (20 mg, 17%).  
[]D
24 +37.5 (c 0.01, CH3OH); IR 2960, 2926, 2850, 1739, 1671, 1463, 1266, 1085, 
1028, 805 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.71 (s, 1H, H-10), 7.36–7.16 (m, 
15H, HAr), 6.96 (br s, 1H, NH), 6.09 (dd, J=15.6, 7.5 Hz, 1H), 5.73–5.59 (m, 1H), 5.55 
(td, J=7.2, 3.7 Hz, 1H), 4.99 (dd, J=16.8, 7.8 Hz, 1H, H-12), 4.03 (d, J=11.5 Hz, 1H, H-
6), 3.94 (dd, J=17.1, 4.0 Hz, 1H, H-12), 3.49 (d, J=4.0 Hz, 2H, H-3), 3.33 (d, J=11.5 
Hz, 1H, H-6), 2.78–2.61 (m, 2H, H-2 or H-14), 2.56–2.42 (m, 2H, H-2 or H-14), 2.39–
2.22 (m, 2H, H-19), 2.18–1.95 (m, 2H, H-18), 1.68 (s, 3H, H-7);  
13C NMR (100 MHz, CDCl3) ʴ ppm 174.1 (C, CO), 171.5 (C, CO), 169.7 (C, CO), 
167.5 (C, C-11), 162.0 (C, C-8), 148.0 (C, C-9), 144.7 (3C, CAr), 132.0 (CH, C-17),     Experimental Procedures For Chapter 2 
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129.9 (CH, C-16), 129.6 (6CH, CAr), 127.9 (6CH, CAr), 126.7 (3CH, CAr), 124.1 (CH, 
C-10), 84.6 (C, C-5), 73.0 (CH, C-15), 66.9 (C, CPh3), 42.7 (CH2), 42.3 (CH2), 40.9 
(CH2), 35.4 (CH2), 33.8 (CH2), 31.4 (CH2), 31.3 (CH2), 25.5 (CH3, C-7); ES
+ MS m/z 
733  ([M+Na]
+);  HRMS  (ESI)  m/z  calcd.  for  C38H38N4NaO4S3  (M+Na)
+  733.1947, 
found 733.1947.  
 
 
(5R,12S)-12-((E)-4-Mercaptobut-1-en-1-yl)-5-methyl-11-oxa-3,18-dithia-7,15,20,21-
tetra-azatricyclo[15.2.1.12,5]henicosa-1(19),2(21),17(20)-triene-6,10,14-trione 
(2.180) 
 
S-Trityl macrocycle 2.189 (16.1 mg, 23 µmol, 1 equiv) was dissolved in CH2Cl2 (5.5 
mL) and cooled to 0 ºC. The mixture was successively treated with Et3SiH (10 µL, 130 
µmol, 2.7 equiv) and TFA (320 µL, 6.93 mmol, 64 equiv). The reaction mixture was 
warmed  to  rt  and  stirred  for  2  h,  before  being  concentrated  and  purified  by  flash 
chromatography with EtOAc as eluent to provide 2.180 as a white solid (9 mg, 85%).  
[]D
24 +1.6 (c 0.36, CH3OH); mp 80–82 ºC; IR 3353, 2926, 2854, 1739, 1671, 1542, 
1179, 1039 cm
–1; 
1H NMR (400 MHz, CDCl3/CD3OD) ʴ ppm 7.78 (br s, 1H, NH), 
7.65 (s, 1H, H-10), 7.19 (br s, 1H, NH), 5.65 (t, J=5.0 Hz, 2H, H-16; H-17), 5.51–5.34 
(m, 1H, H-15), 3.92 (d, J=11.5 Hz, 1H, H-6), 3.39 (q, J=5.0 Hz, 2H, H-3), 3.24 (d, 
J=11.5 Hz, 1H, H-6), 2.72 (dd, J=15.8, 6.8 Hz, 1H, H-14), 2.58–2.34 (m, 5H, H-2; H-
14;  H-19),  2.34–2.15  (m,  2H,  H-18),  1.65  (s,  3H,  H-7); 
13C  NMR  (100  MHz, 
CDCl3/CD3OD) ʴ ppm 174.4 (C, CO), 171.3 (C, CO), 170.8 (C, CO), 167.8 (C, C-11), 
163.3 (C, C-8), 147.5 (C, C-9), 131.2 (CH, C-17), 129.9 (CH, C-16), 124.1 (CH, C-10), 
84.1 (C, C-5), 72.6 (CH, C-15), 42.1 (CH2), 41.9 (CH2), 40.5 (CH2), 35.9 (CH2), 34.8 
(CH2), 33.1 (CH2), 25.1 (CH3, C-7), 23.4 (CH2); ES
+ MS m/z 491 ([M+Na]
+); HRMS 
(ESI) m/z calcd. for C19H24N4NaO4S3 (M+Na)
+ 491.0852, found 491.0850.      Experimental Procedures For Chapter 2 
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Methyl  2-(2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxamido)-2-
methylpropanoate (2.190) 
 
To a solution of 2.147 (200 mg, 0.77 mmol, 1.1 equiv) in CH2Cl2 (10 mL) cooled at 0 
°C, PyBOP (549 mg, 0.93 mmol, 1.1 equiv) and Hünig’s base (405 µL, 2.33 mmol, 3 
equiv) were added. After 10 min, 2-aminoisobutyric acid methyl ester hydrochloride 
(108 mg, 0.70 mmol, 1 equiv) in solution in CH2Cl2 (10 mL) was added dropwise. The 
reaction  mixture  was  stirred  at  rt  overnight  and  concentrated  in  vacuo.  The  crude 
material was purified by flash chromatography (EtOAc/hexane 3:7) to afford 2.190 as a 
white solid (244 mg, 97%).  
mp 91.7–93.6 ºC; IR 3338, 2986, 2933, 1746, 1712, 1667, 1538, 1448, 1368, 1285, 
1247, 1149 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.00 (s, 1H, H-3), 7.74 (br s, 1H, 
NH), 5.28 (br s, 1H, NH), 4.60 (d, J=5.9 Hz, 2H, H-1), 3.77 (s, 3H, H-8), 1.67 (s, 6H, 
CMe2), 1.48 (s, 9H, CMe3); 
13C NMR (75 MHz, CDCl3) ʴ ppm 174.7 (C, CO), 169.2 
(C), 160.2 (C), 150.0 (C), 149.8 (C), 123.6 (CH, C-3), 80.5 (C, CMe3), 56.4 (C, C-6), 
52.7 (CH3, C-8), 42.3 (CH2, C-1), 28.3 (3CH3, CMe3), 25.0 (2CH3, CMe2); ES
+ MS m/z 
380 ([M+Na]
+); HRMS (ESI) m/z calcd. for C15H23N3NaO5S (M+Na)
+ 380.1251, found 
380.1249.  
 
 
2-(2-((tert-Butoxycarbonylamino)methyl)thiazole-4-carboxamido)-2-methyl-
propanoic acid (2.191) 
 
To a solution of 2.190 (242 mg, 0.68 mmol, 1 equiv) in 8 mL of THF/water (3:1) at 0 
°C was added LiOH (49 mg, 2.03 mmol, 3 equiv). The reaction mixture was stirred at rt     Experimental Procedures For Chapter 2 
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overnight. The solution was diluted with water (3 mL) and acidified to pH 1–2 with a 
saturated KHSO4 solution. This aqueous layer was extracted twice with EtOAc (10 mL). 
The  combined  organic  layers  were  washed  with  brine,  dried  over  MgSO4  and 
concentrated in vacuo to provide 2.191 as a yellow solid (225 mg, 96%).  
mp 171–173 ºC; IR 3342, 2930, 2850, 2363, 2340, 1712, 1656, 1542, 1455, 1376, 
1278, 1251, 1160 cm
–1; 
1H NMR (400 MHz, CD3OD) ʴ ppm 8.10 (s, 1H, H-3) 4.55 (s, 
2H, H-1) 1.66 (s, 6H, CMe2) 1.50 (s, 9H, CMe3); 
13C NMR (100 MHz, CD3OD) ʴ 
ppm 177.8 (C, CO), 173.0 (C), 162.7 (C), 158.5 (C), 150.9 (C), 124.9 (CH, C-3), 81.1 
(C, CMe3), 57.7 (C, C-6), 43.3 (CH2, C-1), 28.8 (3CH3, CMe3), 25.3 (2CH3, CMe2); 
ES
+ MS m/z 366 ([M+Na]
+); HRMS (ESI) m/z calcd. for C14H21N3NaO5S (M+Na)
+ 
366.1094, found 366.1094.  
 
 
(S,E)-2-(Trimethylsilyl)ethyl  3-((S)-2-(2-(2-((tert-butoxycarbonylamino)methyl)-
thiazole-4-carboxamido)-2-methylpropanamido)-3-methylbutanoyloxy)-7-
(tritylthio)hept-4-enoate (2.192) 
 
Carbamate 2.86 (371 mg, 0.44 mmol) was dissolved in anhydrous acetonitrile (4 mL) 
and diethylamine (229 µl, 2.21 mmol). After stirring for 2 h, the reaction mixture was 
concentrated  in  vacuo.  The  free  amine  was  purified  by  flash  chromatography 
(EtOAc/hexane 1:1).  
To a solution of 2.191 (86.2 mg, 0.25 mmol, 1.1 equiv) in anhydrous CH2Cl2 (5 mL) 
cooled to 0 °C, PyBOP (162 mg, 0.27 mmol, 1.2 equiv) and Hünig’s base (119 µL, 0.69 
mmol, 3 equiv) were added. After 10 min, the previous deprotected amine (141 mg, 
0.23 mmol, 1 equiv) in solution in CH2Cl2 (5 mL) was added dropwise. The reaction 
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purified by flash chromatography (EtOAc/hexane 3:7) to afford 2.192 as a white solid 
(134 mg, 62%).  
[]D
25 +5.4 (c 0.26, CHCl3); mp 61–63 ºC; IR 3338, 2960, 2926, 1731, 1682, 1535, 
1497, 1444, 1391, 1365, 1251, 1172, 1028 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 
8.10 (s, 1H, H-17), 7.81 (s, 1H, NH), 7.54–7.40 (m, 6H, HAr), 7.40–7.22 (m, 9H, HAr), 
7.19 (d, J=8.5 Hz, 1H, NH), 5.82–5.57 (m, 2H, H-5; H-22), 5.41 (dd, J=15.6, 7.5 Hz, 
1H, H-21), 5.34 (br s, 1H, NH), 4.66 (d, J=5.5 Hz, 2H, H-19), 4.58 (dd, J=8.5, 4.0 Hz, 
1H, H-7), 4.30–4.09 (m, 2H, H-2), 2.72 (dd, J=15.8, 7.8 Hz, 1H, H-4), 2.58 (dd, J=15.6, 
6.0 Hz, 1H, H-4), 2.35–2.15 (m, 3H, H-8; H-24), 2.09 (q, J=6.5 Hz, 2H, H-23), 1.73 (s, 
3H, H-13 or H-14), 1.76 (s, 3H, H-13 or H-14), 1.55 (s, 9H, CMe3), 1.09–0.79 (m, 8H, 
H-1; H-9; H-10), 0.10 (s, 9H, SiMe3); 
13C NMR (100 MHz, CDCl3) ʴ ppm 173.9 (C), 
170.7 (C), 169.6 (C), 169.4 (C), 160.7 (C), 155.6 (C), 149.8 (C), 144.8 (3C, CAr), 133.7 
(CH, C-22), 129.5 (6CH, CAr), 127.83 (6CH, CAr), 127.78 (CH, C-21), 126.6 (3CH, 
CAr), 123.8 (CH, C-17), 80.5 (C, C-12), 71.6 (CH, C-5), 66.6 (C, CPh3), 63.1 (CH2), 
57.6 (C, C-12), 57.1 (CH, C-7), 42.3 (CH2), 39.7 (CH2), 31.3 (CH, C-8), 31.1 (2CH2), 
28.3 (3CH3, CMe3), 25.8 (CH3, C-13 or C-14), 25.0 (CH3, C-13 or C-14), 19.0 (CH3, C-
9 or C-10), 17.4 (CH3, C-9 or C-10), 17.3 (CH2, C-1), –1.5 (3CH3, SiMe3); ES
+ MS m/z 
965 ([M+Na]
+). HRMS (ESI) m/z calcd. for C50H66N4NaO8S2Si (M+Na)
+ 965.3984, 
found 965.3964. 
 
 
(7S,10S,E)-7-Isopropyl-4,4-dimethyl-10-(4-(tritylthio)but-1-enyl)-9-oxa-16-thia-
3,6,13,18-tetraaza-bicyclo[13.2.1]octadec-1(17)-ene-2,5,8,12-tetraone (2.193) 
 
Acyclic precursor 2.192 (218 mg, 0.23 mmol) was dissolved in CH2Cl2 (11 mL), cooled 
to 0 ºC and treated with TFA (2.3 mL). The reaction mixture was warmed to rt, stirred 
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TFA. The crude amino acid (172 mg, 0.23 mmol, 1 equiv) was then taken up in CH2Cl2 
(20 mL) and added dropwise to a vigorously stirred solution of Hünig’s base (242 µL, 
1.39 mmol, 6 equiv), HOBt (63 mg, 0.46 mmol, 2 equiv) and HATU (176 mg, 0.46 
mmol, 2 equiv) in acetonitrile (165 mL). The reaction mixture was stirred overnight, 
and  then  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography (hexane/ EtOAc 10:1 to 100% EtOAc) to afford 2.193 as a pale yellow 
solid (108 mg, 64%).  
[]D
25 +32.3 (c 0.34, CHCl3); mp 132–134 ºC; IR 3364, 2967, 2926, 2854, 1739, 1678, 
1542, 1493, 1444, 1255, 1179, 839 cm
–1; 
1H NMR (400 MHz, CDCl3/CD3OD) ʴ ppm 
8.32 (s, 1H, H-12), 8.05 (d, J=9.0 Hz, 1H, NH), 7.87 (d, J=2.5 Hz, 1H, NH), 7.64–7.37 
(m, 15H, HAr), 6.00–5.82 (m, 2H, H-17; H-19), 5.75 (dd, J=15.6, 7.0 Hz, 1H, H-18), 
5.26 (d, J=17.6 Hz, 1H, H-14), 4.78 (dd, J=9.3, 4.8 Hz, 1H, H-2), 4.47 (d, J=17.1 Hz, 
1H, H-14), 3.06 (dd, J=17.1, 9.5 Hz, 1H, H-16), 2.90 (d, J=16.1 Hz, 1H, H-16), 2.60–
2.40 (m, 3H, H-3 or H-20; H-21), 2.40–2.17 (m, 2H, H-3 or H-20), 2.12 (s, 3H, H-8 or 
H-9), 1.86 (s, 3H, H-8 or H-9), 1.14 (d, J=7.0 Hz, 3H, H-4 or H-5), 0.97 (d, J=7.0 Hz, 
3H, H-4 or H-5); 
13C NMR (100 MHz, CDCl3/CD3OD) ʴ ppm 175.9 (C), 171.8 (C), 
170.7 (C), 167.9 (C), 163.1 (C), 149.9 (C, C-11), 145.5 (3C, CAr), 133.7 (CH, C-19), 
130.3 (6CH, CAr), 128.9 (CH, C-18), 128.6 (6CH, CAr), 127.4 (3CH, CAr), 124.0 (CH, 
C-12), 72.7 (CH, C-17), 67.5 (C, CPh3), 60.0 (C, C-7), 58.4 (CH, C-2), 41.1 (CH2, C-
14), 40.8 (CH2, C-16), 32.0; 31.9 (CH2, C-20; C-21), 31.8 (CH, C-3), 25.6 (CH3, C-8 or 
C-9), 25.3 (CH3, C-8 or C-9), 19.8 (CH3, C-4 or C-5), 17.5 (CH3, C-4 or C-5); ES
+ MS 
m/z 747 ([M+Na]
+); HRMS (ESI) m/z calcd. for C40H44N4NaO5S2 (M+Na)
+ 747.2645, 
found 747.2641. 
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(7S,10S,E)-7-Isopropyl-10-(4-mercaptobut-1-enyl)-4,4-dimethyl-9-oxa-16-thia-
3,6,13,18-tetraaza-bicyclo[13.2.1]octadec-1(17)-ene-2,5,8,12-tetraone (2.181) 
 
S-Trityl macrocycle 2.193 (73.1 mg, 0.10 mmol, 1 equiv) was dissolved in CH2Cl2 (12 
mL) and cooled to 0 ºC. The mixture was successively treated with Et3SiH (32 µL, 0.20 
mmol, 2 equiv) and TFA (495 µL, 6.93 mmol, 61 equiv). The reaction mixture was 
warmed  to  rt  and  stirred  for  2  h,  before  being  concentrated  and  purified  by  flash 
chromatography with EtOAc as eluent to provide 2.181 as a white solid (6 mg, 12%).  
[]D
25 +61.3 (c 0.24, CHCl3); mp 56–58 ºC; IR 3334, 2960, 2926, 2854, 1734, 1678, 
1542, 1463, 1383, 1256, 974 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 8.03 (s, 1H, H-
12), 7.65 (br s, 1H, NH), 6.60–6.39 (m, 2H, NH), 5.84–5.70 (m, 3H, H-17; H-18 H-19), 
5.16  (dd,  J=17.3,  7.8  Hz,  1H,  H-14),  4.64  (dd,  J=9.5,  4.0  Hz,  1H,  H-2),  4.37  (dd, 
J=17.6, 4.0 Hz, 1H, H-14), 2.86–2.62 (m, 2H, H-16), 2.62–2.46 (m, 2H, H-21), 2.46–
2.21 (m, 3H, H-3; H-20), 1.90 (s, 3H, H-8 or H-9), 1.62 (s, 3H, H-8 or H-9), 1.35 (t, 
J=7.5 Hz, 1H, SH), 0.91 (d, J=6.5 Hz, 3H, H-4 or H-5), 0.72 (d, J=7.0 Hz, 3H, H-4 or 
H-5); 
13C NMR (100 MHz, CDCl3) ʴ ppm 174.4 (C), 170.0 (C), 168.9 (C), 166.9 (C), 
161.0 (C), 149.5 (C, C-11), 132.1 (CH, C-19), 129.0 (CH, C-18), 123.3 (CH, C-12), 
71.8 (CH, C-17), 59.6 (C, C-7), 57.4 (CH, C-2), 41.3 (CH2, C-14), 40.8 (CH2, C-16), 
36.0 (CH2, C-20), 31.3 (CH, C-3), 25.8 (2CH3, C-8; C-9), 23.8 (CH2, C-21), 19.1 (CH3, 
C-4 or C-5), 16.8 (CH3, C-4 or C-5); ES
+ MS m/z 505 ([M+Na]
+); HRMS (ESI) m/z 
calcd. for C21H30N4NaO5S2 (M+Na)
+ 505.1550, found 505.1551.  
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Boc-valine-largazole analogue 2.194 
 
To a solution of Boc-L-Valine (20 mg, 0.09 mmol, 2 equiv) in CH2Cl2 (2 mL) cooled at 
0 °C, PyBOP (53 mg, 0.09 mmol, 2 equiv) and Hünig’s base (16 µL, 0.09 mmol, 2 
equiv) were added. After 15 min, largazole thiol 2.178 (22.3 mg, 0.05 mmol, 1 equiv) in 
solution in CH2Cl2 (2 mL) was added dropwise. The reaction mixture was stirred at rt 
overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography (EtOAc/hexane 1:3) to afford 2.194 as a white solid (31 mg, 100%). 
[]D
24 +11.2 (c 0.23, MeOH); mp 132–134 ºC; IR 3361, 3300, 2971, 2930, 2850, 1720, 
1682, 1508, 1376, 1262, 1172, 1024, 839 cm
–1; 
1H NMR (400 MHz, CD3OD) ʴ ppm 
8.18 (s, 1H, H-12), 7.35 (d, J=9.5 Hz, 1H, NH), 5.94–5.79 (m, 1H, H-19), 5.73–5.58 (m, 
2H, H-17; H-18), 5.17 (d, J=17.6 Hz, 1H, H-14), 4.55 (dd, J=9.3, 3.3 Hz, 1H, H-2), 4.41 
(d, J=17.6 Hz, 1H, H-14), 4.09 (d, J=6.0 Hz, 1H, H-23), 3.98 (d, J=11.5 Hz, 1H, H-8), 
3.44 (d, J=11.5 Hz, 1H, H-8), 3.06 (dd, J=16.6, 10.5 Hz, 1H, H-16), 2.96 (t, J=7.0 Hz, 
2H, H-21), 2.75 (dd, J=16.3, 2.3 Hz, 1H, H-16), 2.36 (q, J=7.0 Hz, 2H, H-20), 2.23 (sxt, 
J=6.5 Hz, 1H, H-3 or H-24), 2.14 (quind, J=7.0, 3.5 Hz, 1H, H-3 or H-24), 1.87 (s, 3H, 
H-9), 1.51 (s, 9H, CMe3), 1.00 (d, J=6.5 Hz, 3H), 0.95 (d, J=7.0 Hz, 3H), 0.75 (d, J=6.5 
Hz, 3H), 0.55 (d, J=7.0 Hz, 3H); 
13C NMR (100 MHz, CDCl3) ʴ ppm 183.2 (C, CO), 
176.1 (C, CO), 172.4 (C, CO), 170.4 (C), 170.1 (C), 168.2 (C), 58.4 (C), 148.3 (C, C-
11),  133.9  (CH,  C-19),  130.1  (CH,  C-18),  126.9  (CH,  C-12),  81.0;  79.6  (2C,  C-7; 
CMe3), 74.1 (CH, C-17), 67.7 (CH, C-23), 59.2 (CH, C-2), 43.8 (CH2, C-8), 42.0 (CH2, 
C-14 or C-16), 40.7 (CH2, C-14 or C-16), 35.6 (CH, C-3), 33.4 (CH2, C-20), 31.9 (CH, 
C-24),  28.92  (3CH3, CMe3),  28.87  (CH2,  C-21),  24.5  (CH3, C-9),  19.9  (CH3),  19.8 
(CH3), 18.2 (CH3), 17.2 (CH3); ES
+ MS m/z 718 ([M+Na]
+); HRMS (ESI) m/z calcd. 
for C31H45N5NaO7S3 (M+Na)
+ 718.2373, found 718.2369. 
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Valine-largazole analogue 2.183 
 
To a solution of 2.194 (28.7 mg, 0.04 mmol, 1 equiv) in CH2Cl2 (2 mL), was added 
TFA (1 mL) at 0 ºC. The reaction mixture was stirred for 1 h, before being concentrated 
and  purified  by  flash  chromatography  using  CH2Cl2/hexane  (1:1)  to 
CH2Cl2/MeOH/NH3 96:3:1 as eluent to provide 2.183 as a white solid (18 mg, 73%). 
[]D
24 + 41.9 (c 0.17, MeOH); mp 76–78 ºC; IR 3380, 2967, 2926, 2877, 1735, 1682, 
1591,  1535,  1504,  1414,  1262,  1194,  1176,  1039,  975  cm
–1; 
1H  NMR  (400  MHz, 
CDCl3) ʴ ppm 8.18 (s, 1H, H-12), 7.34 (d, J=9.0 Hz, 1H, NH), 5.92–5.77 (m, 1H, H-
19), 5.72–5.59 (m, 2H, H-17; H-18), 5.15 (d, J=17.6 Hz, 1 H, H-14), 4.61–4.50 (m, 1H, 
H-2), 4.42 (d, J=17.6 Hz, 1H, H-14), 3.97 (d, J=11.5 Hz, 1H, H-8), 3.53–3.40 (m, 2H, 
H-8; H-23), 3.13–2.94 (m, 3H, H-16; H-21), 2.74 (dd, J=16.6, 2.5 Hz, 1H, H-16), 2.45–
2.31 (m, 2H, H-20), 2.20–2.07 (m, 2H, H-3; H-24), 1.97 (s, 2H, NH2), 1.87 (s, 3H, H-9), 
1.04 (d, J=7.0 Hz, 3H), 0.96 (d, J=6.5 Hz, 3H), 0.74 (d, J=7.0 Hz, 3H), 0.54 (d, J=6.5 
Hz, 3H); 
13C NMR (100 MHz, CDCl3) ʴ ppm 176.1 (C, CO), 176.0 (C, CO), 172.4 (C, 
CO), 170.4 (C), 170.1 (C), 168.2 (C), 148.3 (C), 133.6 (CH, C-19), 130.3 (CH, C-18), 
126.9 (CH, C-12), 85.3 (C, C-7), 74.1 (CH, C-17), 68.0 (CH, C-23), 59.1 (CH, C-2), 
43.8 (CH2, C-8), 41.9 (CH2, C-14 or C-16), 40.7 (CH2, C-14 or C-16), 35.6 (CH, C-3), 
33.5 (CH2, C-20), 33.4 (CH, C-24), 28.9 (CH2, C-21), 24.5 (CH3, C-9), 19.8 (2CH3), 
17.6 (CH3), 17.2 (CH3); ES
+ MS m/z 596 ([M+H]
+), 618 ([M+Na]
+). 
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5.3.2. Experimental procedures for thailandepsins and burkholdacs 
 
5.3.2.1. Towards the synthesis of first structures of thailandepsins  
(9H-Fluoren-9-yl)methyl  (S)-1-((R)-1-hydroxy-3-phenylpropan-2-ylamino)-1-oxo-
3-(tritylthio)propan-2-ylcarbamate (2.201) 
 
To  Fmoc-D-Cys(Tr)-OH  (500  mg,  0.9  mmol,  1  equiv)  in  CH2Cl2  (12  mL),  N-
methylmorpholine (282 µL, 2.6 mmol, 3 equiv), PyBOP (554 mg, 0.939 mmol, 1.1 
equiv) and HOBt (127 mg, 0.9 mmol, 1.1 equiv) were added at 0 °C under argon. (R)-
Phenylalaninol (173 mg, 1.1 mmol, 1.34 equiv) was added after 5 min. The reaction 
mixture was stirred at rt overnight and then concentrated in vacuo. The crude material 
was purified by flash chromatography (hexane/EtOAc 1:1) to afford 2.201 as a white 
solid (607 mg, 99%). 
[]D
25 +2.5 (c 0.17, CHCl3); mp 88–90 ºC; IR 3300, 3058, 3020, 2964, 1705, 1656, 
1523, 1493, 1448, 1262, 1032, 911 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.90 (t, 
J=6.5 Hz, 2H, HAr), 7.70 (d, J=6.5 Hz, 2H, HAr), 7.59–7.24 (m, 25H, HAr, NH), 6.05 (d, 
J=8.0 Hz, 1H, NH), 5.00 (d, J=7.0 Hz, 1H), 4.52 (d, J=6.5 Hz, 2H, H-8), 4.32 (t, J=6.5 
Hz, 1H, H-9), 4.25–4.15 (m, 1H), 3.85-3.73 (m, 2H), 3.64 (dd, J=11.0, 5.0 Hz, 1H), 
2.96  (dd,  J=13.6,  7.0  Hz,  1H,  H-5),  2.89  (dd,  J=14.1,  7.5  Hz,  1H,  H-5),  2.77  (dd, 
J=13.6, 7.5 Hz, 1H, H-1), 2.70 (dd, J=13.1, 5.5 Hz, 1H, H-1); 
13C NMR (100 MHz, 
CDCl3) ʴ ppm 170.3 (C, C=O), 155.9 (C, C=O), 144.3 (3C, CAr), 143.6 (2C, CAr), 
141.3 (2C, CAr), 137.3 (C, CAr), 129.5 (6CH, CAr), 129.1 (2CH, CAr), 128.6 (2CH, CAr), 
128.1 (6CH, CAr), 127.8 (2CH, CAr), 127.1 (2CH, CAr), 127.0 (3CH, CAr), 126.6 (CH, 
CAr), 125.0 (2CH, CAr), 120.0 (2CH, CAr), 67.4 (C, CPh3), 66.9 (CH2, C-6 or C-8), 63.6 
(CH2, C-6 or C-8), 54.3 (CH, C-2 or C-4), 53.1 (CH, C-2 or C-4), 47.1 (CH, C-9), 36.7     Experimental Procedures For Chapter 2 
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(CH2,  C-5),  33.6  (CH2,  C-1);  ES
+  MS  m/z  741  ([M+Na]
+);  HRMS  m/z  calcd.  for 
C46H42N2NaO4S (M+Na)
+ 741.2757, found 741.2743. 
 
 
(S)-2-Amino-N-((R)-1-hydroxy-3-phenylpropan-2-yl)-3-(tritylthio)propanamide 
(2.202) 
 
To  a  solution  of  the  2.201  (596  mg,  0.83  mmol,  1  equiv)  in  acetonitrile  (10  mL), 
diethylamine (430 µL, 4.15 mmol, 5 equiv) was added. After stirring for 2 h at rt, the 
reaction  mixture  was  concentrated.  The  crude  material  was  purified  by  flash 
chromatography (hexane/EtOAc 9:1 to 1:1 to 100% EtOAc) to afford 2.202 as a white 
solid (397 mg, 90%). 
 
 
(9H-Fluoren-9-yl)methyl  (R)-1-((S)-1-((R)-1-hydroxy-3-phenylpropan-2-ylamino)-
1-oxo-3-(tritylthio)propan-2-ylamino)-1-oxopropan-2-ylcarbamate (2.203) 
 
To  Fmoc-D-alanine  (383  mg,  1.23  mmol,  1.3  equiv)  in  CH2Cl2  (13  mL),  N-
methylmorpholine (303 µL, 2.76 mmol, 3 equiv), PyBOP (814 mg, 1.38 mmol, 1.5 
equiv) and HOBt (186 mg, 1.38 mmol, 1.5 equiv) were added at 0°C under argon. 
Compound 2.202 (456 mg, 0.92 mmol, 1 equiv) was added after 5 min. The reaction 
mixture was stirred at rt overnight and then concentrated in vacuo. The crude material 
was purified by flash chromatography (hexane/EtOAc 1:1) to afford 2.203 as a white 
solid (724 mg, 99%).     Experimental Procedures For Chapter 2 
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[]D
24 –25.1 (c 0.49, MeOH); mp 82–84 ºC; IR 3383, 3296, 3058, 3032, 2922, 1671, 
1512, 1444, 1300, 1247, 1077, 1036, 847 cm
–1; 
1H NMR (400 MHz, CD3OD) ʴ ppm 
7.97–7.13 (m, 28H, HAr), 4.41–4.26 (m, 2H), 4.23–4.03 (m, 4H), 3.54 (dd, J=5.0, 3.5 
Hz, 2H, H-6), 2.93 (dd, J=13.7, 6.1 Hz, 1H, H-5), 2.78 (dd, J=13.6, 7.9 Hz, 1H, H-5), 
2.72–2.61 (m, 1H, H-1), 2.57 (dd, J=12.5, 5.3 Hz, 1H, H-1), 1.37 (d, J=7.0 Hz, 2H, H-
9); 
13C NMR (100 MHz, CD3OD) ʴ ppm 175.5 (C, C=O), 171.9 (C, C=O), 158.8 (C, 
C=O), 145.9 (3C, CAr), 145.3 (2C, CAr), 142.7 (2C, CAr), 139.6 (C, CAr), 130.7 (6CH, 
CAr), 130.3 (2CH, CAr), 129.5 (2CH, CAr), 129.1 (6CH, CAr), 128.9 (2CH, CAr), 128.3 
(2CH, CAr), 128.0 (3CH, CAr), 127.4 (CH, CAr), 126.3 (2CH, CAr), 121.0 (2CH, CAr), 
68.4 (CH2, C-11), 68.1 (C, CPh3), 64.0 (CH2, C-6), 54.5; 54.4; 54.3; 52.7 (4CH, C-2; C-
4; C-8; C-12), 37.8 (CH2, C-5), 34.5 (CH2, C-1), 17.8 (CH3, C-9); ES
+ MS m/z 812 
([M+Na]
+); HRMS (ESI)  m/z  calcd.  for C49H47N3NaO5S (M+Na)
+ 812.3129,  found 
812.3120. 
 
 
(S)-2-((R)-2-Aminopropanamido)-N-((R)-1-hydroxy-3-phenylpropan-2-yl)-3-
(tritylthio)-propanamide (2.198) 
 
To a solution of the 2.203 (787 mg, 1 mmol, 1 equiv) in a mixture acetonitrile/CH2Cl2 
(20:5 mL), diethylamine (515 µL, 10 mmol, 10 equiv) was added. After stirring for 2 h 
at rt, the reaction mixture was concentrated. The crude material was purified by flash 
chromatography (hexane/EtOAc 9:1 to 1:1 to 100% EtOAc) to afford 2.198 as a white 
solid (413 mg, 73%). 
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5.3.2.2. Total synthesis of Cheng’s revised thailandepsin A  
(R)-Allyl 4-(tert-butoxycarbonylamino)-6-(methylthio)-3-oxohexanoate (2.221)  
 
To a solution of Boc-D-Met-OH (1 g, 4.0 mmol, 1 equiv) in CH2Cl2 (20 mL), were 
added DMAP (98 mg, 0.8 mmol, 0.2 equiv), pentafluorophenol (812 mg, 4.4 mmol, 1.1 
equiv) and EDCI.HCl (923 mg, 4.8 mmol, 1.2 equiv). The reaction mixture was stirred 
at rt for 4 h. The layers were separated after addition of HCl (1 M) to the reaction 
mixture. The organic layer was washed with saturated NaHCO3 solution followed by 
saturated brine, then dried and concentrated in vacuo. The resulting white solid was 
placed under high vacuum. 
To a solution of diisopropylamine (1.85 mL, 12.9 mmol, 3.3 equiv) in THF (10 mL), 
were added dropwise at –78 °C a solution of BuLi in hexanes (1.6 M, 9 mL, 14.1 mmol, 
3.6 equiv) followed by allylacetate (1.37 mL, 12.4 mmol, 3.2 equiv). The reaction was 
stirred for 30 min at –78 °C and a solution in THF (15 mL) of the intermediate ester of 
Boc-D-Met-OH was added. After stirring at –78 °C for 3 h, the reaction mixture was 
quenched with HCl solution (1 M, 25 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (3 x 25 mL). The combined organic layers were washed 
with saturated NaHCO3 solution (25 mL) and then with saturated brine (25 mL), dried 
over  MgSO4,  and  concentrated  in  vacuo.  The  residue  was  purified  by  flash 
chromatography using EtOAc/hexane (1:9) to afford 2.221 as a yellow oil (918.5 mg, 
71%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 6.08–5.77 (m, 1H, H-2), 5.46–5.10 (m, 3H, NH, 
H-1), 4.76–4.56 (m, 2H, H-3), 4.56–4.38 (m, 1H, H-7), 3.63 (app dd, J=16.2, 3.0 Hz, 
2H, H-5), 2.54 (t, J=7.2 Hz, 2H, H-9), 2.32–2.19 (m, 1H, H-8), 2.10 (s, 3H, H-10), 1.87 
(dt, J=14.2, 7.0 Hz, 1H, H-8), 1.45 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
206 reported in the literature. 
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(3S,4R)-Allyl  4-(tert-butoxycarbonylamino)-3-hydroxy-6-(methylthio)hexanoate 
(2.222) 
 
To a solution of 2.221 (887.7 mg, 2.68 mmol, 1 equiv) in anhydrous MeOH (10 mL) at 
–78 °C, was added KBH4 in portions (506 mg, 9.37 mmol, 3.5 equiv). The reaction was 
stirred for 10 min at –78 °C, warmed to –20 °C for 30 min and to 0 °C for 10 min. The 
reaction mixture was quenched by dropwise addition of glacial acetic acid (not pH < 6). 
The mixture was concentrated in vacuo and EtOAc/water (1:1, 20 mL) were added. The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 10 mL). The 
combined  organic  layers  were  dried  over  MgSO4,  and  concentrated  in  vacuo.  The 
residue was  purified by flash  chromatography  using EtOAc/hexane (2:8) to  provide 
2.222 as a white solid (719 mg, 81%).  
1H NMR (300 MHz, CDCl3) ʴ ppm 6.08–5.77 (m, 1H, H-2), 5.52–5.19 (m, 2H, H-1), 
4.77 (d, J=7.7 Hz, 1H, NH), 4.68–4.59 (m, 2H, H-3), 4.17–3.97 (m, 1H, H-6), 3.80–
3.59 (m, 1H, H-7), 3.39 (br s, 1H, OH), 2.74–2.44 (m, 4H, H-5; H-9), 2.11 (s, 3H, H-
10), 1.91 (m, 1H, H-8), 1.80–1.57 (m, 1H, H-8), 1.45 (s, 9H, CMe3). 
The spectroscopic data are consistent with that
206 reported in the literature. 
 
 
(3S,4R)-Allyl  4-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(trityl-thio)-
propanamido)-3-hydroxy-6-(methylthio)hexanoate (2.223) 
 
Compound 2.222 (150 mg, 0.24 mmol, 1 equiv) was treated with TFA (3.9 mL) in 
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coevaporation with CH3CN and CHCl3 was performed to afford the free amine (495 mg, 
100%).  
To a solution of Fmoc-D-Cys(Tr)-OH (726 mg, 2.12 mmol, 1 equiv) in CH2Cl2 (30 mL) 
cooled at 0 °C, PyBOP (1.3 g, 2.50 mmol, 1.2 equiv), and Hünig’s base (1.3 mL, 7.43 
mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before the 
previous free amine (495 mg, 2.12 mmol, 1 equiv) was added. The reaction mixture was 
stirred overnight and concentrated in vacuo. The crude material was purified by flash 
chromatography using EtOAc/hexane (3:7) as eluent to give 2.223 as a colourless oil 
(830 mg, 50%).  
[]D
28 –2 (c 0.1, CH3OH); IR 3318, 3060, 2925, 2901, 1712, 1654, 1524, 1446, 1250, 
1176, 1037 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.87–7.67 (m, 2H, HAr), 7.57 (d, 
J=7.2 Hz, 2H, HAr), 7.50–7.37 (m, 8H, HAr), 7.36–7.14 (m, 11H, HAr), 6.14 (d, J=8.5 
Hz, 1H, NH), 5.98–5.73 (m, 1H, H-2), 5.38–5.09 (m, 2H, H-1), 4.95 (d, J=7.0 Hz, 1H, 
NH), 4.58 (d, J=5.6 Hz, 2H, H-3), 4.41 (d, J=6.0 Hz, 2H, H-16), 4.26–4.16 (m, 1H, H-
17), 4.05–3.89 (m, 2H), 3.89–3.68 (m, 1H), 3.32 (d, J=3.9 Hz, 1H, OH), 2.82–2.68 (m, 
1H, H-13), 2.65–2.36 (m, 5H, H-5; H-9; H-13), 2.01 (s, 3H, H-10), 1.97–1.80 (m, 1H, 
H-8), 1.78–1.61 (m, 1H, H-8); 
13C NMR (100 MHz, CDCl3) ʴ ppm 172.2 (C, CO), 
170.1 (C, CO), 158.9 (C, CO), 144.2 (3C, CAr), 143.7 (C, CAr), 143.6 (C, CAr), 141.3 
(2C, CAr), 131.7 (CH, C-2), 129.5 (6CH, CAr), 128.1 (6CH, CAr), 127.8 (2CH, CAr), 
127.1 (2CH, CAr), 127.0 (3CH, CAr), 124.9 (2CH, CAr), 120.0 (2CH, CAr), 118.7 (CH2, 
C-1), 70.0 (CH, C-6), 67.4 (C, CPh3), 66.0 (CH2, C-3 or C-16), 65.5 (CH2, C-3 or C-
16), 54.3 (CH, C-7 or C-12), 52.7 (CH, C-7 or C-12), 47.1 (CH, C-17), 38.1 (CH2, C-5), 
33.6 (CH2, C-13), 30.6 (CH2, C-8 or C-9), 28.6 (CH2, C-8 or C-9), 15.5 (CH3, C-10); 
ES
+  MS  m/z  823  ([M+Na]
+  100%);  HRMS  (ESI)  m/z  calcd.  for  C29H44N4NaO7 
(M+Na)
+ 823.2846, found 823.2849.  
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(5R,8S,11R,12S)-Allyl  5-((R)-sec-butyl)-1-(9H-fluoren-9-yl)-12-hydroxy-11-(2-
(methylthio)ethyl)-3,6,9-trioxo-8-((tritylthio)methyl)-2-oxa-4,7,10-triazatetra-
decan-14-oate (2.224) 
 
Compound 2.223 (325 mg, 0.41 mmol, 1 equiv) was treated with diethylamine (1 mL) 
in  CH3CN  (10  mL)  for  2  h.  The  reaction  mixture  was  concentrated  in  vacuo,  and 
coevaporation with CH3CN and CHCl3 was performed to afford the free amine (235 mg, 
100%).  
To a solution of Fmoc-D-Ile-OH (158 mg, 0.45 mmol, 1.1 equiv) in CH2Cl2 (30 mL) 
cooled at 0 °C, PyBOP (254 g, 0.49 mmol, 1.2 equiv), and Hünig’s base (213 µL, 1.22 
mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before the 
previous free amine (235 mg, 0.41 mmol, 1 equiv) was added. The reaction mixture was 
stirred overnight and concentrated in vacuo. The crude material was purified by flash 
chromatography using EtOAc/hexane (1:4 to 3:7) as eluent to afford 2.224 as a white 
solid (265 mg, 99%). 
[]D
23 +33.9 (c 0.20, CH3OH); mp 60–62 °C; IR 3288, 3056, 3036, 2966, 2962, 2921, 
1707,  1646,  1536,  1446,  1234,  1172,  1033,  841  cm
–1; 
1H  NMR  (400  MHz, 
CDCl3/CD3OD) ʴ ppm 7.79 (d, J=7.5 Hz, 2H, HAr), 7.59 (d, J=7.5 Hz, 2H, HAr), 7.56 
(d, J=7.5 Hz, 8H, HAr), 7.47–7.17 (m, 11H, HAr), 6.04–5.79 (m, 1H, H-2), 5.31 (dd, 
J=17.1, 1.5 Hz, 1H, H-1), 5.23 (dd, J= 10.3, 1.3 Hz, 1H, H-1), 4.60 (dd, J=5.5, 1.0 Hz, 
2H, H-3), 4.52 (dd, J=10.5, 6.5 Hz, 1H, H-22), 4.30 (dd, J=10.0, 6.5 Hz, 1H, H-22), 
4.20–3.88 (m, 5H, H-6; H-7; H-12; H-16; H-23), 2.78 (dd, J=12.3, 6.3 Hz, 1H, H-13), 
2.66–2.38 (m, 5H, H-5; H-9; H-13), 2.05 (s, 3H, H-10), 2.01–1.92 (m, 1H, H-8), 1.88–
1.83 (m, 2H, H-8; H-17), 1.53–1.32 (m, 1H, H-19), 1.17–1.00 (m, 1H, H-19), 0.98–0.81 
(m, 6H, H-18; H-20); 
13C NMR (100 MHz, CDCl3/CD3OD) ʴ ppm 172.2 (C, CO), 
171.5 (C, CO), 170.0 (C, CO), 156.9 (C, CO), 144.1 (3C, CAr), 143.7 (C, CAr), 143.4 (C, 
CAr), 141.2 (2C, CAr), 131.7 (CH, C-2), 129.3 (6CH, CAr), 128.0 (6CH, CAr), 127.7 
(2CH, CAr), 127.0 (2CH, CAr), 126.8 (3CH, CAr), 124.9 (CH, CAr), 124.8 (CH, CAr),     Experimental Procedures For Chapter 2 
282 
 
119.9 (2CH, CAr), 118.4 (CH2, C-1), 70.0 (CH, C-6), 67.0 (C; CH2, CPh3; C-22), 65.4 
(CH2, C-3), 60.0 (CH), 52.9 (CH), 52.4 (CH), 47.0 (CH, C-23), 38.1 (CH2), 36.9 (CH), 
32.9 (CH2), 30.5 (CH2), 29.0 (CH2), 24.7 (CH2, C-19), 15.4; 15.3 (2CH3, C-10; C-18), 
11.3 (CH3, C-20); ES
+ MS m/z 936 ([M+Na]
+ 100%); HRMS (ESI) m/z calcd. for 
C29H44N4NaO7 (M+Na)
+ 936.3687, found 936.3704. 
 
 
(S,E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (2.219) 
 
To a solution of compound 2.47 (937 mg, 1.7 mmol, 1 equiv) in a mixture of THF/water 
(30 mL:10 mL) was added LiOH (120 mg, 5.0 mmol, 3 equiv). The reaction was stirred 
overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography using EtOAc/hexane (2:8) then 100% EtOAc as eluent to afford 2.219 
as yellow oil (374 mg, 55%). 
 
 
(7S,11R,14R,17R,18R,E)-Allyl  11-((R)-sec-butyl)-7,18-dihydroxy-17-(2-(methyl-
thio)-ethyl)-9,12,15-trioxo-1,1,1-triphenyl-14-((tritylthio)methyl)-2-thia-10,13,16-
triazanonadec-5-en-19-oate (2.225) 
 
The  tetrapeptide  fragment  2.224  (264  mg,  0.29  mmol,  1  equiv)  was  treated  with 
diethylamine (1 mL) in CH3CN (10 mL) for 2 h. The reaction mixture was concentrated 
in vacuo, and coevaporation with CH3CN and CHCl3 was performed to afford the free 
amine (200 mg, 100%).      Experimental Procedures For Chapter 2 
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To a solution of the -hydroxy acid 2.219 (130 mg, 0.32 mmol, 1.1 equiv) in CH2Cl2 
(10 mL) cooled at 0 °C, PyBOP (180 mg, 0.35 mmol, 1.2 equiv) and Hünig’s base (151 
µL, 0.87 mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before 
the previous free amine (200 mg, 0.29 mmol, 1 equiv) was added. The reaction mixture 
was stirred overnight and concentrated in vacuo. The crude material was purified by 
flash chromatography using EtOAc/hexane (1:1) as eluent to provide 2.225 as a white 
solid (206 mg, 65%).  
[]D
23 +40.5 (c 0.127, CH3OH). mp 58–60 °C; IR 3273, 3052, 2958, 2929, 1740, 1630, 
1531, 1487, 1446, 1180, 854 cm
–1; 
1H NMR (400 MHz, CDCl3/CD3OD) ʴ ppm 7.47–
7.17 (m, 30H, HAr), 5.97–5.74 (m, 1H, H-2), 5.59–5.45 (m, 1H, H-25), 5.44–5.34 (m, 
1H, H-24), 5.34–5.26 (m, 1H, H-1), 5.21 (dd, J=10.3, 1.3 Hz, 1H, H-1), 4.58 (d, J=5.5 
Hz, 2H, H-3), 4.35 (q, J=6.2 Hz, 1H, H-23), 4.14 (dd, J=7.5, 5.5 Hz, 1H, H-12), 4.11–
4.07 (m, 1H, H-16), 4.07–3.97 (m, 1H, H-6 or H-7), 3.89 (ddd, J=10.5, 5.0, 3.0 Hz, 1H, 
H-6 or H-7), 2.66–2.36 (m, 7H, H-5; H-9; H-13), 2.33 (d, J=6.5 Hz, 2H, H-22), 2.26–
2.16 (m, 2H, H-27), 2.09 (q, J=7.4 Hz, 2H, H-26), 2.00 (s, 3H, H-10), 1. 97–1.83 (m, 
2H, H-8; H-17), 1.76–1.64 (m, 1H, H-8), 1.51–1.32 (m, 1H, H-19), 1.15 (ddd, J=13.6, 
9.5,  7.0  Hz,  1H,  H-19),  0.98–0.82  (m,  6H,  H-18;  H-20); 
13C  NMR  (100  MHz, 
CDCl3/CD3OD) ʴ ppm 173.1 (C, CO), 172.1 (C, CO), 171.6 (C, CO), 170.4 (C, CO), 
144.7 (3C, CAr), 144.1 (3C, CAr), 132.4 (CH), 131.7 (CH), 130.0 (CH), 129.4 (6CH, 
CAr), 129.3 (6CH, CAr), 127.9 (6CH, CAr), 127.7 (6CH, CAr), 126.8 (3CH, CAr), 126.5 
(3CH, CAr), 118.2 (CH2, C-1), 70.1 (CH), 69.3 (CH), 66.8 (C, CPh3), 66.5 (C, CPh3), 
65.4 (CH2, C-3), 59.2 (CH), 52.9 (CH), 52.6 (CH), 43.2 (CH2), 38.2 (CH2), 35.9 (CH), 
32.9 (CH2), 31.3 (CH2), 31.1 (CH2), 30.4 (CH2), 28.9 (CH2), 24.6 (CH2, C-19), 15.6; 
15.1 (CH3, C-10; C-18), 11.4 (CH3, C-20); ES
+ MS m/z 1115 ([M+Na]
+ 100%). 
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Thailandepsin A (2.217) 
 
To  a  solution  of  2.225  (186  mg,  0.17  mmol,  1  equiv)  in  methanol,  were  added 
morpholine (32 µL, 0.36 mmol, 2.1 equiv) and Pd(PPh3)4 (19.7 mg, 17 µmol, 0.1 equiv). 
After 2.5 h of stirring, the solvent was removed and the residue was purified by flash 
chromatography (CH2Cl2 followed by a gradient of 5% then 10% MeOH in CH2Cl2) to 
afford the carboxylic acid as a yellow solid (162 mg, 90%). 
A solution of the previous carboxylic acid (161.8 mg, 0.15 mmol, 1 equiv) in CH2Cl2 
(115  mL)  was  added  very  slowly  to  a  stirred  solution  of  2-methyl-6-nitrobenzoic 
anhydride (MNBA) (63.5 mg, 0.18 mmol, 1.2 equiv) in CH2Cl2 (30 mL) containing 
DMAP (45 mg, 0.37 mmol, 2.4 equiv) at room temperature over 3.5 h. The reaction was 
stirred at rt overnight. The reaction mixture was concentrated in vacuo, and the residue 
was  purified  by  column  chromatography  (CH2Cl2/MeOH  1:0  to  98:2)  to  give  the 
protected dithiol 2.226 (37.9 mg, 24%) as a white amorphous solid. 
To a vigorously stirring solution of I2 (93 mg, 0.37 mmol, 10 equiv) in CH2Cl2/MeOH 
(70  mL:40  mL)  was  added  the  protected  dithiol  (38  mg,  37  µmol,  1  equiv)  in 
MeOH/CH2Cl2 (7 mL:4 mL) dropwise over 2.5 h and stirred for a  further 30 min. 
Na2S2O3  solution  (0.01  M,  20  mL)  was  added,  followed  by  brine  (8  mL)  and  the 
aqueous phase extracted twice with EtOAc (30 mL). The combined organic layers were 
dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by 
flash chromatography (hexane/ CH2Cl2 1:1 to MeOH/ CH2Cl2 1:99 then 2:98) to give 
2.217 as a white solid (7.7 mg, 38%). 
[]D
32 –30.7 (c 0.29, CH3OH); mp 86–88 °C; IR 3383, 3322, 2966, 2925, 1728, 1654, 
1536, 1515, 1270, 1160 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.57 (d, J=7.0 Hz, 
1H, NH), 6.74 (d, J=9.0 Hz, 1H, NH), 6.51 (t, J=13.1 Hz, 1H, H-22), 5.88 (d, J=4.1 Hz, 
1H, NH), 5.66 (dt, J=15.3, 1.6 Hz, 1H, H-23), 5.48 (dd, J=3.8, 1.9 Hz, 1H, H-9), 4.91 
(td, J=8.4, 3.3 Hz, 1H, H-18), 4.55–4.31 (m, 1H, H-12), 4.18 (dd, J=5.6, 4.5 Hz, 1H, H-    Experimental Procedures For Chapter 2 
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2), 3.60–3.38 (m, 2H, H-8; H-19), 3.25–3.05 (m, 2H, H-13; H-19), 2.85–2.31 (m, 9H, 
H-8; H-11; H-15; H-20; H-21), 2.10 (s, 3H, H-16), 2.09–1.96 (m, 1H, H-3), 1.70–1.56 
(m, 3H, H-5; H-14), 1.36–1.16 (m, 1H, H-5), 1.06 (d, J=6.9 Hz, 3H, H-4), 0.99 (t, J=7.3 
Hz, 3H, H-6); 
13C NMR (100 MHz, CDCl3) ʴ ppm 171.4 (C, CO), 171.2 (C, CO), 
169.9 (C, CO), 169.0 (C, CO), 133.9 (CH, C-22), 128.1 (CH, C-23), 70.6 (CH), 70.5 
(CH),  61.2  (CH),  56.9  (CH),  54.5  (CH),  42.3  (CH2),  40.8  (CH2),  40.4  (CH2),  38.8 
(CH2), 35.7 (CH, C-3), 33.6 (CH2), 31.2 (CH2), 29.3 (CH2), 26.1 (CH2), 16.1 (CH3), 
15.4 (CH3), 11.4 (CH3, C-6); ES
+ MS m/z 570 ([M+Na]
+ 100%); HRMS (ESI) m/z 
calcd. for C23H37N3NaO6S3 (M+Na)
+ 570.1737, found 570.1745.  
 
 
5.3.2.3. Total synthesis of the Brady’s proposed diastereomer 
(4S,5S)-Allyl 4-(tert-butoxycarbonylamino)-5-methyl-3-oxoheptanoate (2.227)  
 
To a solution of Boc-L-Ile-OH (949 mg, 4.0 mmol, 1 equiv) in CH2Cl2 (15 mL), were 
added DMAP (96.5 mg, 0.8 mmol, 0.2 equiv), pentafluorophenol (800 mg, 4.4 mmol, 
1.1 equiv) and EDCI (909 mg, 4.7 mmol, 1.2 equiv). The reaction mixture was stirred at 
rt for 4 h. The layers were separated after addition of HCl (1 M) to the reaction mixture. 
The organic layer was washed with saturated NaHCO3 solution followed by saturated 
brine, then dried and concentrated in vacuo. The resulting white solid was placed under 
high vacuum. 
To a solution of diisopropylamine (1.83 mL, 13.0 mmol, 3.3 equiv) in THF (4.5 mL), 
was added dropwise a solution of BuLi in hexanes (2.5 M, 5.7 mL, 14.2 mmol, 3.6 
equiv) followed by allylacetate (1.35 mL, 12.5 mmol, 3.2 equiv) at –78 °C. The reaction 
was stirred at –78 °C for 30 min and a solution in THF (13 mL) of the intermediate ester 
of Boc-L-Ile-OH was added. After stirring at –78 °C for 3 h, the reaction mixture was 
quenched with HCl solution (1 M). The layers were separated and the aqueous layer 
was extracted with EtOAc (3 times). The combined organic layers were washed with 
saturated  NaHCO3  solution  and  then  with  saturated  brine,  dried  over  MgSO4,  and     Experimental Procedures For Chapter 2 
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concentrated  in  vacuo.  The  residue  was  purified  by  flash  chromatography  using 
EtOAc/hexane (1:9) to afford 2.227 as a colourless oil (875 mg, 70%). 
[]D
23 –31.9 (c 0.42, CH3OH); IR 3347, 2967, 2933, 1751, 1702, 1517, 1457, 1363, 
1318, 1246, 1160, 1013, 990 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 6.06–5.84 (m, 
1H, H-2), 5.34 (dq, J=17.2, 1.5 Hz, 1H, H-1), 5.26 (dd, J=10.6, 1.0 Hz, 1H, H-1), 5.05 
(d, J=8.1 Hz, 1H, NH), 4.64 (d, J=5.6 Hz, 2H, H-3), 4.33 (dd, J=8.6, 4.5 Hz, 1H, H-7), 
3.68–3.52 (m, 2H, H-5), 2.09–1.88 (m, 1H, H-8), 1.45 (s, 9H, CMe3), 1.41–1.24 (m, 1H, 
H-10), 1.17–1.03 (m, 1H, H-10), 0.99 (d, J=7.1 Hz, 3H, H-9), 0.94–0.87 (m, 3H, H-11). 
 
 
(3R,4S,5S)-Allyl  4-(tert-butoxycarbonylamino)-3-hydroxy-5-methylheptanoate 
(2.228) 
 
To a solution of 2.227 (467 mg, 1.5 mmol, 1 equiv) in anhydrous MeOH (5 mL) at –78 
°C, was added KBH4 in portions (281 mg, 5.2 mmol, 3.5 equiv). The reaction was 
stirred for 10 min at –78 °C, warmed to –20 °C for 30 min and to 0 °C for 10 min. The 
reaction mixture was quenched by dropwise addition of glacial acetic acid (not pH < 6). 
The mixture was concentrated in vacuo and EtOAc/water (1:1, 20 mL) were added. The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 10 mL). The 
combined  organic  layers  were  dried  over  MgSO4,  and  concentrated  in  vacuo.  The 
residue was  purified by flash  chromatography  using EtOAc/hexane (1:9) to  provide 
2.228 as a colourless oil (295 mg, 63%). 
1H NMR (400 MHz, CDCl3) ʴ ppm 6.07–5.81 (m, 1H, H-2), 5.34 (dd, J=17.2, 1.5 Hz, 
1H, H-1), 5.26 (d, J=10.6 Hz, 1H, H-1), 4.63 (d, J=6.1 Hz, 2H, H-3), 4.40 (d, J=9.6 Hz, 
1H, NH), 4.13–3.93 (m, 1H, H-6), 3.66–3.48 (m, 1H, H-7), 3.24 (br d, J=4.5 Hz, 1H, 
OH), 2.62 (dd, J=16.2, 2.0 Hz, 1H, H-5), 2.56–2.41 (m, 1H, H-5), 1.93–1.68 (m, 1H, H-
8), 1.68–1.51 (m, 1H, H-10), 1.45 (s, 9H, H-14), 1.12–0.84 (m, 7H, H-9; H-10; H-11). 
The spectroscopic data are consistent with that
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(3R,4S,5S)-Allyl  4-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(trityl-
thio)-propanamido)-3-hydroxy-5-methylheptanoate (2.229) 
 
Compound  2.228  (282  mg,  0.89  mmol,  1  equiv)  was  treated  with  TFA  (2  mL)  in 
CH2Cl2  (5  mL)  for  1  h.  The  reaction  mixture  was  concentrated  in  vacuo,  and 
coevaporation with CH3CN and CHCl3 was performed to afford the free amine.  
To a solution of Fmoc-D-Cys(Tr)-OH (428 mg, 1.25 mmol, 1.4 equiv) in CH2Cl2 (6 mL) 
cooled at 0 °C, PyBOP (744 mg, 1.43 mmol, 1.6 equiv), and Hünig’s base (467 µL, 2.68 
mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before the 
previous free amine in CH2Cl2 (2 mL) was added. The reaction mixture was stirred 
overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography  using  EtOAc/hexane  (1:9  then  2:8)  as  eluent  to  give  2.229  as  a 
colourless oil (477 mg, 68%). 
[]D
23 +8.6 (c 0.14, CH3OH); mp 48–50 °C; IR 3407, 3326, 3056, 2962, 2929, 2868, 
1716, 1659, 1524, 1446, 1315, 1250, 1172, 1042, 988, 903 cm
–1; 
1H NMR (400 MHz, 
CDCl3) ʴ ppm 7.78 (dd, J=7.3, 5.3 Hz, 2H, HAr), 7.58 (t, J=6.1 Hz, 2H, HAr), 7.52–7.37 
(m, 8H, HAr), 7.35–7.16 (m, 11H, HAr), 5.98–5.73 (m, 2H, H-2; NH), 5.25 (dd, J=17.4, 
1.3 Hz, 1H, H-1), 5.16 (dd, J=10.1, 1.0 Hz, 1H, H-1), 5.03 (d, J=7.1 Hz, 1H, NH), 4.54 
(dd, J=5.8, 1.3 Hz, 2H, H-3), 4.40 (t, J=5.8 Hz, 2H, H-17), 4.21 (t, J=6.6 Hz, 1H, H-18), 
4.09–3.97 (m, 1H, H-6), 3.94–3.71 (m, 2H, H-7; H-13), 2.80 (dd, J=13.1, 7.1 Hz, 1H, 
H-14), 2.64–2.48 (m, 2H, H-5; H-14), 2.43 (dd, J=9.1 Hz, 1H, H-5), 1.88–1.68 (m, 1H, 
H-8), 1.63–1.41 (m, 1H, H-10), 1.00–0.73 (m, 7H, H-9; H-10; H-11); 
13C NMR (100 
MHz, CDCl3) ʴ ppm 172.6 (C, CO), 170.7 (C, CO), 156.1 (C, CO), 144.3 (3C, CAr), 
143.7 (C, CAr), 143.6 (C, CAr), 141.3 (2C, CAr), 131.8 (CH, C-2), 129.5 (6CH, CAr), 
128.1 (6CH, CAr), 127.8 (2CH, CAr), 127.1 (2CH, CAr), 127.0 (3CH, CAr), 125.0 (2CH, 
CAr), 120.0 (2CH, CAr), 118.5 (CH2, C-1), 68.6 (CH, C-6), 67.4 (C, CPh3), 67.2 (CH2, 
C-3 or C-17), 65.4 (CH2, C-3 or C-17), 57.7 (CH, C-7 or C-13), 54.4 (CH, C-7 or C-13), 
47.0 (CH, C-18), 38.0 (CH2, C-5), 34.5 (CH, C-8), 33.5 (CH2, C-14), 23.5 (CH2, C-10),     Experimental Procedures For Chapter 2 
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16.3 (CH3, C-9), 11.5 (CH3, C-11); ES
+ MS m/z 805 ([M+Na]
+ 100%); HRMS (ESI) 
m/z calcd. for C48H51N2O6S1 (M+H)
+ 783.3462, found 783.3461. 
 
 
(5S,8S,11S,12R)-Allyl  11-((S)-sec-butyl)-1-(9H-fluoren-9-yl)-12-hydroxy-5-(2-
(methyl-thio)ethyl)-3,6,9-trioxo-8-((tritylthio)methyl)-2-oxa-4,7,10-triazatetra-
decan-14-oate (2.230) 
 
Compound 2.229 (470 mg, 0.6 mmol, 1 equiv) was treated with diethylamine (2.3 mL) 
in CH3CN (11.6 mL) for 2 h. The reaction mixture was concentrated in vacuo, and 
coevaporation with CH3CN and CHCl3 was performed to afford the free amine.  
To a solution of Fmoc-L-Met-OH (290 mg, 0.8 mmol, 1.3 equiv) in CH2Cl2 (5 mL) 
cooled at 0 °C, PyBOP (500 g, 1.0 mmol, 1.6 equiv), and Hünig’s base (314 µL, 1.8 
mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before the 
previous free amine was added in CH2Cl2 (1 mL). The reaction mixture was stirred 
overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography using EtOAc/hexane (2:8 then 3:7 then 4:6) as eluent to afford 2.230 as 
a colourless oil (495 mg, 90%).  
[]D
23 –1.2 (c 0.35, CH3OH); IR 3305, 3060, 2958, 2921, 1712, 1650, 1520, 1438, 
1250, 1172, 1050 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.77 (d, J=7.2 Hz, 2H, 
HAr), 7.62–7.49 (m, 2H, HAr), 7.49–7.12 (m, 19H, HAr), 6.53 (d, J=7.5 Hz, 1H, NH), 
6.23 (d, J=9.8 Hz, 1H, NH), 5.82 (tdd, J=16.9, 10.9, 5.5 Hz, 1H, H-2), 5.55 (d, J=7.2 
Hz, 1H, NH), 5.24 (d, J=17.3 Hz, 1H, H-1), 5.16 (d, J=10.2 Hz, 1H, H-1), 4.52 (d, 
J=5.7 Hz, 2H, H-3), 4.47–4.23 (m, 2H, H-22), 4.20–4.02 (m, 3H, H-6; H-17; H-23), 
4.02–3.91 (m, 1H, H-13), 3.91–3.77 (m, 1H, H-7), 3.26 (d, J=5.3 Hz, 1H, OH), 2.81 
(dd, J=12.8, 7.5 Hz, 1H, H-14), 2.69–2.31 (m, 5H, H-5; H-14; H-19), 2.17–1.98 (m, 4H, 
H-18; H-20), 1.97–1.81 (m, 1H, H-18), 1.75–1.59 (m, 1H, H-8), 1.59–1.39 (m, 1H, H-
10), 1.04–0.72 (m, 7H, H-9; H-10; H-11); 
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(C, CO), 171.4 (C, CO), 170.3 (C, CO), 156.3 (C, CO), 144.3 (3C, CAr), 143.6 (C, CAr), 
143.5 (C, CAr), 141.3 (2C, CAr), 131.9 (CH, C-2), 129.5 (6CH, CAr), 128.1 (6CH, CAr), 
127.8 (2CH, CAr), 127.1 (2CH, CAr), 126.9 (3CH, CAr), 125.0 (CH, CAr), 124.9 (CH, 
CAr), 120.0 (2CH, CAr), 118.5 (CH2, C-1), 68.7 (CH, C-6), 67.2 (C, CPh3), 67.1 (CH2, 
C-22), 65.4 (CH2, C-3), 57.8 (CH, C-7), 54.0 (CH, C-17), 52.6 (CH, C-13), 47.1 (CH, 
C-23), 37.7 (CH2, C-5), 34.7 (CH, C-8), 32.9 (CH2, C-14), 30.4; 30.1 (2CH2, C-18; C-
19), 24.0 (CH2, C-10), 16.1 (CH3, C-9), 15.2 (CH3, C-20), 11.3 (CH3, C-11); ES
+ MS 
m/z  936  ([M+Na]
+  100%);  HRMS  (ESI)  m/z  calcd.  for  C53H60N3O7S2  (M+H)
+ 
914.3867, found 914.3867. 
 
 
(7S,11S,14R,17S,18R,E)-Allyl  17-((S)-sec-butyl)-7,18-dihydroxy-11-(2-(methyl-
thio)-ethyl)-9,12,15-trioxo-1,1,1-triphenyl-14-((tritylthio)methyl)-2-thia-10,13,16-
triazanonadec-5-en-19-oate (2.231) 
 
Compound 2.230 (478 mg, 0.53 mmol, 1 equiv) was treated with diethylamine (2 mL) 
in  CH3CN  (10  mL)  for  2  h.  The  reaction  mixture  was  concentrated  in  vacuo,  and 
coevaporation with CH3CN and CHCl3 was performed to afford the free amine. 
To a solution of the -hydroxy acid 2.219 (298 mg, 0.73 mmol, 1.4 equiv) in CH2Cl2 
(10 mL) cooled at 0 °C, PyBOP (435 mg, 0.84 mmol, 1.6 equiv), and Hünig’s base (274 
µL, 1.57 mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before 
the previous free amine was added. The reaction mixture was stirred overnight and 
concentrated in vacuo. The crude material was purified by flash chromatography using 
EtOAc/hexane (4:6 then 1:1) as eluent to provide 2.231 as a white solid (347 mg, 61%). 
[]D
23 +2.1 (c 0.26, CH3OH); mp 130-132 °C; IR 3395, 3056, 2966, 2933, 1728, 1654, 
1536,  1487,  1438,  1270,  1180,  1025,  976,  849  cm
–1;
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CDCl3/CD3OD) ʴ ppm 7.61–7.04 (m, 30H, HAr), 5.97–5.76 (m, 1H, H-2), 5.60–5.45 
(m, 1H, H-25), 5.39 (t, J=6.1 Hz, 1H, H-24), 5.28 (d, J=17.2 Hz, 1H, H-1), 5.19 (d, 
J=10.6 Hz, 1H, H-1), 4.56 (d, J=5.6 Hz, 2H, H-3), 4.39–4.29 (m, 1H, H-23), 4.24 (t, 
J=7.1 Hz, 1H, H-17), 4.18–4.02 (m, 2H, H-6; H-13), 3.87–3.70 (m, 1H, H-7), 2.64–2.16 
(m, 10H, H-5; H-14; H-19; H-22; H-27), 2.16–1.98 (m, 6H, H-18; H-20; H-26), 1.92 
(td, J=14.4, 7.5 Hz, 1H, H-18), 1.59 (q, J=7.6 Hz, 1H, H-8), 1.54–1.40 (m, 1H, H-10), 
1.02–0.73 (m, 7H, H-9; H-10; H-11); 
13C NMR (100 MHz, CDCl3/CD3OD) ʴ ppm 
172.40 (C, CO), 172.36 (C, CO), 171.9 (C, CO), 171.0 (C, CO), 144.7 (3C, CAr), 144.2 
(3C, CAr), 132.4 (CH), 131.7 (CH), 129.5 (CH), 129.4 (6CH, CAr), 129.3 (6CH, CAr), 
127.8 (6CH, CAr), 127.7 (6CH, CAr), 126.7 (3CH, CAr), 126.4 (3CH, CAr), 118.1 (CH2, 
C-1), 68.6 (CH, C-23), 68.4 (CH, C-6), 66.8 (C, CPh3), 66.4 (C, CPh3), 65.3 (CH2, C-3), 
57.7 (CH, C-7), 52.8 (CH, C-17), 52.5 (CH, C-13), 42.6 (CH2), 40.0 (CH2), 37.3 (CH2), 
34.5 (CH, C-8), 32.9 (CH2), 31.3 (CH2), 31.1 (CH2), 29.9 (CH2), 24.1 (CH2, C-10), 15.8 
(CH3, C-9), 14.9 (CH3, C-20), 10.8 (CH3, C-11); ES
+ MS m/z 1115 ([M+Na]
+ 100%). 
 
 
(1S,5S,6S,9R,20S,E)-6-((S)-sec-Butyl)-5-hydroxy-20-(2-(methylthio)ethyl)-2-oxa-
11,12-dithia-7,19,22-triazabicyclo[7.7.6]docos-15-ene-3,8,18,21-tetraone (2.29) 
 
To a solution of 2.231 (326 mg, 0.30 mmol, 1 equiv) in methanol (10 mL), were added 
morpoline (55 µL, 0.63 mmol, 2.1 equiv) and Pd(PPh3)4 (35 mg, 30 µmol, 0.1 equiv). 
After 2.5 h of stirring, the solvent was removed and the residue was purified by flash 
chromatography (CH2Cl2 then 5% of MeOH in CH2Cl2 with formic acid) to afford the 
carboxylic acid as a yellow solid (315 mg, 100%). 
A solution of the previous carboxylic acid (315 mg, 0.30 mmol, 1 equiv) in CH2Cl2 
(250  mL)  was  added  very  slowly  to  a  stirred  solution  of  2-methyl-6-nitrobenzoic 
anhydride (MNBA) (124 mg, 0.36 mmol, 1.2 equiv) in CH2Cl2 (60 mL) containing     Experimental Procedures For Chapter 2 
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DMAP (88 mg, 0.72 mmol, 2.4 equiv) at room temperature over 4 h. The reaction was 
stirred at rt overnight. The reaction mixture was concentrated in vacuo, and the residue 
was purified by column chromatography (CH2Cl2 then CH2Cl2/MeOH 99:1) to give the 
protected dithiol (224 mg, 68%) as a yellow solid. 
To a vigorously stirring solution of I2 (528 mg, 2.10 mmol, 10 equiv) in CH2Cl2/MeOH 
(390 mL:39 mL) was added the protected dithiol (215 mg, 0.21 mmol, 1 equiv) in 
MeOH/CH2Cl2 (220 mL:22 mL) dropwise over 2.5 h and stirred for a further 30 min. 
Na2S2O3 (50 mL) was added, followed by brine (5 mL) and the aqueous phase extracted 
with EtOAc (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered, 
and  concentrated  in  vacuo.  The  residue  was  purified  by  flash  chromatography 
(hexane/CH2Cl2 1:1 then CH2Cl2 then MeOH/CH2Cl2 1:99 to 2:98) to give 2.29 as a 
white solid (74 mg, 65%). 
[]D
32 –139.1 (c 0.40, CH3OH); mp 148–150 °C; IR 3375, 3305, 2962, 2917, 1736, 
1663, 1552, 1438, 1295, 1238, 1168 cm
–1; 
1H NMR (400 MHz, CD2Cl2) ʴ ppm 
1H 
NMR (400 MHz, CD2Cl2) ʴ ppm 7.07–6.94 (m, 2H, NH), 6.65 (br s, 1H, NH), 5.94 (t, 
J=11.1 Hz, 1H, H-22), 5.67 (d, J=15.2 Hz, 1H, H-23), 5.67–5.64 (m, 1H, H-8), 4.91–
4.79 (m, 1H, H-18), 4.19 (td, J=8.6, 4.3 Hz, 1H, H-11), 4.04–3.91 (m, 1H, H-2), 3.80 
(dt, J=9.5, 4.3 Hz, 1H, H-12), 3.49–3.30 (m, 2H, H-19; H-20), 3.15–3.03 (m, 1H, H-19), 
2.98 (dd, J=13.1, 7.1 Hz, 1H, H-7), 2.81–2.40 (m, 9H, OH; H-3; H-4; H-7; H-10; H-20; 
H-21), 2.40–2.22 (m, 2H, H-3; H-21), 2.09 (s, 3H, H-5), 1.92–1.77 (m, 1H, H-13), 1.61 
(dtd, J=21.2, 7.5, 3.5 Hz, 1H, H-14), 1.02 (ddd, J=13.8, 6.7, 3.3 Hz, 1H, H-14), 0.95–
0.77 (m, 6H, H-15; H-16); 
13C NMR (100 MHz, CD2Cl2) ʴ ppm 171.6 (C, CO), 170.6 
(C, CO), 170.4 (C, CO), 170.2 (C, CO), 132.1 (CH, C-22), 130.4 (CH, C-23), 69.7 
(2CH, C-8; C-11), 60.3 (CH, C-12), 56.8 (CH, C-18), 54.8 (CH, C-2), 42.9 41.4, 41.0 
(4CH2, C-7; C-10; C-19; C-20), 36.0 (CH, C-13), 32.5 (CH2, C-21), 31.5 (CH2, C-4), 
27.1 (CH2, C-3), 23.4 (CH2, C-14), 16.7 (CH3, C-16), 15.2 (CH3, C-5), 12.1 (CH3, C-
15); HRMS (ESI) m/z calcd. for C23H38N3O6S3 (M+H)
+ 548.1917, found 548.1901. 
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5.3.2.4. Total synthesis of epi-burkholdac B 
(4R,5R)-Allyl 4-(tert-butoxycarbonylamino)-5-methyl-3-oxoheptanoate (2.232)  
 
To a solution of Boc-D-Ile-OH (527 mg, 2.5 mmol, 1 equiv) in CH2Cl2 (10 mL), were 
added DMAP (61 mg, 0.5 mmol, 0.2 equiv), pentafluorophenol (507 mg, 2.8 mmol, 1.1 
equiv) and EDCI (577 mg, 3.0 mmol, 1.2 equiv). The reaction mixture was stirred at rt 
for 4 h. The layers were separated after addition of HCl (1 M) to the reaction mixture. 
The organic layer was washed with saturated NaHCO3 solution followed by saturated 
brine, then dried and concentrated in vacuo. The resulting white solid was placed under 
high vacuum.  
To a solution of diisopropylamine (1.06 mL, 7.5 mmol, 3.3 equiv) in THF (2.5 mL), 
were added dropwise a solution of BuLi in hexanes (2.5 M, 3.3 mL, 8.2 mmol, 3.6 
equiv) followed by allylacetate (779 µL, 7.2 mmol, 3.2 equiv) at –78 °C. The reaction 
was stirred at –78 °C for 30 min and a solution in THF (7.5 mL) of the intermediate 
ester of Boc-D-Ile-OH was added. After stirring at –78 °C for 3 h, the reaction mixture 
was quenched with HCl solution (1 M). The layers were separated and the aqueous 
layer was extracted with EtOAc (3 times). The combined organic layers were washed 
with saturated NaHCO3 solution and then with saturated brine, dried over MgSO4, and 
concentrated  in  vacuo.  The  residue  was  purified  by  flash  chromatography  using 
EtOAc/hexane (1:9) to afford 2.232 as a colourless oil (480.3 mg, 67%). 
[]D
28 +42.7 (c 0.08, CH3OH); IR 3342, 2966, 2925, 1753, 1704, 1503, 1458, 1368, 
1307, 1246, 1160, 984, 935 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 6.06–5.81 (m, 
1H, H-2), 5.34 (dd, J=17.2, 1.5 Hz, 1H, H-1), 5.26 (dd, J=10.1, 1.0 Hz, 1H, H-1), 5.03 
(br d, J=8.1 Hz, 1H, NH), 4.64 (d, J=6.1 Hz, 2H, H-3), 4.33 (dd, J=8.6, 4.5 Hz, 1H, H-
7), 3.67–3.52 (m, 2H, H-5), 2.07–1.88 (m, 1H, H-8), 1.45 (s, 9H, CMe3), 1.41–1.27 (m, 
1H, H-10), 1.16–1.04 (m, 1H, H-10), 1.00 (d, J=6.6 Hz, 3H, H-9), 0.96–0.85 (m, 3H, H-
11); 
13C NMR (100 MHz, CDCl3) ʴ ppm 202.2 (C, CO), 166.4 (C, CO), 155.7 (C, 
CO), 131.5 (CH, C-2), 118.8 (CH2, C-1), 80.0 (C, CMe3), 66.0 (CH2, C-3), 64.3 (CH, 
C-7), 47.2 (CH2, C-5), 36.3 (CH, C-8), 28.3 (3CH3, CMe3), 24.1 (CH2, C-10), 16.0     Experimental Procedures For Chapter 2 
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(CH3,  C-9),  11.6  (CH3,  C-11);  ES
+  MS  m/z  336  ([M+Na]
+  100%),  377 
([M+Na+CH3CN]
+  100%);  HRMS  (ESI)  m/z  calcd.  for  C16H27NNaO5  (M+Na)
+ 
336.1781, found 336.1781. 
 
 
(3S,4R,5R)-Allyl  4-(tert-butoxycarbonylamino)-3-hydroxy-5-methylheptanoate 
(2.233) 
 
To a solution of 2.232 (465 mg, 1.49 mmol, 1 equiv) in anhydrous MeOH (5 mL) at –78 
°C, was added KBH4 in portions (281 mg, 5.22 mmol, 3.5 equiv). The reaction was 
stirred for 10 min at –78 °C, warmed to –20 °C for 30 min and to 0 °C for 10 min. The 
reaction mixture was quenched by dropwise addition of glacial acetic acid (not pH < 6). 
The mixture was concentrated in vacuo and EtOAc/water (1:1, 20 mL) were added. The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 10 mL). The 
combined  organic  layers  were  dried  over  MgSO4,  and  concentrated  in  vacuo.  The 
residue was purified by flash chromatography using EtOAc/hexane (1:9 then 2:8) to 
provide 2.233 as a white solid (342 mg, 73%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 6.05–5.78 (m, 1H, H-2), 5.34 (dd, J=17.3, 1.5 Hz, 
1H, H-1), 5.26 (d, J=10.5 Hz, 1H, H-1), 4.63 (d, J=5.7 Hz, 2H, H-3), 4.41 (d, J=10.2 
Hz, 1H, NH), 4.12–3.95 (m, 1H, H-6), 3.69–3.48 (m, 1H, H-7), 3.26 (d, J=4.9 Hz, 1H, 
OH), 2.62 (dd, J=3.0 Hz, 1H, H-5), 2.49 (dd, J=9.0 Hz, 1H, H-5), 1.88–1.67 (m, 1H, H-
8), 1.61–1.50 (m, 1H, H-10), 1.45 (s, 9H, CMe3), 1.11–0.83 (m, 7H, H-9; H-10; H-11); 
ES
+ MS m/z 338 ([M+Na]
+ 100%), 379 ([M+Na+CH3CN]
+ 100%). 
The spectroscopic data are consistent with that
206 reported in the literature. 
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(3S,4R,5R)-Allyl  4-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(trityl 
thio)-propanamido)-3-hydroxy-5-methylheptanoate (2.234) 
 
Compound  2.233  (336  mg,  1.07  mmol,  1  equiv)  was  treated  with  TFA  (2  mL)  in 
CH2Cl2  (5  mL)  for  1  h.  The  reaction  mixture  was  concentrated  in  vacuo,  and 
coevaporation with CH3CN and CHCl3 was performed to afford the free amine.  
To a solution of Fmoc-D-Cys(Tr)-OH (401 mg, 1.17 mmol, 1 equiv) in CH2Cl2 (4 mL) 
at 0 °C, PyBOP (665 mg, 1.28 mmol, 1.2 equiv), and Hünig’s base (557 µL, 3.19 mmol, 
3 equiv) were added. After 10 min, the previous deprotected amine in CH2Cl2 (2 mL) 
was added. The reaction mixture was stirred overnight and concentrated in vacuo. The 
crude material was purified by flash chromatography using EtOAc/hexane (1:9 then 
2:8) as eluent to give 2.234 as a white solid (432.3 mg, 52%). 
[]D
28 +0.6 (c 0.47, CH3OH); mp 60–62 °C; IR 3314, 3052, 2966, 1708, 1659, 1520, 
1446, 1258, 1172, 1033 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.76 (t, J=7.3 Hz, 
2H, HAr), 7.56 (t, J=7.6 Hz, 2H, HAr), 7.53–7.36 (m, 8H, HAr), 7.36–7.10 (m, 11H, HAr), 
5.82 (br d, J=9.6 Hz, 2H, H-2; NH), 5.29 (d, J=16.7 Hz, 1H, H-1), 5.21 (d, J=10.6 Hz, 
1H, H-1), 4.93 (d, J=7.6 Hz, 1H, NH), 4.56 (d, J=5.1 Hz, 2H, H-3), 4.49–4.30 (m, 2H, 
H-17), 4.30–4.14 (m, 1H, H-18), 4.05–3.90 (m, 1H, H-6), 3.90–3.77 (m, 1H, H-7), 3.73 
(q, J=6.4 Hz, 1H, H-13), 3.25 (br s, 1H, OH), 2.77–2.59 (m, 2H, H-14), 2.53 (d, J=16.2 
Hz, 1H, H-5), 2.40 (dd, J=16.4, 9.3 Hz, 1H, H-5), 1.87–1.70 (m, 1H, H-8), 1.58–1.45 
(m, 1H, H-10), 1.00–0.75 (m, 7H, H-9; H-10; H-11); 
13C NMR (100 MHz, CDCl3) ʴ 
ppm 172.6 (C, CO), 170.6 (C, CO), 156.1 (C, CO), 144.3 (3C, CAr), 143.58 (C, CAr), 
143.56 (C, CAr), 141.3 (2C, CAr), 131.8 (CH, C-2), 129.5 (6CH, CAr), 128.1 (6CH, CAr), 
127.8 (2CH, CAr), 127.1 (2CH, CAr), 126.9 (3CH, CAr), 124.92 (CH, CAr), 124.86 (CH, 
CAr), 120.0 (2CH, CAr), 118.5 (CH2, C-1), 68.5 (CH, C-6), 67.4 (C, CPh3), 67.0 (CH2, 
C-3 or C-17), 65.4 (CH2, C-3 or C-17), 57.5 (CH, C-7), 54.2 (CH, C-13), 47.0 (CH, C-
18), 38.1 (CH2, C-5), 34.3 (CH, C-8), 33.2 (CH2, C-14), 23.3 (CH2, C-10), 16.2 (CH3,     Experimental Procedures For Chapter 2 
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C-9), 11.6 (CH3, C-11); ES
+ MS m/z 805 ([M+Na]
+ 100%); HRMS (ESI) m/z calcd. for 
C48H50N2NaO6S (M+Na)
+ 805.3282, found 805.3280. 
 
 
(5R,8S,11R,12S)-Allyl  11-((R)-sec-butyl)-1-(9H-fluoren-9-yl)-12-hydroxy-5-(2-
(methyl-thio)ethyl)-3,6,9-trioxo-8-((tritylthio)methyl)-2-oxa-4,7,10-
triazatetradecan-14-oate (2.235) 
 
Compound 2.234 (405 mg, 0.52 mmol, 1 equiv) was treated with diethylamine (2 mL) 
in  CH3CN  (10  mL)  for  2  h.  The  reaction  mixture  was  concentrated  in  vacuo,  and 
coevaporation with CH3CN and CHCl3 was performed to afford the free amine.  
To a solution of Fmoc-D-Met-OH (250 mg, 0.67 mmol, 1.3 equiv) in CH2Cl2 (5 mL) 
cooled at 0 °C, PyBOP (431 g, 0.83 mmol, 1.6 equiv), and Hünig’s base (271 µL, 1.55 
mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before the 
previous free amine was added in CH2Cl2 (1 mL). The reaction mixture was stirred 
overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography using EtOAc/Petroleum ether (2:8 then 3:7 then 4:6) as eluent to afford 
2.235 as a white foam (398 mg, 84%). 
[]D
23 +22.9 (c 0.29, CH3OH); mp 144–146 °C; IR 3293, 3060, 2962, 2925, 1708, 
1650, 1524, 1438, 1266, 1221, 1172, 1025 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 
7.78 (d, J=7.6 Hz, 2H, HAr), 7.54 (dd, J=7.6, 3.5 Hz, 2H, HAr), 7.49–7.36 (m, 8H, HAr), 
7.36–7.06 (m, 11H, HAr), 6.49 (d, J=6.1 Hz, 1H, NH), 6.09 (d, J=9.1 Hz, 1H, NH), 
5.97–5.77 (m, 1H, H-2), 5.58 (d, J=6.1 Hz, 1H, NH), 5.30 (dd, J=17.2, 1.5 Hz, 1H, H-
1), 5.21 (dd, J=10.4, 1.3 Hz, 1H, H-1), 4.70–4.50 (m, 2H, H-3), 4.43 (dd, J=10.4, 7.3 
Hz, 1H, H-22), 4.37–3.79 (m, 6H, H-6; H-13; H-17; H-22; H-23), 3.93–3.79 (m, 1H, H-
7), 3.24 (br s, 1H, OH), 2.86 (dd, J=12.6, 6.1 Hz, 1H, H-14), 2.61–2.34 (m, 5H, H-5; H-
14; H-19), 2.18–1.94 (m, 4H, H-18; H-20), 1.94–1.73 (m, 2H, H-8; H-18), 1.47–1.63 
(m, 1H, H-10), 1.06–0.77 (m, 7H, H-9; H-10; H-11); 
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ppm 172.7 (C, CO), 171.0 (C, CO), 170.1 (C, CO), 156.2 (C, CO), 144.2 (3C, CAr), 
143.7 (C, CAr), 143.4 (C, CAr), 141.33 (C, CAr), 141.29 (C, CAr), 131.9 (CH, C-2), 129.4 
(6CH, CAr), 128.1 (6CH, CAr), 127.8 (2CH, CAr), 127.1 (2CH, CAr), 126.9 (3CH, CAr), 
124.9 (2CH, CAr), 120.0 (2CH, CAr), 118.3 (CH2, C-1), 68.5 (CH, C-6), 67.22 (C, CPh3), 
67.19 (CH2, C-22), 65.3 (CH2, C-3), 57.7 (CH, C-7), 54.6 (CH, C-17), 52.8 (CH, C-13), 
47.0 (CH, C-23), 38.0 (CH2, C-5), 34.4 (CH, C-8), 32.9 (CH2, C-14), 31.0 (CH2, C-18), 
30.2 (CH2, C-19), 23.6 (CH2, C-10), 16.2 (CH3, C-9), 15.3 (CH3, C-20), 11.6 (CH3, C-
11); ES
+ MS m/z 936 ([M+Na]
+ 100%); HRMS (ESI) m/z calcd. for C53H59N3NaO7S2 
(M+Na)
+ 936.3687, found 936.3679. 
 
 
(7R,11R,14S,17R,18S,Z)-Allyl 17-sec-butyl-7,18-dihydroxy-11-(2-(methylthio)-
ethyl)-9,12,15-trioxo-1,1,1-triphenyl-14-(tritylthiomethyl)-2-thia-10,13,16-
triazaicos-5-en-20-oate (2.236)  
 
2.235 (374 mg, 0.41 mmol, 1 equiv) was treated with diethylamine (2 mL) in CH3CN 
(10 mL) for 2 h. The reaction mixture was concentrated in vacuo, and coevaporation 
with CH3CN and CHCl3 was performed to afford the free amine. 
To a solution of the -hydroxy acid 2.219 (233 mg, 0.57 mmol, 1.4 equiv) in CH2Cl2 
(10 mL) cooled at 0 °C, PyBOP (340 mg, 0.65 mmol, 1.6 equiv), and Hünig’s base (214 
µL, 1.23 mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before 
the previous free amine was added. The reaction mixture was stirred overnight and 
concentrated in vacuo. The crude material was purified by flash chromatography using 
EtOAc/hexane (4:6 then 1:1) as eluent to provide 2.236 as a white solid (375 mg, 84%). 
[]D
23 +15.3 (c 0.32, CH3OH); mp 84–86 °C; IR 3286, 3011, 2957, 2931, 1726, 1639, 
1527, 1489, 1438, 1214, 1176, 1035, 974, 914 cm
–1; 
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ppm 7.55–7.12 (m, 31H, NH, HAr), 6.68 (d, J=7.1 Hz, 1H, NH), 6.14 (d, J=9.6 Hz, 1H, 
NH), 6.01–5.77 (m, 1H, H-2), 5.53–5.42 (m, 1H, H-25), 5.42–5.25 (m, 2H, H-1; H-24), 
5.25–5.13 (m, 1H, H-1), 4.57 (dd, J=5.6, 1.5 Hz, 2H, H-3), 4.49–4.23 (m, 2H, H-17; H-
23), 4.20–3.99 (m, 2H, H-6; H-13), 3.85 (dt, J=9.6, 6.3 Hz, 1H, H-7), 3.29 (d, J=4.5 Hz, 
1H, OH), 2.92 (br s, 1H, OH), 2.74–2.62 (m, 1H, H-14), 2.60–2.16 (m, 9H, H-5; H-14; 
H-19; H-22; H-27), 2.15–2.02 (m, 6H, H-18; H-20; H-26), 2.02–1.89 (m, 1H, H-18), 
1.87–1.68 (m, 1H, H-8), 1.64–1.46 (m, 1H, H-10), 1.05–0.79 (m, 7H, H-9; H-10; H-11); 
13C NMR (100 MHz, CDCl3) ʴ ppm 172.6 (C, CO), 172.0 (C, CO), 171.0 (C, CO), 
170.5 (C, CO), 144.8 (3C, CAr), 144.2 (3C, CAr), 132.3 (CH, C-25), 132.0 (CH, C-24), 
130.4 (CH, C-2), 129.5 (6CH, CAr), 129.4 (6CH, CAr), 128.1 (6CH, CAr), 127.9 (6CH, 
CAr), 126.9 (3CH, CAr), 126.6 (3CH, CAr), 118.3 (CH2, C-1), 69.9 (CH, C-23), 68.7 
(CH, C-6), 66.9 (C, CPh3), 66.6 (C, CPh3), 65.3 (CH2, C-3), 57.8 (CH, C-7), 53.9 (CH, 
C-17), 52.9 (CH, C-13), 44.1 (CH2), 37.9 (CH2), 34.5 (CH, C-8), 33.1 (CH2), 31.3 
(CH2), 31.2 (CH2), 30.5 (CH2), 30.1 (CH2), 23.9 (CH2, C-10), 16.2 (CH3, C-9), 15.4 
(CH3, C-20), 11.5 (CH3, C-11); ES
+ MS m/z 1115 ([M+Na]
+ 100%). 
 
 
Epi-Burkholdac B (2.237) 
 
To a solution of 2.236 (345.7 mg, 0.32 mmol, 1 equiv) in methanol (10 mL), were 
added morpoline (58 µL, 0.66 mmol, 2.1 equiv) and Pd(PPh3)4 (37 mg, 31.6 µmol, 0.1 
equiv). After 2.5 h of stirring, the solvent was removed and the residue was purified by 
flash chromatography (CH2Cl2 then 5% of MeOH in CH2Cl2 with formic acid) to afford 
the carboxylic acid as a yellow solid (333 mg, 100%). 
A solution of the previous carboxylic acid (333 mg, 0.32 mmol, 1 equiv) in CH2Cl2 
(250  mL)  was  added  very  slowly  to  a  stirred  solution  of  2-methyl-6-nitrobenzoic 
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DMAP (93 mg, 0.76 mmol, 2.4 equiv) at room temperature over 5 h. The reaction was 
stirred at rt overnight. The reaction mixture was concentrated in vacuo, and the residue 
was purified by column chromatography (CH2Cl2 then CH2Cl2/MeOH 99:1) to give the 
protected dithiol (224 mg, 68%) as a yellow solid. 
To a vigorously stirring solution of I2 (471 mg, 1.90 mmol, 10 equiv) in CH2Cl2/MeOH 
(350 mL: 35 mL) was added the protected dithiol (192 mg, 0.19 mmol, 1 equiv) in 
MeOH/CH2Cl2 (200 mL:20 mL) dropwise over 2.5 h and stirred for a further 30 min. 
Na2S2O3 (50 mL) was added, followed by brine (5 mL) and the aqueous phase extracted 
with EtOAc (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered, 
and  concentrated  in  vacuo.  The  residue  was  purified  by  flash  chromatography 
(hexane/CH2Cl2 1:1 then CH2Cl2 then MeOH/CH2Cl2 1:99 to 2:98) to give 2.237 as a 
white solid (60 mg, 59%). 
[]D
23 –45 (c 0.26, CH3OH); mp 108–110 °C; IR 3324, 2960, 2918, 1724, 1653, 1529, 
1431, 1261, 1160, 1047, 1020, 979 cm
–1; 
1H NMR (400 MHz, CD2Cl2) ʴ ppm 7.41 (br 
s, 2H, NH), 6.74 (d, J=9.1 Hz, 1H, NH), 6.31 (t, J=13.1 Hz, 1H, H-22), 5.71 (d, J=15.7 
Hz, 1H, H-23), 5.59–5.43 (m, 1H, H-8), 4.81 (dt, J=9.1, 3.5 Hz, 1H, H-18), 4.57–4.40 
(m, 1H, H-11), 4.30 (td, J=8.5, 4.6 Hz, 1H, H-2), 3.44–3.21 (m, 3H, H-7; H-19; H-20), 
3.14 (d, J=15.2 Hz, 1H, H-19), 2.99 (d, J=10.1 Hz, 1H, OH), 2.86–2.56 (m, 8H, H-4; H-
7; H-10; H-12; H-20; H-21), 2.56–2.37 (m, 1H, H-21), 2.32–2.14 (m, 5H, H-3; H-5; H-
13), 2.10–1.96 (m, 1H, H-3), 1.68–1.49 (m, 1H, H-14), 1.12–1.03 (m, 1H, H-14), 1.00 
(d, J=6.6 Hz, 3H, H-16), 0.85 (t, J=7.6 Hz, 3H, H-15); 
13C NMR (100 MHz, CD2Cl2) ʴ 
ppm 172.5 (C, C-9), 171.7 (C, C-6), 170.6 (C, C-1), 169.4 (C, C-17), 133.7 (CH, C-22), 
129.8 (CH, C-23), 71.4 (CH, C-8), 70.1 (CH, C-11), 62.9 (CH, C-12), 58.0 (CH, C-2), 
55.3 (CH, C-18), 41.9 (CH2, C-19), 41.4 (2CH2, C-7; C-20), 40.3 (CH2, C-10), 36.3 
(CH, C-13), 33.9 (CH2, C-21), 31.7 (CH2, C-4), 28.8 (CH2, C-3), 26.5 (CH2, C-14), 16.9 
(CH3, C-16), 15.8 (CH3, C-5), 11.1 (CH3, C-15); ES
+ MS m/z 570 ([M+Na]
+ 100%); 
HRMS (ESI) m/z calcd. for C23H37N3NaO6S (M+Na)
+ 570.1737, found 570.1738. 
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5.3.2.5. Total synthesis of burkholdac B 
(4R,5S)-Allyl 4-(tert-butoxycarbonylamino)-5-methyl-3-oxoheptanoate (2.238)  
 
To a solution of Boc-D-allo-Ile-OH (870 mg, 3.8 mmol, 1 equiv) in anhydrous CH2Cl2 
(15 mL), were added DMAP (92 mg, 0.8 mmol, 0.2 equiv), pentafluorophenol (762 mg, 
4.1 mmol, 1.1 equiv) and EDCI (865 mg, 4.5 mmol, 1.2 equiv). The reaction mixture 
was stirred at rt overnight. The layers were separated after addition of HCl (1 M) to the 
reaction  mixture.  The  organic  layer  was  washed  with  saturated  NaHCO3  solution 
followed  by  saturated  brine,  then  dried  and  concentrated  in  vacuo.  The  resulting 
colourless oil was placed under high vacuum.  
To a solution of diisopropylamine (1.75 mL, 12.4 mmol, 3.3 equiv) in anhydrous THF 
(4.5 mL), were added dropwise a solution of BuLi in hexanes (2.5 M, 5.4 mL, 9.4 
mmol, 3.6 equiv) followed by allylacetate (1.3 mL, 12.0 mmol, 3.2 equiv) at –78 °C. 
The reaction was stirred at –78 °C for 30 min and a solution in anhydrous THF (13 mL) 
of the intermediate ester of Boc-D-allo-Ile-OH was added. After stirring at –78 °C for 3 
h,  the  reaction  mixture  was  quenched  with  HCl  solution  (1  M).  The  layers  were 
separated and the aqueous layer was extracted with EtOAc (3 times). The combined 
organic layers were washed with saturated NaHCO3 solution and then with saturated 
brine, dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
chromatography using EtOAc/hexane (1:9) to afford 2.238 as a colourless oil (851 mg, 
72%). 
[]D
23 +13.5 (c 0.28, CH3OH); IR 3363, 2970, 2921, 2876, 1753, 1704, 1511, 1462, 
1368, 1238, 1156, 993 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 6.06–5.80 (m, 1H, H-
2), 5.34 (dd, J=17.2, 1.5 Hz, 1H, H-1), 5.26 (dd, J=10.6, 1.0 Hz, 1H, H-1), 5.05 (br d, 
J=9.1 Hz, 1H, NH), 4.64 (d, J=5.6 Hz, 2H, H-3), 4.48 (dd, J=9.1, 3.0 Hz, 1H, H-7), 3.57 
(s, 2H, H-5), 2.07–1.89 (m, 1H, H-8), 1.45 (s, 9H, CMe3), 1.28 (dquin, J=14.0, 7.2 Hz, 
1H, H-10), 0.97 (t, J=7.3 Hz, 3H, H-11), 0.94–0.82 (m, 1H, H-10), 0.79 (d, J=7.1 Hz, 
3H, H-9); 
13C NMR (100 MHz, CDCl3) ʴ ppm 202.2 (C, CO), 166.4 (C, CO), 155.9 
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(CH, C-7), 46.7 (CH2, C-5), 35.9 (CH, C-8), 28.3 (3CH3, CMe3), 26.8 (CH2, C-10), 13.8 
(CH3, C-9), 11.8 (CH3, C-11). 
 
 
(3S,4R,5S)-Allyl  4-(tert-butoxycarbonylamino)-3-hydroxy-5-methylheptanoate 
(2.239)  
 
To a solution of 2.238 (819 mg, 2.6 mmol, 1 equiv) in anhydrous MeOH (9 mL) at –78 
°C, was added KBH4 in portions (493 mg, 9.1 mmol, 3.5 equiv). The reaction was 
stirred for 10 min at –78 °C, warmed to –20 °C for 30 min and to 0 °C for 10 min. The 
reaction mixture was quenched by dropwise addition of glacial acetic acid (not pH < 6). 
The mixture was concentrated in vacuo and EtOAc/water (1:1, 40 mL) were added. The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 10 mL). The 
combined  organic  layers  were  dried  over  MgSO4,  and  concentrated  in  vacuo.  The 
residue was purified by flash chromatography using EtOAc/hexane (1:9 then 2:8) to 
provide 2.239 as a colourless oil (571.6 mg, 69%).  
[]D
23 –1.2 (c 0.52, CH3OH); IR 3436, 3367, 2966, 2933, 2872, 1691, 1516, 1458, 
1393, 1360, 1242, 1156, 1070, 980, 931 cm
–1; 
1H NMR (300 MHz, CDCl3) ʴ ppm 
6.05–5.82 (m, 1H, H-2), 5.33 (dd, J=17.2, 1.0 Hz, 1H, H-1), 5.25 (d, J=10.6 Hz, 1H, H-
1), 4.62 (d, J=5.6 Hz, 2H, H-3), 4.43 (br d, J=10.1 Hz, 1H, NH), 3.93 (dt, J=8.5, 2.3 Hz, 
1H, H-6), 3.71–3.54 (m, 1H, H-7), 3.23 (br s, 1H, OH), 2.66 (dd, J=17.2, 3.0 Hz, H-5), 
2.59–2.36 (m, 1H, H-5), 2.02–1.80 (m, 1H, H-8), 1.44 (s, 9H, CMe3), 1.41–1.31 (m, 1H, 
H-10), 1.29–1.11 (m, 1H, H-10), 0.92 (t, J=7.6 Hz, 3H, H-11), 0.86 (d, J=6.6 Hz, 3H, 
H-9); 
13C NMR (100 MHz, CDCl3) ʴ ppm 173.0 (C, C-4), 156.2 (C, CO), 131.8 (CH, 
C-2), 118.6 (CH2, C-1), 79.5 (C, CMe3), 69.1 (CH, C-6), 65.4 (CH2, C-3), 56.6 (CH, C-
7), 38.5 (CH2, C-5), 33.9 (CH, C-8), 28.3 (3CH3, CMe3), 27.0 (CH2, C-10), 13.2 (CH3, 
C-9), 11.7 (CH3, C-11); ES
+ MS m/z 338 ([M+Na]
+ 100%), 379 ([M+Na+CH3CN]
+ 
100%); HRMS (ESI) m/z calcd. for C16H30NO5 (M+H)
+ 316.2118 found 316.2122. 
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(3S,4R,5S)-Allyl 4-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(tritylthio)-
propanamido)-3-hydroxy-5-methylheptanoate (2.240) 
 
Compound 2.239 (547.6 mg, 1.74 mmol, 1 equiv) was treated with TFA (4 mL) in 
CH2Cl2  (10  mL)  for  3  h.  The  reaction  mixture  was  concentrated  in  vacuo,  and 
coevaporation with CH3CN and CHCl3 was performed to afford the free amine.  
To a solution of Fmoc-D-Cys(Tr)-OH (832 mg, 2.40 mmol, 1 equiv) in CH2Cl2 (8 mL) 
cooled at 0 °C, PyBOP (1.45 g, 2.78 mmol, 1.2 equiv), and Hünig’s base (908 µL, 5.20 
mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before the 
previous free amine in CH2Cl2 (4 mL) was added. The reaction mixture was stirred 
overnight  and  concentrated  in  vacuo.  The  crude  material  was  purified  by  flash 
chromatography using EtOAc/hexane (1:9 then 2:8) as eluent to give 2.240 as a white 
foam (907 mg, 67%). 
[]D
24 +8.3 (c 0.45, CH3OH); mp 44–46 °C; IR 3403, 3322, 3060, 2958, 1708, 1667, 
1511, 1450, 1258, 1172, 1033, 988 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.75 (t, 
J=6.8 Hz, 2H, HAr), 7.54 (t, J=8.3 Hz, 2H, HAr), 7.49–7.34 (m, 8H, HAr), 7.33–7.13 (m, 
11H, HAr), 5.97–5.72 (m, 2H, H-2; NH), 5.28 (d, J=17.2 Hz, 1H, H-1), 5.20 (d, J=10.6 
Hz, 1H, H-1), 4.93 (d, J=7.6 Hz, 1H, NH), 4.64–4.48 (m, 2H, H-3), 4.48–4.30 (m, 2H, 
H-17), 4.18 (t, J=6.6 Hz, 1H, H-18), 4.00–3.81 (m, 2H, H-6; H-7), 3.70 (q, J=6.4 Hz, 
1H, H-13), 3.22 (d, J=4.5 Hz, 1H, OH), 2.76–2.51 (m, 3H, H-5; H-14), 2.43 (dd, J=8.6 
Hz, 1H, H-5), 1.89 (qd, J=6.9, 3.0 Hz, 1H, H-8), 1.19 (sxt, J=6.9 Hz, 1H, H-10), 1.07 
(spt,  J=7.2  Hz,  1H,  H-10),  0.91–0.66  (m,  6H,  H-9;  H-11); 
13C  NMR  (100  MHz, 
CDCl3) ʴ ppm 172.9 (C, CO), 170.3 (C, CO), 156.1 (C, CO), 144.3 (3C, CAr), 143.6 
(C, CAr), 143.5 (C, CAr), 141.3 (2C, CAr), 131.7 (CH, C-2), 129.5 (6CH, CAr), 128.1 
(6CH, CAr), 127.8 (2CH, CAr), 127.1 (2CH, CAr), 126.9 (3CH, CAr), 124.91 (CH, CAr), 
124.86 (CH, CAr), 120.0 (2CH, CAr), 118.5 (CH2, C-1), 68.5 (CH, C-6), 67.4 (C, CPh3), 
67.0 (CH2, C-17), 65.4 (CH2, C-3), 55.1 (CH, C-7), 54.2 (CH, C-13), 47.0 (CH, C-18), 
38.3 (CH2, C-5), 33.6 (CH, C-8), 33.2 (CH2, C-14), 27.0 (CH2, C-10), 13.2 (CH3, C-9),     Experimental Procedures For Chapter 2 
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11.6 (CH3, C-11); ES
+ MS m/z 805 ([M+Na]
+ 100%); HRMS (ESI) m/z calcd. for 
C48H51N2O6S1 (M+H)
+ 783.3462, found 783.3457. 
 
 
(5R,8S,11R,12S)-Allyl  11-((S)-sec-butyl)-1-(9H-fluoren-9-yl)-12-hydroxy-5-(2-
(methyl-thio)ethyl)-3,6,9-trioxo-8-((tritylthio)methyl)-2-oxa-4,7,10-
triazatetradecan-14-oate (2.241) 
 
Compound 2.240 (617.5 mg, 0.79 mmol, 1 equiv) was treated with diethylamine (3 mL) 
in CH3CN (15 mL) for 2.5 h. The reaction mixture was concentrated in vacuo, and 
coevaporation with CH3CN and CHCl3 was performed to afford the free amine.  
To a solution of Fmoc-D-Met-OH (381 mg, 1.03 mmol, 1.3 equiv) in CH2Cl2 (10 mL) 
cooled at 0 °C, PyBOP (657 mg, 1.26 mmol, 1.6 equiv), and Hünig’s base (413 µL, 2.37 
mmol, 3 equiv) were added. The reaction mixture was stirred for 10 min before the 
previous free amine was added in CH2Cl2 (5 mL). The reaction mixture was stirred 
overnight and then concentrated in vacuo. The crude material was purified by flash 
chromatography using EtOAc/Petroleum ether (2:8 then 3:7 then 4:6) as eluent to afford 
2.241 as a white foam (661.7 mg, 92%). 
[]D
23 +28.1 (c 0.42, CH3OH); mp 66–68 °C; IR 3309, 3060, 2962, 2925, 2868, 1699, 
1650, 1524, 1442, 1238, 1172, 1037, 907 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 
7.87 (d, J=7.6 Hz, 2H, HAr), 7.64 (dd, J=7.3, 3.8 Hz, 2H, HAr), 7.58–7.45 (m, 8H, HAr), 
7.45–7.19 (m, 11H, HAr), 6.56 (d, J=6.6 Hz, 1H, NH), 6.22–6.06 (m, 1H, NH), 6.06–
5.86 (m, 1H, H-2), 5.63 (d, J=6.6 Hz, 1H, NH), 5.39 (dd, J=17.2, 1.5 Hz, 1H, H-1), 5.30 
(dd, J=10.4, 1.3Hz, 1H, H-1), 4.76–4.58 (m, 2H, H-3), 4.55–4.45 (m, 1H, H-22), 4.45–
4.36 (m, 1H, H-22), 4.36–4.19 (m, 2H, H-17; H-23), 4.11–3.96 (m, 3H, H-6; H-7; H-
13), 3.34 (d, J=4.0 Hz, 1H, OH), 2.92 (dd, J=12.6, 6.6 Hz, 1H, H-14), 2.75–2.45 (m, 
5H, H-5; H-14; H-19), 2.24–2.06 (m, 4H, H-18; H-20), 2.06–1.86 (m, 2H, H-8; H-18), 
1.46–1.29 (m, 1H, H-10), 1.29–1.14 (m, 1H, H-10), 1.04–0.84 (m, 6H, H-9; H-11); 
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NMR (100 MHz, CDCl3) ʴ ppm 173.0 (C, CO), 171.0 (C, CO), 169.8 (C, CO), 156.2 
(C, CO), 144.2 (3C, CAr), 143.7 (C, CAr), 143.5 (C, CAr), 141.33 (C, CAr), 141.29 (C, 
CAr), 131.8 (CH, C-2), 129.4 (6CH, CAr), 128.1 (6CH, CAr), 127.8 (2CH, CAr), 127.1 
(2CH, CAr), 126.9 (3CH, CAr), 124.9 (2CH, CAr), 120.0 (2CH, CAr), 118.4 (CH2, C-1), 
68.5 (CH, C-6), 67.21 (C, CPh3), 67.17 (CH2, C-22), 65.3 (CH2, C-3), 55.4 (CH, C-7), 
54.4 (CH, C-17), 52.8 (CH, C-13), 47.1 (CH, C-23), 38.3 (CH2, C-5), 33.9 (CH, C-8), 
32.9 (CH2, C-14), 31.2 (CH2, C-18), 30.2 (CH2, C-19), 27.0 (CH2, C-10), 15.3 (CH3, C-
20), 13.4 (CH3, C-9), 11.7 (CH3, C-11); ES
+ MS m/z 936 ([M+Na]
+ 100%); HRMS 
(ESI) m/z calcd. for C53H60N3O7S2 (M+H)
+ 914.3867, found 914.3863. 
 
 
(7S,11R,14R,17R,18R,E)-Allyl  17-((S)-sec-butyl)-7,18-dihydroxy-11-(2-(methyl--
thio)-ethyl)-9,12,15-trioxo-1,1,1-triphenyl-14-((tritylthio)methyl)-2-thia-10,13,16-
triazanona-dec-5-en-19-oate (2.242) 
 
2.241 (601 mg, 0.66 mmol, 1 equiv) was treated with diethylamine (3.2 mL) in CH3CN 
(15 mL) for 2 h. The reaction mixture was concentrated in vacuo, and coevaporation 
with CH3CN and CHCl3 was performed to afford the free amine. 
To a solution of the -hydroxy acid 2.219 (374 mg, 0.92 mmol, 1.4 equiv) in anhydrous 
CH2Cl2 (18 mL) cooled at 0 °C, PyBOP (547 mg, 1.05 mmol, 1.6 equiv) and Hünig’s 
base (344 µL, 1.97 mmol, 3 equiv) were added. After 10 min, the previous deprotected 
amine was added. The reaction mixture was stirred overnight and concentrated in vacuo. 
The crude material was purified by flash chromatography using EtOAc/hexane (4:6 then 
1:1) as eluent to provide 2.242 as a white solid (503 mg, 70%). 
[]D
23 +19.4 (c 0.41, CH3OH); mp 134–136 °C; IR 3273, 3077, 3056, 2958, 2909, 
1720, 1630, 1544, 1483, 1442, 1385, 1250, 1176, 1074, 1033, 980, 903 cm
–1; 
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(400 MHz, CDCl3) ʴ ppm 7.53–7.33 (m, 12H, HAr), 7.33–7.03 (m, 19H, NH; HAr), 
6.57 (d, J=7.6 Hz, 1H, NH), 5.98 (d, J=9.6 Hz, 1H, NH), 5.91–5.75 (m, 1H, H-2), 5.51–
5.39 (m, 1H, H-25), 5.39–5.22 (m, 2H, H-1; H-24), 5.18 (dd, J=10.4, 1.3 Hz, 1H, H-1), 
4.54 (dd, J=5.3, 3.8 Hz, 2H, H-3), 4.47–4.26 (m, 2H, H-17; H-23), 4.05–3.77 (m, 3H, 
H-6; H-7; H-13), 3.27 (d, J=4.5 Hz, 1H, OH), 2.95 (d, J=3.0 Hz, 1H, OH), 2.71–2.12 
(m, 10H, H-5; H-14; H-19; H-22; H-27), 2.12–1.97 (m, 6H, H-18; H-20; H-26), 1.97–
1.79 (m, 2H, H-8; H-18), 1.23 (dq, J=13.9, 7.0 Hz, 1H, H-10), 1.10 (spt, J=7.4 Hz, 1H, 
H-10), 0.93–0.63 (m, 6H, H-9; H-11); 
13C NMR (100 MHz, CDCl3) ʴ ppm 172.9 (C, 
CO), 171.8 (C, CO), 171.0 (C, CO), 170.2 (C, CO), 144.8 (3C, CAr), 144.2 (3C, CAr), 
132.3 (CH), 131.9 (CH), 130.4 (CH), 129.6 (6CH, CAr), 129.4 (6CH, CAr), 128.1 (6CH, 
CAr), 127.9 (6CH, CAr), 126.9 (3CH, CAr), 126.6 (3CH, CAr), 118.3 (CH2, C-1), 69.9 
(CH, C-23), 68.5 (CH, C-6), 67.0 (C, CPh3), 66.6 (C, CPh3), 65.3 (CH2, C-3), 55.5 (CH, 
C-7), 53.6 (CH, C-17), 52.9 (CH, C-13), 44.0 (CH2), 38.3 (CH2), 33.9 (CH, C-8), 33.2 
(CH2), 31.3 (CH2), 31.2 (CH2), 30.4 (CH2), 30.2 (CH2), 27.0 (CH2, C-10), 15.4 (CH3, C-
20), 13.6 (CH3, C-9), 11.7 (CH3, C-11); ES
+ MS m/z 1115 ([M+Na]
+ 100%).  
 
 
Burkholdac B (2.243)  
 
To a solution of 2.242 (473 mg, 0.43 mmol, 1 equiv) in anhydrous methanol (12 mL), 
were added morpoline (80 µL, 0.91 mmol, 2.1 equiv) and Pd(PPh3)4 (50 mg, 43 µmol, 
0.1 equiv). After 2.5 h of stirring, the solvent was removed and the residue was purified 
by flash chromatography (CH2Cl2 then 5% of MeOH in CH2Cl2 with formic acid) to 
afford the carboxylic acid as a yellow solid (456 mg, 100%). 
A solution of the previous carboxylic acid (456 mg, 0.43 mmol, 1 equiv) in CH2Cl2 
(343  mL)  was  added  dropwise  to  a  stirred  solution  of  2-methyl-6-nitrobenzoic 
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containing DMAP (127 mg, 1.04 mmol, 2.4 equiv) at room temperature over 5 h. The 
reaction was stirred at rt overnight. The reaction mixture was concentrated in vacuo, and 
the residue was purified by column chromatography (CH2Cl2 then CH2Cl2/MeOH 99:1 
to 98:2) to give the protected dithiol (170 mg, 38%) as a yellow solid. 
To a vigorously stirring solution of I2 (417 mg, 1.64 mmol, 10 equiv) in anhydrous 
CH2Cl2/MeOH (310 mL:31 mL) was added the protected dithiol (170 mg, 0.16 mmol, 1 
equiv) in anhydrous CH2Cl2/MeOH (177 mL:18 mL) dropwise over 2.5 h and stirred for 
a further 30 min. Na2S2O3 solution (50 mL) was added, followed by brine (5 mL) and 
the aqueous phase extracted with EtOAc (3 x 50 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified 
by flash chromatography (hexane/ CH2Cl2 1:1 then CH2Cl2 then MeOH/CH2Cl2 1:99 to 
2:98) to give burkholdac B (2.243) as a white solid (36 mg, 39%).  
[]D
32 –62.6 (c 0.34, CH3OH), []
25
D –23.3 (c 0.08, CH3CN), [lit.
85 []
24
D –22.8 (c 
1.00, CH3CN)]; mp 110–112 °C; IR 3334, 2962, 2925, 1728, 1650, 1520, 1430, 1274, 
1160, 980 cm
–1; 
1H NMR (400 MHz, CD2Cl2) ʴ ppm 7.41 (br s, 1H, NH), 7.24 (d, 
J=7.1 Hz, 1H, NH), 6.74 (d, J=9.6 Hz, 1H, NH), 6.45–6.26 (m, 1H, H-22), 5.71 (dt, 
J=15.7, 2.0 Hz, 1H, H-23), 5.55–5.44 (m, 1H, H-8), 4.84 (td, J=8.8, 3.5 Hz, 1H, H-18), 
4.64–4.47 (m, 1H, H-11), 4.30 (td, J=8.7, 4.5 Hz, 1H, H-2), 3.46–3.31 (m, 1H, H-19), 
3.26 (dd, J=13.1, 7.1 Hz, 2H, H-7; H-20), 3.10 (d, J=12.6 Hz, 1H, H-19), 2.94–2.82 (m, 
2H, OH; H-12), 2.82–2.59 (m, 7H, H-4; H-7; H-10; H-20; H-21), 2.56–2.40 (m, 1H, H-
21), 2.34–2.20 (m, 1H, H-3), 2.17 (s, 3H, H-5), 2.10–1.97 (m, 2H, H-3; H-13), 1.59–
1.42 (m, 1H, H-14), 1.29–1.15 (m, 1H, H-14), 0.91 (t, J=7.6 Hz, 3H, H-15), 0.88 (d, 
J=6.6 Hz, 3H, H-16); 
13C NMR (100 MHz, CD2Cl2) ʴ ppm 172.4 (C, C-9), 171.6 (C, 
C-6), 170.7 (C, C-1), 169.6 (C, C-17), 133.6 (CH, C-22), 129.7 (CH, C-23), 71.3 (CH, 
C-8), 68.7 (CH, C-11), 62.1 (CH, C-12), 57.9 (CH, C-2), 55.1 (CH, C-18), 42.1 (CH2, 
C-19), 41.6; 41.4 (2CH2,C-7; C-20), 40.1 (CH2, C-10), 36.8 (CH, C-13), 34.0 (CH2, C-
21), 31.7 (CH2, C-4), 28.8 (CH2, C-3), 27.7 (CH2, C-14), 15.8 (2CH3, C-5; C-16), 11.9 
(CH3, C-15); HRMS (ESI) m/z calcd. for C23H41N4O6S3 (M+NH4)
+ 565.2183, found 
565.2170. 
The spectroscopic data are consistent with that
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5.4. EXPERIMENTAL  DATA  FOR  CHAPTER  3:  HISTONE 
DEMETHYLASE INHIBITORS 
 
5.4.1. Tranylcypromine analogues 
 
5.4.1.1. Synthesis of tranylcypromine analogues 
(–)-Tranylcypromine (3.63) 
 
L-(+)-tartaric  acid  (193  mg,  1.28  mmol,  1  equiv)  was  dissolved  in  EtOH  and  (±)-
tranylcypromine 3.6 (171 mg, 1.28 mmol, 1 equiv) was added. The reaction mixture 
was stirred 15 min at 0 °C and 30 min at rt. The salts precipitated after a few minutes. 
The reaction mixture was cooled and the diastereomeric tartrates were filtered, dried 
under high vacuum to provide a white solid (280 mg). Two recrystallisations using a 
mixture of iPrOH/water (3:1) were performed to afford 19.6 mg of a crystalline product 
(ee 89%).  
[]D
29 –26.8 (c 0.26, H2O) [lit.
165 [ʱ]D
 25 –30.1 (c 1, H2O)]. 
(–)-Tranylcypromine (+)-tartrate (19.6 mg) was taken up in water and the solution was 
made basic to pH 12 with KOH (60%) and the solution was extracted with ether. The 
combined ether extracts were washed with water, dried and concentrated. Water was 
added to the crude material and HCl (1 M) was added. The resulting salt was filtered, 
washed with diethyl ether to afford 3.63 as a white solid (6 mg, 6%). 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.43–7.02 (m, 5H, HAr), 2.85 (ddd, J=7.8, 3.7, 
3.6 Hz, 1H, H-1), 2.40 (ddd, J=10.0, 6.5, 3.7 Hz, 1H, H-2), 1.43 (ddd, J=10.0, 6.7, 4.6 
Hz, 1H, H-3), 1.33 (dt, J=8.0, 6.6 Hz, 1H, H-3); 
13C NMR (75 MHz, CD3OD) ʴ ppm 
139.9 (C, CAr), 129.8 (CH, CAr), 128.0 (CH, CAr), 127.5 (CH, CAr), 32.1 (CH, C-1), 22.7 
(CH, C-2), 13.9 (CH2, C-3). 
The spectroscopic data are consistent with that
57 reported in the literature.  
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(+)-Tranylcypromine (3.64) 
 
D-(–)-tartaric  acid  (175  mg,  1.16  mmol,  1  equiv)  was  dissolved  in  EtOH  and  (±)-
tranylcypromine 3.6 (155 mg, 1.16 mmol, 1 equiv) was added. The reaction mixture 
was stirred 5 min at 0 °C and 30 min at rt. The salts precipitated after a few minutes. 
The mixture was cooled and the diastereomeric tartrates were filtered, dried under high 
vacuum to provide a white solid (246 mg). Two recrystallisations using a mixture of 
iPrOH/water (3:1) were performed to provide 43 mg of a white crystals product (ee 
72%).  
[]D
24 +21.7 (c 0.30, H2O) [lit.
165 [ʱ]D
 25 +30.1 (c 1, H2O)]. 
(+)-tranylcypromine (–)-tartrate (43 mg) was taken up in water and the solution was 
made basic to pH 12 with KOH (60%) and the solution was extracted with ether. The 
combined ether extracts were washed with water, dried and concentrated. Water was 
added to the crude material and HCl (1 M) was added. The resulting salt was filtered, 
washed with diethyl ether to afford 3.64 as a white solid (11 mg, 11%). 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.38–7.10 (m, 5H, HAr), 2.85 (ddd, J=7.8, 3.7, 
3.6 Hz, 1H, H-1), 2.39 (ddd, J=10.2, 6.6, 3.7 Hz, 1H, H-2), 1.43 (ddd, J=10.2, 7.0, 4.4 
Hz, 1H, H-3), 1.34 (dt, J=7.8, 6.7 Hz, 1H, H-3); 
13C NMR (75 MHz, CD3OD) ʴ ppm 
139.9 (C, CAr), 129.8 (CH, CAr), 128.0 (CH, CAr), 127.5 (CH, CAr), 32.1 (CH, C-1), 22.7 
(CH, C-2), 13.9 (CH2, C-3). 
The spectroscopic data are consistent with that
57 reported in the literature. 
 
 
Styrene asymmetric cyclopropanation to 3.67a-3.67e 
(S,S)-2,2'-Isopropylidene-bis(4-tert-butyl-2-oxazoline)  (0.01  equiv)  and  copper  (II) 
trifluoromethanesulfonate (0.01 equiv) were dissolved in chloroform and stirred for 45 
min  under  argon.  Styrene  derivatives  3.65  (5  equiv)  and  tert-butyl  diazoacetate  (1 
equiv)  were  then  added  and  the  reaction  mixture  was  stirred  for  5  h,  followed  by     Experimental Procedures For Chapter 3 
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concentration in vacuo and purification of the crude material by flash chromatography 
using CH2Cl2/hexane (2:8) to provide the pure trans-diastereoisomers 3.67.  
 
(R,R)-tert-Butyl 2-(4-methoxyphenyl)cyclopropanecarboxylate (3.67a)  
 
[]
23
D –192.2 (c 0.24, CHCl3), [lit.
208 []
24
D –241.4 (c 1.0, CHCl3)]; 
1H NMR (400 
MHz, CDCl3) ʴ ppm 7.03 (d, J=8.5 Hz, 2H, HAr), 6.83 (d, J=9.0 Hz, 2H, HAr), 3.79 (s, 
3H, OMe), 2.47–2.34 (m, 1H, H-2), 1.76 (dt, J=8.7, 4.6 Hz, 1H, H-1), 1.52–1.50 (m, 
1H, H-3), 1.48 (s, 9H, CMe3), 1.18 (ddd, J=8.0, 6.5, 4.5 Hz, 1H, H-3); ES
+ MS m/z 303 
([M+Na+MeOH]
+); Yield 77%. 
The spectroscopic data are consistent with that
209 reported in the literature. 
 
(R,R)-tert-Butyl 2-(4-fluorophenyl)cyclopropanecarboxylate (3.67b)  
 
[]
25
D –213.9 (c 0.44, CHCl3), [lit.
209 []
20
D –182 (c 0.64, CHCl3)]; 
1H NMR (300 
MHz,  CDCl3)  ʴ  ppm  7.10–7.02  (m,  2H,  HAr),  7.01–6.93  (m,  2H,  HAr),  2.43  (ddd, 
J=9.2, 6.5, 4.1 Hz, 1H, H-2), 1.78 (ddd, J=8.5, 5.3, 4.2 Hz, 1H, H-1), 1.52 (dd, J=9.5, 
4.4 Hz, 1H, H-3), 1.48 (s, 9H, CMe3), 1.19 (ddd, J=8.4, 6.4, 4.5 Hz, 1H, H-3); Yield 
46%. 
The spectroscopic data are consistent with that
209 reported in the literature. 
 
(R,R)-tert-Butyl 2-(4-bromophenyl)cyclopropanecarboxylate (3.67c)
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[]
25
D –196.1 (c 0.41, CHCl3), [lit. 
209 []
24
D –216.7 (c 1.00, CHCl3)]; 
1H NMR (300 
MHz, CDCl3) ʴ ppm 7.10–7.02 (br d, J=8.5 Hz, 2H, HAr), 6.70 (br d, J=8.2 Hz, 2H, 
HAr), 2.40 (ddd, J=9.2, 6.3, 4.1 Hz, 1H, H-2), 1.80 (ddd, J=8.4, 5.4, 4.2 Hz, 1H, H-1), 
1.54 (td, J=4.6, 0.8 Hz, 1H, H-3), 1.47 (s, 9H, CMe3), 1.20 (ddd, J=8.5, 6.4, 4.5 Hz, 1H, 
H-3); Yield 45%. 
The spectroscopic data are consistent with that
208 reported in the literature. 
 
(R,R)-tert-Butyl 2-(3-bromophenyl)cyclopropanecarboxylate (3.67d)  
 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.33 (dq, J=7.7, 1.0 Hz, 1H, HAr), 7.23 (t, J=1.8 
Hz, 1H, HAr), 7.14 (t, J=7.9 Hz, 1H, HAr), 7.03 (dt, J=7.8, 1.4 Hz, 1H, HAr), 2.41 (ddd, 
J=9.1, 6.2, 4.0 Hz, 1H, H-2), 1.83 (ddd, J=8.4, 5.3, 4.2 Hz, 1H, H-1), 1.61–1.50 (m, 1H, 
H-3), 1.48 (s, 9H, CMe3), 1.22 (ddd, J=8.5, 6.3, 4.6 Hz, 1H, H-3); Yield 21%. 
The spectroscopic data are consistent with that
210 reported in the literature. 
 
(R,R)-tert-Butyl 2-(2-bromophenyl)cyclopropanecarboxylate (3.67e) 
 
[]
25
D –66.3 (c 0.27, CH3OH); Colourless oil; IR 3060, 1716, 1442 cm
–1; 
1H NMR 
(300 MHz, CDCl3) ʴ ppm 7.57 (dd, J=7.9, 1.3 Hz, 1H, HAr), 7.23 (td, J=7.5, 1.3 Hz, 
1H, HAr), 7.09 (td, J=7.7, 1.8 Hz, 1H, HAr), 7.01 (dd, J=7.6, 1.5 Hz, 1H, HAr), 2.64 (ddd, 
J=9.0, 6.7, 4.5 Hz, 1H, H-2), 1.69 (dt, J=8.6, 5.1 Hz, 1H, H-1), 1.56 (dt, J=9.2, 4.7 Hz, 
1H, H-3), 1.50 (s, 9H, CMe3), 1.29 (ddd, J=8.4, 6.7, 4.6 Hz, 1H, H-3); 
13C NMR (75 
MHz, CDCl3) ʴ ppm 172.4 (C, CO), 139.4 (C, CAr), 132.6 (CH, CAr), 128.0 (CH, CAr), 
127.4 (CH, CAr), 127.3 (CH, CAr), 126.4 (C, CAr), 80.6 (C, CMe3), 28.2 (3CH3, CMe3), 
26.8 (CH, C-2), 24.3 (CH, C-1), 15.1 (CH2, C-3); EI MS m/z 240, 242 ([M–tBu]
+); 
Yield 30%.     Experimental Procedures For Chapter 3 
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Ester hydrolysis of 3.67 to 3.68 
 
The carboxylate esters 3.67 (1 equiv), TFA (13 equiv) and triethylsilane (2.5 equiv) 
were taken up in CH2Cl2. The reaction mixture was stirred  for 90 min followed by 
concentration in vacuo. The crude material was used with no further purification or 
purified by flash chromatography using CH2Cl2 as eluent if required to provide 3.68. 
 
(R,R)-2-(4-Methoxyphenyl)cyclopropane carboxylic acid (3.68a)  
 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.05 (d, J=8.7 Hz, 2H, HAr), 6.84 (d, J=8.7 Hz, 
2H, HAr), 3.80 (s, 3H, OMe), 2.61–2.41 (m, 1H, H-2), 1.84 (dt, J=8.6, 4.6 Hz, 1H, H-1), 
1.63 (dt, J=9.4, 4.8 Hz, 1H, H-3), 1.41–1.15 (m, 1H, H-3); Yield 78%.  
The spectroscopic data are consistent with that
176 reported in the literature. 
 
(R,R)-2-(4-Fluorophenyl)cyclopropane carboxylic acid (3.68b)  
 
1H NMR (300 MHz, CDCl3) ʴ ppm 10.76 (br s, 1H, CO2H), 7.32–7.20 (m, 2H, HAr), 
7.20–7.08 (m, 2H, HAr), 2.62 (ddd, J=9.3, 6.6, 4.2 Hz, 1H, H-2), 1.88 (ddd, J=9.1, 5.1, 
4.0 Hz, 1H, H-1), 1.68 (dt, J=9.4, 4.9 Hz, 1H, H-3), 1.39 (ddd, J=8.4, 6.7, 4.7 Hz, 1H, 
H-3); Yield 92%. 
The spectroscopic data are consistent with that
176 reported in the literature. 
 
(R,R)-2-(4-Bromophenyl)cyclopropanecarboxylic acid (3.68c)  
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1H NMR (300 MHz, CDCl3) ʴ ppm 7.42 (br d, J=8.4 Hz, 2H, HAr), 6.99 (br d, J=8.4 
Hz, 2H, HAr), 2.57 (ddd, J=9.2, 6.6, 4.0 Hz, 1H, H-2), 1.88 (ddd, J=8.5, 5.2, 4.2 Hz, 
1H, H-1), 1.68 (dt, J=9.4, 5.0 Hz, 1H, H-3), 1.38 (ddd, J=8.4, 6.6, 4.8 Hz, 1H, H-3); 
Yield 98%. 
The spectroscopic data are consistent with that
211 reported in the literature. 
 
(R,R)-2-(3-Bromophenyl)cyclopropanecarboxylic acid (3.68d)
  
 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.40–7.33 (m, 1H, HAr), 7.28–7.25 (m, 1H, HAr), 
7.17 (t, J=7.7 Hz, 1H, HAr), 7.05 (dt, J=7.8, 1.4 Hz, 1H, HAr), 2.58 (ddd, J=9.2, 6.6, 4.0 
Hz, 1H, H-2), 1.91 (ddd, J=8.5, 5.2, 4.2 Hz, 1H, H-1), 1.68 (dt, J=9.9, 5.1 Hz, 1H, H-3), 
1.41 (ddd, J=8.4, 6.8, 4.6 Hz, 1H, H-3); Yield 99%. 
The spectroscopic data are consistent with that
212 reported in the literature. 
 
(R,R)-2-(2-Bromophenyl)cyclopropanecarboxylic acid (3.68e)  
 
[]
25
D –76.4 (c 0.29, CHCl3), [lit.
212 (S,S)-enantiomer []D +109.9 (c 0.77, CHCl3)]; 
1H 
NMR (300 MHz, CDCl3) ʴ ppm 7.59 (dd, J=7.9, 1.3 Hz, 1H, HAr), 7.24 (td, J=7.7, 1.1 
Hz, 1H, HAr), 7.12 (td, J=7.6, 1.7 Hz, 1H, HAr), 7.05 (dd, J=7.7, 1.5 Hz, 1H, HAr), 2.80 
(ddd, J=9.2, 7.0, 4.4 Hz, 1H, H-2), 1.83 (dt, J=8.4, 5.1 Hz, 1H, H-1), 1.71 (dt, J=9.2, 4.7 
Hz, 1H, H-3), 1.44 (ddd, J=8.4, 7.0, 4.8 Hz, 1H, H-3); Yield 99%. 
The spectroscopic data are consistent with that
213 reported in the literature. 
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Curtius rearrangement of 3.68 to 3.69 
The acids 3.68 (1 equiv), diphenylphosphoryl azide (1.1 equiv) and triethylamine (1.5 
equiv) were combined in tert-butanol under argon and heated at reflux for 48 h. The 
mixture was diluted with EtOAc and saturated Na2CO3 solution. The organic layer was 
separated and the aqueous layer was extracted with EtOAc. The organics layers were 
combined,  dried  over  MgSO4  and  concentrated  in  vacuo.  The  crude  material  was 
purified by flash chromatography (EtOAc/hexane 2:8) to provide the desired carbamates 
3.69.  
 
(1R,2S)-tert-Butyl 2-(4-methoxyphenyl)cyclopropylcarbamate (3.69a)  
 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.15–7.05 (m, 2H, HAr), 6.90–6.76 (m, 2H, HAr), 
4.91 (br s, 1H, NH), 3.78 (s, 3H, OMe), 2.70–2.64 (m, 1H, H-1), 2.05–1.95 (m, 1H, H-
2), 1.48 (s, 9H, CMe3), 1.16–1.03 (m, 2H, H-3); Yield 47%. 
The spectroscopic data are consistent with that
176 reported in the literature. 
 
(1R,2S)-tert-Butyl 2-(4-fluorophenyl)cyclopropylcarbamate (3.69b)  
 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.15–7.11 (m, 2H, HAr), 7.01–6.88 (m, 2H, HAr), 
4.83 (br s, 1H, NH), 2.76–2.60 (m, 1H, H-1), 2.12–1.98 (m, 1H, H-2), 1.46 (s, 9H, 
CMe3), 1.19–1.04 (m, 2H, H-3); Yield 46%. 
The spectroscopic data are consistent with that reported in the literature. 
 
(1R,2S)-tert-Butyl 2-(4-bromophenyl)cyclopropylcarbamate (3.69c)  
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1H NMR (300 MHz, CDCl3) ʴ ppm 7.38 (br d, J=8.3 Hz, 2H, HAr), 7.03 (br d, J=8.3 
Hz, 2H, HAr), 4.82 (br s, 1H, NH), 2.73–2.64 (m, 1H, H-1), 2.09–1.94 (m, 1H, H-2), 
1.46 (s, 9H, CMe3), 1.19–1.08 (m, 2H, H-3); ES
+ MS m/z 334, 336 ([M+Na]
+); Yield 
73%. 
The spectroscopic data are consistent with that
214 reported in the literature. 
 
(1R,2S)-tert-Butyl 2-(3-bromophenyl)cyclopropylcarbamate (3.69d)  
 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.43–7.37 (m, 1H, HAr), 7.31 (m, 1H, HAr), 7.13 (t, 
J=7.8 Hz, 1H, HAr), 7.10–7.04 (m, 1H, HAr), 4.82 (br s, 1H, NH), 2.77–2.69 (m, 1H, H-
1), 2.02 (td, J=7.8, 3.0 Hz, 1H, H-2), 1.46 (s, 9H, CMe3), 1.20–1.13 (m, 2H, H-3); ES
+ 
MS m/z 334, 336 ([M+Na]
+); Yield 52%. 
The spectroscopic data are consistent with that
215 reported in the literature. 
 
(1R,2S)-tert-Butyl 2-(2-bromophenyl)cyclopropylcarbamate (3.69e)  
 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.64–7.53 (m, 1H, HAr), 7.36–7.22 (m, 1H, HAr), 
7.18–7.04 (m, 2H, HAr), 5.05 (br s, 1H, NH), 2.90–2.65 (dt, J=7.9, 4.1 Hz, 1H, H-1), 
2.25 (ddd, J=9.8, 6.4, 3.4 Hz, 1H, H-2), 1.52 (s, 9H, CMe3), 1.40–1.14 (m, 2H, H-3); 
ES
+ MS m/z 334, 336 ([M+Na]
+); Yield 33%. 
The spectroscopic data are consistent with that
216 reported in the literature. 
 
 
Suzuki coupling of 3.69c-e to 3.69f-h 
To a solution of the aryl bromide in a mixture of toluene/methanol/water (80:18:2) were 
added  tetrakis(triphenylphosphine)palladium  (0.2  equiv),  phenylboronic  acid  or  4-    Experimental Procedures For Chapter 3 
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pyridylboronic acid (4 equiv), and Na2CO3 (2 equiv). The reaction mixture was refluxed 
overnight. The mixture was then diluted with EtOAc, washed with water and brine and 
purified by flash chromatography (EtOAc/hexane 5:95) to provide the biphenyl product.  
 
(1R,2S)-tert-Butyl-2-(biphenyl-4-yl)cyclopropylcarbamate (3.69f)  
 
[]
23
D –99.4 (c 0.25, CHCl3); mp 98–100 °C; IR 3338, 1687, 1523, 1483 cm
–1; 
1H 
NMR (300 MHz, CDCl3) ʴ ppm 7.61–7.48 (m, 4H, HAr), 7.44 (t, J=7.5 Hz, 2H, HAr), 
7.35 (d, J=7.4 Hz, 1H, HAr), 7.21 (d, J=8.1 Hz, 2H, HAr), 4.88 (br s, 1H, NH), 2.85–2.72 
(m, 1H, H-1), 2.09 (ddd, J=9.3, 6.4, 3.1 Hz, 1H, H-2), 1.48 (s, 9H, CMe3), 1.33–1.08 
(m, 2H, H-3); 
13C NMR (75 MHz, CDCl3) ʴ ppm 156.3 (C, CO), 141.0 (C, CAr), 139.9 
(C, CAr), 139.0 (C, CAr), 128.7 (2CH, CAr), 127.0 (3CH, CAr), 126.9 (2CH, CAr), 126.8 
(2CH, CAr), 79.7 (C, CMe3), 32.6 (CH, C-1), 28.4 (3CH3, CMe3), 24.8 (CH, C-2), 16.4 
(CH2, C-3); ES
+ MS m/z 332 ([M+Na]
+); HRMS (ESI) m/z calcd. for C20H23NNaO2 
(M+Na)
+ 332.1621, found 332.1616; Yield 73%. 
 
(1R,2S)-tert-Butyl-2-(biphenyl-3-yl)cyclopropylcarbamate (3.69g)  
 
[]
25
D –50.8 (c 0.52, CH3OH); mp 68–70 °C; IR 3330, 1687, 1511, 1483 cm
–1; 
1H 
NMR (400 MHz, CDCl3) ʴ ppm 7.67–7.52 (m, 2H, HAr), 7.50–7.39 (m, 3H, HAr), 
7.38–7.31 (m, 3H, HAr), 7.13 (d, J=7.6 Hz, 1H, HAr), 4.87 (br s, 1H, NH), 2.89–2.73 (m, 
1H, H-1), 2.12 (ddd, J=9.5, 6.4, 3.3 Hz, 1H, H-2), 1.48 (s, 9H, CMe3), 1.32–1.13 (m, 
2H, H-3); 
13C NMR (100 MHz, CDCl3) ʴ ppm 156.2 (C, CO), 141.3 (C, CAr), 141.2 
(2C, CAr), 128.73 (CH, CAr), 128.69 (2CH, CAr), 127.23 (CH, CAr), 127.19 (2CH, CAr), 
125.4 (CH, CAr), 125.3 (CH, CAr), 125.0 (CH, CAr), 79.7 (C, CMe3), 32.6 (CH, C-1), 
28.4  (3CH3,  CMe3),  25.1  (CH,  C-2),  16.6  (CH2,  C-3);  ES
+  MS  m/z  373     Experimental Procedures For Chapter 3 
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([M+Na+CH3CN]
+);  HRMS  (ESI)  m/z  calcd.  for  C20H23NNaO2  (M+Na)
+  332.1621, 
found 332.1628; Yield 66%. 
 
(1R,2S)-tert-Butyl-2-(biphenyl-2-yl)cyclopropylcarbamate (3.69h)  
 
mp 64–66 °C; IR 3338, 1696, 1480 cm
–1; 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.45 (d, 
J=5.1 Hz, 4H, HAr), 7.38 (dq, J=8.8, 4.3 Hz, 1H, HAr), 7.33–7.20 (m, 3H, HAr), 7.04 (d, 
J=7.1 Hz, 1H, HAr), 4.56 (br s, 1H, NH), 2.87–2.62 (m, 1H, H-1), 2.00 (ddd, J=9.9, 6.3, 
3.0 Hz, 1H, H-2), 1.46 (s, 9H, CMe3), 1.15 (q, J=6.1 Hz, 1H, H-3), 1.08–0.98 (m, 1H, 
H-3); 
13C NMR (100 MHz, CDCl3) ʴ ppm 156.2 (C, CO), 142.5 (C, CAr), 141.6 (C, 
CAr), 137.8 (C, CAr), 129.7 (2CH, CAr), 129.6 (2CH, CAr), 128.0 (CH, CAr), 127.5 (CH, 
CAr), 126.9 (CH, CAr), 125.9 (CH, CAr), 125.0 (CH, CAr), 79.5 (C, CMe3), 33.2 (CH, C-
1),  28.3  (3CH3,  CMe3),  23.3  (CH,  C-2),  17.0  (CH2,  C-3);  ES
+  MS  m/z  373 
([M+Na+CH3CN]
+);  HRMS  (ESI)  m/z  calcd.  for  C20H23NNaO2  (M+Na)
+  332.1621, 
found 332.1626; Yield 18%. 
 
tert-Butyl ((1R,2S)-2-(4-(pyridin-4-yl)phenyl)cyclopropyl)carbamate (3.74) 
 
1H NMR (300 MHz, CDCl3) ʴ ppm 8.63 (d, J=5.3 Hz, 2H, HAr), 7.54 (br d, J=8.3 Hz, 
2H, HAr), 7.47 (br d, J=6.4 Hz, 2H, HAr), 7.24 (br d, J=8.3 Hz, 2H, HAr), 5.01 (br s, 1H, 
NH), 2.82–2.72 (m, 1H, H-1), 2.15–2.06 (m, 1H, H-2), 1.46 (s, 9H, CMe3), 1.32–1.10 
(m, 2H, H-3); 
13C NMR (100 MHz, CDCl3) ʴ ppm 156.3 (C), 150.1 (2CH, CAr), 148.0 
(C, CAr), 142.1 (C, CAr), 135.7 (C, CAr), 127.1 (2CH, CAr), 126.9 (2CH, CAr), 121.3     Experimental Procedures For Chapter 3 
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(2CH, CAr), 79.7 (C, CMe3), 32.8 (CH, C-1), 28.4 (3C, CMe3), 25.0 (CH, C-2), 16.4 
(CH2, C-3); Yield 43%.  
 
Suzuki coupling of furyl derivatives (3.72 and 3.73) 
3.69c or 3.69d (1 equiv), Pd(PPh3)4 (0.16 equiv) and 2- or 3- furanylboronic acid (4 
equiv) were dissolved in DME (4 mL), and the mixture was degassed for 1 min and 
stirred for 10 min at rt. To the mixture was added K2CO3 solution (2 M). The mixture 
was degassed again for 1 min and stirred at 85 °C for 2 days in a sealed tube. The 
resulting mixture was cooled to rt and poured into a mixture of HCl (0.1 N)/EtOAc 
(1:1).  After  partition,  the  organic  layer  was  washed  with  water,  ﬁltered,  and 
concentrated. The residue was purified by flash chromatography using 2.5-5% EtOAc in 
hexane to afford 3.72 or 3.73 as a yellow solid. 
 
tert-Butyl ((1R,2S)-2-(4-(furan-2-yl)phenyl)cyclopropyl)carbamate (3.72) 
 
1H NMR (400 MHz, CDCl3) ʴ ppm 7.57 (d, J=8.5 Hz, 2H, HAr), 7.45 (d, J=1.0 Hz, 
1H, HAr), 7.15 (d, J=8.0 Hz, 2H, HAr), 6.60 (d, J=3.0 Hz, 1H, HAr), 6.46 (dd, J=3.3, 1.8 
Hz, 1H, HAr), 4.85 (br s, 1H, NH), 2.90–2.62 (m, 1H, H-1), 2.05 (ddd, J=9.5, 6.5, 3.5 
Hz,  1H, H-2), 1.47 (s, 9H, CMe3), 1.22–1.12 (m, 2H, H-3); 
13C NMR (100 MHz, 
CDCl3) ʴ ppm 156.3 (C), 154.0 (C), 141.8 (CH, CAr), 140.0 (C, CAr), 128.8 (C, CAr), 
126.7 (2CH, CAr), 123.8 (2CH, CAr), 111.6 (CH, CAr), 104.4 (CH, CAr), 79.7 (C, CMe3), 
32.6 (CH, C-1), 28.4 (3CH3, CMe3), 25.0 (CH, C-2), 16.4 (CH2, C-3). Yield 21%. 
 
tert-Butyl ((1R,2S)-2-(3-(furan-2-yl)phenyl)cyclopropyl)carbamate (3.73) 
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1H NMR (400 MHz, CDCl3) ʴ ppm 7.55–7.38 (m, 3H, HAr), 7.27 (td, J=7.6, 1.3 Hz, 
1H, HAr), 7.04 (d, J=7.5 Hz, 1H, HAr), 6.66–6.62 (m, 1H, HAr), 6.46 (dt, J=3.4, 1.7 Hz, 
1H, HAr), 4.85 (br s, 1H, NH), 2.84–2.75 (m, 1H, H-1), 2.15–1.98 (m, 1H, H-2), 1.47 (s, 
9H, CMe3), 1.29–1.08 (m, 2H, H-3); 
13C NMR (100 MHz, CDCl3) ʴ ppm 156.3 (C), 
153.9 (C), 142.0 (CH, CAr), 141.2 (C, CAr), 130.9 (C, CAr), 128.7 (CH, CAr), 125.6 (CH, 
CAr), 121.7; 121.6 (2CH, CAr), 111.6 (CH, CAr), 105.0 (CH, CAr), 79.7(C, CMe3), 32.5 
(CH, C-1), 28.4 (3CH3, CMe3), 25.0 (CH, C-2), 16.5 (CH2, C-3); Yield 24%. 
 
 
Boc deprotection of 3.69 to 3.70 
Carbamate derivative 3.69 was taken up in anhydrous EtOAc cooled at 0 °C and HCl(g) 
was bubbled into the solution for 40-90 min. The reaction was monitored by TLC. The 
resulting HCl salt 3.70 was filtered and washed with diethyl ether. 
 
(1R,2S)-2-(4-Methoxyphenyl)cyclopropanamine hydrochloride (3.70a)  
 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.09 (d, J=8.8 Hz, 2H, HAr), 6.85 (d, J=8.4 Hz, 
2H, HAr), 3.75 (s, 3H, OMe), 2.76 (dt, J=7.7, 3.7 Hz, 1H, H-1), 2.34 (ddd, J=10.2, 6.5, 
3.5 Hz, 1H, H-2), 1.37 (ddd, J=10.4, 6.4, 4.4 Hz, 1H, H-3), 1.25 (q, J=6.6 Hz, 1H, H-3); 
HRMS (ESI) m/z calcd. for C10H14NO (M+H)
+ 164.1070, found 164.1074; Yield 77%. 
The spectroscopic data are consistent with that
176 reported in the literature. 
 
(1R,2S)-2-(4-Fluorophenyl)cyclopropanamine hydrochloride (3.70b)  
 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.25–7.14 (m, 2H, HAr), 7.10–6.96 (m, 2H, HAr), 
2.89–2.65 (m, 1H, H-1), 2.39 (ddd, J=10.1, 6.5, 3.6 Hz, 1H, H-2), 1.42 (ddd, J=10.2, 
6.7,  4.4  Hz,  1H,  H-3),  1.30  (dt,  J=7.8,  6.7  Hz,  1H,  H-3);  ES
+  MS  m/z  193 
([M+H+CH3CN]
+);  HRMS  (ESI)  m/z  calcd.  for  C9H11FN  (M+H)
+  152.0870,  found 
152.0870; Yield 35%.     Experimental Procedures For Chapter 3 
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The spectroscopic data are consistent with that
176 reported in the literature. 
 
(1R,2S)-2-(4-Bromophenyl)cyclopropanamine hydrochloride (3.70c)  
 
1H NMR (400 MHz, CD3OD) ʴ ppm 7.51 (d, J=8.5 Hz, 2H, HAr), 7.16 (d, J=8.5 Hz, 
2H, HAr), 2.90 (quin, J=7.9 Hz, 1H, H-1), 2.42 (ddd, J=10.3, 6.5, 3.8 Hz, 1H, H-2), 1.49 
(ddd, J=10.3, 6.8, 4.5 Hz, 1H, H-3), 1.39 (q, J=7.0 Hz, 1H, H-3); ES
+ MS m/z 253, 255 
([M+H+CH3CN]
+); HRMS (ESI) m/z calcd. for C9H11BrN (M+H)
+ 212.0069, found 
212.0073; Yield 51%. 
The spectroscopic data are consistent with that
215 reported in the literature. 
 
(1R,2S)-2-(3-Bromophenyl)cyclopropanamine hydrochloride (3.70d)  
 
1H NMR (400 MHz, CD3OD) ʴ ppm 7.48–7.40 (m, 2H, HAr), 7.29 (t, J=7.8 Hz, 1H), 
7.23–7.17 (m, 1H, HAr), 2.93 (quin, J=8.0 Hz, 1H, H-1), 2.42 (ddd, J=10.0, 6.5, 3.5 Hz, 
1H, H-2), 1.49 (ddd, J=10.3, 6.3, 4.5 Hz, 1H, H-3), 1.41 (q, J=7.0 Hz, 1H, H-3); ES
+ 
MS m/z 253, 255 ([M+H+CH3CN]
+); HRMS (ESI) m/z calcd. for C9H11BrN (M+H)
+ 
212.0069, found 212.0072; Yield 25%. 
The spectroscopic data are consistent with that
215 reported in the literature. 
 
(1R,2S)-2-(2-Bromophenyl)cyclopropanamine hydrochloride (3.70e)  
 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.63 (d, J=7.9 Hz, 1H, HAr), 7.34 (t, J=7.5 Hz, 
1H, HAr), 7.18 (dd, J=16.2, 7.5 Hz, 2H, HAr), 2.96–2.79 (m, 1H, H-1), 2.73–2.53 (m, 
1H, H-2), 1.62–1.35 (m, 2H, H-3); Yield 77%. 
The spectroscopic data are consistent with that
216 reported in the literature.     Experimental Procedures For Chapter 3 
 
319 
 
(1R,2S)-2-(Biphenyl-4-yl)cyclopropanamine hydrochloride (3.70f)  
 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.70–7.53 (m, 4H, HAr), 7.44 (t, J=7.5 Hz, 2H, 
HAr), 7.39–7.21 (m, 3H, HAr), 2.91 (quin, J=4.1 Hz, 1H, H-1), 2.44 (ddd, J=10.1, 6.7, 
3.6 Hz, 1H, H-2), 1.54–1.33 (m, 2H, H-3); ES
+ MS m/z 251 ([M+H+CH3CN]
+); HRMS 
(ESI) m/z calcd. for C15H16N (M+H)
+ 210.1277, found 210.1282; Yield 94%. 
The spectroscopic data are consistent with that
217 reported in the literature. 
 
(1R,2S)-2-(Biphenyl-3-yl)cyclopropanamine hydrochloride (3.70g)  
 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.73–7.56 (m, 2H, HAr), 7.56–7.32 (m, 6H, HAr), 
7.18 (br d, J=7.5 Hz, 1H, HAr), 2.95 (quin, J=7.7 Hz, 1H, H-1), 2.50 (ddd, J=10.1, 6.7, 
3.6  Hz,  1H,  H-2),  1.58–1.38  (m,  2H,  H-3);  ES
+  MS  m/z  210  ([M+H]
+),  251 
([M+H+CH3CN]
+);  HRMS  (ESI)  m/z  calcd.  for  C15H16N  (M+H)
+  210.1277,  found 
210.1281; Yield 100%. 
The spectroscopic data are consistent with that
217 reported in the literature. 
 
(1R,2S)-2-(Biphenyl-2-yl)cyclopropanamine hydrochloride (3.70h)  
 
[]
25
D –15.3 (c 0.07, CH3OH); mp 52–54 °C; IR 1597, 1487, 1454 cm
–1; 
1H NMR (400 
MHz, CD3OD) ʴ ppm 7.56–7.26 (m, 8H, HAr), 7.12–6.98 (m, 1H, HAr), 3.03–2.87 (m, 
1H, H-1), 2.39 (td, J=8.6, 3.5 Hz, 1H, H-2), 1.07–1.45 (m, 2H, H-3); 
13C NMR (100 
MHz, CD3OD) ʴ ppm 143.9 (C, CAr), 142.5 (C, CAr), 136.7 (C, CAr), 130.9 (CH, CAr), 
130.5 (2CH, CAr), 129.5 (2CH, CAr), 128.9 (CH, CAr), 128.3 (CH, CAr), 127.7 (CH, CAr),     Experimental Procedures For Chapter 3 
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125.4 (CH, CAr), 32.3 (CH, C-1), 21.0 (CH, C-2), 14.8 (CH2, C-3); ES
+ MS m/z 210 
([M+H]
+),  251  ([M+H+CH3CN]
+);  HRMS  (ESI)  m/z  calcd.  for  C15H16N  (M+H)
+ 
210.1277, found 210.1279; Yield 100%. 
 
 
5.4.1.2. Biological testing of tranylcypromine analogues 
Expression and purification of full length human LSD1 (performed by Dr P. Duriez) 
The plasmid pET15b-His-tagged full length human LSD1 (provided by Fei Lan in Dr. 
Yang Shi’s laboratory) was expressed in E. Coli BL21 RIPL Codon Plus (DE3) cells 
(Stratagene). The protein expression was induced with IPTG (0.1 mM) for 3 h at rt. The 
bacteria were centrifuged at 6,500 rpm for 10 min at 4 ºC. The supernatant was removed 
and the bacteria pellet was frozen down at –20 ºC. The bacterial pellet was lysed (40 
mM Tris–HCl pH 8.0, 300 mM NaCl, 0.2% Triton X100, 5% glycerol, 10 µg/ml DNase 
I  and  10  mM  MgCl2  in  the  presence  of  protease  inhibitors),  sonicated  on  ice  and 
centrifuged at 15,000 rpm for 20 min at 4 ºC. The supernatant was used to purify LSD1 
recombinant protein using an AKTA Prime FPLC system. Three chromatography steps 
(Nickel, gel filtration and Q-sepharose columns) were successively performed and the 
purified protein was stored in 20 mM Tris–HCl pH 8.0, 300 mM NaCl and 5% glycerol 
at –80 °C.  
 
Mass spectrometric LSD1 enzyme assay (performed by Dr P. Duriez with the help of 
Dr B. Zeidan and Prof P. Townsend) 
In a total volume of 50 µL, 50 µM of tranylcypromine was incubated alone or in the 
presence  of  2.4  µg  of  LSD1  at  rt  for  10  min.  The  peptide 
ARTK(me2)QTARKSTGGKAPRKQLA was added at a concentration of 35 µM and 
the reaction was carried out for an extra 20 min at rt. The samples were kept on ice 
before mass spectrometric analysis, carried out with NP20 ProteinChip (BioRad) arrays. 
An  NP20  array  was  pre-rinsed  with  5  µL  of  ultrapure  H2O  and  3  µL  sample  was 
subsequently applied on each spot. The sample-loaded arrays were then incubated for 
15 min in a humidity chamber at rt. Then, 1 µL of energy absorbing matrix [EAM; a-
cyano-4-hydroxycinnamic acid (CHCA) in 200 µL acetonitrile and 200 µL of 1% TFA] 
was added to each spot, air dried and reapplied. ProteinChips were read using a PBS II 
SELDI  mass  spectrometer  (Bio-Rad).  Data  acquisition  was  performed  using  the     Experimental Procedures For Chapter 3 
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following parameters: mass range between 0.5 and 20 kDa with a focus mass of 3 kDa 
and detector blinding at 0.5 kDa. The laser settings used were: intensity of 3000 nJ and 
18 shots, 2 warming shots at an intensity of 3300 nJ, acquisition of one shot every four 
pixels in a randomised fashion.  
 
Fluorescence based LSD1 enzyme assay 
LSD1 enzymatic activity was measured with a synthetic peptide corresponding to the 
first  21  amino  acids  of  human  H3  dimethylated  on  lysine  4: 
ARTK(me2)QTARKSTGGKAPRKQLA (PeptideSynthetics). Assays were carried out 
in a final volume of 100 µL in white 96 microplate wells (Greiner). An aliquot of 1.25 
µg of recombinant LSD1 enzyme was added to a 50 µL reaction containing 35 µM of 
peptide substrate in 50 mM potassium phosphate pH 7.2 and the reaction mixture was 
incubated at rt for 20 min. 50 µL of Amplex® Red/HRP were added and the reaction 
mixture kept at rt for another 30 min before quenching by adding 20 µL of Amplex® 
Red  Stop  solution  (InVitrogen).  Fluorescence  was  measured  on  a  Varioskan  Flash 
microplate reader (Thermo Fisher) (λ excitation = 530 nm and λ emission = 590 nm).  
 
Preparation of Amplex® Red  
The following reagents were added to prepare the Amplex® Red/HRP solution required 
for 10 assays: 
  5 µL of 10 mM Amplex® Red (InVitrogen) 
  10 µL of 10 U/mL HRP (prepared with 2 µL of 1000 U/mL HRP stock 
solution (Sigma) in 198 µL of 50 mM potassium phosphate buffer) 
  485 µL of 50 mM potassium phosphate buffer. 
If the number of assay is higher, the quantities used are increased proportionally. 50 µL 
of this mix is added in each well. 
 
Reconstitution of Amplex® Red Stop reagent 
Amplex® Red Stop reagent contained in one vial (InVitrogen) was dissolved in ethanol 
(1.45 mL). 1.35 mL of this solution was transferred in a vial and diluted with 1.35 mL 
of water. The solution was stored in a cold room in the dark.  
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For assays with inhibitors, the compound was incubated with LSD1 for 10 min prior to 
the addition of the peptide substrate. The RFU is taken for several concentrations (5 to 8 
concentrations). Ki(inact) values are determined from two to three dose–response curves 
for each compound  (Table 5.1). The sigmoidal  dose response  curves  were obtained 
using GraphPad Prism software. 
 
Compound  Structure 
Ki (1) 
µM 
Ki (2) 
µM 
Ki (3) 
µM 
Ki 
average 
STDEV 
PCPA 
racemic 
 
25.29  34.25  15.31  24.95  9.5 
(-)-PCPA 
 
30.06  39.98  14.31  28.12  12.9 
(+)-PCPA 
 
26.62  38.07  13.73  26.14  12.2 
3.70c 
 
3.82  4.146  3.227  3.73  0.5 
3.70d 
 
12.32  8.436  6.077  8.94  3.2 
3.70e 
 
11.32  12.75  11.05  11.71  0.9 
3.70f 
 
5.18  8.714  9.047  7.65  2.1 
3.81 
 
1.29  3.46  /  2.38  1.5     Experimental Procedures For Chapter 3 
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3.82 
 
4.76  7.84  /  6.30  2.2 
3.83 
 
4.3  9.06  /  6.68  3.4 
3.84 
 
13.38  9.24  /  11.31  2.9 
3.85 
 
15.17  11.6  /  13.39  2.5 
3.86 
 
20.81  12.65  /  16.73  5.8 
3.90 
 
0.62  0.91  /  0.77  0.2 
3.91 
 
1.49  2.64  /  2.06  0.8 
3.92 
 
2.02  2.25  /  2.13  0.2 
3.93 
 
6.31  7.08  /  6.70  0.5 
Table 5.1 : Activity of the tranylcypromine derivatives in LSD1 enzyme assay     Experimental Procedures For Chapter 3 
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LNCaP cell growth inhibition assay  
This experiment was done by Rosemary Bulleid, Annette Hayden and Simon Crabb. 
 
Tranylcypromine analogues prepared:  
Six-day proliferation assay were undertaken using the LNCaP prostate adenocarcinoma 
cell  line  to  produce  IC50  values  for  inhibition.  The  IC50  are  obtained  from  two 
experiments for each compound (Table 5.2).  
 
Compound  Substitution 
IC50 (μM)  Mean 
(μM) 
STDEV  SEM 
IC50 (1)  IC50 (2) 
(±)-
Tranylcypromine  /  236200  111800  174000  87964.08  62200 
3.70a  4-OMe  1790  1621  1705.5  119.501  84.5 
3.70b  4-F  189400  297600  243500  76508.95  54100 
3.70c  4-Br  38.63  183.6  111.115  102.5093  72.485 
3.70d  3-Br  126.9  131.4  129.15  3.181981  2.25 
3.70e  2-Br  6201  5537  5869  469.5189  332 
3.70f  4-Ph  88.2  131.7  109.95  30.75914  21.75 
3.70g  3-Ph  298.1  155.1  226.6  101.1  5.75 
3.70h  2-Ph  175.8  187.3  181.6  8.1  71.5 
Table 5.2 : Activity of the tranylcypromine derivatives in LNCaP growth inhibition 
 
Examples of dose response obtained for LNCaP cell growth inhibition assay: (for 4-Ph, 
4-F, tranylcypromine, 3-Br, 4-Br and 4-OMe) 
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First IC50 determination: 
 
Second IC50 determination: 
LNCAP
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38r
4Br
4Meo
 
     BOTTOM
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-4.055
8.820e-005
4F
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-0.7227
0.1894
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-20100
101.4
-0.6268
0.2362
38r
-22.29
127.4
-3.896
0.0001269
4Br
-12.24
116.3
-4.413
3.863e-005
4Meo
-95.63
101.9
-2.747
0.001790
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-1.488
0.001314
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German compounds activity in LNCaP growth inhibition: 
 
The IC50 are also obtained from two experiments for each compound (Table 5.3). 
 
Compound 
IC50(µM) 
Mean (µM)  SEM 
IC50 (1)  IC50 (2) 
PCPA  1204  1060  1132  72.00 
3.90  11.15  2.18  6.67  4.48 
3.91  1.139  1.93  1.53  0.40 
3.92  35.67  10.78  23.23  12.45 
3.93  3.06  2.46  2.76  0.30 
Table 5.3 : Activity of the German compounds in LNCaP growth inhibition 
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5.4.2. Phenelzine analogues 
 
5.4.2.1. Synthesis of phenelzine analogues 
2-(4-Bromophenyl)ethanol (3.114) 
 
To a solution of 4-bromophenylacetic acid (1 g, 4.7 mmol, 1 equiv) in THF (10 mL) 
was added dropwise BH3.Me2S (850 µL, 14.0 mmol, 3 equiv) in THF (3 mL) at 0 °C. 
The reaction mixture was stirred at 0 °C for 3 h, and then warming up at rt for 3 h. To 
the reaction mixture cooled to 0 °C was added dropwise a solution of sodium hydroxide 
(3 M). The mixture was stirred at rt overnight. Granulated sodium hydroxide was added 
to adjust the pH to 11. The aqueous layer was saturated with potassium carbonate and 
the THF layer was separated. The aqueous layer was extracted twice with ethyl acetate. 
The combined organic layers were dried over MgSO4 and evaporated to provide 3.114 
as a colourless oil (935 mg, 100%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.44 (d, J=8.3 Hz, 2H, HAr), 7.12 (d, J=8.3 Hz, 
2H, HAr), 3.86 (t, J=6.6 Hz, 2H, CH2OH), 2.84 (t, J=6.6 Hz, 2H, CH2-Ph), 1.48 (br s, 
1H, OH). 
The spectroscopic data are consistent with that
218 reported in the literature. 
 
 
2-(para-Bromophenyl)ethyl tosylate (3.112) 
 
To a solution of 2-(4-bromophenyl)ethanol (3.114) (970 mg, 4.8 mmol, 1 equiv) in 
CH2Cl2  (20  mL)  were  added  triethylamine  (1.68  mL,  12.0  mmol,  2.5  equiv)  and 
tosylchloride (1.4 g, 7.2 mmol, 1.5 equiv) at 0 °C. The reaction mixture was stirred at rt 
overnight.  The  reaction  mixture  was  washed  with  a  saturated  NH4Cl  solution.  The 
organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude     Experimental Procedures For Chapter 3 
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material was purified by flash chromatography (Hexane/EtOAc 9:1) to afford 3.112 as a 
white solid (1.57 g, 92%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.66 (d, J=8.3 Hz, 2H, HAr), 7.35 (d, J=8.3 Hz, 
2H, HAr), 7.28 (d, J=7.5 Hz, 2H, HAr), 6.97 (d, J=8.3 Hz, 2H, HAr), 4.21 (t, J=6.6 Hz, 
2H, CH2O), 2.91 (t, J=6.6 Hz, 2H, CH2-Ph), 2.45 (s, 3H, Me). 
The spectroscopic data are consistent with that
219 reported in the literature. 
 
 
2-(4-Bromophenyl)acetaldehyde (3.119)
 
 
To  a  solution  of  2-(4-bromophenyl)ethanol  3.114  (0.92  g,  4.57  mmol,  1  equiv)  in 
CH2Cl2 (0.33 M, 15 mL) Dess-Martin Periodinane (2.33 g, 5.49 mmol, 1.2 equiv) was 
added slowly at 0 °C. The reaction mixture was allowed to warm to rt and stirred for 19 
h under argon at rt. After adding CH2Cl2 (45 mL) and Na2S2O3 solution (1 M, 60 mL) 
the reaction mixture was stirred for another 10 min. The aqueous layer was extracted 
with CH2Cl2 (2 x 50 mL) and the combined organic layers were then washed with 
NaHCO3 solution (5%, 2 x 100 mL) and brine (100 mL). The combined organic layers 
were dried over MgSO4 and the solvent was removed in vacuo to provide 3.119 as 
colourless needles (950 mg, 100%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 9.74 (t, J=2.3 Hz, 1H, -CHO), 7.56–7.45 (m, 2H, 
HAr), 7.16–7.03 (m, 2H, HAr), 3.67 (d, J=2.3 Hz, 2H, CH2). 
The spectroscopic data are consistent with that
220 reported in the literature. 
 
 
tert-Butyl-2-(2-(4-bromophenyl)ethylidene)hydrazinecarboxylate (3.120)
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The aldehyde 3.119 (0.95 g, 4.77 mmol, 1 equiv) was dissolved in anhydrous toluene 
(16 mL) and tert-butyl carbazate (0.63 g, 4.77 mmol, 1 equiv) was added. The solution 
was stirred for 2 h at 50 °C under argon. Reducing the volume of toluene and cooling 
overnight resulted in the precipitation of a white solid. The supernatant was removed 
and the solid washed with cold toluene (2 x 5 mL) to obtain the hydrazone 3.120 as a 
colourless powder (1.13 g, 76%). 
 
 
tert-Butyl-2-(4-bromophenethyl)hydrazinecarboxylate (3.115)
 
 
To a solution of hydrazone 3.120 (0.71 g, 2.27 mmol, 1 equiv) in anhydrous CH2Cl2 (8 
mL), NaBH(OAc)3 (1.2 g, 5.68 mmol, 2.5 equiv) and anhydrous acetic acid (0.13 mL, 
2.27 mmol, 1 equiv) were added. The reaction mixture was allowed to stir for 18 h 
under argon at rt. NaOH solution (1 M, 10 mL) was added and the solution was stirred 
for another 20 min. The CH2Cl2 layer was separated and the solvent removed in vacuo, 
the crude product was dissolved in NaOH solution (1 M, 10 mL) and extract with Et2O 
(3 x 10 mL). The combined organic layers were dried over MgSO4 and the solvent was 
removed  in  vacuo.  The  crude  material  was  purified  by  flash  chromatography 
(hexane/EtOAc 9:1) to afford 3.115 as a colourless solid (600 mg, 84%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.38 (d, J=8.4 Hz, 2H, HAr), 7.07 (d, J=8.4 Hz, 
2H, HAr), 2.96 (m, 2H, CH2NH), 2.79–2.72 (m, 2H, CH2Ar), 1.47 (s, 9H, CMe3); 
13C 
NMR (75 MHz, CDCl3) ʴ ppm 155.7 (C, CO), 138.8 (C, CAr), 131.7 (CH, CAr), 130.5 
(CH, CAr), 119.8 (C, CAr), 81.9 (C, CMe3), 52.6 (CH2, CH2NH), 33.6 (CH2, CH2Ar), 
28.3 (3CH3, CMe3). 
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2-(4-Bromophenethyl)hydrazinium chloride (3.121)
 
 
The Boc-protected hydrazine 3.115 (23.2 mg, 0.07 mmol, 1 equiv) was dissolved in a 
solution of HCl in dioxane (4 M, 1.2 mL). After 30 min of stirring the solvent was 
evaporated  and  was  coevaporated  with  toluene,  MeCN  and  twice  with  CHCl3.  The 
unprotected hydrazine chloride salt  3.121 was obtained as  a  yellow solid (18.3 mg, 
99%). 
1H NMR (300 MHz, CD3OD) ʴ ppm 7.49–7.37 (m, 2H, HAr), 7.24–7.07 (m, 2H, HAr), 
3.27 (dt, J=3.2, 1.8 Hz, 2H, CH2NH), 2.91 (d, J=7.9 Hz, 2H, CH2Ar). 
The spectroscopic data are consistent with that
221 reported in the literature. 
 
 
tert-Butyl-2-(2-(4-biphenyl)acetyl)hydrazinecarboxylate (3.117)
 
 
The arylbromide 3.115 (100 mg, 0.32 mmol, 1 equiv) was dissolved in MeCN (0.3 M, 2 
mL) then phenylboronic acid (67 mg, 0.32 mmol, 1 equiv) and of K2CO3 solution (0.5 
M, 2 mL) were added. The reaction mixture was heated to reflux for 10 min. After 
adding Pd(PPh3)4 (14.7 mg, 0.01 mmol, 0.04 equiv) the dispersion was refluxed for 
another 16 h. The reaction mixture was cooled to rt, filtered and the filtrate diluted with 
HCl solution (1 M, 20 mL) and extracted with CH2Cl2 (2 x 20 mL) and EtOAc (2 x 20 
mL). The organic layer was washed with brine (2 x 10 mL), dried with MgSO4 and the 
solvent removed in vacuo. The crude product was purified by flash chromatography 
(hexane/EtOAc 9:1) to give the biphenyl compound 3.117 as a yellow solid (17.4 mg, 
18%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.60–7.24 (m, 9H, HAr), 3.02 (m, 2H, CH2NH), 
2.92–2.80 (m, 2H, CH2Ar), 1.53–1.40 (s, 9H, CMe3); 
13C NMR (75 MHz, CDCl3) ʴ     Experimental Procedures For Chapter 3 
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ppm 140.0 (C, CAr), 138.0 (C, CAr), 130.4 (CH, CAr), 129.5 (CH, CAr), 128.2 (CH, CAr), 
127.7 (CH, CAr), 126.0 (CH, CAr), 79.0 (C, CMe3), 58.5 (CH2, CH2NH), 32.3 (CH2, 
CH2Ar), 27.4 (3CH3, CMe3). 
 
 
2-(4-Diphenethyl)hydrazinium chloride (3.122)
 
 
The  Boc-protected  biphenyl  compound  3.117  (15  mg,  0.05  mmol,  1  equiv)  was 
dissolved in a solution of HCl in dioxane (4 M, 1 mL) and stirred at rt for 90 min. After 
removing  the  solvent  in  vacuo,  the  remaining  solid  was  washed  with  Et2O.  The 
hydrochloride salt 3.122 was obtained as a yellow solid (11.3 mg, 94%). 
1H NMR (300 MHz, CDCl3) ʴ ppm 7.64–7.21 (m, 9H, HAr), 3.28 (m, 2H, CH2NH), 
3.04 (m, 2H, CH2Ar). 
The spectroscopic data are consistent with that
222 reported in the literature 
 
 
5.4.2.2. Biological testing of phenelzine  
LNCaP cell growth inhibition assay  
 
Six-day proliferation assay was performed using the LNCaP prostate adenocarcinoma 
cell line to give the IC50 for the inhibition by phenelzine sulfate.  
 
Compound 
IC50 (μM)  mean 
(μM) 
SEM 
IC50 (1)  IC50 (2) 
Phenelzine sulfate 
(3.123) 
121.8  121.6  121.7  0.1 
Table 5.4 : Activity of phenelzine in LNCaP growth inhibition      
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6. APPENDIX 
 
6.1. X-RAY CRYSTAL STRUCTURE DATA FOR 1.48 
 
 
 
 
 
Table 1. Crystal data and structure refinement details. 
   
Identification code   2010sot0230     
Empirical formula   C22H26N4O6S 
Formula weight   474.53 
Temperature   120(2) K 
Wavelength   0.71073 Å 
Crystal system   Monoclinic 
Space group   P21  
Unit cell dimensions  a = 10.8208(8) Å   
  b = 10.2781(8) Å   = 110.432(4)° 
  c = 10.8216(8) Å   
Volume  1127.83(15) Å
3 
Z  2 
Density (calculated)  1.397 Mg / m
3 
Absorption coefficient  0.191 mm
1 
F(000)  500 
Crystal  Lath; Colourless 
Crystal size  0.30  0.12  0.03 mm
3 
 range for data collection  3.03  25.03° 
Index ranges  12  h  11, 12  k  12, 11  l  12 
Reflections collected  9619 
Independent reflections  2108 [Rint = 0.0658] 
Completeness to  = 25.03°  99.4%  
Absorption correction  Semiempirical from equivalents 
Max. and min. transmission  0.9943 and 0.9450 
Refinement method  Full-matrix least-squares on F
2 
Data / restraints / parameters  2108 / 7 / 298 
Goodness-of-fit on F
2  1.204 
Final R indices [F
2 > 2(F
2)]  R1 = 0.1047, wR2 = 0.2662 
R indices (all data)  R1 = 0.1118, wR2 = 0.2706 
Absolute structure parameter  Not reliably determined 
Largest diff. peak and hole  1.352 and 0.467 e Å
3 
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Thermal ellipsoids are drawn at the 35% probability level     Appendix 
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6.2. X-RAY CRYSTAL STRUCTURE DATA FOR 1.59 
 
 
 
Table 1. Crystal data and structure refinement details. 
   
Identification code   2010sot0301 (HB6/15) 
Empirical formula   C37H51N7O6S, 4(H2O) 
Formula weight   793.97 
Temperature   120(2) K 
Wavelength   0.71073 Å 
Crystal system   Monoclinic 
Space group   P21  
Unit cell dimensions  a = 7.6044(3) Å   
  b = 12.4594(6) Å   = 95.416(3)° 
  c = 22.9801(11) Å   
Volume  2167.56(17) Å
3 
Z  2 
Density (calculated)  1.217 Mg / m
3 
Absorption coefficient  0.134 mm
1 
F(000)  852 
Crystal  Rod; Colourless 
Crystal size  0.30  0.10  0.08 mm
3 
 range for data collection  2.91  27.48° 
Index ranges  9  h  9, 16  k  16, 29  l  29 
Reflections collected  25060 
Independent reflections  5171 [Rint = 0.0761] 
Completeness to  = 27.48°  99.7%  
Absorption correction  Semiempirical from equivalents 
Max. and min. transmission  0.9893 and 0.9608 
Refinement method  Full-matrix least-squares on F
2 
Data / restraints / parameters  5171 / 25 / 528 
Goodness-of-fit on F
2  1.181 
Final R indices [F
2 > 2(F
2)]  R1 = 0.1121, wR2 = 0.2526 
R indices (all data)  R1 = 0.1444, wR2 = 0.2731 
Absolute structure parameter  10(10) 
Largest diff. peak and hole  0.770 and 0.368 e Å
3 
 
 
 
     Appendix 
336 
 
 
 
 
 
Thermal ellipsoids drawn at the 35% probability level, solvent water and selected 
hydrogens omitted for clarity. 
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6.3. NMR SPECTRA 
 
1H NMR spectrum of 1.38 
HB5-91.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
N
H
O
NH2 Boc
1.38
 
 
1H NMR spectrum of 1.39 
 
HB5-92.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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S
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1.39
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1H NMR spectrum of 1.40 
 
HB6-50.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
N
N
Boc S
O
O
H
1.40
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1H and 
13C NMR spectra of 1.42 
 
HB6-51.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
N
N
S
O
O
O
N O
O
H
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13C-HB6-51.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
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O
O
O
N
O
O
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1H and 
13C NMR spectra of 1.48 
 
HB6-24.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
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S
O
O
O
N O
O2N
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13C_HB6-24.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
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S
O
O
O
N O
O2N
1.48
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1H NMR spectrum of 1.52 
 
HB5-96.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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N
O
N
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1H and 
13C NMR spectra of 1.54 
 
HB6-02.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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O
N
O
N
O
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H
H
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13C_HB6_02.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
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O
N
O
N
O
N
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H
H
1.54
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1H and 
13C NMR spectra of 1.56 
 
HB6-05.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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N
O
N
O
N
O
N
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H
H
H
1.56
 
 
 
 
13C-HB6-05.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
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O
O
N
O
N
O
N
O
N
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H
H
H
1.56
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1H NMR spectrum of 1.59 
 
SOTON_HB6_15_MINUS10DEG_1H
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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O
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N
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O
N
O
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O
O
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1H NMR spectrum of 1.69 
 
HB6-49 ALA_PHE.ESP
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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N
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N
H
O
O
O
1.69
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1H and 
13C NMR spectra of 1.65 
 
ap3010hb1.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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N
S
O
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N
O
O
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O
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H
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192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
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N
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O
O
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O
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1H NMR spectrum of 1.63 
 
HB6_60_1H_MJ.esp
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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1H NMR spectrum of 1.133 
 
HB8-53.ESP
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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O
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1H NMR spectrum of 1.134 
 
NOV22-2011-HANAE.010.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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S
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1H NMR spectrum of 1.72 
 
ma0211hb2.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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S
O
O
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H
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1H NMR spectrum of 1.135 
 
HB8-57.ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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O
O
O
N
O
O
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1H NMR spectrum of 1.75 
 
HB8_67_DMSO_1H
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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N
O
N H O
O
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1H NMR spectrum of 1.137 
 
AUG18-2011-HANAE.010.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
N
H
O
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1H NMR spectrum of 1.138 
 
NOV25-2011-HANAE.020.esp
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
N
H
S
NH2 Boc
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1H and 
13C NMR spectra of 1.77 
 
Nov22-2011-Hanae.020.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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N
S
O
O
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H
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Nov22-2011-Hanae.021.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
N
N
S
O
O
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H
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1H and 
13C NMR spectra of 1.139 
 
Nov22-2011-Hanae.030.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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O
O
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192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
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N O
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1H NMR spectrum of 1.101 
 
RSTBU.ESP
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1H NMR spectrum of 1.112 
 
HB7-27.ESP
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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1H NMR spectrum of 1.115 
 
HB7-34.esp
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1H NMR spectrum of 1.116 
 
HB7-36.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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1H NMR spectrum of 1.117 
 
HB7-37.esp
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O
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1H and 
13C NMR spectra of 1.119 
 
HB7-45.ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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O
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O
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O
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se1410hb4.011.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
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O
O
O
O
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1H NMR spectrum of 1.124 
 
HB7-39-C2.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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1H and 
13C NMR spectra of 1.126 
 
HB7-49.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
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N
N
O
O
O
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se1310hb1.011.esp
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N
O
O
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1H NMR spectrum of 1.128 
 
se2710hb2.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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O
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1H NMR spectrum of 1.130 
 
HB7_88_38.jcamp
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1H NMR spectrum of 1.20 
 
SSAPROTON8_20_10
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1H NMR spectrum of 2.144 
 
HB4_94.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
H2N OH
2.144
 
 
1H NMR spectrum of 2.145 
 
se0909hb3.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
2.145
S HN
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1H NMR spectrum of 2.46 
 
se1109hb2.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
2.46
S N
S O
 
 
1H NMR spectrum of 2.38 
 
se1609hb2.010.esp
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
O STr
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1H NMR spectrum of 2.47 
 
se2109hb1.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
OH
N
O
S
S
TrS
2.47
 
 
1H NMR spectrum of 2.86 
 
fe0709hb1.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
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O
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O
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1H and 
13C NMR spectra of 2.153 
 
JU0408HB1.010.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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ju0408hb3.010.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
O
H
N
O
NH2
O
2.153
 
 
     Appendix 
365 
 
1H and 
13C NMR spectra of 2.154 
 
ju0608hb2.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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ju2008hb2.011.esp
216 208 200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
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1H and 
13C NMR spectra of 2.155 
se2608ls2.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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N
O
N
S
O
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se2608ls2.011.esp
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1H and 
13C NMR spectra of 2.156 
 
se0308hb1.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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se0308hb1.011.esp
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1H NMR spectrum of 2.158 
 
au1208hb3.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
H2N
S
O
OH
Ph
Ph
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1H NMR spectrum of 2.159 
 
jy2508hb1.001.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
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1H and 
13C NMR spectra of 2.160 
 
se0608hb2.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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se0608hb2.011.esp
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Chemical Shift (ppm)
N
H
N
S
HN
O
CO2Me
S
2.160
O
O
Ph3C
 
 
     Appendix 
370 
 
1H and 
13C NMR spectra of 2.163 
 
dc1408ls4.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
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N
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dc1408ls4.011.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
O
H
N
O
N
S
NH2
O
2.163
 
 
     Appendix 
371 
 
1H and 
13C NMR spectra of 2.164 
 
dc0508hb1.010.esp
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dc0608hb1.010.esp
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1H and 
13C NMR spectra of 2.165 
 
dc1408ls2.010.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
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dc1408ls2.011.esp
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1H and 
13C NMR spectra of 2.166 
 
dc0408hb1.010.esp
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1H NMR spectrum of 2.171 
 
ma1509hb1.010.esp
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1H NMR spectrum of 2.149 
 
ma1709hb2.010.esp
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1H NMR spectrum of 2.151 
 
ma1809hb5.010.esp
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1H NMR spectrum of 2.147 
 
fe2608hb2.010.esp
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1H NMR spectrum of 2.176 
 
1H_HB76_ma2609hb3.1r.esp
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1H NMR spectrum of 2.100 
 
1H_HB77_ma3009hb4.1r.esp
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1H NMR spectrum of 2.173 
 
my1508hb3.010.esp
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1H NMR spectrum of 2.174 
 
oc2708hb2.010.esp
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1H NMR spectrum of 2.175 
 
nv0908hb1.010.esp
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1H NMR spectrum of 2.109 
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1H NMR spectrum of 2.177 
 
1H_HB95_ma3109hb1.010.esp
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1H NMR spectrum of 2.178 
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1H spectrum of 2.18 
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1H and 
13C NMR spectra of 2.184 
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1H NMR spectrum of 2.186 
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1H and 
13C NMR spectra of 2.188 
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1H and 
13C NMR spectra of 2.179 
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1H and 
13C NMR spectra of 2.185 
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1H and 
13C NMR spectra of 2.187 
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1H and 
13C NMR spectra of 2.189 
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1H and 
13C NMR spectra of 2.180 
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1H and 
13C NMR spectra of 2.190 
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1H and 
13C NMR spectra of 2.191 
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1H and 
13C NMR spectra of 2.192 
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1H and 
13C NMR spectra of 2.193 
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1H and 
13C NMR spectra of 2.181 
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1H and 
13C NMR spectra of 2.194 
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1H and 
13C NMR spectra of 2.183 
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1H and 
13C NMR spectra of 2.201 
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1H and 
13C NMR spectra of 2.203 
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1H and 
13C NMR spectra of 2.223 
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1H and 
13C NMR spectra of 2.224 
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1H and 
13C NMR spectra of 2.225 
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1H and 
13C NMR spectra of 2.217 
 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
O H
S
N H O
NH
O N H
O
O
O
S
S
2.217
 
 
 
 
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0 -8
Chemical Shift (ppm)
2.217
O H
S
N H O
NH
O N H
O
O
O
S
S
 
     Appendix 
402 
 
1H and 
13C NMR spectra of 2.229 
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1H and 
13C NMR spectra of 2.230 
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1H and 
13C NMR spectra of 2.231 
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1H and 
13C NMR spectra of 2.29 
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1H and 
13C NMR spectra of 2.232 
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1H and 
13C NMR spectra of 2.234 
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1H and 
13C NMR spectra of 2.235 
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1H and 
13C NMR spectra of 2.236 
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1H and 
13C NMR spectra of 2.237 
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1H and 
13C NMR spectra of 2.238 
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1H and 
13C NMR spectra of 2.239 
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1H and 
13C NMR spectra of 2.240 
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1H and 
13C NMR spectra of 2.241 
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1H and 
13C NMR spectra of 2.242 
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1H and 
13C NMR spectra of 2.243 
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1H NMR spectrum of 3.63 
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1H NMR spectrum of 3.64 
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1H NMR spectrum of 3.67a 
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1H NMR spectrum of 3.67b 
 
nv0908hb3.010.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
(R)
(R)
F
3.67b
O
O
 
     Appendix 
419 
 
1H NMR spectrum of 3.67c 
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1H and 
13C NMR spectra of 3.67e 
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1H NMR spectrum of 3.68a 
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1H NMR spectrum of 3.68b 
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1H NMR spectrum of 3.68c 
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1H NMR spectrum of 3.68d 
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1H NMR spectrum of 3.68e 
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1H NMR spectrum of 3.69c 
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1H NMR spectrum of 3.69d 
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1H NMR spectrum of 3.69e 
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1H and 
13C NMR spectra of 3.69f 
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1H and 
13C NMR spectra of 3.69g 
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1H and 
13C NMR spectra of 3.69h 
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1H and 
13C NMR spectra of 3.73 
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1H and 
13C NMR spectra of 3.72 
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1H and 
13C NMR spectra of 3.74 
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1H NMR spectrum of 3.70a 
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1H NMR spectrum of 3.70b 
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1H NMR spectrum of 3.70c 
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1H NMR spectrum of 3.70d 
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1H NMR spectrum of 3.70f 
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1H NMR spectrum of 3.70g 
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1H and 
13C NMR spectra of 3.70h 
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1H NMR spectrum of 3.114 
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1H NMR spectrum of 3.112 
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1H NMR spectrum of 3.115 
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